Optogenetic induction of neurodegenerative disease pathology

By using nucleotide sequences and expression vectors encoding chimeric polypeptides in cells and animals, combined with light induction technology, inducing neurodegenerative disease pathology, the limitations of relying on gene mutations or overexpression in the prior art are solved, and the limitations of gene mutations or overexpression have been achieved. More accurate simulation and research of neurodegenerative diseases.

CN110831669BActive Publication Date: 2024-11-19UNIV OF PITTSBURGH OF THE COMMONWEALTH SYST OF HIGHER EDUCATION
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201880024360.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2017-03-07
Filing Date
2018-03-07
Publication Date
2024-11-19
Estimated Expiration
2038-03-07

AI Technical Summary

Technical Problem

The prior art is difficult to effectively induce neurodegenerative disease pathology in cellular and animal models, especially the lack of methods that do not rely on gene mutations or overexpression, and existing models cannot accurately simulate human neuropathology.

Method used

Developed nucleotide sequences and expression vectors encoding chimeric polypeptides, including light-induced oligomerization domains and low-complexity domains of target proteins for neurodegenerative diseases, induced protein aggregation through blue light stimulation, simulated neurodegenerative diseases. pathology.

Benefits of technology

A new approach to inducing neurodegenerative disease pathology in cells and animals is realized, without gene mutation or overexpression, and can finely control protein aggregation in time and space, improving the translability of the model and the ability to simulate human diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN110831669B_ABST
    Figure CN110831669B_ABST
Patent Text Reader

Abstract

The present disclosure relates to compounds, compositions and methods for inducing neurodegenerative disease pathology. In one aspect, disclosed herein is a nucleotide sequence encoding a chimeric polypeptide, the nucleotide sequence comprising: a first nucleotide sequence encoding a light-induced oligomerization domain and a second nucleotide sequence encoding a neurodegenerative disease target protein. Disclosed herein is a method for inducing neurodegenerative disease pathology in a cell, the method comprising the following steps: introducing an expression vector encoding a chimeric polypeptide into a cell, the expression vector comprising: a first nucleotide sequence encoding a light-induced oligomerization domain and a second nucleotide sequence encoding a low complexity domain from a neurodegenerative disease target protein, wherein the first nucleotide sequence is operably linked to a promoter; expressing the chimeric polypeptide; and inducing oligomerization of the chimeric polypeptide by stimulation with blue light.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the benefit of U.S. Provisional Patent Application Serial No. 62 / 468,065, filed March 7, 2017, the disclosure of which is expressly incorporated herein by reference. Technical Field

[0003] The present disclosure relates to compounds, compositions, and methods for inducing neurodegenerative disease pathology. Background Art

[0004] The world is aging. By 2050, the proportion of people over 60 will have increased from 605 million in 2000 to 2 billion. Unfortunately, aging is the greatest risk factor for developing fatal neurodegenerative diseases. This, in turn, will significantly increase the number of patients with dementias such as Alzheimer's disease (AD), Lewy body dementia (LBD), and frontotemporal dementia (FTD), and movement disorders such as Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS). Currently, nearly 6.5 million people in the United States suffer from one of these diseases, and the associated costs are unsustainable.

[0005] In the United States, the current economic burden of AD, PD, and ALS is estimated to be $241 billion annually. Patients with AD and ALS / FTD can incur personal medical expenses of up to $100,000 to $250,000 annually. For AD, it is estimated that 13.8 million people will be diagnosed in the United States by 2050, compared to 4.7 million in 2010, while the number of ALS cases worldwide will increase by approximately 31% by 2040. Currently, there are no effective treatments for these diseases. Although a variety of genetic mutations contribute to these neurodegenerative diseases, there is no known single cause. However, despite this diversity, nearly all patients within each disease exhibit common neuropathological hallmarks in the form of intracellular protein aggregates. Animal models that recapitulate these neuropathologies currently require the use of genetic mutations or severely overexpressed proteins, which generally do not mimic the pathology seen in patients. New and improved methods are needed for inducing neurodegenerative disease pathology in cell lines and animal models.

[0006] The compounds, compositions, and methods disclosed herein address these and other needs. Summary of the Invention

[0007] Disclosed herein are compounds, compositions, and methods for inducing neurodegenerative disease pathology in cells or animals. The inventors have developed novel methods for inducing neurodegenerative disease pathology in cells and animals without the need for genetic mutations or severely overexpressed neurodegenerative disease proteins.

[0008] In one aspect, disclosed herein are nucleotide sequences encoding a chimeric polypeptide comprising: a first nucleotide sequence encoding a light-induced oligomerization domain and a second nucleotide sequence encoding a low complexity domain from a neurodegenerative disease target protein.

[0009] In one aspect, disclosed herein is an expression vector encoding a chimeric polypeptide, comprising: a first nucleotide sequence encoding a light-induced oligomerization domain and a second nucleotide sequence encoding a low complexity domain from a neurodegenerative disease target protein, wherein the first nucleotide sequence is operably linked to a promoter.

[0010] In one aspect, disclosed herein is a cell comprising a nucleotide sequence encoding a chimeric polypeptide, the cell comprising: a first nucleotide sequence encoding a light-induced oligomerization domain and a second nucleotide sequence encoding a neurodegenerative disease target protein.

[0011] In one aspect, disclosed herein is a chimeric polypeptide comprising: a light-induced oligomerization domain; and a low complexity domain from a neurodegenerative disease target protein.

[0012] In one aspect, disclosed herein is a method of inducing neurodegenerative disease pathology in a cell, the method comprising the steps of:

[0013] An expression vector encoding a chimeric polypeptide is introduced into a cell, wherein the expression vector comprises:

[0014] a first nucleotide sequence encoding a light-induced oligomerization domain and a second nucleotide sequence encoding a low complexity domain from a neurodegenerative disease target protein, wherein the first nucleotide sequence is operably linked to a promoter;

[0015] expressing the chimeric polypeptide; and

[0016] Oligomerization of the chimeric polypeptides was induced by stimulation with blue light.

[0017] In another aspect, disclosed herein is a method for screening for an agent that modulates protein aggregation, the method comprising the steps of:

[0018] An expression vector encoding a chimeric polypeptide is introduced into a cell, wherein the expression vector comprises:

[0019] a first nucleotide sequence encoding a light-induced oligomerization domain and a second nucleotide sequence encoding a low complexity domain from a neurodegenerative disease target protein, wherein the first nucleotide sequence is operably linked to a promoter;

[0020] expressing a chimeric polypeptide;

[0021] introducing the agent into a culture medium containing cells;

[0022] inducing oligomerization of the chimeric polypeptide by stimulation with blue light; and

[0023] Modulation of protein aggregation by the agent is determined.

[0024] In one embodiment, the light-induced oligomerization domain is selected from the group consisting of: CRYPHR, CRY2OLIG, NcVVD, NcVVDY50W, NcLOV, VfAU1, YtvA, EL222, RsLOV, and AsLOV2. In one embodiment, the light-induced oligomerization domain is selected from the list of domains in Table 2. In one embodiment, the light-induced oligomerization domain is NcVVDY50W. In one embodiment, the light-induced oligomerization domain is CRY2OLIG. In one embodiment, the light-induced oligomerization domain is CRYPHR.

[0025] In one embodiment, the light-induced oligomerization domain is selected from the group consisting of a CRY2 PHR domain (e.g., CRY2PHR, CRY2OLIG) or a light-oxygen voltage sensing (LOV) domain (e.g., NcVVD, NcVVDY50W, VfAU1, YtvA, EL222, RsLOV, AsLOV2).

[0026] In one embodiment, the low complexity domain from a neurodegenerative disease target protein is selected from the group consisting of: TDP-43, alpha synuclein, Tau, Fus, TIA1, SOD1, Huntingtin, Ataxin 2, hnRNPA1, hnRNPA2B1, EWS RNA binding protein 1, and TATA box binding protein factor 15. In one embodiment, the low complexity domain from a neurodegenerative disease target protein is selected from Table 3. In one embodiment, the low complexity domain from a neurodegenerative disease target protein is TDP-43. In one embodiment, the low complexity domain from a neurodegenerative disease target protein is alpha synuclein. In one embodiment, the low complexity domain from a neurodegenerative disease target protein is Tau.

[0027] In one embodiment, the cell is a mammalian cell. In one embodiment, the cell is a human cell.

[0028] In one embodiment, the wavelength of the blue light is between 405 nm and 499 nm. In one embodiment, the wavelength of the blue light is about 465 nm. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] The accompanying drawings are incorporated in and constitute a part of this specification and illustrate several aspects described below.

[0030] Figure 1 Examples of genetic causes of ALS and common neuropathologies are shown. The left panel shows a graph showing the number of genes that cause ALS on the Y-axis and the year each mutation was discovered on the X-axis. Figure 1 The left panel shows that ALS exhibits extreme genetic heterogeneity, particularly since these mutations are found in only approximately 10% of ALS cases. As described in Table 1, despite these genetic causes of ALS, nearly all patients exhibit the same neuropathology in the motor cortex and spinal cord. The right panel shows an example of ALS neuropathology using H and E staining of paraffin tissue sections from the motor cortex of ALS patients. Shown are cytoplasmic aggregates of TDP-43. In normal cells, TDP-43 is primarily nuclear, as indicated by the *. In ALS, as indicated by the arrows, TDP-43 is absent from the nucleus and aggregates in the cytoplasm. While ALS is used as an example, cytoplasmic aggregate neuropathology is a common feature of many neurodegenerative diseases (see Table 1).

[0031] Figures 2A-2B Methods for light-induced neuropathological aggregated proteins containing LCD / IDR / prion-like domains using TDP-43 and CRY2OLIG as examples are described. Various protein arrangements and blue light exposure paradigms were developed to induce protein aggregation of proteins and protein fragments containing LCD / IDR / prion-like domains, promoting mislocalization of nuclear proteins and reproducing the neuropathology of neurodegenerative diseases. TDP-43 is primarily a nuclear protein containing DR / IDD / prion-like domains and, as an example, mislocalizes and aggregates in patients with ALS, FTD, and certain AD. DNA sequences were designed to generate amino acid sequences encoding CRY2OLIG proteins that cluster upon exposure to blue light, producing fusion proteins, either the entire TDP-43 protein (cry2-TDP43-mCh) or only the low complexity domain (LCD / IDD / prion-like domain), which makes TDP-43 prone to aggregation (Cry2-274-mCh). As a control, only CRY2OLIG was used. All constructs were fused to a fluorescent protein called mCherry (mCh) to visualize the proteins in living cells. CRY2OLIG-mCh aggregated reversibly upon stimulation with blue light, but CRY2OLIG-TDP-43-mCh or the truncated CRY2OLIG-274-mCh formed irreversible aggregates using a specific blue light stimulation paradigm. Figure 2A Examples of the CRY2OLIG-TDP-43 arrangement and the truncated CRY2OLIG-274 arrangement used in this work are shown. Figure 2B A model of the described technique is shown.

[0032] Figure 3 Schematic diagrams depicting blue light-induced oligomerization and aggregation of proteins using NcVVD, NcVVDY50W, or NcLOV photoreceptors are shown. NcVVD or LOV domains exhibit homodimerization using only blue light stimulation. A light exposure paradigm was developed to induce oligomerization and aggregation. The upper figure shows a schematic diagram of how a single acute stimulation with blue light (405nm-499nm) induces homodimerization of LOV protein when fused to a protein of interest. The lower figure shows that chronic stimulation with blue light promotes homo-oligomerization of NcVVD or LOV fusion proteins containing a prion-like domain / LCD / IDD.

[0033] Figures 4A-4E Light-induced aggregation of low-complexity domain proteins is shown. Using light stimulation, optogenetic TDP-43 fragments containing low-complexity domains (LCDs) undergo progressive aggregation. ( Figures 4A-4B ) When monitored by live confocal microscopy, the C-terminal fragment of TDP-43 (optoRRM2+LCD / optoLCD) rapidly oligomerized after a brief pulse of blue light (8 seconds, 10% laser power, 488 nm). These oligomers persisted longer than Cry2 photoreceptors alone (approximately 10 minutes of disassembly). ( Figures 4C-4D The optogenetic LCD fragments also continued to aggregate after the brief light pulse, growing in size over time. Figure 4E ) Sustained blue light stimulation of TDP-43 LCD forms intracellular aggregates in cells. Fluorescence recovery after photobleaching (FRAP) experiments revealed persistent light LCD inclusions that could not be recovered from FRAP, indicating that these are insoluble.

[0034] Figures 5A-5K They showed that chronic blue light stimulation induced mislocalization and aggregation of optoTDP43, which recapitulated the pathological features seen in patient CNS tissue. HEK293 cells expressing optoTDP43-mCh were exposed to 488 nm LED stimulation or darkness for up to 36 hours. Figures 5A-5C ) Representative images show optoTDP43 ( Figure 5B ) first undergoes gradual cytoplasmic mislocalization, ( Figure 5C ) which was confirmed by nuclear / cytoplasmic fractions. ( Figure 5D ) As measured by simultaneous chronic blue light exposure and high-throughput automated confocal microscopy, optoTDP43 aggregation was followed by mislocalization, which tended to increase with increasing exposure. ( Figure 5E) Fluorescence recovery after photobleaching (FRAP) imaging was performed to assess the dynamics of optoTDP43 structure. The lack of fluorescence recovery indicated that the photoinduced optoTDP43 aggregates were non-dynamic, immobile particles, reminiscent of aggregated structures. ( Figure 5F ) Detergent solubility of optoTDP43 constructs was assessed by subcellular fractionation to confirm the aggregation state of light-induced optoTDP43 particles. (Left lane) Non-optogenetic TDP-43 (TDP43-mCh) showed no change in solubility with or without light treatment, while upon chronic blue light stimulation, optoTDP43 (right lane) showed a dramatic shift toward an insoluble fraction. In addition to increasing the insolubility of exogenous full-length optoTDP43 (upper lane), chronic blue light exposure also led to the recruitment of aberrant optoTDP43 cleavage products (middle lane) as well as endogenous full-length TDP-43 and disease-associated cleavage products (bottom lane), such as those observed in patient tissues, to the detergent-insoluble, urea-soluble fraction of cellular cleavages. ( Figure 5G To confirm the direct recruitment of non-optogenetic TDP-43 species to exogenous light-induced optoTDP43 inclusions, EGFP-tagged TDP-43 was co-expressed with optoTDP43 or Cry2-only photoreceptor controls. In cells exposed to chronic blue light stimulation, strong colocalization was observed between optoTDP43 inclusions and EGFP-TDP43, confirming the ability of optoTDP43 inclusions to directly recruit other TDP-43 species. This recruitment appeared to be dependent on the TDP43:TDP43 interaction, as no colocalization of Cry2-mCh puncta was observed after blue light exposure. Figures 5H-5J ) performed immunofluorescence analysis of light-induced optoTDP43 aggregates to confirm the pathological hallmarks seen in patient tissue. The optoTDP43 inclusions appear to be ( Figure 5H ) ubiquitinated, ( Figure 5I ) hyperphosphorylated and ( Figure 5J )p62 positive, all of which have been observed with TDP-43 inclusion in the CNS of patients. Figure 5K) performed automated high-throughput confocal microscopy to assess the light-induced neurotoxicity of optoTDP43 inclusions. Human ReN neurons expressing TDP43-mCh or optoTDP43 were exposed to chronic blue light stimulation, and their viability was simultaneously monitored by longitudinal imaging. Neurons expressing non-optogenetic TDP43-mCh did not show a significant decrease in survival rate when exposed or not to blue light. However, neurons expressing optoTDP43 exposed to blue light stimulation showed a significant decrease in viability over time, indicating that optoTDP43 inclusions are neurotoxic. * = p < .05, ** = p < .01

[0035] Figures 6A-6E Chronic stimulation of CRY2OLIG α-synuclein or α-synuclein LOV was shown to induce clustering and aggregation. Chronic stimulation of CRY2-asyn-mCh was tested to induce α-synuclein aggregation. Figure 6A shows a chronic stimulation paradigm, Figure 6B Representative images of α-synuclein clustering over time using light are shown, as well as Figure 6C These data demonstrate that this optogenetic system can be used to induce clustering and aggregation of a variety of aggregation-prone neurodegenerative disease proteins, namely those containing prion-like domains / LCDs / IDDs. Figure 6D Alpha-synuclein fused to LOV (dimeric photoreceptors) is shown to form intracellular clusters of alpha-synuclein. Figure 6E We show that light-induced α-synuclein LOV aggregates exhibit pathological features of synucleinopathies, including phosphorylation of serine 129 and p62 positivity.

[0036] Figures 7A-7D Shown is a Cry2-Tau fusion protein that displays various pathological markers of tauopathies. Figures 7A-7C HEK293 cells expressing Cry2 photoreceptors alone or Cry2-Tau fusion protein were exposed to chronic blue light stimulation (16 hours, 488 nm, 10 mW). Cells expressing Cry2-Tau showed similar expression to the phosphorylated Tau antibody AT8 ( Figure 7A ) and PHF1( Figure 7B ) and the pathological conformation-dependent Tau antibody MC1 ( Figure 7C ) Co-stained fibril-like aggregates. ( Figure 7D ) Overview showing various optogenetic Tau constructs colocalizing with pathological Tau antibodies after light-induced neurofibrillary tangle formation.

[0037] Figures 8A-8EIt was shown that the LOV-Tau fusion protein also displayed various pathological markers of tauopathies and was insoluble. Figure 8A-8B HEK293 cells expressing VVD-Tau or VfAU-Tau fusion proteins were exposed to chronic blue light stimulation (16 hours, 488 nm, 10 mW). Both fusion proteins were co-stained with phosphorylated Tau antibodies AT8 and PHF1 and pathological conformation-dependent Tau antibody MC1. ( Figure 8C ) Differentiated MAP2+ human ReN neurons expressing VVD-Tau also showed the formation of neurofibrillary tangles after chronic light treatment that colocalized with AT8. ( Figure 8D ) Fluorescence recovery after photobleaching analysis was performed on the light-induced entanglements and showed a lack of fluorescence recovery, which indicates a non-dynamically fixed structure. ( Figure 8E ) Next, urea extraction was performed to identify insoluble tau species in HEK293 cells expressing VVD-Tau treated with light. Cells exposed to chronic light showed increased levels of both soluble and insoluble 150 kDa tau species, which are present in tissues from patients with Alzheimer's disease and frontotemporal dementia.

[0038] Figures 9A-9B The clustering potential of CRY2 or VVD fusion proteins was shown to depend on the combination of protein arrangement and light stimulation paradigm. The study showed that the ability of CRY2 or VVD to stimulate photoreceptor clustering and activation depends on the protein arrangement as well as the light stimulation paradigm. Figure 9A showed that the TDP-43-CRY2OLIG-mCh protein mislocalized but did not exhibit the ability to aggregate as the CRY2OLIG-TDP-43-mCh arrangement. Figure 9B mCh-aSyn-NvVVDY50W was shown to be aggregation-incompetent. These data suggest that protein alignment and the light stimulation paradigm are crucial for inducing neuropathic protein aggregation, as observed in CNS tissues of patients with neurodegenerative diseases.

[0039] Figures 10A-10B We show that blue light-induced TDP-43 aggregates or truncated LCD / IDR / prion-like domain aggregates are toxic to cells. Figure 10A We show that acute stimulation of HEK cells expressing CRY2OLIG-TDP274-mCh can induce the formation of pathological aggregates within 1 hour. Over time, these aggregates grow in size and become toxic. Figure 10B Schematic diagram of a screening pipeline that uses the induction of neurodegenerative disease pathology to identify therapeutic compounds that can rescue toxicity and prevent or abrogate the development of the induced neurodegenerative disease pathology. DETAILED DESCRIPTION

[0040] Disclosed herein are compounds, compositions, and methods for inducing neurodegenerative disease pathology in cells or animals. The inventors have developed novel methods for inducing neurodegenerative disease pathology in cells and animals without requiring genetic mutation or severe overexpression of neurodegenerative disease proteins.

[0041] Reference will now be made in detail to embodiments of the present invention, examples of which are illustrated in the accompanying drawings and the Examples. This invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein.

[0042] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. As used herein, the term "comprising" and its variations are used synonymously with the term "including" and its variations and are open, non-restrictive terms. Although the terms "comprising" and "including" have been used herein to describe various embodiments, the terms "consisting essentially of" and "consisting of" may be used instead of "comprising" and "including" to provide more specific embodiments and are also disclosed.

[0043] The following definitions are provided to provide a complete understanding of the terms used in this specification.

[0044] the term

[0045] As used herein, the articles "a," "an," and "the" mean "at least one," unless the context in which the article is used clearly indicates otherwise.

[0046] As used herein, the term "about" when referring to a measurable value such as an amount, a percentage, etc., is meant to encompass variations of ±20%, ±10%, ±5%, or ±1% from the measurable value.

[0047] As used herein, the terms "may," "optionally," and "may optionally" are used interchangeably and are intended to include instances where a condition occurs as well as instances where it does not.

[0048] As used herein, the term "nucleic acid" refers to a polymer composed of nucleotides (eg, deoxyribonucleotides or ribonucleotides).

[0049] As used herein, the terms "ribonucleic acid" and "RNA" refer to polymers composed of ribonucleotides.

[0050] As used herein, the terms "deoxyribonucleic acid" and "DNA" refer to a polymer composed of deoxyribonucleotides.

[0051] The term "oligonucleotide" refers to a single-stranded or double-stranded nucleotide polymer having a length of about 2 to as many as about 100 nucleotides. Suitable oligonucleotides can be prepared by the phosphoramidite method described in Beaucage and Carruthers, Tetrahedron Lett., 22:1859-1862 (1981), or according to Matteucci et al., J.Am.Chem.Soc., 103:3185 (1981) triester method, both of which are prepared by reference or by using a commercial automated oligonucleotide synthesizer or VLSIPS. TM Other chemical methods of the technology are incorporated herein.When oligonucleotides are referred to as "double-stranded", it will be understood by those skilled in the art that a pair of oligonucleotides are present in a spiral array of hydrogen bonds commonly associated with, for example, DNA.In addition to the 100% complementary form of double-stranded oligonucleotides, the term "double-stranded" as used herein also means those forms that include such structural features (such as protrusions and loops), which are more fully described in biochemical texts such as Stryer, Biochemistry, 3rd edition, (1988), which are incorporated herein by reference for all purposes.

[0052] The terms "polynucleotide," "nucleotide sequence," and "nucleic acid sequence" are used interchangeably herein and refer to a single- or double-stranded polymer composed of nucleotide monomers.

[0053] The term "polypeptide" refers to a compound composed of a single chain of D- or L-amino acids, or a mixture of D- and L-amino acids, linked by peptide bonds.

[0054] The term "complementary" refers to the topological compatibility or matching together of the interaction surfaces of the probe molecule and its target. Thus, a target and its probe can be described as complementary if, in addition, the contact surface properties complement each other.

[0055] The term "hybridization" refers to the process of establishing non-covalent sequence-specific interactions between two or more complementary nucleic acid strands into a single hybrid, which in the case of two strands is called a duplex.

[0056] The term "annealing" refers to a process in which a single-stranded nucleic acid sequence pairs with a complementary sequence through hydrogen bonds to form a double-stranded nucleic acid sequence, which includes reorganization (renaturation) of complementary chains separated by heat (thermal denaturation).

[0057] The term "melting" refers to the denaturation of double-stranded nucleic acid sequences due to high temperature, thereby separating the double strand into two single strands by breaking the hydrogen bonds between the strands.

[0058] The term "promoter" or "regulatory element" refers to a region or sequence determinant located upstream or downstream of transcription initiation and involved in the recognition and binding of RNA polymerase and other proteins to initiate transcription. Promoters need not be of bacterial origin, for example, promoters derived from viruses or other organisms can be used in compositions, systems or methods as described herein. The term "regulatory element" is intended to include promoters, enhancers, internal ribosome entry sites (IRES) and other expression control elements (e.g., transcription termination signals, such as polyadenylation signals and poly-U sequences). Such regulatory elements are described, for example, in Goeddel, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif (1990). Regulatory elements include those that direct constitutive expression of nucleotide sequences in many types of host cells and those (e.g., tissue-specific regulatory sequences) that direct expression of nucleotide sequences only in certain host cells. Tissue-specific promoters can direct expression primarily in desired target tissues, such as muscle, neurons, bones, skin, blood, specific organs (e.g., liver, pancreas) or specific cell types (e.g., lymphocytes). Regulatory elements can also direct expression in a time-dependent manner, such as in a cell cycle-dependent or developmental stage-dependent manner, which may or may not be tissue-specific or cell type-specific. In certain embodiments, the vector comprises one or more pol III promoters (e.g., 1, 2, 3, 4, 5, or more pol I promoters), one or more pol II promoters (e.g., 1, 2, 3, 4, 5, or more pol II promoters), one or more pol I promoters (e.g., 1, 2, 3, 4, 5, or more pol I promoters), or a combination thereof. Examples of pol III promoters include, but are not limited to, U6 and H1 promoters. Examples of pol II promoters include, but are not limited to, the retroviral Rous sarcoma virus (RSV) LTR promoter (optionally with an RSV enhancer), the cytomegalovirus (CMV) promoter (optionally with a CMV enhancer) [see, e.g., Boshart et al., Cell, 41:521-530 (1985)], the SV40 promoter, the dihydrofolate reductase promoter, the β-actin promoter, the phosphoglycerate kinase (PGK) promoter, and the EF1α promoter.The term "regulatory element" also includes enhancer elements such as WPRE; CMV enhancer; R-U5' segment in the LTR of HTLV-I (Mol. Cell. Biol., Vol. 8 (1), pp. 466-472, 1988); SV40 enhancer; and the intron sequence between exons 2 and 3 of rabbit β-globin (Proc. Natl. Acad. Sci. USA., Vol. 78 (3), pp. 1527-31, 1981). Those skilled in the art will recognize that the design of the expression vector may depend on factors such as the choice of the host cell to be transformed, the desired expression level, etc.

[0059] The term "recombination" refers to a nucleic acid (e.g., polynucleotide) or a copy or complement of a nucleic acid (e.g., polynucleotide) that is artificially manipulated, or if it relates to a protein (i.e., "recombinant protein"), a protein encoded by a recombinant nucleic acid (e.g., polynucleotide). In an embodiment, the recombinant expression cassette comprising a promoter operably connected to a second nucleic acid (e.g., polynucleotide) can include a promoter that is heterologous to the second nucleic acid (e.g., polynucleotide) due to artificial manipulation (e.g., by methods described below, Sambrook et al., Molecular Cloning—A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, (1989) or Current Protocols in Molecular Biology Vol. 1-3, John Wiley & Sons, Inc. (1994-1998)). In another example, the recombinant expression cassette can include nucleic acids (e.g., polynucleotides) combined in such a way that it is highly unlikely that the nucleic acid (e.g., polynucleotide) will be found in nature. For example, artificially manipulated restriction sites or plasmid vector sequences can flank or separate the promoter from the second nucleic acid (e.g., polynucleotide). Those skilled in the art will recognize that nucleic acids (e.g., polynucleotides) can be manipulated in many ways and are not limited to the above examples.

[0060] Term " expression cassette " refers to nucleic acid construct, and when it is introduced into host cell, it causes the transcription and / or translation of RNA or polypeptide respectively.In embodiments, the expression cassette comprising the promoter being operably connected to the second nucleic acid (such as polynucleotide) can include due to artificial manipulation (such as, by the method described below, Sambrook etc., Molecular Cloning—A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, (1989) or Current Protocols in Molecular Biology the 1-3 volumes, John Wiley&Sons, Inc. (1994-1998)) and with the second nucleic acid (such as polynucleotide) be heterologous promoter.In some embodiments, the expression cassette comprising the terminator (or termination sequence) being operably connected to the second nucleic acid (such as polynucleotide) can include due to artificial manipulation and with the terminator being heterologous to the second nucleic acid (such as polynucleotide).In some embodiments, expression cassette comprises the promoter being operably connected to the second nucleic acid (such as polynucleotide) as artificial manipulation result and the terminator being operably connected to the second nucleic acid (such as polynucleotide). In certain embodiments, the expression cassette comprises an endogenous promoter. In certain embodiments, the expression cassette comprises an endogenous terminator. In certain embodiments, the expression cassette comprises a synthetic (or non-natural) promoter. In certain embodiments, the expression cassette comprises a synthetic (or non-natural) terminator.

[0061] In the context of two or more nucleic acid or polypeptide sequences, the terms "same" or "percent identity" refer to the comparison of two or more sequences or subsequences or amino acid residues or nucleotide sequences having a specified percentage (i.e., about 60% identity over a specified region, preferably 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity over a specified region, when compared and aligned for maximum correspondence over a comparison window or specified region). 2.0 sequence comparison algorithm or by manual comparison and visual inspection identical inspection (for example, referring to NCBI website etc.) measure identical.Then, such sequence is considered to be " substantially identical ".This definition also refers to or can be applied to the complementation of test sequence.This definition also includes sequences with deletion and / or addition and sequences with substitution.As described below, preferred algorithm can consider room etc.Preferably, identity is present in the region of at least about 10 amino acids or 20 nucleotides in length, or more preferably is present in the region of 10 to 50 amino acids or 20 to 50 nucleotides in length.As used herein, amino acid sequence identity percentage (%) is defined as the percentage of the amino acid identical with the amino acid in the reference sequence in the candidate sequence, after aligning the sequences and introducing room (if necessary), to realize maximum sequence identity percentage.Comparison for determining sequence identity percentage can be realized in a variety of ways within the scope of the art, for example, using publicly available computer software, such as BLAST, BLAST-2, ALIGN, ALIGN-2 or Megalign (DNASTAR) software. Appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared, can be determined by known methods.

[0062] In order to perform sequence comparison, a sequence is usually used as a reference sequence to which a test sequence is compared. When using a sequence comparison algorithm, the test sequence and the reference sequence are input into a computer, subsequence coordinates are specified if necessary, and sequence algorithm program parameters are specified. Preferably, default program parameters can be used, or alternative parameters can be specified. The sequence comparison algorithm then calculates the sequence identity percentage of the test sequence relative to the reference sequence based on the program parameters.

[0063] An example of an algorithm suitable for determining sequence identity and sequence similarity percentages is BLAST and BLAST 2.0 algorithms, which are described in Altschul et al. (1977) Nuc. Acids Res. 25: 3389-3402, and Altschul et al. (1990) J. Mol. Biol. 215: 403-410. Software for BLAST analysis is publicly available through the National Center for Biotechnology Information (http: / / www.ncbi.nlm.nih.gov / ). The algorithm involves first identifying high-scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence that match or meet some positive threshold score T when aligned with words of the same length in the database sequence. T is referred to as a contiguous word score threshold (Altschul et al. (1990) J. Mol. Biol. 215: 403-410). These initial contiguous word hits serve as seeds for initiating searches to find longer HSPs that contain them. The word hits are extended in both directions along each sequence for as long as the cumulative alignment score can be increased. For nucleotide sequences, the cumulative score is calculated using the parameters M (reward score for a pair of matching residues; always >0) and N (penalty score for mismatched residues; always <0). For amino acid sequences, a scoring matrix is ​​used to calculate the cumulative score. The extension of the word hits in each direction will be stopped when: the cumulative alignment score decreases by a number X from its maximum achieved value; the cumulative score becomes below zero due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses a word length (W) of 11, an expectation (E) of 10, M=5, N=-4, and a comparison of both chains by default. For amino acid sequences, the BLASTP program uses as defaults a wordlength of 3 and an expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff and Henikoff (1989) Proc. Natl. Acad. Sci. USA 89:10915) with an alignment (B) of 50, an expectation (E) of 10, M=5, N=-4, and a comparison of both strands.

[0064] The BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-5787). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability that a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.2, more preferably less than about 0.01.

[0065] The phrase "codon-optimized" refers to a gene or coding region of a nucleic acid molecule used to transform a variety of hosts, and refers to the alteration of codons in a gene or coding region of a polynucleic acid molecule to reflect the typical codon usage of a selected organism without altering the polypeptide encoded by the DNA. Such optimization includes replacing at least one or more, or one or more codons, with one or more codons that are more frequently used in the genes of the selected organism.

[0066] When a nucleic acid is in a functional relationship with another nucleic acid sequence, the nucleic acid is "operably linked". For example, if the DNA of a presequence or secretory leader sequence is expressed as a preprotein that participates in the secretion of a polypeptide, the presequence or secretory leader sequence is operably linked to the DNA of the polypeptide; if a promoter or enhancer affects the transcription of a coding sequence, the promoter or enhancer is operably linked to the coding sequence; or if a ribosome binding site is positioned so as to facilitate translation, the ribosome binding site is operably linked to the coding sequence. Generally, "operably linked" refers to that the DNA sequences being linked are close to each other, and in the case of a secretory leader sequence, are continuous and are in the reading phase. However, operably linked nucleic acids (such as enhancers and coding sequences) do not have to be continuous. Connection is accomplished by connecting at convenient restriction sites. If there is no such site, a synthetic oligonucleotide linker or joint is used according to conventional practice. In an embodiment, when a promoter is able to affect (e.g., regulate relative to the absence of a promoter) the expression of a protein from the coding sequence (i.e., the coding sequence is under the transcriptional control of the promoter), the promoter is operably linked to the coding sequence.

[0067] As used herein, the term "variant" or "derivative" refers to an amino acid sequence derived from the amino acid sequence of a parent protein having one or more amino acid substitutions, insertions and / or deletions.

[0068] Chimeric constructs

[0069] In one aspect, disclosed herein are nucleotide sequences encoding a chimeric polypeptide comprising: a first nucleotide sequence encoding a light-induced oligomerization domain and a second nucleotide sequence encoding a low complexity domain from a neurodegenerative disease target protein.

[0070] In one aspect, disclosed herein is an expression vector encoding a chimeric polypeptide, comprising: a first nucleotide sequence encoding a light-induced oligomerization domain and a second nucleotide sequence encoding a low complexity domain from a neurodegenerative disease target protein, wherein the first nucleotide sequence is operably linked to a promoter.

[0071] In some embodiments, the expression vector encoding the chimeric polypeptide is contained in a plasmid or a virus or a viral vector. The plasmid or viral vector can be capable of extrachromosomal replication, or alternatively, can be integrated into the host genome. As used herein, the term "integrated" for an expression vector (e.g., a plasmid or viral vector) refers to the introduction (physical insertion or connection) of an expression vector or a portion thereof into the chromosomal DNA of a host cell. As used herein, a "viral vector" refers to a virus-like particle containing genetic material that can be introduced into eukaryotic cells without causing substantial pathogenic effects on eukaryotic cells. A variety of viruses or viral vectors can be used for transduction, but should be compatible with the cell type to which the virus or viral vector is transduced (e.g., low toxicity, ability to enter cells). Among other things, suitable viruses and viral vectors include adenoviruses, lentiviruses, and retroviruses. In some embodiments, the expression vector encoding the chimeric polypeptide is naked DNA or contained in nanoparticles (e.g., liposome vesicles, porous silicon nanoparticles, gold-DNA conjugate particles, polyethyleneimine polymer particles, cationic peptides, etc.).

[0072] In certain embodiments, the expression vectors disclosed herein are capable of inducing neurodegenerative disease pathology in a cell (e.g., inducing aggregation of a protein) without substantially changing the expression level of a protein involved in the neurodegenerative disease pathology. For example, but not limited to, an expression vector can induce aggregation of a protein having a low complexity domain from a neurodegenerative disease target protein without substantially increasing or decreasing the expression level of an endogenous target protein comprising the same low complexity domain. In this way, a cell comprising a nucleotide sequence encoding a chimeric polypeptide disclosed herein can have an endogenous neurodegenerative disease target protein comprising a low complexity domain at a substantially unchanged expression level compared to a cell of the same cell type that does not comprise a nucleotide sequence encoding a chimeric polypeptide. As used herein, the term "substantially unchanged expression level" refers to a change in expression level, if any, to an extent that is unknown or not suspected of causing or being associated with neurodegenerative disease pathology in the cell.

[0073] In certain embodiments, the expression vectors disclosed herein are capable of inducing neurodegenerative disease pathology in cells (e.g., inducing aggregation of the protein) using a wild-type form of a low-complexity domain from a neurodegenerative disease target protein. Thus, in certain embodiments, the low-complexity domain from a neurodegenerative disease target protein does not include a mutation that is different from the wild-type sequence and is known or suspected of causing or associated with neurodegenerative disease pathology in a cell. For example, but not limited to, an expression vector may comprise a low-complexity domain from a wild-type TDP-43 protein that does not include a mutation known to cause or be associated with ALS, such as Q331K.

[0074] In one aspect, disclosed herein is a cell comprising a nucleotide sequence encoding a chimeric polypeptide, the cell comprising: a first nucleotide sequence encoding a light-induced oligomerization domain and a second nucleotide sequence encoding a neurodegenerative disease target protein.

[0075] In certain embodiments, the cell is a cell that can be affected by a neurodegenerative disease. For example, the cell can be a glial cell or a neuronal cell.

[0076] In one aspect, disclosed herein are chimeric polypeptides comprising: a light-induced oligomerization domain; and a low complexity domain from a neurodegenerative disease target protein.

[0077] In one embodiment, the light-induced oligomerization domain is selected from the group consisting of: CRYPHR, CRY2OLIG, NcVVD, NcVVDY50W, and NcLOV. In one embodiment, the light-induced oligomerization domain is selected from the group consisting of: CRYPHR, CRY2OLIG, NcVVD, NcVVDY50W, NcLOV, VfAU1, YtvA, EL222, RsLOV, and AsLOV2. In one embodiment, the light-induced oligomerization domain is selected from the list of domains in Table 2. In one embodiment, the light-induced oligomerization domain is selected from a variant of: CRYPHR, CRY2OLIG, NcVVD, NcVVDY50W, NcLOV, VfAU1, YtvA, EL222, RsLOV, or AsLOV2. In one embodiment, the light-induced oligomerization domain is selected from a fragment of CRYPHR, CRY2OLIG, NcVVD, NcVVDY50W, NcLOV, VfAU1, YtvA, EL222, RsLOV, or AsLOV2.

[0078] In one embodiment, the light-induced oligomerization domain is NcVVDY50W. In one embodiment, the light-induced oligomerization domain is CRY2OLIG. In one embodiment, the light-induced oligomerization domain is CRYPHR. In one embodiment, the light-induced oligomerization domain comprises the LOV domain from the VVD protein. In one embodiment, the light-induced oligomerization domain comprises the LOV domain from the LOV protein. In one embodiment, the light-induced oligomerization domain comprises the PHR domain. In one embodiment, the light-induced oligomerization domain comprises the PHR domain from the CRY2 protein. In one embodiment, the light-induced oligomerization domain is VfAU1. In one embodiment, the light-induced oligomerization domain is YtvA. In one embodiment, the light-induced oligomerization domain is EL222. In one embodiment, the light-induced oligomerization domain is RsLOV. In one embodiment, the light-induced oligomerization domain is AsLOV2.

[0079] In one embodiment, the light-induced oligomerization domain is at least 90% identical to CRYPHR. In one embodiment, the light-induced oligomerization domain is at least 90% identical to NcVVD. In one embodiment, the light-induced oligomerization domain is at least 90% identical to NcVVDY50W. In one embodiment, the light-induced oligomerization domain is at least 90% identical to NcLOV. In one embodiment, the light-induced oligomerization domain is at least 90% identical to CRY2OLIG. In one embodiment, the light-induced oligomerization domain is at least 90% identical to VfAU1. In one embodiment, the light-induced oligomerization domain is at least 90% identical to YtvA. In one embodiment, the light-induced oligomerization domain is at least 90% identical to EL222. In one embodiment, the light-induced oligomerization domain is at least 90% identical to RsLOV. In one embodiment, the light-induced oligomerization domain is at least 90% identical to AsLOV2.

[0080] In certain embodiments, the first nucleotide sequence may comprise a nucleotide sequence encoding a light-induced oligomerization domain selected from the group consisting of CRYPHR, CRY2OLIG, NcVVD, NcVVDY50W, NcLOV, and VfAU1LOV.

[0081] In certain embodiments, the first nucleotide sequence can comprise a nucleotide sequence encoding an amino acid sequence that is at least 70% identical to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, or SEQ ID NO: 102. In certain embodiments, the first nucleotide sequence can encode an amino acid sequence that is at least 75% identical, at least 80% identical, at least 85% identical, at least 90% identical, at least 95% identical, or at least 99% identical to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, or SEQ ID NO: 102. In certain embodiments, the first nucleotide sequence may comprise SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101 or SEQ ID NO: 102. In certain embodiments, the first nucleotide sequence may comprise SEQ ID NO: 94. The nucleotide sequence may be the nucleotide sequence of a wild-type nucleic acid sequence encoding an amino acid sequence disclosed herein. In certain embodiments, the nucleotide sequence is modified from a wild-type sequence, but due to the degeneracy of the genetic code, the same amino acid sequence can still be encoded. In certain embodiments, the nucleotide sequence is a variant of one of the sequences disclosed herein (or encoding a variant protein sequence). In certain embodiments, the nucleotide sequence is a fragment of one of the nucleic acids herein, or a fragment encoding one of the amino acids disclosed herein. In certain embodiments, the nucleotide sequence is codon-optimized (e.g., to improve expression).

[0082] In one embodiment, the light-induced oligomerization domain is selected from the group consisting of a CRY2 PHR domain (e.g., CRY2PHR, CRY2OLIG) or a light-oxygen voltage sensing (LOV) domain (e.g., NcVVD, NcVVDY50W, VfAU1, YtvA, EL222, RsLOV, AsLOV2).

[0083] In one embodiment, the low complexity domain from a neurodegenerative disease target protein is selected from the group consisting of: TDP-43, alpha synuclein, Tau, Fus, TIA1, SOD1, huntingtin, Ataxin 2, and hnRNPA2B1. In one embodiment, the low complexity domain from a neurodegenerative disease target protein is selected from the group consisting of: TDP-43, alpha synuclein, Tau, Fus, TIA1, SOD1, huntingtin, Ataxin 2, hnRNPA1, and hnRNPA2B1. In one embodiment, the low complexity domain from a neurodegenerative disease target protein is selected from the group consisting of: TDP-43, alpha synuclein, Tau, Fus, TIA1, SOD1, huntingtin, Ataxin 2, hnRNPA1, hnRNPA2B1, EWS RNA binding protein 1, and TATA box binding protein factor 15. In one embodiment, the low complexity domain from the neurodegenerative disease target protein is selected from a variant of TDP-43, alpha synuclein, Tau, TIA1, SOD1, huntingtin, Ataxin 2, hnRNPA1, hnRNPA2B1, EWS RNA binding protein 1, or TATA box binding protein factor 15. In one embodiment, the low complexity domain from the neurodegenerative disease target protein is selected from a fragment of TDP-43, alpha synuclein, Tau, TIA1, SOD1, huntingtin, Ataxin 2, hnRNPA1, hnRNPA2B1, EWS RNA binding protein 1, or TATA box binding protein factor 15. In one embodiment, a fragment of TDP-43, alpha-synuclein, Tau, TIA1, SOD1, Huntingtin, Ataxin 2, hnRNPA1, hnRNPA2B1, EWS RNA binding protein 1, or TATA box binding protein factor 15 comprises a low complexity domain (or fragment thereof) within each neurodegenerative disease target protein.

[0084] In one embodiment, the low complexity domain from a neurodegenerative disease target protein is selected from Table 3. In one embodiment, the low complexity domain is from any neurodegenerative disease target protein that aggregates in a neurodegenerative disease.

[0085] In one embodiment, the low complexity domain from a neurodegenerative disease target protein is selected from the group consisting of an amino acid sequence that is at least 90% identical to TDP-43, alpha-synuclein, Tau, Fus, TIA1, SOD1, huntingtin, Ataxin 2, hnRNPA1, hnRNPA2B1, EWS RNA-binding protein 1, and TATA-box binding protein factor 15. In one embodiment, the low complexity domain from a neurodegenerative disease target protein is selected from an amino acid sequence that is at least 90% identical to a low complexity domain from a neurodegenerative disease target protein selected from Table 3. In one embodiment, the low complexity domain from a neurodegenerative disease target protein is selected from an ortholog of the group consisting of TDP-43, alpha-synuclein, Tau, Fus, TIA1, SOD1, huntingtin, Ataxin 2, hnRNPA1, hnRNPA2B1, EWS RNA-binding protein 1, and TATA-box binding protein factor 15.

[0086] In one embodiment, the low complexity domain from a neurodegenerative disease target protein is selected from the group consisting of an amino acid sequence that is at least 60% (e.g., at least 60%, at least 70%, at least 80%, at least 90%, at least 95%) identical to TDP-43, alpha-synuclein, Tau, Fus, TIA1, SOD1, Huntingtin, Ataxin 2, hnRNPA1, hnRNPA2B1, EWS RNA binding protein 1, and TATA box binding protein factor 15 (or a fragment thereof).

[0087] In one embodiment, the low complexity domain from a neurodegenerative disease target protein is TDP-43. In one embodiment, the low complexity domain from a neurodegenerative disease target protein is alpha-synuclein. In one embodiment, the low complexity domain from a neurodegenerative disease target protein is Tau. In one embodiment, the low complexity domain from a neurodegenerative disease target protein is Fus. In one embodiment, the low complexity domain from a neurodegenerative disease target protein is TIA1. In one embodiment, the low complexity domain from a neurodegenerative disease target protein is SOD1. In one embodiment, the low complexity domain from a neurodegenerative disease target protein is huntingtin. In one embodiment, the low complexity domain from a neurodegenerative disease target protein is Ataxin2. In one embodiment, the low complexity domain from a neurodegenerative disease target protein is hnRNPA1. In one embodiment, the low complexity domain from a neurodegenerative disease target protein is hnRNPA2B1. In one embodiment, the low complexity domain from a neurodegenerative disease target protein is EWS RNA binding protein 1. In one embodiment, the low complexity domain from a neurodegenerative disease target protein is TATA box binding protein factor 15.

[0088] In one embodiment, the VVD light-induced oligomerization domain is fused to the low complexity domain of TDP-43. In one embodiment, the VVD light-induced oligomerization is fused to full-length TDP-43 (comprising the low complexity domain). In one embodiment, the light-induced oligomerization domain is fused to a low complexity domain from any neurodegenerative disease target protein that aggregates in neurodegenerative diseases.

[0089] In one embodiment, the light-induced oligomerization domain is fused to the low complexity domain of TDP-43, wherein the sequence of the low complexity domain of TDP-43 comprises SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 9, or SEQ ID NO: 98 (or a fragment thereof).

[0090] In one embodiment, the nucleotide sequence encoding the chimeric polypeptide may further include a third nucleotide sequence encoding a reporter protein (such as a fluorescent protein to allow visualization of protein aggregates by fluorescence). In one embodiment, the fluorescent protein is mCherry (mCh). In certain embodiments, the fluorescent protein is GFP or YFP. In certain embodiments, the first nucleotide sequence may encode a light-induced oligomerization domain comprising the PHR domain of the Arabidopsis cryptochrome 2 protein (e.g., CRYPHR). In certain embodiments, the light-induced oligomerization domain may comprise the wild-type CRYPHR amino acid sequence as disclosed in SEQ ID NO: 1, or alternatively, may comprise a mutated CRYPHR amino acid sequence as disclosed in SEQ ID NO: 2. In certain embodiments, the mutated CRYPHR amino acid sequence may comprise an E490G mutation, which may increase clustering efficiency upon blue light stimulation compared to the wild-type CRYPHR amino acid sequence. In certain embodiments, the first nucleotide sequence may encode a light-induced oligomerization domain, wherein the light-induced oligomerization domain comprises a polypeptide sequence having at least 70% identity to SEQ ID NO: 1 or SEQ ID NO: 2. In certain embodiments, the first nucleotide sequence may encode a light-induced oligomerization domain, wherein the light-induced oligomerization domain comprises a polypeptide sequence having at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, at least 95% identity, or at least 99% identity to SEQ ID NO: 1 or SEQ ID NO: 2. In certain embodiments, the first nucleotide sequence may encode a light-induced oligomerization domain comprising the polypeptide sequence of SEQ ID NO: 1 or SEQ ID NO: 2.

[0091] In certain embodiments, the first nucleotide sequence can encode a light-induced oligomerization domain comprising a light-oxygen voltage sensing domain (LOV) from Neurospora activin (e.g., LOV, NcVVD, NcVVDY50W, NcLOV, VfAU1, YtvA, EL222, RsLOV, and / or AsLOV2). In certain embodiments, the light-induced oligomerization domain can comprise a wild-type LOV amino acid sequence as disclosed in SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, or SEQ ID NO: 102, or alternatively, can comprise a mutant LOV amino acid sequence, such as disclosed in SEQ ID NO: 5. In certain embodiments, the mutant LOV amino acid sequence can comprise a Y50W mutation, which can reduce the dissipation rate from the dimeric state compared to the wild-type LOV amino acid sequence. In certain embodiments, the first nucleotide sequence may encode a light-induced oligomerization domain, wherein the light-induced oligomerization domain comprises a polypeptide sequence that is at least 70% identical to SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, or SEQ ID NO: 102. In certain embodiments, the first nucleotide sequence may encode a light-induced oligomerization domain, wherein the light-induced oligomerization domain comprises a polypeptide sequence that is at least 75% identical, at least 80% identical, at least 85% identical, at least 90% identical, at least 95% identical, or at least 99% identical to SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, or SEQ ID NO: 102. In some embodiments, the first nucleotide sequence can encode a light-induced oligomerization domain comprising a polypeptide sequence of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:92, SEQ ID NO:93, SEQ ID NO:99, SEQ ID NO:100, SEQ ID NO:101, or SEQ ID NO:102.

[0092] In certain embodiments, the first nucleotide sequence can encode a light-induced oligomerization domain comprising a PHR domain of an Arabidopsis cryptochrome 2 protein (e.g., CRYPHR), and the second nucleotide sequence can encode a low complexity domain from a neurodegenerative disease target protein. In certain embodiments, the first nucleotide sequence can encode a light-induced oligomerization domain comprising a PHR domain of an Arabidopsis cryptochrome 2 protein (e.g., CRYPHR), and the second nucleotide sequence can encode a low complexity domain from a neurodegenerative disease target protein comprising TDP-43. In certain embodiments, the second nucleotide sequence can encode a low complexity domain from a neurodegenerative disease target protein comprising full-length TDP-43 (e.g., SEQ ID NO: 6 or SEQ ID NO: 7). In certain embodiments, the second nucleotide sequence can encode a low complexity domain from a neurodegenerative disease target protein comprising a truncated TDP-43 (e.g., SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, or SEQ ID NO: 13). In certain embodiments, the truncated TDP-43 comprises or consists of amino acids 105-414, 191-414, or 274-414 of the full-length TDP-43 amino acid sequence. Thus, in certain embodiments, the first nucleotide sequence can encode a light-induced oligomerization domain comprising CRYPHR, and the second nucleotide sequence can encode a low complexity domain from a neurodegenerative disease target protein comprising full-length or truncated TDP-43, wherein the first nucleotide sequence and the second nucleotide sequence encode a chimeric polypeptide sequence having at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, at least 95% identity, or at least 99% identity to SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, or SEQ ID NO: 13. In certain embodiments, the first nucleotide sequence and the second nucleotide sequence encode a chimeric polypeptide sequence according to SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, or SEQ ID NO: 13. In certain embodiments, SEQ ID NO: 6 is selected. In certain embodiments, SEQ ID NO: 11 is selected.

[0093] In certain embodiments, the nucleotide sequence encoding the chimeric polypeptide comprising the first nucleotide sequence and the second nucleotide sequence may further comprise a third nucleotide sequence encoding a reporter protein or a fragment thereof (eg, a fluorescent protein such as mCherry, also known as mCH). Thus, in certain embodiments, the first nucleotide sequence can encode a light-induced oligomerization domain comprising CRYPHR, the second nucleotide sequence can encode a low complexity domain from a neurodegenerative disease target protein comprising full-length or truncated TDP-43, and the third nucleotide sequence can encode an mCherry protein, wherein the first, second, and third nucleotide sequences encode a chimeric polypeptide sequence that is at least 75% identical, at least 80% identical, at least 85% identical, at least 90% identical, at least 95% identical, or at least 99% identical to SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, or SEQ ID NO: 25. In certain embodiments, the first, second, and third nucleotide sequences encode a chimeric polypeptide sequence according to SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, or SEQ ID NO: 25. In certain embodiments, SEQ ID NO: 14 is selected. In certain embodiments, SEQ ID NO: 23 is selected.

[0094] In certain embodiments, the first nucleotide sequence may encode a light-induced oligomerization domain comprising a LOV photoreceptor domain (e.g., NcVVD, NcVVDY50W, NcLOV, VfAU1, YtvA, EL222, RsLOV, and AsLOV2), and the second nucleotide sequence may encode a low complexity domain from a neurodegenerative disease target protein. In certain embodiments, the first nucleotide sequence may encode a light-induced oligomerization domain comprising a LOV photoreceptor domain (e.g., NcVVD, NcVVDY50W, NcLOV, VfAU1, YtvA, EL222, RsLOV, and AsLOV2), and the second nucleotide sequence may encode a low complexity domain from a neurodegenerative disease target protein comprising TDP-43. In certain embodiments, the second nucleotide sequence can encode a low complexity domain from a neurodegenerative disease target protein comprising a full-length TDP-43 (e.g., SEQ ID NO: 2 or SEQ ID NO: 27). In certain embodiments, the second nucleotide sequence can encode a low complexity domain from a neurodegenerative disease target protein comprising a truncated TDP-43 (e.g., SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, or SEQ ID NO: 33). In certain embodiments, the truncated TDP-43 consists of amino acids 105-414, 191-414, or 274-414 of the full-length TDP-43 amino acid sequence. Thus, in certain embodiments, the first nucleotide sequence can encode a light-induced oligomerization domain comprising NcVVDY50W, and the second nucleotide sequence can encode a low complexity domain from a neurodegenerative disease target protein comprising full-length or truncated TDP-43, wherein the first nucleotide sequence and the second nucleotide sequence encode a chimeric polypeptide sequence that is at least 75% identical, at least 80% identical, at least 85% identical, at least 90% identical, at least 95% identical, or at least 99% identical to SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, or SEQ ID NO:33. In certain embodiments, the first nucleotide sequence and the second nucleotide sequence encode a chimeric polypeptide sequence according to SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, or SEQ ID NO:33.

[0095] In certain embodiments, the nucleotide sequence encoding the chimeric polypeptide comprising the first nucleotide sequence and the second nucleotide sequence may further comprise a third nucleotide sequence encoding a reporter protein or a fragment thereof (e.g., a fluorescent protein, such as mCherry). Thus, in certain embodiments, the first nucleotide sequence may encode a light-induced oligomerization domain comprising NcVVDY50W, the second nucleotide sequence may encode a low complexity domain from a neurodegenerative disease target protein comprising full-length or truncated TDP-43, and the third nucleotide sequence may encode an mCherry protein, wherein the first, second, and third nucleotide sequences encode a chimeric polypeptide sequence having at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, at least 95% identity, or at least 99% identity to SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, or SEQ ID NO: 41. In certain embodiments, the first, second, and third nucleotide sequences encode a chimeric polypeptide sequence according to SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, or SEQ ID NO: 41. In certain embodiments, SEQ ID NO: 34 is selected. In certain embodiments, SEQ ID NO: 41 is selected.

[0096] In certain embodiments, the first nucleotide sequence can encode a light-induced oligomerization domain comprising the PHR domain of the Arabidopsis cryptochrome 2 protein (e.g., CRY2OLIG), and the second nucleotide sequence can encode a low complexity domain from a neurodegenerative disease target protein comprising α-synuclein. Thus, in certain embodiments, the first nucleotide sequence can encode a light-induced oligomerization domain comprising CRY2OLIG, and the second nucleotide sequence can encode a low complexity domain from a neurodegenerative disease target protein comprising α-synuclein, wherein the first nucleotide sequence and the second nucleotide sequence encode a chimeric polypeptide sequence having at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, at least 95% identity, or at least 99% identity to SEQ ID NO: 42 or SEQ ID NO: 43. In certain embodiments, the first nucleotide sequence and the second nucleotide sequence encode a chimeric polypeptide sequence according to SEQ ID NO: 42 or SEQ ID NO: 43.

[0097] In certain embodiments, the nucleotide sequence encoding the chimeric polypeptide comprising the first nucleotide sequence and the second nucleotide sequence may further comprise a third nucleotide sequence encoding a reporter protein or a fragment thereof (e.g., a fluorescent protein, such as mCherry). Thus, in certain embodiments, the first nucleotide sequence may encode a light-induced oligomerization domain comprising CRY2OLIG, the second nucleotide sequence may encode a low complexity domain from a neurodegenerative disease target protein comprising α-synuclein, and the third nucleotide sequence may encode an mCherry protein, wherein the first, second, and third nucleotide sequences encode chimeric polypeptide sequences having at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, at least 95% identity, or at least 99% identity to SEQ ID NO: 44, SEQ ID NO: 45, or SEQ ID NO: 46. In certain embodiments, the first, second, and third nucleotide sequences encode chimeric polypeptide sequences according to SEQ ID NO: 44, SEQ ID NO: 45, or SEQ ID NO: 46. In certain embodiments, SEQ ID NO: 44 is selected.

[0098] In certain embodiments, the first nucleotide sequence can encode a light-induced oligomerization domain comprising a LOV photoreceptor domain (e.g., NcVVD, NcVVDY50W, NcLOV, VfAU1, YtvA, EL222, RsLOV, and AsLOV2), and the second nucleotide sequence can encode a low complexity domain from a neurodegenerative disease target protein comprising α-synuclein. Thus, in certain embodiments, the first nucleotide sequence can encode a light-induced oligomerization domain comprising NcVVDY50W, and the second nucleotide sequence can encode a low complexity domain from a neurodegenerative disease target protein comprising α-synuclein, wherein the first nucleotide sequence and the second nucleotide sequence encode a chimeric polypeptide sequence having at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, at least 95% identity, or at least 99% identity to SEQ ID NO: 47 or SEQ ID NO: 48. In certain embodiments, the first nucleotide sequence and the second nucleotide sequence encode a chimeric polypeptide sequence according to SEQ ID NO:47 or SEQ ID NO:48.

[0099] In certain embodiments, the nucleotide sequence encoding the chimeric polypeptide comprising the first nucleotide sequence and the second nucleotide sequence may further comprise a third nucleotide sequence encoding a reporter protein or a fragment thereof (e.g., a fluorescent protein, such as mCherry). Thus, in certain embodiments, the first nucleotide sequence may encode a light-induced oligomerization domain comprising NcVVDY50W, the second nucleotide sequence may encode a low complexity domain from a neurodegenerative disease target protein comprising α-synuclein, and the third nucleotide sequence may encode an mCherry protein, wherein the first, second, and third nucleotide sequences encode a chimeric polypeptide sequence having at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, at least 95% identity, or at least 99% identity to SEQ ID NO: 49, SEQ ID NO: 50, or SEQ ID NO: 51. In certain embodiments, the first, second, and third nucleotide sequences encode a chimeric polypeptide sequence according to SEQ ID NO: 49, SEQ ID NO: 50, or SEQ ID NO: 51. In certain embodiments, SEQ ID NO: 51 is selected.

[0100] In certain embodiments, the first nucleotide sequence is located upstream of the second nucleotide sequence. In certain embodiments, the first nucleotide sequence is located downstream of the second nucleotide sequence.

[0101] In certain embodiments, when the sequences disclosed herein contain a methionine at the beginning of the protein, proteins that do not contain a methionine are also disclosed. In certain embodiments, when the sequences disclosed herein do not contain a methionine at the beginning of the protein, proteins that have a methionine at the beginning of the protein are also disclosed.

[0102] In certain embodiments, the nucleotide sequence encoding the chimeric polypeptide comprises a sequence selected from the group consisting of SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 84, ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:90 or SEQ ID NO:91.

[0103] method

[0104] In one aspect, disclosed herein is a method of inducing neurodegenerative disease pathology in a cell, the method comprising the steps of:

[0105] An expression vector encoding a chimeric polypeptide is introduced into a cell, wherein the expression vector comprises:

[0106] a first nucleotide sequence encoding a light-induced oligomerization domain and a second nucleotide sequence encoding a low complexity domain from a neurodegenerative disease target protein, wherein the first nucleotide sequence is operably linked to a promoter;

[0107] expressing the chimeric polypeptide; and

[0108] Oligomerization of the chimeric polypeptides was induced by stimulation with blue light.

[0109] In another aspect, disclosed herein is a method for screening for an agent that modulates protein aggregation, the method comprising the steps of:

[0110] An expression vector encoding a chimeric polypeptide is introduced into a cell, wherein the expression vector comprises:

[0111] a first nucleotide sequence encoding a light-induced oligomerization domain and a second nucleotide sequence encoding a low complexity domain from a neurodegenerative disease target protein, wherein the first nucleotide sequence is operably linked to a promoter;

[0112] expressing a chimeric polypeptide;

[0113] introducing the agent into a culture medium containing cells;

[0114] inducing oligomerization of the chimeric polypeptide by stimulation with blue light; and

[0115] Determine the effects of agents on the regulation of protein aggregation.

[0116] In one embodiment, the light-induced oligomerization domain is selected from the group consisting of a CRY2 PHR domain (e.g., CRY2PHR, CRY2OLIG) or a light-oxygen voltage sensing (LOV) domain (e.g., NcVVD, NcVVDY50W, VfAU1, YtvA, EL222, RsLOV, AsLOV2).

[0117] In one embodiment, the light-induced oligomerization domain is selected from the group consisting of: CRYPHR, CRY2OLIG, NcVVD, NcVVDY50W, and NcLOV. In one embodiment, the light-induced oligomerization domain is selected from the group consisting of: CRYPHR, CRY2OLIG, NcVVD, NcVVDY50W, NcLOV, VfAU1, YtvA, EL222, RsLOV, and AsLOV2. In one embodiment, the light-induced oligomerization domain is selected from the list of domains in Table 2. In one embodiment, the light-induced oligomerization domain is selected from a variant of: CRYPHR, CRY2OLIG, NcVVD, NcVVDY50W, NcLOV, VfAU1, YtvA, EL222, RsLOV, or AsLOV2. In one embodiment, the light-induced oligomerization domain is selected from a fragment of CRYPHR, CRY2OLIG, NcVVD, NcVVDY50W, NcLOV, VfAU1, YtvA, EL222, RsLOV, or AsLOV2.

[0118] In one embodiment, the light-induced oligomerization domain is NcVVDY50W. In one embodiment, the light-induced oligomerization domain is CRY2OLIG. In one embodiment, the light-induced oligomerization domain is CRYPHR. In one embodiment, the light-induced oligomerization domain comprises the LOV domain from the VVD protein. In one embodiment, the light-induced oligomerization domain comprises the LOV domain from the LOV protein. In one embodiment, the light-induced oligomerization domain comprises the PHR domain. In one embodiment, the light-induced oligomerization domain comprises the PHR domain from the CRY2 protein. In one embodiment, the light-induced oligomerization domain is VfAU1. In one embodiment, the light-induced oligomerization domain is YtvA. In one embodiment, the light-induced oligomerization domain is EL222. In one embodiment, the light-induced oligomerization domain is RsLOV. In one embodiment, the light-induced oligomerization domain is AsLOV2.

[0119] In one embodiment, the low complexity domain from a neurodegenerative disease target protein is selected from the group consisting of: TDP-43, alpha synuclein, Tau, Fus, TIA1, SOD1, huntingtin, Ataxin 2, hnRNPA1, and hnRNPA2B1. In one embodiment, the low complexity domain from a neurodegenerative disease target protein is selected from the group consisting of: TDP-43, alpha synuclein, Tau, Fus, TIA1, SOD1, huntingtin, Ataxin 2, hnRNPA1, hnRNPA2B1, EWS RNA binding protein 1, and TATA box binding protein factor 15. In one embodiment, the low complexity domain from a neurodegenerative disease target protein is selected from a variant of: TDP-43, alpha synuclein, Tau, TIA1, SOD1, huntingtin, Ataxin 2, hnRNPA1, hnRNPA2B1, EWS RNA binding protein 1, or TATA box binding protein factor 15. In one embodiment, the low complexity domain from the neurodegenerative disease target protein is selected from the following fragments: TDP-43, alpha synuclein, Tau, TIA1, SOD1, huntingtin, Ataxin 2, hnRNPA1, hnRNPA2B1, EWS RNA binding protein 1 or TATA box binding protein factor 15. In one embodiment, the fragments of TDP-43, alpha synuclein, Tau, TIA1, SOD1, huntingtin, Ataxin 2, hnRNPA1, hnRNPA2B1, EWS RNA binding protein 1 or TATA box binding protein factor 15 are contained in the low complexity domain within each neurodegenerative disease target protein.

[0120] In one embodiment, the low complexity domain from a neurodegenerative disease target protein is selected from Table 3. In one embodiment, the low complexity domain is from any neurodegenerative disease target protein that aggregates in a neurodegenerative disease.

[0121] In one embodiment, the low complexity domain from the neurodegenerative disease target protein is selected from an amino acid sequence having at least 90% identity with TDP-43, alpha synuclein, Tau, Fus, TIA1, SOD1, huntingtin, Ataxin 2, hnRNPA1, hnRNPA2B1, EWS RNA binding protein 1, and TATA box binding protein factor 15. In one embodiment, the low complexity domain from the neurodegenerative disease target protein is selected from an amino acid sequence having at least 90% identity with a low complexity domain from a neurodegenerative disease target protein selected from Table 3. In one embodiment, the low complexity domain from the neurodegenerative disease target protein is selected from an ortholog of the group consisting of TDP-43, alpha synuclein, Tau, Fus, TIA1, SOD1, huntingtin, Ataxin 2, hnRNPA1, hnRNPA2B1, EWS RNA binding protein 1, and TATA box binding protein factor 15.

[0122] In one embodiment, the low complexity domain from a neurodegenerative disease target protein is selected from the group consisting of an amino acid sequence that is at least 60% (e.g., at least 60%, at least 70%, at least 80%, at least 90%, at least 95%) identical to TDP-43, alpha synuclein, Tau, Fus, TIA1, SOD1, Huntingtin, Ataxin 2, hnRNPA1, hnRNPA2B1, EWS RNA binding protein 1, and TATA box binding protein factor 15 (or a fragment thereof).

[0123] In one embodiment, the low complexity domain from a neurodegenerative disease target protein is TDP-43. In one embodiment, the low complexity domain from a neurodegenerative disease target protein is alpha-synuclein. In one embodiment, the low complexity domain from a neurodegenerative disease target protein is Tau. In one embodiment, the low complexity domain from a neurodegenerative disease target protein is Fus. In one embodiment, the low complexity domain from a neurodegenerative disease target protein is TIA1. In one embodiment, the low complexity domain from a neurodegenerative disease target protein is SOD1. In one embodiment, the low complexity domain from a neurodegenerative disease target protein is huntingtin. In one embodiment, the low complexity domain from a neurodegenerative disease target protein is Ataxin2. In one embodiment, the low complexity domain from a neurodegenerative disease target protein is hnRNPA1. In one embodiment, the low complexity domain from a neurodegenerative disease target protein is hnRNPA2B1. In one embodiment, the low complexity domain from a neurodegenerative disease target protein is EWS RNA binding protein 1. In one embodiment, the low complexity domain from a neurodegenerative disease target protein is TATA box binding protein factor 15.

[0124] In one embodiment, the cell is a mammalian cell. In one embodiment, the cell is a human cell. In one embodiment, the cell is selected from the group consisting of yeast, insect, bird, fish, worm, amphibian, clawed frog, bacteria, algae, and mammalian cells. In one embodiment, disclosed herein is a non-human transgenic organism, wherein the organism is an insect, fish, bird, worm, amphibian, clawed frog, or a non-human mammal.

[0125] Inducing neurodegenerative disease pathology refers to an action that causes neurodegenerative disease pathology or increases the phenotype, symptoms, or severity of neurodegenerative disease pathology compared to not taking the selected action.

[0126] Neurodegenerative disease pathology can include a series of pathologies known or suspected to be associated with any one or more neurodegenerative diseases. Examples of such pathologies include, but are not limited to, protein aggregation in the cytoplasm, mislocalization of nuclear proteins to, for example, the cytoplasm, increased expression of ubiquitin, cell degeneration and / or death, extracellular amyloid β (Aβ) aggregation and / or intracellular and / or cytoplasmic aggregation of Tau protein. In certain embodiments, protein aggregates can be co-localized with p62 protein, can be hyperphosphorylated, can include endogenous proteins (e.g., endogenous TDP-43) or combinations thereof that contain low complexity domains from neurodegenerative disease target proteins.

[0127] Ubiquitination increase or ubiquitin expression increase can be the phenotypic characteristic of neurodegenerative disease.Ubiquitin has a variety of cellular effects, and it is included in " marking " protein (for example, by covalent bond connection) for degradation in proteasome.Usually the increase of ubiquitin expression in cell is compared with control.In certain embodiments, compared with control, the cell with increased ubiquitin has the ubiquitin expression of at least 50% increase.In certain embodiments, compared with control, the cell with increased ubiquitin has the ubiquitin expression of at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98% or at least 99% increase.

[0128] Ubiquitin expression in cells can be determined at the transcriptional level, translational level, or a combination thereof, and can be measured by a variety of methods for measuring gene or polypeptide expression levels. In certain embodiments, ubiquitin expression can be measured at the gene transcription level. For example, but not limited to, the level of ubiquitin mRNA transcripts can be determined by: radiation absorbance (e.g., ultraviolet absorption at 260 nm, 280 nm, or 230 nm), quantification of fluorescent dye or label emission (e.g., ethidium bromide intercalation), quantitative polymerase chain reaction (qPCR) of cDNA generated from mRNA transcripts, southern blot analysis, gene expression microarrays, or other suitable methods. Increases in mRNA transcript levels can be used to infer or estimate increases in polypeptide expression levels. In certain embodiments, ubiquitin expression can be measured at the post-translational level. For example, but not limited to, the level of ubiquitin polypeptides can be determined by: radiation absorbance (e.g., ultraviolet), bicinchoninic acid (BCA) assay, Bradford assay, biuret test, Lowry method, Coomassie brilliant blue staining, functional or enzymatic assays, immunoassays, and / or Western blot analysis, or other suitable methods.

[0129] As used herein, the term "introduction", "import" and grammatical variants thereof, which relate to the introduction of an expression vector into a cell, refer to any method suitable for transferring an expression vector into a cell. The term includes, but is not limited to, for example, conjugation, transformation / transfection (e.g., divalent cation exposure, heat shock, electroporation), nuclear microinjection, incubation with calcium phosphate polynucleotide precipitates, high-speed bombardment of polynucleotide-coated microparticles (e.g., by a gene gun), liposome transfection, cationic polymer complexation (e.g., DEAE-dextran, polyethyleneimine), dendrimer complexation, mechanical deformation of the cell membrane (e.g., cell extrusion), ultrasonic poration, optical transfection, impalefection, hydrodynamic polynucleotide delivery, Agrobacterium-mediated transformation, transduction (e.g., transduction with a virus or viral vector), natural or artificial competence, protoplast fusion, magnetofection, nuclear transfection, or a combination thereof. The introduced expression vector or the polynucleotide therefrom can be genetically integrated or present outside the chromosome.

[0130] A range of blue light wavelengths can be used in the methods of the present disclosure. In one embodiment, the wavelength of blue light is from about 400 nm to about 500 nm. In one embodiment, the wavelength of blue light is from about 405 nm to about 499 nm. In one embodiment, the wavelength of blue light is from about 420 nm to about 490 nm. In one embodiment, the wavelength of blue light is from about 450 nm to about 490 nm. In one embodiment, the wavelength of blue light is from about 460 nm to about 495 nm. In one embodiment, the wavelength of blue light is from about 488 nm. In one embodiment, the wavelength of blue light is from about 475 nm. In one embodiment, the wavelength of blue light is from about 465 nm.

[0131] In one embodiment, the wavelength of blue light is about 405 nm, about 410 nm, about 415 nm, about 420 nm, about 425 nm, about 430 nm, about 435 nm, about 440 nm, about 445 nm, about 450 nm, about 455 nm, about 460 nm, about 465 nm, about 470 nm, about 475 nm, about 480 nm, about 485 nm, about 490 nm, about 495 nm, or about 500 nm.

[0132] The methods may include various degrees of blue light stimulation. In certain embodiments, the stimulation is acute or, alternatively, chronic. Acute stimulation refers to stimulation with pulses of blue light of about 0.2 seconds to about 60 seconds, wherein the wavelength of the blue light can be any blue light wavelength disclosed herein. In certain embodiments, acute stimulation comprises pulses of blue light of about 0.5 seconds to about 30 seconds, about 1 second to about 20 seconds, or about 5 seconds. The blue light can be provided by a blue light source filtered for the disclosed wavelengths or a broad spectrum light source.

[0133] In certain embodiments, acute stimulation can result in transient aggregation of light-induced oligomerization domains (e.g., cytoplasmic prion-like domain / LCD / IDD protein fragments). In certain embodiments, transient aggregation comprises protein aggregation observable by the methods disclosed herein for less than about twenty minutes, or alternatively less than about fifteen minutes, less than about ten minutes, or less than about five minutes. In certain embodiments, acute stimulation does not result in aggregation of cytoplasmic prion-like domain / LCD / IDD protein fragments for more than twenty minutes.

[0134] In certain embodiments, acute stimulation can result in aggregation of a light-induced oligomerization domain that lasts shorter than the aggregation of a light-induced oligomerization domain fused to a low complexity domain from a neurodegenerative disease target protein. In certain embodiments, acute stimulation can result in aggregation of a light-induced oligomerization domain fused to a low complexity domain from a neurodegenerative disease target protein that lasts shorter than the aggregation of the same protein with an amino acid mutation known to cause or be associated with a neurodegenerative disease (e.g., TDP-43Q331K).

[0135] Chronic stimulation is achieved by applying a current of approximately 0.1 mW / cm 2 Up to 8mW / cm 2 Exposure to blue light having a wavelength of about 400 nm to about 500 nm for a period of time greater than about 1 minute (e.g., at least 1 minute, at least 5 minutes, at least 10 minutes, at least 30 minutes, at least 60 minutes, at least 2 hours, at least 4 hours, at least 8 hours, at least 12 hours, at least 24 hours, at least 36 hours or more) (within a wavelength of 400 nm to 500 nm).

[0136] In certain embodiments, the methods disclosed herein can induce neurodegenerative disease pathology (e.g., aggregation of a protein) in a cell without substantially altering the expression level of a protein involved in the neurodegenerative disease pathology. For example, but not limited to, the methods can induce aggregation of a chimeric polypeptide comprising TDP-43 (which can include aggregation of endogenous TDP-43) without substantially increasing or decreasing the expression level of endogenous TDP-43. In certain or other embodiments, the methods can induce neurodegenerative disease pathology in a cell using a wild-type form of a low-complexity domain from a neurodegenerative disease target protein. Thus, in certain embodiments, the low-complexity domain from a neurodegenerative disease target protein does not include a mutation that differs from the wild-type sequence and is known or suspected to cause neurodegenerative disease pathology in a cell or is associated with inducing neurodegenerative disease pathology. For example, but not limited to, the methods can induce aggregation of a chimeric polypeptide comprising a wild-type TDP-43 protein or a fragment thereof, the chimeric polypeptide not comprising a mutation known to cause or be associated with ALS, such as Q331K.

[0137] Example

[0138] The following examples are listed below to illustrate compounds, compositions, methods and results according to the disclosed subject matter. These examples are not intended to include all aspects of the subject matter disclosed herein, but are intended to illustrate representative methods and results. These examples are not intended to exclude equivalents and variations of the present invention that would be apparent to those skilled in the art.

[0139] Example 1. Optogenetic Induction of Neurodegenerative Disease Pathology

[0140] The world is aging. By 2050, the proportion of people aged 60 and over will double from 605 million in 2000 to 2 billion. Unfortunately, aging is the greatest risk factor for developing fatal neurodegenerative diseases. Conversely, the number of people living with dementias, such as Alzheimer's disease (AD), Lewy body dementia (LBD), frontotemporal dementia (FTD), and movement disorders, such as Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS), is expected to increase significantly. Nearly 6.5 million people in the United States currently suffer from one of these conditions, and the associated costs are prohibitive. The current economic burden of AD, PD, and ALS in the United States is estimated to be $241 billion annually. Individuals with AD and ALS / FTD can incur personal medical expenses of between $100,000 and $250,000 annually. For AD, it is estimated that 13.8 million individuals will be diagnosed in the United States by 2050, up from 4.7 million in 2010, while the number of ALS cases worldwide will rise by approximately 31% by 2040. Furthermore, there are currently no effective treatments for these diseases.

[0141] Two decades of genetic analysis have revealed numerous mutations associated with neurodegenerative diseases. However, these have only been found in patients with AD, LBD, FTD, PD, and ALS (Table 1).

[0142] Table 1. List of common neurodegenerative diseases, their pathologies, and the contributions of their genetic components.

[0143]

[0144] Table 1 describes a selection of neurodegenerative diseases, their primary symptoms, the affected areas of the central nervous system (CNS), the aggregated neuropathology observed in the patient's CNS, the percentage of patients who exhibit this pathology, and the percentage of patients with a genetic component to the disease (known or unknown mutations in the family). Alzheimer's disease (AD) is characterized by memory impairment and confusion due to degeneration of the hippocampus and entorhinal cortex. Only 1-3% of patients have a predisposing gene mutation; however, all patients exhibit a common aggregate pathology in the affected tissues. This is characterized by extracellular amyloid β (Aβ) aggregation and intracellular and cytoplasmic aggregation of Tau protein. Frontotemporal dementia (FTD) is characterized by progressive degeneration of the frontal and temporal lobes, and although 20-25% of patients may carry the genetic cause of the disease, 80-75% of patients have no family history. However, all patients exhibit some form of cytoplasmic protein aggregation, including TDP-43 (45% of cases), Tau (45% of cases), or FUS (5% of cases) proteins. Parkinson's disease (PD) is characterized by the progressive degeneration of dopaminergic neurons in the substantia nigra, and although only 10% of patients have a known genetic cause, nearly all patients (99%) show cytoplasmic aggregates of α-synuclein. Amyotrophic lateral sclerosis (ALS) is characterized by the rapid degeneration of motor neurons in the motor cortex of the spinal cord, leading to paralysis and death in patients. Only 10% of ALS patients have a family history of the disease, and nearly 90% of cases are sporadic. To date, nearly 35 pathogenic gene mutations have been identified in various genes (see Figure 1 Despite this genetic diversity, nearly all ALS patients display the same neuropathology. Nearly 97% of ALS patients show cytoplasmic mislocalization of the predominantly nuclear TDP-43 protein in affected regions. Patients with mutations in the SOD1 or FUS genes also display cytoplasmic aggregation of these proteins, but this occurs in only 2% and 1% of all ALS cases, respectively.

[0145] In summary, this table highlights that the major unifying factor across many neurodegenerative diseases is the hallmark neuropathology. These neuropathologies primarily occur in the form of intracellular protein aggregates, and in most cases, these intracellular protein aggregates form regardless of any known genetic cause. Furthermore, these neuropathologies primarily develop in the regions and cell types most affected in each disease.

[0146] Interestingly, despite the lack of a known genetic or environmental cause, these are common neuropathological features across patients for each disorder. Thus, despite the lack of a known genetic cause, the vast majority of patients (90-100% of all patients depending on the disorder) exhibit the same pathology in the central nervous system. These pathological hallmarks manifest as insoluble protein clumps or aggregates in the central nervous system (Table 1, Figure 1 ).

[0147] Until now, it has been impossible to model neurodegenerative disease aggregation that accurately mimics human neuropathology. For each neurodegenerative disease, a major component of intracellular protein aggregates consists of protein domains that, when present in high local concentrations, predispose these proteins to aggregation (also known as prion-like domains, low-complexity domains, intrinsically disordered domains, or intrinsically disordered regions). Therefore, current approaches to modeling these neurodegenerative disease aggregates rely on overexpressing these aggregation-prone proteins in vitro or in vivo, as aggregates can form at high cellular concentrations in some models. Alternatively or in addition, another approach to modeling these diseases involves expressing mutant forms of proteins that contain neurodegenerative disease aggregates. These mutations are found in a small subset of patients and often enhance the protein's ability to aggregate. Unfortunately, these approaches fail to recapitulate the patient cellular environment, as the vast majority of patients do not carry any disease-causing mutations and do not fully overexpress the aggregate components. Indeed, many models fail to exhibit human neuropathology despite fully overexpressing these proteins. This disconnect between patient biology and model systems significantly contributes to the lack of translatability of current neurodegenerative disease models.

[0148] In this example, novel methods are described that induce protein aggregates in space and time without simply overexpressing aggregate-susceptible genes or expressing mutant forms of these genes. Therefore, the method better recapitulates the human disease condition. Here, an innovative approach has been taken to harness the power of optogenetics (controlling the function of proteins with light) to address this challenging biological problem. A series of new DNA arrangements have been constructed that can induce neurodegenerative disease pathology, as observed in patients only when cells are exposed to specific light stimuli. This method is used to create in vitro and in vivo model systems to mimic the neuropathology observed in patients and to induce this pathology only after cells are exposed to specific wavelengths of light. This new approach can change the modeling of neurodegenerative diseases and, unlike the expression of mutant transgenes, can be used to generate a variety of disease models that are applicable to the vast majority of patients and can be induced both temporally and spatially.

[0149] A series of DNA arrangements have been developed that include PHR domains (CRY2OLIG or CRY2PHR) or light-oxygen voltage sensing (LOV) domains (NcVVD, NcVVDY50W, Vfau1, YtvA, EL222, RsLOV, AsLOV2) that cluster or homodimerize in response to blue light exposure, respectively (Table 2) and DNA sequences of genes encoding proteins containing low complexity domains (LCDs) and comprising neurodegenerative disease protein aggregates (Table 3).

[0150] Table 2. List of photoreceptor / light-induced oligomerization domains that induce neurodegenerative pathology by optogenetics in cells exposed to blue light.

[0151]

[0152] Table 2 lists the photoreceptors used for optogenetic induction of neurodegenerative pathology in cells under blue light exposure. Variants of the PHR domain of the cryptochrome 2 protein found in Arabidopsis plants will be one family of photoreceptors used (named CRY2PHR and CRY2OLIG in this document, respectively). When exposed to a single blue light pulse (in the range of 405nm-499nm), the PHR domain of the CRY2 protein and its variants have the ability to cluster / homo-oligomerize for about 5 minutes. CRY2PHR is an endogenous protein sequence found in Arabidopsis. Although CRY2OLIG is an endogenous amino acid sequence, it has an E490G mutation and shows slightly higher clustering efficiency under blue light stimulation. The self-binding of CRY2PHR and CRY2OLIG works through the same mechanism and requires intracellular FAD+. Various permutations of CRY2OLIG and target proteins, including aggregates of neuropathic proteins, have been generated to demonstrate modulation of the light-induced clustering properties of CRY2OLIG to induce neurodegenerative disease pathology in both predominantly cytoplasmic and predominantly nuclear proteins. This includes inducing cytoplasmic mislocalization of nuclear proteins, as observed in patient neuropathology. Additionally, these protein domains have been used to induce aggregation of intrinsically disordered domains, prion-like domains, and low-complexity domains of truncated forms of these neurodegenerative proteins.

[0153] Vivid (VVD) is a protein produced in Neurospora organisms and is a photoreceptor that homodimerizes in response to blue light (within the range of 405nm-499nm). The light oxygen voltage sensing (LOV) domain is common in many organisms, but this domain is very small in this organism. NcLOV is just the LOV domain of the VVD protein, but it is conserved in other species. NcVVD contains a small fragment of the N-terminal VVD protein and the VVD LOV domain. However, the NcVVDY50W from the NcVVD protein sequence is changed by the Y50W change, which promotes the ability to dissipate slowly from the dimer state. It is shown here that when fused to a protein containing LCD, the sustained dimerization of the LOV domain induces oligomerization with chronic light (Figures 6 and 8). Although there is no report that the LOV domain forms oligomers, a light stimulation paradigm has been developed herein to induce protein aggregation of specific protein arrangements of these photoreceptors and specific target neurodegenerative disease proteins. Other LOV domains used herein include VfAU1, YtvA, EL222, RsLOV, and AsLOV2.

[0154] Table 3. Target neurodegenerative disease proteins.

[0155]

[0156] Abbreviations: ALS, amyotrophic lateral sclerosis; FTD, frontotemporal dementia; PD, Parkinson's disease; AD, Alzheimer's disease; CTE, chronic traumatic encephalopathy; LBD, Lewy body dementia

[0157] Table 3 lists a list of target neurodegenerative disease proteins that produce protein arrangements summarizing neurodegenerative disease pathology. This article discloses a new arrangement of photoreceptors in Table 2 fused to neurodegenerative disease proteins (such as those listed in Table 3), which respond to these various blue light exposure paradigms to summarize neurodegenerative disease pathology. This technology is also used to aggregate truncated forms of prion-like domains / LCDs / IDDs containing these components of the patient's neuropathological aggregates. In this embodiment, CRY2OLIG and LOV fused to TDP-43, α-synuclein, and Tau protein have been studied. In another embodiment, the target neurodegenerative disease protein can be a huntingtin gene / protein (accession number NM_002111; NP_002102.4). However, due to the created light treatment paradigm, a method that can be applied to any photoreceptor with dimerization or oligomerization ability has been developed. The main purpose of this method is to control the local concentration of neurodegenerative disease proteins within a specific time period, forcing the intramolecular crowding of proteins containing LCDs and aggregated in neurodegenerative diseases. Each neurodegenerative disease protein and photoreceptor arrangement may require specific light stimulation parameters due to the nature of the protein. For example, cytoplasmic proteins or truncated forms of nuclear proteins that are localized in the cytoplasm often (but not always) require a brief stimulation paradigm, while nuclear proteins are primarily targeted with chronic stimulation because they need to be trapped in the cytoplasm during translation (e.g., TDP-43, FUS). The details of the stimulation paradigms are discussed below.

[0158] Light exposure then forces these unique fusion proteins into close proximity, and using chronic or repeated light stimulation, neurodegenerative disease aggregate pathology can be achieved with either full-length proteins or only LCDs. This temporal and spatial control of neurodegenerative disease aggregates is novel because it does not require overexpression or mutations that are only relevant to a small subset of patients with each disease (Table 1). Rather than filling cells with these aggregation-prone proteins, these proteins are forced to interact and form the disease pathology that occurs in human patients.

[0159] In addition to protein aggregation, the system can also create light-induced pathologies that mimic key pathological features found in patients, making it unique compared to overexpression systems. The TDP-43 protein containing LCD is combined with the CRY2OLIG photoreceptor domain, which clusters when exposed to blue light and becomes insoluble and aggregates under continuous light treatment. Fusion proteins with full-length and partial LCD sequences were produced to recapitulate the pathology of human neurodegenerative diseases, including cytoplasmic mislocalization of nuclear proteins that occur in ALS and FTD patients. The system can induce neurodegenerative disease protein aggregates (Figures 4-5) by exposing living HEK cells to various blue light stimulation paradigms. In addition, biochemical markers of ALS, FTD and AD were produced (Figure 7), which shows that despite the addition of these tags, cells respond to light-induced aggregates as observed in the patient's CNS. It is worth noting that TDP-43 neuropathology is one of the more complex neuropathologies to be simulated because it is a major nuclear protein but is found to be mislocalized in the cytoplasm in patients. Taking this DNA arrangement and light stimulation system as an example, cytoplasmic TDP-43 aggregates were obtained, which were also ubiquitinated, cleaved and hyperphosphorylated as observed in ALS, FTD and AD patients. TDP-43 pathology can also be found in AD and chronic traumatic encephalopathy (CTE), highlighting the potential disease relevance of this work. In addition, protein arrangement and light stimulation paradigms were developed to induce aggregation of α-synuclein (Figure 6), which is found in the CNS of patients diagnosed with Parkinson's disease and Lewy body dementia. Methods for inducing intracellular aggregation of Tau protein using Cry-PHR and LOV photoreceptors (Figure 7) and continuous blue light stimulation have also been developed. These tau tangles are pathological hallmarks of AD, FTD and CTE in HEK cells. These also show the pathological features of Tau disease observed in patients, including hyperphosphorylation (Figures 7-8) using specific antibodies developed for pathological tau inclusions. Finally, we show that this method can be used to seed aggregates, as aggregates of TDP-43 formed using this method recruit endogenous TDP-43 to seed pathogenic neuropathology ( Figure 5F 、 5G ).

[0160] We also developed a new method to force oligomerization and aggregation of LOV domain proteins fused to LCD-containing proteins. LOV domains including NcVVDY50W showed dimerization only upon blue light stimulation. Using a chronic blue light stimulation paradigm (in Figure 3 6-8 ), induced oligomerization and ultimately aggregation of LCD-containing proteins fused to the LOV sequence. This amino acid sequence is significantly smaller than the PHR domain of CRY2 and may serve as a surrogate for the CRY2 PHR, as it is less likely to interfere with the function of endogenous target proteins.

[0161] In certain embodiments, a DNA array is constructed that encodes a PHR domain (CRY2PHR or CRY2OLIG) or LOV photoreceptor protein (NcVVD, NcVVDY50W, Vfau1, YtvA, EL222, RsLOV, AsLOV2) (or 90% similarity) fused to an LCD fragment or a full-length neurodegenerative disease protein listed in Table 3 (or 90% similarity). In certain embodiments, disclosed herein are methods for inducing the pathology of these neurodegenerative diseases using a blue light exposure treatment paradigm. In other embodiments, the resulting protein aggregates and cell viability are used as readouts for neurodegenerative disease drug screening ( FIG. 10 ). Novel compounds for treating specific neurodegenerative diseases can be identified by using a system that pharmacologically or genetically alleviates the pathological formation or residence time of a neurodegenerative disease. The following embodiments are also disclosed:

[0162] 1. Generation of novel model systems: Inserting these photoreceptor sequences into the genomes of various in vitro and in vivo systems can serve as new models for studying neurodegenerative diseases. Some examples of in vitro use include human and rodent cell lines, induced pluripotent stem cells (iPSCs), or yeast. Some examples of in vivo use include invertebrates: Drosophila melanogaster (fruit fly), Caenorhabditis elegans (roundworm), or zebrafish (Danio rerio, zebrafish). Other examples of in vivo use include vertebrates: mouse, rat, or non-human primate.

[0163] 2. These compounds, methods, and systems (such as iPSCs) with edited genomes are used in high-throughput drug screening systems. To this end, neurodegenerative disease pathology is induced by stimulating cells with light. Cell viability and the formation and residence time of protein aggregates / pathology in the presence of the compound library are then examined. In addition, the assay also involves survival and neuropathology using in vivo models after light induction.

[0164] sequence Amino acid sequence of photoreceptor tool

[0165] Amino acid sequence of the photolyase homology region (PHR) domain of Arabidopsis cryptochrome 2 protein:

[0166] SEQ ID NO: 1. Cryptochrome 2 PHR domain; Cry2PHR:

[0167] MKMDKKTIVWFRRDLRIEDNPALAAAAHEGSVFPVFIWCPEEEGQFYPGRASRWWMKQSLAH

[0168] LSQSLKALGSDLTLIKTHNTISAILDCIRVTGATKVVFNHLYDPVSLVRDHTVKEKLVERGISVQS

[0169] YNGDLLYEPWEIYCEKGKPFTSFNSYWKKCLDMSIESVMLPPPWRLMPITAAAEAIWACSIEEL

[0170] GLENEAEKPSNALLTRAWSPGWSNADKLLNEFIEKQLIDYAKNSKKVVGNSTSLLSPYLHFGEIS

[0171] VRHVFQCARMKQIIWARDKNSEGEESADLFLRGIGLREYSRYICFNFPFTHEQSLLSHLRFFPWD

[0172] ADVDKFKAWRQGRTGYPLVDAGMRELWATGWMHNRIRVIVSSFAVKFLLLPWKWGMKYFWD

[0173] TLLDADLECDILGWQYISGSIPDGHELDRLDNPALQGAKYDPEGEYIRQWLPELARLPTEWIHH

[0174] PWDAPLTVLKASGVELGTNYAKPIVDIDTARELLAKAISRTREAQIMIGAA

[0175] SEQ ID NO:2. Cryptochrome 2 PHR domain with E490G substitution; Cry2Olig:( E490G bold)

[0176] MKMDKKTIVWFRRDLRIEDNPALAAAAHEGSVFPVFIWCPEEEGQFYPGRASRWWMKQSLAH

[0177] LSQSLKALGSDLTLIKTHNTISAILDCIRVTGATKVVFNHLYDPVSLVRDHTVKEKLVERGISVQS

[0178] YNGDLLYEPWEIYCEKGKPFTSFNSYWKKCLDMSIESVMLPPPWRLMPITAAAEAIWACSIEEL

[0179] GLENEAEKPSNALLTRAWSPGWSNADKLLNEFIEKQLIDYAKNSKKVVGNSTSLLSPYLHFGEIS

[0180] VRHVFQCARMKQIIWARDKNSEGEESADLFLRGIGLREYSRYICFNFPFTHEQSLLSHLRFFPWD

[0181] ADVDKFKAWRQGRTGYPLVDAGMRELWATGWMHNRIRVIVSSFAVKFLLLPWKWGMKYFWD

[0182] TLLDADLECDILGWQYISGSIPDGHELDRLDNPALQGAKYDPEGEYIRQWLPELARLPTEWIHH

[0183] PWDAPLTVLKASGVELGTNYAKPIVDIDTARELLAKAISRTRGAQIMIGAA

[0184] Contains live protein from Neurospora (Neutralax) Light-oxygen voltage sensing domain (LOV )'s amino acid sequence:

[0185] SEQ ID NO: 3. VVD LOV domain only:

[0186] M TSCALILCDLKQKDTPIVYASEAFLYMTGYSNAEVLGRNCRFLQSPDGMVKPKSTRKYVDSN

[0187] TINTMRKAIDRNAEVQVEVVNFKKNGQRFVNFLTMIPVRDETGEYRYSMGFQCETE

[0188] SEQ ID NO: 4. NcVivid (NcVVD):

[0189] HTLYAPGGYDIMGYLIQIMNRPNPQVELGPVD TSCALILCDLKQKDTPIVYASEAFLYMTGYSN

[0190] AEVLGRNCRFLQSPDGMVKPKSTRKYVDSNTINTMRKAIDRNAEVQVVVNFKKNGQRFVNF

[0191] LTMIPVRDETGEYRYSMGFQCETE

[0192] SEQ ID NO: 5. NcVivid Y50W substitution; NcVVDY50W: (Y50W in bold)

[0193] HTLYAPGGYDIMGWLIQIMNRPNPQVELGPVD TSCALILCDLKQKDTPIVYASEAFLYMTGYSN

[0194] AEVLGRNCRFLQSPDGMVKPKSTRKYVDSNTINTMRKAIDRNAEVQVVVNFKKNGQRFVNF

[0195] LTMIPVRDETGEYRYSMGFQCETE

[0196] The resulting TDP-43 protein array:

[0197] 1. Amino acid sequence of Cry2olig fusion protein:

[0198] A) Full-length TDP-43 protein without reporter gene

[0199] SEQ ID NO:6. Cry2olig-TDP-43:

[0200] MKMDKKTIVWFRRDLRIEDNPALAAAAHEGSVFPVFIWCPEEEGQFYPGRASRWWMKQSLAH

[0201] LSQSLKALGSDLTLIKTHNTISAILDCIRVTGATKVVFNHLYDPVSLVRDHTVKEKLVERGISVQS

[0202] YNGDLLYEPWEIYCEKGKPFTSFNSYWKKCLDMSIESVMLPPPWRLMPITAAAEAIWACSIEEL

[0203] ​​​​​​​​​​​​​​​NDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGILHAPDAGWGNLVYV

[0209] VNYPKDNKRKMDETDASSAVKVKRAVQKTSDLIVLGLPWKTTEQDLKEYFSTFGEVLMVQVK

[0210] KDLKTGHSKGFGFVRFTEYETQVKVMSQRHMIDGRWCDCKLPNSKQSQDEPLRSRKVFVGRC

[0211] TEDMTEDELREFFSQYGDVMDVFIPKPFRAFAFVTFADDQIAQSLCGEDLIIKGISVHISNAEPKH

[0212] NSNRQLERSGRFGGNPGGFGNQGGFGNSRGGGAGLGNNQGSNMGGGMNFGAFSINPAMMAA

[0213] AQAALQSSWGMMGMLASQQNQSGPSGNNQNQGNMQREPNQAFGSGNNSYSGSNSGAAIGW

[0214] GSASNAGSGSGFNGGFGSSMDSKSSGWGM

[0215] SEQ ID NO:7.TDP-43-Cry2olig:

[0216] MSEYIRVTEDENDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGILHAPD

[0217] AGWGNLVYVVNYPKDNKRKMDETDASSAVKVKRAVQKTSDLIVLGLPWKTTEQDLKEYFSTF

[0218] GEVLMVQVKKDLKTGHSKGFGFVRFTEYETQVKVMSQRHMIDGRWCDCKLPNSKQSQDEPL

[0219] RSRKVFVGRCTEDMTEDELREFFSQYGDVMDVFIPKPFRAFAFVTFADDQIAQSLCGEDLIIKGI

[0220] SVHISNAEPKHNSNRQLERSGRFGGNPGGFGNQGGFGNSRGGGAGLGNNQGSNMGGGMNFG

[0221] AFSINPAMMAAAQAALQSSWGMMGMLASQQNQSGPSGNNQNQGNMQREPNQAFGSGNNSY

[0222] SGSNSGAAIGWGSASNAGSGSGFNGGFGSSMDSKSSGWGM LEAT

[0223] MKMDKKTIVWFRRDLRIEDNPALAAAAHEGSVFPVFIWCPEEEGQFYPGRASRWWMKQSLAH

[0224] LSQSLKALGSDLTLIKTHNTISAILDCIRVTGATKVVFNHLYDPVSLVRDHTVKEKLVERGISVQS

[0225] YNGDLLYEPWEIYCEKGKPFTSFNSYWKKCLDMSIESVMLPPPWRLMPITAAAEAIWACSIEEL

[0226] GLENEAEKPSNALLTRAWSPGWSNADKLLNEFIEKQLIDYAKNSKKVVGNSTSLLSPYLHFGEIS

[0227] VRHVFQCARMKQIIWARDKNSEGEESADLFLRGIGLREYSRYICFNFPFTHEQSLLSHLRFFPWD

[0228] ADVDKFKAWRQGRTGYPLVDAGMRELWATGWMHNRIRVIVSSFAVKFLLLPWKWGMKYFWD

[0229] TLLDADLECDILGWQYISGSIPDGHELDRLDNPALQGAKYDPEGEYIRQWLPELARLPTEWIHH

[0230] PWDAPLTVLKASGVELGTNYAKPIVDIDTARELLAKAISRTRGAQIMIGAA

[0231] B) Truncated TDP-43 protein has no reporter gene

[0232] SEQ ID NO:8.TDP-43 (AA274-414) -Cry2olig:

[0233] MGRFGGNPGGFGNQGGFGNSRGGGAGLGNNQGSNMGGGMNFGAFSINPAMMAAAQAALQS

[0234] SWGMMGMLASQQNQSGPSGNNQNQGNMQREPNQAFGSGNNSYSGSNSGAAIGWGSASNAG

[0235] SGSGFNGGFGSSMDSKSSGWGMLEATMKMDKKTIVWFRRDLRIEDNPALAAAAHEGSVFPVFI

[0236] WCPEEEGQFYPGRASRWWMKQSLAHLSQSLKALGSDLTLIKTHNTISAILDCIRVTGATKVVFN

[0237] HLYDPVSLVRDHTVKEKLVERGISVQSYNGDLLYEPWEIYCEKGKPFTSFNSYWKKCLDMSIES

[0238] VMLPPPWRLMPITAAAEAIWACSIEELGLENEAEKPSNALLTRAWSPGWSNADKLLNEFIEKQLI

[0239] DYAKNSKKVVGNSTSLLSPYLHFGEISVRHVFQCARMKQIIWARDKNSEGEESADLFLRGIGLR

[0240] EYSRYICFNFPFTHEQSLLSHLRFFPWDADVDKFKAWRQGRTGYPLVDAGMRELWATGWMHN

[0241] RIRVIVSSFAVKFLLLPWKWGMKYFWDTLLDADLECDILGWQYISGSIPDGHELDRLDNPALQG

[0242] AKYDPEGEYIRQWLPELARLPTEWIHHPWDAPLTVLKASGVELGTNYAKPIVDIDTARELLAKA

[0243] ISRTRGAQIMIGAA

[0244] SEQ ID NO:9.TDP-43 (AA191-414) -Cry2olig:

[0245] MRKVFVGRCTEDMTEDELREFFSQYGDVMDVFIPKPFRAFAFVTFADDQIAQSLCGEDLIIKGIS

[0246] VHISNAEPKHNSNRQLERSGRFGGNPGGFGNQGGFGNSRGGGAGLGNNQGSNMGGGMNFGA

[0247] FSINPAMMAAAQAALQSSWGMMGMLASQQNQSGPSGNNQNQGNMQREPNQAFGSGNNSYS

[0248] GSNSGAAIGWGSASNAGSGSGFNGGFGSSMDSKSSGWGMLEATMKMDKKTIVWFRRDLRIED

[0249] NPALAAAAHEGSVFPVFIWCPEEEGQFYPGRASRWWMKQSLAHLSQSLKALGSDLTLIKTHNTI

[0250] SAILDCIRVTGATKVVFNHLYDPVSLVRDHTVKEKLVERGISVQSYNGDLLYEPWEIYCEKGKPF

[0251] TSFNSYWKKCLDMSIESVMLPPPWRLMPITAAAEAIWACSIEELGLENEAEKPSNALLTRAWSP

[0252] GWSNADKLLNEFIEKQLIDYAKNSKKVVGNSTSLLSPYLHFGEISVRHVFQCARMKQIIWARDK

[0253] NSEGEESADLFLRGIGLREYSRYICFNFPFTHEQSLLSHLRFFPWDADVDKFKAWRQGRTGYPL

[0254] VDAGMRELWATGWMHNRIRVIVSSFAVKFLLLPWKWGMKYFWDTLLDADLECDILGWQYISG

[0255] SIPDGHELDRLDNPALQGAKYDPEGEYIRQWLPELARLPTEWIHHPWDAPLTVLKASGVELGT

[0256] NYAKPIVDIDTARELLAKAISRTRGAQIMIGAA

[0257] SEQ ID NO:10.TDP-43 (AA105-414) -Cry2olig:

[0258] MDLIVLGLPWKTTEQDLKEYFSTFGEVLMVQVKKDLKTGHSKGFGFVRFTEYETQVKVMSQR

[0259] HMIDGRWCDCKLPNSKQSQDEPLRSRKVFVGRCTEDMTEDELREFFSQYGDVMDVFIPKPFRA

[0260] FAFVTFADDQIAQSLCGEDLIIKGISVHISNAEPKHNSNRQLERSGRFGGNPGGFGNQGGFGNSR

[0261] GGGAGLGNNQGSNMGGGMNFGAFSINPAMMAAAQAALQSSWGMMGMLASQQNQSGPSGN

[0262] NQNQGNMQREPNQAFGSGNNSYSGSNSGAAIGWGSASNAGSGSGFNGGFGSSMDSKSSGWG

[0263] M

[0264] LEATMKMDKKTIVWFRRDLRIEDNPALAAAAHEGSVFPVFIWCPEEEGQFYPGRASRWWMKQ

[0265] SLAHLSQSLKALGSDLTLIKTHNTISAILDCIRVTGATKVVFNHLYDPVSLVRDHTVKEKLVERGI

[0266] SVQSYNGDLLYEPWEIYCEKGKPFTSFNSYWKKCLDMSIESVMLPPPWRLMPITAAAEAIWACS

[0267] IEELGLENEAEKPSNALLTRAWSPGWSNADKLLNEFIEKQLIDYAKNSKKVVGNSTSLLSPYLHF

[0268] GEISVRHVFQCARMKQIIWARDKNSEGEESADLFLRGIGLREYSRYICFNFPFTHEQSLLSHLRFF

[0269] PWDADVDKFKAWRQGRTGYPLVDAGMRELWATGWMHNRIRVIVSSFAVKFLLLPWKWGMKY

[0270] FWDTLLDADLECDILGWQYISGSIPDGHELDRLDNPALQGAKYDPEGEYIRQWLPELARLPTE

[0271] WIHHPWDAPLTVLKASGVELGTNYAKPIVDIDTARELLAKAISRTRGAQIMIGAA

[0272] SEQ ID NO:11.Cry2olig-TDP-43 (AA274-414) :

[0273] MKMDKKTIVWFRRDLRIEDNPALAAAAHEGSVFPVFIWCPEEEGQFYPGRASRWWMKQSLAH

[0274] LSQSLKALGSDLTLIKTHNTISAILDCIRVTGATKVVFNHLYDPVSLVRDHTVKEKLVERGISVQS

[0275] YNGDLLYEPWEIYCEKGKPFTSFNSYWKKCLDMSIESVMLPPPWRLMPITAAAEAIWACSIEEL

[0276] GLENEAEKPSNALLTRAWSPGWSNADKLLNEFIEKQLIDYAKNSKKVVGNSTSLLSPYLHFGEIS

[0277] VRHVFQCARMKQIIWARDKNSEGEESADLFLRGIGLREYSRYICFNFPFTHEQSLLSHLRFFPWD

[0278] ADVDKFKAWRQGRTGYPLVDAGMRELWATGWMHNRIRVIVSSFAVKFLLLPWKWGMKYFWD

[0279] TLLDADLECDILGWQYISGSIPDGHELDRLDNPALQGAKYDPEGEYIRQWLPELARLPTEWIHH

[0280] PWDAPLTVLKASGVELGTNYAKPIVDIDTARELLAKAISRTRGAQIMIGAAARGGRFGGNPGGF

[0281] GNQGGFGNSRGGGAGLGNNQGSNMGGGMNFGAFSINPAMMAAAQAALQSSWGMMGMLAS

[0282] QQNQSGPSGNNQNQGNMQREPNQAFGSGNNSYSGSNSGAAIGWGSASNAGSGSGFNGGFGSS

[0283] MDSKSSGWGM

[0284] SEQ ID NO:12.Cry2olig-TDP-43 (AA191-414) :

[0285] MKMDKKTIVWFRRDLRIEDNPALAAAAHEGSVFPVFIWCPEEEGQFYPGRASRWWMKQSLAH

[0286] LSQSLKALGSDLTLIKTHNTISAILDCIRVTGATKVVFNHLYDPVSLVRDHTVKEKLVERGISVQS

[0287] YNGDLLYEPWEIYCEKGKPFTSFNSYWKKCLDMSIESVMLPPPWRLMPITAAAEAIWACSIEEL

[0288] GLENEAEKPSNALLTRAWSPGWSNADKLLNEFIEKQLIDYAKNSKKVVGNSTSLLSPYLHFGEIS

[0289] VRHVFQCARMKQIIWARDKNSEGEESADLFLRGIGLREYSRYICFNFPFTHEQSLLSHLRFFPWD

[0290] ADVDKFKAWRQGRTGYPLVDAGMRELWATGWMHNRIRVIVSSFAVKFLLLPWKWGMKYFWD

[0291] TLLDADLECDILGWQYISGSIPDGHELDRLDNPALQGAKYDPEGEYIRQWLPELARLPTEWIHH

[0292] PWDAPLTVLKASGVELGTNYAKPIVDIDTARELLAKAISRTRGAQIMIGAAARGRKVFVGRCTE

[0293] DMTEDELREFFSQYGDVMDVFIPKPFRAFAFVTFADDQIAQSLCGEDLIIKGISVHISNAEPKHNS

[0294] NRQLERSGRFGGNPGGFGNQGGFGNSRGGGAGLGNNQGSNMGGGMNFGAFSINPAMMAAA

[0295] QAALQSSWGMMGMLASQQNQSGPSGNNQNQGNMQREPNQAFGSGNNSYSGSNSGAAIGWG

[0296] SASNAGSGSGFNGGFGSSMDSKSSGWGM

[0297] SEQ ID NO:13.Cry2olig-TDP-43 (AA105-414) :

[0298] MKMDKKTIVWFRRDLRIEDNPALAAAAHEGSVFPVFIWCPEEEGQFYPGRASRWWMKQSLAH

[0299] LSQSLKALGSDLTLIKTHNTISAILDCIRVTGATKVVFNHLYDPVSLVRDHTVKEKLVERGISVQS

[0300] YNGDLLYEPWEIYCEKGKPFTSFNSYWKKCLDMSIESVMLPPPWRLMPITAAAEAIWACSIEEL

[0301] GLENEAEKPSNALLTRAWSPGWSNADKLLNEFIEKQLIDYAKNSKKVVGNSTSLLSPYLHFGEIS

[0302] VRHVFQCARMKQIIWARDKNSEGEESADLFLRGIGLREYSRYICFNFPFTHEQSLLSHLRFFPWD

[0303] ADVDKFKAWRQGRTGYPLVDAGMRELWATGWMHNRIRVIVSSFAVKFLLLPWKWGMKYFWD

[0304] TLLDADLECDILGWQYISGSIPDGHELDRLDNPALQGAKYDPEGEYIRQWLPELARLPTEWIHH

[0305] PWDAPLTVLKASGVELGTNYAKPIVDIDTARELLAKAISRTRGAQIMIGAAARGDLIVLGLPWK

[0306] TTEQDLKEYFSTFGEVLMVQVKKDLKTGHSKGFGFVRFTEYETQVKVMSQRHMIDGRWCDC

[0307] KLPNSKQSQDEPLRSRKVFVGRCTEDMTEDELREFFSQYGDVMDVFIPKPFRAFAFVTFADDQI

[0308] AQSLCGEDLIIKGISVHISNAEPKHNSNRQLERSGRFGGNPGGFGNQGGFGNSRGGGAGLGNNQ

[0309] GSNMGGGMNFGAFSINPAMMAAAQAALQSSWGMMGMLASQQNQSGPSGNNQNQGNMQRE

[0310] PNQAFGSGNNSYSGSNSGAAIGWGSASNAGSGSGFNGGFGSSMDSKSSGWGM

[0311] C) Full-length TDP-43 protein + mCherry reporter gene

[0312] SEQ ID NO:14.Cry2olig-TDP-43-mCherry

[0313] MKMDKKTIVWFRRDLRIEDNPALAAAAHEGSVFPVFIWCPEEEGQFYPGRASRWWMKQSLAH

[0314] LSQSLKALGSDLTLIKTHNTISAILDCIRVTGATKVVFNHLYDPVSLVRDHTVKEKLVERGISVQS

[0315] YNGDLLYEPWEIYCEKGKPFTSFNSYWKKCLDMSIESVMLPPPWRLMPITAAAEAIWACSIEEL

[0316] GLENEAEKPSNALLTRAWSPGWSNADKLLNEFIEKQLIDYAKNSKKVVGNSTSLLSPYLHFGEIS

[0317] VRHVFQCARMKQIIWARDKNSEGEESADLFLRGIGLREYSRYICFNFPFTHEQSLLSHLRFFPWD

[0318] ADVDKFKAWRQGRTGYPLVDAGMRELWATGWMHNRIRVIVSSFAVKFLLLPWKWGMKYFWD

[0319] TLLDADLECDILGWQYISGSIPDGHELDRLDNPALQGAKYDPEGEYIRQWLPELARLPTEWIHH

[0320] PWDAPLTVLKASGVELGTNYAKPIVDIDTARELLAKAISRTRGAQIMIGAAARG

[0321] MSEYIRVTEDENDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGILHAPD

[0322] AGWGNLVYVVNYPKDNKRKMDETDASSAVKVKRAVQKTSDLIVLGLPWKTTEQDLKEYFSTF

[0323] GEVLMVQVKKDLKTGHSKGFGFVRFTEYETQVKVMSQRHMIDGRWCDCKLPNSKQSQDEPL

[0324] RSRKVFVGRCTEDMTEDELREFFSQYGDVMDVFIPKPFRAFAFVTFADDQIAQSLCGEDLIIKGI

[0325] SVHISNAEPKHNSNRQLERSGRFGGNPGGFGNQGGFGNSRGGGAGLGNNQGSNMGGGMNFG

[0326] AFSINPAMMAAAQAALQSSWGMMGMLASQQNQSGPSGNNQNQGNMQREPNQAFGSGNNSY

[0327] SGSNSGAAIGWGSASNAGSGSGFNGGFGSSMDSKSSGWGMSRDPPVATMVSKGEEDNMAIIKE

[0328] FMRFKVHMEGSVNGHEFEIEGEGEGRPYEGTQTAKLKVTKGGPLPFAWDILSPQFMYGSKAYV

[0329] KHPADIPDYLKLSFPEGFKWERVMNFEDGGVVTVTQDSSLQDGEFIYKVKLRGTNFPSDGPVM

[0330] QKKTMGWEASSERMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTYKAKKPVQLPGAYNVNI

[0331] KLDITSHNEDYTIVEQYERAEGRHSTGGMDELYK

[0332] SEQ ID NO:15.TDP-43-Cry2olig-mCherry:

[0333] MSEYIRVTEDENDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGILHAPD

[0334] AGWGNLVYVVNYPKDNKRKMDETDASSAVKVKRAVQKTSDLIVLGLPWKTTEQDLKEYFSTF

[0335] GEVLMVQVKKDLKTGHSKGFGFVRFTEYETQVKVMSQRHMIDGRWCDCKLPNSKQSQDEPL

[0336] RSRKVFVGRCTEDMTEDELREFFSQYGDVMDVFIPKPFRAFAFVTFADDQIAQSLCGEDLIIKGI

[0337] SVHISNAEPKHNSNRQLERSGRFGGNPGGFGNQGGFGNSRGGGAGLGNNQGSNMGGGMNFG

[0338] AFSINPAMMAAAQAALQSSWGMMGMLASQQNQSGPSGNNQNQGNMQREPNQAFGSGNNSY

[0339] SGSNSGAAIGWGSASNAGSGSGFNGGFGSSMDSKSSGWGMLEATMKMDKKTIVWFRRDLRIE

[0340] DNPALAAAAHEGSVFPVFIWCPEEEGQFYPGRASRWWMKQSLAHLSQSLKALGSDLTLIKTHN

[0341] TISAILDCIRVTGATKVVFNHLYDPVSLVRDHTVKEKLVERGISVQSYNGDLLYEPWEIYCEKGK

[0342] PFTSFNSYWKKCLDMSIESVMLPPPWRLMPITAAAEAIWACSIEELGLENEAEKPSNALLTRAWS

[0343] PGWSNADKLLNEFIEKQLIDYAKNSKKVVGNSTSLLSPYLHFGEISVRHVFQCARMKQIIWARD

[0344] KNSEGEESADLFLRGIGLREYSRYICFNFPFTHEQSLLSHLRFFPWDADVDKFKAWRQGRTGYP

[0345] LVDAGMRELWATGWMHNRIRVIVSSFAVKFLLLPWKWGMKYFWDTLLDADLECDILGWQYIS

[0346] GSIPDGHELDRLDNPALQGAKYDPEGEYIRQWLPELARLPTEWIHHPWDAPLTVLKASGVELG

[0347] TNYAKPIVDIDTARELLAKAISRTRGAQIMIGAAARDPPVATMVSKGEEDNMAIIKEFMRFKVH

[0348] MEGSVNGHEFEIEGEGEGRPYEGTQTAKLKVTKGGPLPFAWDILSPQFMYGSKAYVKHPADIPD

[0349] YLKLSFPEGFKWERVMNFEDGGVVTVTQDSSLQDGEFIYKVKLRGTNFPSDGPVMQKKTMGW

[0350] EASSERMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTYKAKKPVQLPGAYNVNIKLDITSHNE

[0351] DYTIVEQYERAEGRHSTGGMDELYK

[0352] SEQ ID NO:16.mCherry-TDP-43-Cry2olig:

[0353] MVSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEGRPYEGTQTAKLKVTKGGPLPFAW

[0354] DILSPQFMYGSKAYVKHPADIPDYLKLSFPEGFKWERVMNFEDGGVVTVTQDSSLQDGEFIYK

[0355] VKLRGTNFPSDGPVMQKKTMGWEASSERMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTYK

[0356] AKKPVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDELYKMSEYIRVTEDENDEP

[0357] IEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGILHAPDAGWGNLVYVVNYP

[0358] KDNKRKMDETDASSAVKVKRAVQKTSDLIVLGLPWKTTEQDLKEYFSTFGEVLMVQVKKDLK

[0359] TGHSKGFGFVRFTEYETQVKVMSQRHMIDGRWCDCKLPNSKQSQDEPLRSRKVFVGRCTEDM

[0360] TEDELREFFSQYGDVMDVFIPKPFRAFAFVTFADDQIAQSLCGEDLIIKGISVHISNAEPKHNSNR

[0361] QLERSGRFGGNPGGFGNQGGFGNSRGGGAGLGNNQGSNMGGGMNFGAFSINPAMMAAAQA

[0362] ALQSSWGMMGMLASQQNQSGPSGNNQNQGNMQREPNQAFGSGNNSYSGSNSGAAIGWGSA

[0363] SNAGSGSGFNGGFGSSMDSKSSGWGMLEATMKMDKKTIVWFRRDLRIEDNPALAAAAHEGSV

[0364] FPVFIWCPEEEGQFYPGRASRWWMKQSLAHLSQSLKALGSDLTLIKTHNTISAILDCIRVTGATK

[0365] VVFNHLYDPVSLVRDHTVKEKLVERGISVQSYNGDLLYEPWEIYCEKGKPFTSFNSYWKKCLD

[0366] MSIESVMLPPPWRLMPITAAAEAIWACSIEELGLENEAEKPSNALLTRAWSPGWSNADKLLNEFI

[0367] EKQLIDYAKNSKKVVGNSTSLLSPYLHFGEISVRHVFQCARMKQIIWARDKNSEGEESADLFLR

[0368] GIGLREYSRYICFNFPFTHEQSLLSHLRFFPWDADVDKFKAWRQGRTGYPLVDAGMRELWATG

[0369] WMHNRIRVIVSSFAVKFLLLPWKWGMKYFWDTLLDADLECDILGWQYISGSIPDGHELDRLDN

[0370] PALQGAKYDPEGEYIRQWLPELARLPTEWIHHPWDAPLTVLKASGVELGTNYAKPIVDIDTARE

[0371] LLAKAISRTRGAQIMIGAAD)-truncated TDP-43 protein + mCherry reporter gene

[0372] SEQ ID NO:17. TDP-43 (AA274-414) -Cry2olig-mCherry:

[0373] MGRFGGNPGGFGNQGGFGNSRGGGAGLGNNQGSNMGGGMNFGAFSINPAMMAAAQAALQS

[0374] SWGMMGMLASQQNQSGPSGNNQNQGNMQREPNQAFGSGNNSYSGSNSGAAIGWGSASNAG

[0375] SGSGFNGGFGSSMDSKSSGWGMLEATMKMDKKTIVWFRRDLRIEDNPALAAAAHEGSVFPVFI

[0376] WCPEEEGQFYPGRASRWWMKQSLAHLSQSLKALGSDLTLIKTHNTISAILDCIRVTGATKVVFN

[0377] HLYDPVSLVRDHTVKEKLVERGISVQSYNGDLLYEPWEIYCEKGKPFTSFNSYWKKCLDMSIES

[0378] VMLPPPWRLMPITAAAEAIWACSIEELGLENEAEKPSNALLTRAWSPGWSNADKLLNEFIEKQLI

[0379] DYAKNSKKVVGNSTSLLSPYLHFGEISVRHVFQCARMKQIIWARDKNSEGEESADLFLRGIGLR

[0380] EYSRYICFNFPFTHEQSLLSHLRFFPWDADVDKFKAWRQGRTGYPLVDAGMRELWATGWMHN

[0381] RIRVIVSSFAVKFLLLPWKWGMKYFWDTLLDADLECDILGWQYISGSIPDGHELDRLDNPALQG

[0382] AKYDPEGEYIRQWLPELARLPTEWIHHPWDAPLTVLKASGVELGTNYAKPIVDIDTARELLAKA

[0383] ISRTRGAQIMIGAAARDPPVATMVSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEGRP

[0384] YEGTQTAKLKVTKGGPLPFAWDILSPQFMYGSKAYVKHPADIPDYLKLSFPEGFKWERVMNFE

[0385] DGGVVTVTQDSSLQDGEFIYKVKLRGTNFPSDGPVMQKKTMGWEASSERMYPEDGALKGEIK

[0386] QRLKLKDGGHYDAEVKTTYKAKKPVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTG

[0387] GMDELYK

[0388] SEQ ID NO:18.TDP-43 (AA191-414) -Cry2olig-mCherry:

[0389] MRKVFVGRCTEDMTEDELREFFSQYGDVMDVFIPKPFRAFAFVTFADDQIAQSLCGEDLIIKGIS

[0390] VHISNAEPKHNSNRQLERSGRFGGNPGGFGNQGGFGNSRGGGAGLGNNQGSNMGGGMNFGA

[0391] FSINPAMMAAAQAALQSSWGMMGMLASQQNQSGPSGNNQNQGNMQREPNQAFGSGNNSYS

[0392] GSNSGAAIGWGSASNAGSGSGFNGGFGSSMDSKSSGWGMLEATMKMDKKTIVWFRRDLRIED

[0393] NPALAAAAHEGSVFPVFIWCPEEEGQFYPGRASRWWMKQSLAHLSQSLKALGSDLTLIKTHNTI

[0394] SAILDCIRVTGATKVVFNHLYDPVSLVRDHTVKEKLVERGISVQSYNGDLLYEPWEIYCEKGKPF

[0395] TSFNSYWKKCLDMSIESVMLPPPWRLMPITAAAEAIWACSIEELGLENEAEKPSNALLTRAWSP

[0396] GWSNADKLLNEFIEKQLIDYAKNSKKVVGNSTSLLSPYLHFGEISVRHVFQCARMKQIIWARDK

[0397] NSEGEESADLFLRGIGLREYSRYICFNFPFTHEQSLLSHLRFFPWDADVDKFKAWRQGRTGYPL

[0398] VDAGMRELWATGWMHNRIRVIVSSFAVKFLLLPWKWGMKYFWDTLLDADLECDILGWQYISG

[0399] SIPDGHELDRLDNPALQGAKYDPEGEYIRQWLPELARLPTEWIHHPWDAPLTVLKASGVELGT

[0400] NYAKPIVDIDTARELLAKAISRTRGAQIMIGAAARDPPVATMVSKGEEDNMAIIKEFMRFKVHM

[0401] EGSVNGHEFEIEGEGEGRPYEGTQTAKLKVTKGGPLPFAWDILSPQFMYGSKAYVKHPADIPDY

[0402] LKLSFPEGFKWERVMNFEDGGVVTVTQDSSLQDGEFIYKVKLRGTNFPSDGPVMQKKTMGWE

[0403] ASSERMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTYKAKKPVQLPGAYNVNIKLDITSHNE

[0404] DYTIVEQYERAEGRHSTGGMDELYK

[0405] SEQ ID NO:19.TDP-43 (AA105-414) -Cry2olig-mCherry:

[0406] MDLIVLGLPWKTTEQDLKEYFSTFGEVLMVQVKKDLKTGHSKGFGFVRFTEYETQVKVMSQR

[0407] HMIDGRWCDCKLPNSKQSQDEPLRSRKVFVGRCTEDMTEDELREFFSQYGDVMDVFIPKPFRA

[0408] FAFVTFADDQIAQSLCGEDLIIKGISVHISNAEPKHNSNRQLERSGRFGGNPGGFGNQGGFGNSR

[0409] GGGAGLGNNQGSNMGGGMNFGAFSINPAMMAAAQAALQSSWGMMGMLASQQNQSGPSGN

[0410] NQNQGNMQREPNQAFGSGNNSYSGSNSGAAIGWGSASNAGSGSGFNGGFGSSMDSKSSGWG

[0411] MLEATMKMDKKTIVWFRRDLRIEDNPALAAAAHEGSVFPVFIWCPEEEGQFYPGRASRWWMK

[0412] QSLAHLSQSLKALGSDLTLIKTHNTISAILDCIRVTGATKVVFNHLYDPVSLVRDHTVKEKLVER

[0413] GISVQSYNGDLLYEPWEIYCEKGKPFTSFNSYWKKCLDMSIESVMLPPPWRLMPITAAAEAIWA

[0414] CSIEELGLENEAEKPSNALLTRAWSPGWSNADKLLNEFIEKQLIDYAKNSKKVVGNSTSLLSPYL

[0415] HFGEISVRHVFQCARMKQIIWARDKNSEGEESADLFLRGIGLREYSRYICFNFPFTHEQSLLSHLR

[0416] FFPWDADVDKFKAWRQGRTGYPLVDAGMRELWATGWMHNRIRVIVSSFAVKFLLLPWKWGM

[0417] KYFWDTLLDADLECDILGWQYISGSIPDGHELDRLDNPALQGAKYDPEGEYIRQWLPELARLPT

[0418] EWIHHPWDAPLTVLKASGVELGTNYAKPIVDIDTARELLAKAISRTRGAQIMIGAAARDPPVAT

[0419] MVSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEGRPYEGTQTAKLKVTKGGPLPFAW

[0420] DILSPQFMYGSKAYVKHPADIPDYLKLSFPEGFKWERVMNFEDGGVVTVTQDSSLQDGEFIYK

[0421] VKLRGTNFPSDGPVMQKKTMGWEASSERMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTYK

[0422] AKKPVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDELYK

[0423] SEQ ID NO:20.mCherry-Cry2olig-TDP-43 (AA274-414) :

[0424] MVSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEGRPYEGTQTAKLKVTKGGPLPFAW

[0425] DILSPQFMYGSKAYVKHPADIPDYLKLSFPEGFKWERVMNFEDGGVVTVTQDSSLQDGEFIYK

[0426] VKLRGTNFPSDGPVMQKKTMGWEASSERMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTYK

[0427] AKKPVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDELYK

[0428] MKMDKKTIVWFRRDLRIEDNPALAAAAHEGSVFPVFIWCPEEEGQFYPGRASRWWMKQSLAH

[0429] LSQSLKALGSDLTLIKTHNTISAILDCIRVTGATKVVFNHLYDPVSLVRDHTVKEKLVERGISVQS

[0430] YNGDLLYEPWEIYCEKGKPFTSFNSYWKKCLDMSIESVMLPPPWRLMPITAAAEAIWACSIEEL

[0431] GLENEAEKPSNALLTRAWSPGWSNADKLLNEFIEKQLIDYAKNSKKVVGNSTSLLSPYLHFGEIS

[0432] VRHVFQCARMKQIIWARDKNSEGEESADLFLRGIGLREYSRYICFNFPFTHEQSLLSHLRFFPWD

[0433] ADVDKFKAWRQGRTGYPLVDAGMRELWATGWMHNRIRVIVSSFAVKFLLLPWKWGMKYFWD

[0434] TLLDADLECDILGWQYISGSIPDGHELDRLDNPALQGAKYDPEGEYIRQWLPELARLPTEWIHH

[0435] PWDAPLTVLKASGVELGTNYAKPIVDIDTARELLAKAISRTRGAQIMIGAAARGGRFGGNPGGF

[0436] GNQGGFGNSRGGGAGLGNNQGSNMGGGMNFGAFSINPAMMAAAQAALQSSWGMMGMLAS

[0437] QQNQSGPSGNNQNQGNMQREPNQAFGSGNNSYSGSNSGAAIGWGSASNAGSGSGFNGGFGSS

[0438] MDSKSSGWGM

[0439] SEQ ID NO:21.mCherry-Cry2olig-TDP-43 (AA191-414) :

[0440] MVSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEGRPYEGTQTAKLKVTKGGPLPFAW

[0441] DILSPQFMYGSKAYVKHPADIPDYLKLSFPEGFKWERVMNFEDGGVVTVTQDSSLQDGEFIYK

[0442] VKLRGTNFPSDGPVMQKKTMGWEASSERMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTYK

[0443] AKKPVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDELYK

[0444] MKMDKKTIVWFRRDLRIEDNPALAAAAHEGSVFPVFIWCPEEEGQFYPGRASRWWMKQSLAH

[0445] LSQSLKALGSDLTLIKTHNTISAILDCIRVTGATKVVFNHLYDPVSLVRDHTVKEKLVERGISVQS

[0446] YNGDLLYEPWEIYCEKGKPFTSFNSYWKKCLDMSIESVMLPPPWRLMPITAAAEAIWACSIEEL

[0447] GLENEAEKPSNALLTRAWSPGWSNADKLLNEFIEKQLIDYAKNSKKVVGNSTSLLSPYLHFGEIS

[0448] VRHVFQCARMKQIIWARDKNSEGEESADLFLRGIGLREYSRYICFNFPFTHEQSLLSHLRFFPWD

[0449] ADVDKFKAWRQGRTGYPLVDAGMRELWATGWMHNRIRVIVSSFAVKFLLLPWKWGMKYFWD

[0450] TLLDADLECDILGWQYISGSIPDGHELDRLDNPALQGAKYDPEGEYIRQWLPELARLPTEWIHH

[0451] PWDAPLTVLKASGVELGTNYAKPIVDIDTARELLAKAISRTRGAQIMIGAAARGRKVFVGRCTE

[0452] DMTEDELREFFSQYGDVMDVFIPKPFRAFAFVTFADDQIAQSLCGEDLIIKGISVHISNAEPKHNS

[0453] NRQLERSGRFGGNPGGFGNQGGFGNSRGGGAGLGNNQGSNMGGGMNFGAFSINPAMMAAA

[0454] QAALQSSWGMMGMLASQQNQSGPSGNNQNQGNMQREPNQAFGSGNNSYSGSNSGAAIGWG

[0455] SASNAGSGSGFNGGFGSSMDSKSSGWGM

[0456] SEQ ID NO:22.mCherry-Cry2olig-TDP-43 (AA105-414) :

[0457] MVSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEGRPYEGTQTAKLKVTKGGPLPFAW

[0458] DILSPQFMYGSKAYVKHPADIPDYLKLSFPEGFKWERVMNFEDGGVVTVTQDSSLQDGEFIYK

[0459] VKLRGTNFPSDGPVMQKKTMGWEASSERMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTYK

[0460] AKKPVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDELYKMKMDKKTIVWFRR

[0461] DLRIEDNPALAAAAHEGSVFPVFIWCPEEEGQFYPGRASRWWMKQSLAHLSQSLKALGSDLTLI

[0462] KTHNTISAILDCIRVTGATKVVFNHLYDPVSLVRDHTVKEKLVERGISVQSYNGDLLYEPWEIYC

[0463] EKGKPFTSFNSYWKKCLDMSIESVMLPPPWRLMPITAAAEAIWACSIEELGLENEAEKPSNALLT

[0464] RAWSPGWSNADKLLNEFIEKQLIDYAKNSKKVVGNSTSLLSPYLHFGEISVRHVFQCARMKQII

[0465] WARDKNSEGEESADLFLRGIGLREYSRYICFNFPFTHEQSLLSHLRFFPWDADVDKFKAWRQGR

[0466] TGYPLVDAGMRELWATGWMHNRIRVIVSSFAVKFLLLPWKWGMKYFWDTLLDADLECDILGW

[0467] QYISGSIPDGHELDRLDNPALQGAKYDPEGEYIRQWLPELARLPTEWIHHPWDAPLTVLKASGV

[0468] ELGTNYAKPIVDIDTARELLAKAISRTRGAQIMIGAAARGDLIVLGLPWKTTEQDLKEYFSTFGE

[0469] VLMVQVKKDLKTGHSKGFGFVRFTEYETQVKVMSQRHMIDGRWCDCKLPNSKQSQDEPLRS

[0470] RKVFVGRCTEDMTEDELREFFSQYGDVMDVFIPKPFRAFAFVTFADDQIAQSLCGEDLIIKGISV

[0471] HISNAEPKHNSNRQLERSGRFGGNPGGFGNQGGFGNSRGGGAGLGNNQGSNMGGGMNFGAF

[0472] SINPAMMAAAQAALQSSWGMMGMLASQQNQSGPSGNNQNQGNMQREPNQAFGSGNNSYSG

[0473] SNSGAAIGWGSASNAGSGSGFNGGFGSSMDSKSSGWGM

[0474] SEQ ID NO:23.Cry2olig-TDP-43 (AA274-414) -mCherry:

[0475] MKMDKKTIVWFRRDLRIEDNPALAAAAHEGSVFPVFIWCPEEEGQFYPGRASRWWMKQSLAH

[0476] LSQSLKALGSDLTLIKTHNTISAILDCIRVTGATKVVFNHLYDPVSLVRDHTVKEKLVERGISVQS

[0477] YNGDLLYEPWEIYCEKGKPFTSFNSYWKKCLDMSIESVMLPPPWRLMPITAAAEAIWACSIEEL

[0478] GLENEAEKPSNALLTRAWSPGWSNADKLLNEFIEKQLIDYAKNSKKVVGNSTSLLSPYLHFGEIS

[0479] VRHVFQCARMKQIIWARDKNSEGEESADLFLRGIGLREYSRYICFNFPFTHEQSLLSHLRFFPWD

[0480] ADVDKFKAWRQGRTGYPLVDAGMRELWATGWMHNRIRVIVSSFAVKFLLLPWKWGMKYFWD

[0481] TLLDADLECDILGWQYISGSIPDGHELDRLDNPALQGAKYDPEGEYIRQWLPELARLPTEWIHH

[0482] PWDAPLTVLKASGVELGTNYAKPIVDIDTARELLAKAISRTRGAQIMIGAAARGGRFGGNPGGF

[0483] GNQGGFGNSRGGGAGLGNNQGSNMGGGMNFGAFSINPAMMAAAQAALQSSWGMMGMLAS

[0484] QQNQSGPSGNNQNQGNMQREPNQAFGSGNNSYSGSNSGAAIGWGSASNAGSGSGFNGGFGSS

[0485] MDSKSSGWGMSRDPPVATMVSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEGRPYE

[0486] GTQTAKLKVTKGGPLPFAWDILSPQFMYGSKAYVKHPADIPDYLKLSFPEGFKWERVMNFEDG

[0487] GVVTVTQDSSLQDGEFIYKVKLRGTNFPSDGPVMQKKTMGWEASSERMYPEDGALKGEIKQR

[0488] LKLKDGGHYDAEVKTTYKAKKPVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGM

[0489] DELYK

[0490] SEQ ID NO:24.Cry2olig-TDP-43 (AA191-414) -mCherry:

[0491] MKMDKKTIVWFRRDLRIEDNPALAAAAHEGSVFPVFIWCPEEEGQFYPGRASRWWMKQSLAH

[0492] LSQSLKALGSDLTLIKTHNTISAILDCIRVTGATKVVFNHLYDPVSLVRDHTVKEKLVERGISVQS

[0493] YNGDLLYEPWEIYCEKGKPFTSFNSYWKKCLDMSIESVMLPPPWRLMPITAAAEAIWACSIEEL

[0494] GLENEAEKPSNALLTRAWSPGWSNADKLLNEFIEKQLIDYAKNSKKVVGNSTSLLSPYLHFGEIS

[0495] VRHVFQCARMKQIIWARDKNSEGEESADLFLRGIGLREYSRYICFNFPFTHEQSLLSHLRFFPWD

[0496] ADVDKFKAWRQGRTGYPLVDAGMRELWATGWMHNRIRVIVSSFAVKFLLLPWKWGMKYFWD

[0497] TLLDADLECDILGWQYISGSIPDGHELDRLDNPALQGAKYDPEGEYIRQWLPELARLPTEWIHH

[0498] PWDAPLTVLKASGVELGTNYAKPIVDIDTARELLAKAISRTRGAQIMIGAAARGRKVFVGRCTE

[0499] DMTEDELREFFSQYGDVMDVFIPKPFRAFAFVTFADDQIAQSLCGEDLIIKGISVHISNAEPKHNS

[0500] NRQLERSGRFGGNPGGFGNQGGFGNSRGGGAGLGNNQGSNMGGGMNFGAFSINPAMMAAA

[0501] QAALQSSWGMMGMLASQQNQSGPSGNNQNQGNMQREPNQAFGSGNNSYSGSNSGAAIGWG

[0502] SASNAGSGSGFNGGFGSSMDSKSSGWGMSRDPPVATMVSKGEEDNMAIIKEFMRFKVHMEGS

[0503] VNGHEFEIEGEGEGRPYEGTQTAKLKVTKGGPLPFAWDILSPQFMYGSKAYVKHPADIPDYLKL

[0504] SFPEGFKWERVMNFEDGGVVTVTQDSSLQDGEFIYKVKLRGTNFPSDGPVMQKKTMGWEASS

[0505] ERMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTYKAKKPVQLPGAYNVNIKLDITSHNEDYTI

[0506] VEQYERAEGRHSTGGMDELYK

[0507] SEQ ID NO:25.Cry2olig-TDP-43 (AA105-414) -mCherry:

[0508] MDLIVLGLPWKTTEQDLKEYFSTFGEVLMVQVKKDLKTGHSKGFGFVRFTEYETQVKVMSQR

[0509] HMIDGRWCDCKLPNSKQSQDEPLRSRKVFVGRCTEDMTEDELREFFSQYGDVMDVFIPKPFRA

[0510] FAFVTFADDQIAQSLCGEDLIIKGISVHISNAEPKHNSNRQLERSGRFGGNPGGFGNQGGFGNSR

[0511] GGGAGLGNNQGSNMGGGMNFGAFSINPAMMAAAQAALQSSWGMMGMLASQQNQSGPSGN

[0512] NQNQGNMQREPNQAFGSGNNSYSGSNSGAAIGWGSASNAGSGSGFNGGFGSSMDSKSSGWG

[0513] MLEATMKMDKKTIVWFRRDLRIEDNPALAAAAHEGSVFPVFIWCPEEEGQFYPGRASRWWMK

[0514] QSLAHLSQSLKALGSDLTLIKTHNTISAILDCIRVTGATKVVFNHLYDPVSLVRDHTVKEKLVER

[0515] GISVQSYNGDLLYEPWEIYCEKGKPFTSFNSYWKKCLDMSIESVMLPPPWRLMPITAAAEAIWA

[0516] CSIEELGLENEAEKPSNALLTRAWSPGWSNADKLLNEFIEKQLIDYAKNSKKVVGNSTSLLSPYL

[0517] HFGEISVRHVFQCARMKQIIWARDKNSEGEESADLFLRGIGLREYSRYICFNFPFTHEQSLLSHLR

[0518] FFPWDADVDKFKAWRQGRTGYPLVDAGMRELWATGWMHNRIRVIVSSFAVKFLLLPWKWGM

[0519] KYFWDTLLDADLECDILGWQYISGSIPDGHELDRLDNPALQGAKYDPEGEYIRQWLPELARLPT

[0520] EWIHHPWDAPLTVLKASGVELGTNYAKPIVDIDTARELLAKAISRTRGAQIMIGAASRDPPVATM

[0521] VSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEGRPYEGTQTAKLKVTKGGPLPFAWD

[0522] ILSPQFMYGSKAYVKHPADIPDYLKLSFPEGFKWERVMNFEDGGVVTVTQDSSLQDGEFIYKV

[0523] KLRGTNFPSDGPVMQKKTMGWEASSERMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTYKA

[0524] KKPVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDELYK

[0525] 2. Amino acid sequence of the NcVVDY50W fusion protein:

[0526] A) Full-length TDP-43 protein without reporter gene

[0527] SEQ ID NO:26. NcVVDY50W-TDP-43

[0528] MHTLYAPGGYDIMGWLIQIMNRPNPQVELGPVDTSCALILCDLKQKDTPIVYASEAFLYMTGYS

[0529] NAEVLGRNCRFLQSPDGMVKPKSTRKYVDSNTINTMRKAIDRNAEVQVEVVNFKKNGQRFVN

[0530] FLTMIPVRDETGEYRYSMGFQCETEAMSEYIRVTEDENDEPIEIPSEDDGTVLLSTVTAQFPGAC

[0531] GLRYRNPVSQCMRGVRLVEGILHAPDAGWGNLVYVVNYPKDNKRKMDETDASSAVKVKRAV

[0532] QKTSDLIVLGLPWKTTEQDLKEYFSTFGEVLMVQVKKDLKTGHSKGFGFVRFTEYETQVKVM

[0533] SQRHMIDGRWCDCKLPNSKQSQDEPLRSRKVFVGRCTEDMTEDELREFFSQYGDVMDVFIPKP

[0534] FRAFAFVTFADDQIAQSLCGEDLIIKGISVHISNAEPKHNSNRQLERSGRFGGNPGGFGNQGGFG

[0535] NSRGGGAGLGNNQGSNMGGGMNFGAFSINPAMMAAAQAALQSSWGMMGMLASQQNQSGP

[0536] SGNNQNQGNMQREPNQAFGSGNNSYSGSNSGAAIGWGSASNAGSGSGFNGGFGSSMDSKSSG

[0537] WGM

[0538] SEQ ID NO:27.TDP-43-NcVVDY50W

[0539] MSEYIRVTEDENDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGILHAPD

[0540] AGWGNLVYVVNYPKDNKRKMDETDASSAVKVKRAVQKTSDLIVLGLPWKTTEQDLKEYFSTF

[0541] GEVLMVQVKKDLKTGHSKGFGFVRFTEYETQVKVMSQRHMIDGRWCDCKLPNSKQSQDEPL

[0542] RSRKVFVGRCTEDMTEDELREFFSQYGDVMDVFIPKPFRAFAFVTFADDQIAQSLCGEDLIIKGI

[0543] SVHISNAEPKHNSNRQLERSGRFGGNPGGFGNQGGFGNSRGGGAGLGNNQGSNMGGGMNFG

[0544] AFSINPAMMAAAQAALQSSWGMMGMLASQQNQSGPSGNNQNQGNMQREPNQAFGSGNNSY

[0545] SGSNSGAAIGWGSASNAGSGSGFNGGFGSSMDSKSSGWGMFRAQRHTLYAPGGYDIMGWLIQI

[0546] MNRPNPQVELGPVDTSCALILCDLKQKDTPIVYASEAFLYMTGYSNAEVLGRNCRFLQSPDGM

[0547] VKPKSTRKYVDSNTINTMRKAIDRNAEVQVEVVNFKKNGQRFVNFLTMIPVRDETGEYRYSM

[0548] GFQCETE

[0549] B) Truncated TDP-43 protein without reporter gene

[0550] SEQ ID NO:28. TDP-43 (AA105-414) -NcVVDY50W

[0551] [[ID=P=20]]MDLIVLGLPWKTTEQDLKEYFSTFGEVLMVQVKKDLKTGHSKGFGFVRFTEYETQVKVMSQR

[0552] HMIDGRWCDCKLPNSKQSQDEPLRSRKVFVGRCTEDMTEDELREFFSQYGDVMDVFIPKPFRA

[0553] FAFVTFADDQIAQSLCGEDLIIKGISVHISNAEPKHNSNRQLERSGRFGGNPGGFGNQGGFGNSR

[0554] GGGAGLGNNQGSNMGGGMNFGAFSINPAMMAAAQAALQSSWGMMGMLASQQNQSGPSGN

[0555] NQNQGNMQREPNQAFGSGNNSYSGSNSGAAIGWGSASNAGSGSGFNGGFGSSMDSKSSGWG

[0556] MFRAQRHTLYAPGGYDIMGWLIQIMNRPNPQVELGPVDTSCALILCDLKQKDTPIVYASEAFLY

[0557] MTGYSNAEVLGRNCRFLQSPDGMVKPKSTRKYVDSNTINTMRKAIDRNAEVQVEVVNFKKNG

[0558] QRFVNFLTMIPVRDETGEYRYSMGFQCETE

[0559] SEQ ID NO:29.TDP-43 (AA191-414) -NcVVDY50W

[0560] MRKVFVGRCTEDMTEDELREFFSQYGDVMDVFIPKPFRAFAFVTFADDQIAQSLCGEDLIIKGIS

[0561] VHISNAEPKHNSNRQLERSGRFGGNPGGFGNQGGFGNSRGGGAGLGNNQGSNMGGGMNFGA

[0562] FSINPAMMAAAQAALQSSWGMMGMLASQQNQSGPSGNNQNQGNMQREPNQAFGSGNNSYS

[0563] GSNSGAAIGWGSASNAGSGSGFNGGFGSSMDSKSSGWGMFRAQRHTLYAPGGYDIMGWLIQI

[0564] MNRPNPQVELGPVDTSCALILCDLKQKDTPIVYASEAFLYMTGYSNAEVLGRNCRFLQSPDGM

[0565] VKPKSTRKYVDSNTINTMRKAIDRNAEVQVEVVNFKKNGQRFVNFLTMIPVRDETGEYRYSM

[0566] GFQCETE

[0567] SEQ ID NO:30.TDP-43 (AA274-414) -NcVVDY50W

[0568] MGRFGGNPGGFGNQGGFGNSRGGGAGLGNNQGSNMGGGMNFGAFSINPAMMAAAQAALQS

[0569] SWGMMGMLASQQNQSGPSGNNQNQGNMQREPNQAFGSGNNSYSGSNSGAAIGWGSASNAG

[0570] SGSGFNGGFGSSMDSKSSGWGMFRAQRHTLYAPGGYDIMGWLIQIMNRPNPQVELGPVDTSC

[0571] ALILCDLKQKDTPIVYASEAFLYMTGYSNAEVLGRNCRFLQSPDGMVKPKSTRKYVDSNTINT

[0572] MRKAIDRNAEVQVEVVNFKKNGQRFVNFLTMIPVRDETGEYRYSMGFQCETE

[0573] SEQ ID NO:31.NcVVDY50W-TDP-43 (AA105-414)

[0574] MHTLYAPGGYDIMGWLIQIMNRPNPQVELGPVDTSCALILCDLKQKDTPIVYASEAFLYMTGYS

[0575] NAEVLGRNCRFLQSPDGMVKPKSTRKYVDSNTINTMRKAIDRNAEVQVEVVNFKKNGQRFVN

[0576] FLTMIPVRDETGEYRYSMGFQCETEADLIVLGLPWKTTEQDLKEYFSTFGEVLMVQVKKDLKT

[0577] GHSKGFGFVRFTEYETQVKVMSQRHMIDGRWCDCKLPNSKQSQDEPLRSRKVFVGRCTEDMT

[0578] EDELREFFSQYGDVMDVFIPKPFRAFAFVTFADDQIAQSLCGEDLIIKGISVHISNAEPKHNSNRQ

[0579] LERSGRFGGNPGGFGNQGGFGNSRGGGAGLGNNQGSNMGGGMNFGAFSINPAMMAAAQAAL

[0580] QSSWGMMGMLASQQNQSGPSGNNQNQGNMQREPNQAFGSGNNSYSGSNSGAAIGWGSASN

[0581] AGSGSGFNGGFGSSMDSKSSGWGM

[0582] SEQ ID NO:32.NcVVDY50W-TDP-43 (AA191-414)

[0583] MHTLYAPGGYDIMGWLIQIMNRPNPQVELGPVDTSCALILCDLKQKDTPIVYASEAFLYMTGYS

[0584] NAEVLGRNCRFLQSPDGMVKPKSTRKYVDSNTINTMRKAIDRNAEVQVEVVNFKKNGQRFVN

[0585] FLTMIPVRDETGEYRYSMGFQCETEARKVFVGRCTEDMTEDELREFFSQYGDVMDVFIPKPFR

[0586] AFAFVTFADDQIAQSLCGEDLIIKGISVHISNAEPKHNSNRQLERSGRFGGNPGGFGNQGGFGNS

[0587] RGGGAGLGNNQGSNMGGGMNFGAFSINPAMMAAAQAALQSSWGMMGMLASQQNQSGPSG

[0588] NNQNQGNMQREPNQAFGSGNNSYSGSNSGAAIGWGSASNAGSGSGFNGGFGSSMDSKSSGW

[0589] GM

[0590] SEQ ID NO:33.NcVVDY50W-TDP-43 (AA274-414)

[0591] HTLYAPGGYDIMGWLIQIMNRPNPQVELGPVDTSCALILCDLKQKDTPIVYASEAFLYMTGYSN

[0592] AEVLGRNCRFLQSPDGMVKPKSTRKYVDSNTINTMRKAIDRNAEVQVEVVNFKKNGQRFVNF

[0593] LTMIPVRDETGEYRYSMGFQCETEAGRFGGNPGGFGNQGGFGNSRGGGAGLGNNQGSNMGG

[0594] GMNFGAFSINPAMMAAAQAALQSSWGMMGMLASQQNQSGPSGNNQNQGNMQREPNQAFGS

[0595] GNNSYSGSNSGAAIGWGSASNAGSGSGFNGGFGSSMDSKSSGWGM

[0596] C) Full-length TDP-43 protein + mCherry reporter gene

[0597] SEQ ID NO:34.NcVVDY50W-TDP-43-mCherry

[0598] MHTLYAPGGYDIMGWLIQIMNRPNPQVELGPVDTSCALILCDLKQKDTPIVYASEAFLYMTGYS

[0599] NAEVLGRNCRFLQSPDGMVKPKSTRKYVDSNTINTMRKAIDRNAEVQVEVVNFKKNGQRFVN

[0600] FLTMIPVRDETGEYRYSMGFQCETEAMSEYIRVTEDENDEPIEIPSEDDGTVLLSTVTAQFPGAC

[0601] GLRYRNPVSQCMRGVRLVEGILHAPDAGWGNLVYVVNYPKDNKRKMDETDASSAVKVKRAV

[0602] QKTSDLIVLGLPWKTTEQDLKEYFSTFGEVLMVQVKKDLKTGHSKGFGFVRFTEYETQVKVM

[0603] SQRHMIDGRWCDCKLPNSKQSQDEPLRSRKVFVGRCTEDMTEDELREFFSQYGDVMDVFIPKP

[0604] FRAFAFVTFADDQIAQSLCGEDLIIKGISVHISNAEPKHNSNRQLERSGRFGGNPGGFGNQGGFG

[0605] NSRGGGAGLGNNQGSNMGGGMNFGAFSINPAMMAAAQAALQSSWGMMGMLASQQNQSGP

[0606] SGNNQNQGNMQREPNQAFGSGNNSYSGSNSGAAIGWGSASNAGSGSGFNGGFGSSMDSKSSG

[0607] WGMFAPVATMVSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEGRPYEGTQTAKLKV

[0608] TKGGPLPFAWDILSPQFMYGSKAYVKHPADIPDYLKLSFPEGFKWERVMNFEDGGVVTVTQDS

[0609] SLQDGEFIYKVKLRGTNFPSDGPVMQKKTMGWEASSERMYPEDGALKGEIKQRLKLKDGGHY

[0610] DAEVKTTYKAKKPVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDELYK

[0611] SEQ ID NO:35.mCherry-TDP-43-NcVVDY50W

[0612] MVSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEGRPYEGTQTAKLKVTKGGPLPFAW

[0613] DILSPQFMYGSKAYVKHPADIPDYLKLSFPEGFKWERVMNFEDGGVVTVTQDSSLQDGEFIYK

[0614] VKLRGTNFPSDGPVMQKKTMGWEASSERMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTYK

[0615] AKKPVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDELYKSGLKMSEYIRVTEDE

[0616] NDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGILHAPDAGWGNLVYV

[0617] VNYPKDNKRKMDETDASSAVKVKRAVQKTSDLIVLGLPWKTTEQDLKEYFSTFGEVLMVQVK

[0618] KDLKTGHSKGFGFVRFTEYETQVKVMSQRHMIDGRWCDCKLPNSKQSQDEPLRSRKVFVGRC

[0619] TEDMTEDELREFFSQYGDVMDVFIPKPFRAFAFVTFADDQIAQSLCGEDLIIKGISVHISNAEPKH

[0620] NSNRQLERSGRFGGNPGGFGNQGGFGNSRGGGAGLGNNQGSNMGGGMNFGAFSINPAMMAA

[0621] AQAALQSSWGMMGMLASQQNQSGPSGNNQNQGNMQREPNQAFGSGNNSYSGSNSGAAIGW

[0622] GSASNAGSGSGFNGGFGSSMDSKSSGWGMFRAQRHTLYAPGGYDIMGWLIQIMNRPNPQVEL

[0623] GPVDTSCALILCDLKQKDTPIVYASEAFLYMTGYSNAEVLGRNCRFLQSPDGMVKPKSTRKYV

[0624] DSNTINTMRKAIDRNAEVQVEVVNFKKNGQRFVNFLTMIPVRDETGEYRYSMGFQCETE

[0625] D) Truncated TDP-43 protein + mCherry reporter gene

[0626] SEQ ID NO:36. mCherry-TDP-43 (AA105-414) -NcVVDY50W

[0627] MVSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEGRPYEGTQTAKLKVTKGGPLPFAW

[0628] DILSPQFMYGSKAYVKHPADIPDYLKLSFPEGFKWERVMNFEDGGVVTVTQDSSLQDGEFIYK

[0629] VKLRGTNFPSDGPVMQKKTMGWEASSERMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTYK

[0630] AKKPVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDELYKSGLKDLIVLGLPWK

[0631] TTEQDLKEYFSTFGEVLMVQVKKDLKTGHSKGFGFVRFTEYETQVKVMSQRHMIDGRWCDC

[0632] KLPNSKQSQDEPLRSRKVFVGRCTEDMTEDELREFFSQYGDVMDVFIPKPFRAFAFVTFADDQI

[0633] AQSLCGEDLIIKGISVHISNAEPKHNSNRQLERSGRFGGNPGGFGNQGGFGNSRGGGAGLGNNQ

[0634] GSNMGGGMNFGAFSINPAMMAAAQAALQSSWGMMGMLASQQNQSGPSGNNQNQGNMQRE

[0635] PNQAFGSGNNSYSGSNSGAAIGWGSASNAGSGSGFNGGFGSSMDSKSSGWGMFRAQRHTLYA

[0636] PGGYDIMGWLIQIMNRPNPQVELGPVDTSCALILCDLKQKDTPIVYASEAFLYMTGYSNAEVLG

[0637] RNCRFLQSPDGMVKPKSTRKYVDSNTINTMRKAIDRNAEVQVEVVNFKKNGQRFVNFLTMIPV

[0638] RDETGEYRYSMGFQCETE

[0639] SEQ ID NO:37.mCherry-TDP-43 (AA191-414) -NcVVDY50W

[0640] MVSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEGRPYEGTQTAKLKVTKGGPLPFAW

[0641] DILSPQFMYGSKAYVKHPADIPDYLKLSFPEGFKWERVMNFEDGGVVTVTQDSSLQDGEFIYK

[0642] VKLRGTNFPSDGPVMQKKTMGWEASSERMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTYK

[0643] AKKPVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDELYKSGLKRKVFVGRCTE

[0644] DMTEDELREFFSQYGDVMDVFIPKPFRAFAFVTFADDQIAQSLCGEDLIIKGISVHISNAEPKHNS

[0645] NRQLERSGRFGGNPGGFGNQGGFGNSRGGGAGLGNNQGSNMGGGMNFGAFSINPAMMAAA

[0646] QAALQSSWGMMGMLASQQNQSGPSGNNQNQGNMQREPNQAFGSGNNSYSGSNSGAAIGWG

[0647] SASNAGSGSGFNGGFGSSMDSKSSGWGMFRAQRHTLYAPGGYDIMGWLIQIMNRPNPQVELG

[0648] PVDTSCALILCDLKQKDTPIVYASEAFLYMTGYSNAEVLGRNCRFLQSPDGMVKPKSTRKYVD

[0649] SNTINTMRKAIDRNAEVQVEVVNFKKNGQRFVNFLTMIPVRDETGEYRYSMGFQCETE

[0650] SEQ ID NO:38.mCherry-TDP-43 (AA274-414) -NcVVDY50W

[0651] MVSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEGRPYEGTQTAKLKVTKGGPLPFAW

[0652] DILSPQFMYGSKAYVKHPADIPDYLKLSFPEGFKWERVMNFEDGGVVTVTQDSSLQDGEFIYK

[0653] VKLRGTNFPSDGPVMQKKTMGWEASSERMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTYK

[0654] AKKPVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDELYKSGLKGRFGGNPGGF

[0655] GNQGGFGNSRGGGAGLGNNQGSNMGGGMNFGAFSINPAMMAAAQAALQSSWGMMGMLAS

[0656] QQNQSGPSGNNQNQGNMQREPNQAFGSGNNSYSGSNSGAAIGWGSASNAGSGSGFNGGFGSS

[0657] MDSKSSGWGMFRAQRHTLYAPGGYDIMGWLIQIMNRPNPQVELGPVDTSCALILCDLKQKDTP

[0658] IVYASEAFLYMTGYSNAEVLGRNCRFLQSPDGMVKPKSTRKYVDSNTINTMRKAIDRNAEVQV

[0659] EVVNFKKNGQRFVNFLTMIPVRDETGEYRYSMGFQCETE

[0660] SEQ ID NO:39.NcVVDY50W-TDP-43 (AA105-414) -mCherry

[0661] MHTLYAPGGYDIMGWLIQIMNRPNPQVELGPVDTSCALILCDLKQKDTPIVYASEAFLYMTGYS

[0662] NAEVLGRNCRFLQSPDGMVKPKSTRKYVDSNTINTMRKAIDRNAEVQVEVVNFKKNGQRFVN

[0663] FLTMIPVRDETGEYRYSMGFQCETEADLIVLGLPWKTTEQDLKEYFSTFGEVLMVQVKKDLKT

[0664] GHSKGFGFVRFTEYETQVKVMSQRHMIDGRWCDCKLPNSKQSQDEPLRSRKVFVGRCTEDMT

[0665] EDELREFFSQYGDVMDVFIPKPFRAFAFVTFADDQIAQSLCGEDLIIKGISVHISNAEPKHNSNRQ

[0666] LERSGRFGGNPGGFGNQGGFGNSRGGGAGLGNNQGSNMGGGMNFGAFSINPAMMAAAQAAL

[0667] QSSWGMMGMLASQQNQSGPSGNNQNQGNMQREPNQAFGSGNNSYSGSNSGAAIGWGSASN

[0668] AGSGSGFNGGFGSSMDSKSSGWGMFAPVATMVSKGEEDNMAIIKEFMRFKVHMEGSVNGHEF

[0669] EIEGEGEGRPYEGTQTAKLKVTKGGPLPFAWDILSPQFMYGSKAYVKHPADIPDYLKLSFPEGFK

[0670] WERVMNFEDGGVVTVTQDSSLQDGEFIYKVKLRGTNFPSDGPVMQKKTMGWEASSERMYPE

[0671] DGALKGEIKQRLKLKDGGHYDAEVKTTYKAKKPVQLPGAYNVNIKLDITSHNEDYTIVEQYER

[0672] AEGRHSTGGMDELYK

[0673] SEQ ID NO:40.NcVVDY50W-TDP-43 (AA191-414) -mCherry

[0674] MHTLYAPGGYDIMGWLIQIMNRPNPQVELGPVDTSCALILCDLKQKDTPIVYASEAFLYMTGYS

[0675] NAEVLGRNCRFLQSPDGMVKPKSTRKYVDSNTINTMRKAIDRNAEVQVEVVNFKKNGQRFVN

[0676] FLTMIPVRDETGEYRYSMGFQCETEARKVFVGRCTEDMTEDELREFFSQYGDVMDVFIPKPFR

[0677] AFAFVTFADDQIAQSLCGEDLIIKGISVHISNAEPKHNSNRQLERSGRFGGNPGGFGNQGGFGNS

[0678] RGGGAGLGNNQGSNMGGGMNFGAFSINPAMMAAAQAALQSSWGMMGMLASQQNQSGPSG

[0679] NNQNQGNMQREPNQAFGSGNNSYSGSNSGAAIGWGSASNAGSGSGFNGGFGSSMDSKSSGW

[0680] GMFAPVATMVSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEGRPYEGTQTAKLKVTK

[0681] GGPLPFAWDILSPQFMYGSKAYVKHPADIPDYLKLSFPEGFKWERVMNFEDGGVVTVTQDSSL

[0682] QDGEFIYKVKLRGTNFPSDGPVMQKKTMGWEASSERMYPEDGALKGEIKQRLKLKDGGHYD

[0683] AEVKTTYKAKKPVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDELYK

[0684] SEQ ID NO:41.NcVVDY50W-TDP-43 (AA274-414) -mCherry

[0685] MHTLYAPGGYDIMGWLIQIMNRPNPQVELGPVDTSCALILCDLKQKDTPIVYASEAFLYMTGYS

[0686] NAEVLGRNCRFLQSPDGMVKPKSTRKYVDSNTINTMRKAIDRNAEVQVEVVNFKKNGQRFVN

[0687] FLTMIPVRDETGEYRYSMGFQCETEAGRFGGNPGGFGNQGGFGNSRGGGAGLGNNQGSNMGG

[0688] GMNFGAFSINPAMMAAAQAALQSSWGMMGMLASQQNQSGPSGNNQNQGNMQREPNQAFGS

[0689] GNNSYSGSNSGAAIGWGSASNAGSGSGFNGGFGSSMDSKSSGWGMFAPVATMVSKGEEDNM

[0690] AIIKEFMRFKVHMEGSVNGHEFEIEGEGEGRPYEGTQTAKLKVTKGGPLPFAWDILSPQFMYGS

[0691] KAYVKHPADIPDYLKLSFPEGFKWERVMNFEDGGVVTVTQDSSLQDGEFIYKVKLRGTNFPSD

[0692] GPVMQKKTMGWEASSERMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTYKAKKPVQLPGA

[0693] YNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDELYK

[0694] The resulting alpha-synuclein protein arrangement:

[0695] 1. Amino acid sequence of Cry2olig fusion protein:

[0696] A) Full-length α-synuclein (asyn) protein without reporter gene

[0697] SEQ ID NO:42. Cry2olig-asyn

[0698] MKMDKKTIVWFRRDLRIEDNPALAAAAHEGSVFPVFIWCPEEEGQFYPGRASRWWMKQSLAH

[0699] LSQSLKALGSDLTLIKTHNTISAILDCIRVTGATKVVFNHLYDPVSLVRDHTVKEKLVERGISVQS

[0700] YNGDLLYEPWEIYCEKGKPFTSFNSYWKKCLDMSIESVMLPPPWRLMPITAAAEAIWACSIEEL

[0701] GLENEAEKPSNALLTRAWSPGWSNADKLLNEFIEKQLIDYAKNSKKVVGNSTSLLSPYLHFGEIS

[0702] VRHVFQCARMKQIIWARDKNSEGEESADLFLRGIGLREYSRYICFNFPFTHEQSLLSHLRFFPWD

[0703] ADVDKFKAWRQGRTGYPLVDAGMRELWATGWMHNRIRVIVSSFAVKFLLLPWKWGMKYFWD

[0704] TLLDADLECDILGWQYISGSIPDGHELDRLDNPALQGAKYDPEGEYIRQWLPELARLPTEWIHH

[0705] PWDAPLTVLKASGVELGTNYAKPIVDIDTARELLAKAISRTRGAQIMIGAAAMDVFMKGLSKA

[0706] KEGVVAAAEKTKQGVAEAAGKTKEGVLYVGSKTKEGVVHGVATVAEKTKEQVTNVGGAVVT

[0707] GVTAVAQKTVEGAGSIAAATGFVKKDQLGKNEEGAPQEGILEDMPVDPDNEAYEMPSEEGYQD

[0708] YEPEA

[0709] SEQ ID NO:43.Asyn-Cry2

[0710] MDVFMKGLSKAKEGVVAAAEKTKQGVAEAAGKTKEGVLYVGSKTKEGVVHGVATVAEKTKE

[0711] QVTNVGGAVVTGVTAVAQKTVEGAGSIAAATGFVKKDQLGKNEEGAPQEGILEDMPVDPDNE

[0712] AYEMPSEEGYQDYEPEADPPVATMKMDKKTIVWFRRDLRIEDNPALAAAAHEGSVFPVFIWCP

[0713] EEEGQFYPGRASRWWMKQSLAHLSQSLKALGSDLTLIKTHNTISAILDCIRVTGATKVVFNHLY

[0714] DPVSLVRDHTVKEKLVERGISVQSYNGDLLYEPWEIYCEKGKPFTSFNSYWKKCLDMSIESVML

[0715] PPPWRLMPITAAAEAIWACSIEELGLENEAEKPSNALLTRAWSPGWSNADKLLNEFIEKQLIDYA

[0716] KNSKKVVGNSTSLLSPYLHFGEISVRHVFQCARMKQIIWARDKNSEGEESADLFLRGIGLREYS

[0717] RYICFNFPFTHEQSLLSHLRFFPWDADVDKFKAWRQGRTGYPLVDAGMRELWATGWMHNRIR

[0718] VIVSSFAVKFLLLPWKWGMKYFWDTLLDADLECDILGWQYISGSIPDGHELDRLDNPALQGAK

[0719] YDPEGEYIRQWLPELARLPTEWIHHPWDAPLTVLKASGVELGTNYAKPIVDIDTARELLAKAISR

[0720] TRGAQIMIGAA

[0721] B) Full-length α-synuclein (asyn) protein + mCherry reporter gene

[0722] SEQ ID NO:44.Cry2olig-asyn-mCherry

[0723] MKMDKKTIVWFRRDLRIEDNPALAAAAHEGSVFPVFIWCPEEEGQFYPGRASRWWMKQSLAH

[0724] LSQSLKALGSDLTLIKTHNTISAILDCIRVTGATKVVFNHLYDPVSLVRDHTVKEKLVERGISVQS

[0725] YNGDLLYEPWEIYCEKGKPFTSFNSYWKKCLDMSIESVMLPPPWRLMPITAAAEAIWACSIEEL

[0726] GLENEAEKPSNALLTRAWSPGWSNADKLLNEFIEKQLIDYAKNSKKVVGNSTSLLSPYLHFGEIS

[0727] VRHVFQCARMKQIIWARDKNSEGEESADLFLRGIGLREYSRYICFNFPFTHEQSLLSHLRFFPWD

[0728] ADVDKFKAWRQGRTGYPLVDAGMRELWATGWMHNRIRVIVSSFAVKFLLLPWKWGMKYFWD

[0729] TLLDADLECDILGWQYISGSIPDGHELDRLDNPALQGAKYDPEGEYIRQWLPELARLPTEWIHH

[0730] PWDAPLTVLKASGVELGTNYAKPIVDIDTARELLAKAISRTRGAQIMIGAAAMDVFMKGLSKA

[0731] KEGVVAAAEKTKQGVAEAAGKTKEGVLYVGSKTKEGVVHGVATVAEKTKEQVTNVGGAVVT

[0732] GVTAVAQKTVEGAGSIAAATGFVKKDQLGKNEEGAPQEGILEDMPVDPDNEAYEMPSEEGYQD

[0733] YEPEADPPVATMVSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEGRPYEGTQTAKLK

[0734] VTKGGPLPFAWDILSPQFMYGSKAYVKHPADIPDYLKLSFPEGFKWERVMNFEDGGVVTVTQD

[0735] SSLQDGEFIYKVKLRGTNFPSDGPVMQKKTMGWEASSERMYPEDGALKGEIKQRLKLKDGGH

[0736] YDAEVKTTYKAKKPVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDELYK

[0737] SEQ ID NO:45.Cry2olig-mCherry-Asyn

[0738] MKMDKKTIVWFRRDLRIEDNPALAAAAHEGSVFPVFIWCPEEEGQFYPGRASRWWMKQSLAH

[0739] LSQSLKALGSDLTLIKTHNTISAILDCIRVTGATKVVFNHLYDPVSLVRDHTVKEKLVERGISVQS

[0740] YNGDLLYEPWEIYCEKGKPFTSFNSYWKKCLDMSIESVMLPPPWRLMPITAAAEAIWACSIEEL

[0741] GLENEAEKPSNALLTRAWSPGWSNADKLLNEFIEKQLIDYAKNSKKVVGNSTSLLSPYLHFGEIS

[0742] VRHVFQCARMKQIIWARDKNSEGEESADLFLRGIGLREYSRYICFNFPFTHEQSLLSHLRFFPWD

[0743] ADVDKFKAWRQGRTGYPLVDAGMRELWATGWMHNRIRVIVSSFAVKFLLLPWKWGMKYFWD

[0744] TLLDADLECDILGWQYISGSIPDGHELDRLDNPALQGAKYDPEGEYIRQWLPELARLPTEWIHH

[0745] PWDAPLTVLKASGVELGTNYAKPIVDIDTARELLAKAISRTRGAQIMIGAAARDPPVATMVSKG

[0746] EEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEGRPYEGTQTAKLKVTKGGPLPFAWDILSPQ

[0747] FMYGSKAYVKHPADIPDYLKLSFPEGFKWERVMNFEDGGVVTVTQDSSLQDGEFIYKVKLRGT

[0748] NFPSDGPVMQKKTMGWEASSERMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTYKAKKPVQ

[0749] LPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDELYKMDVFMKGLSKAKEGVVAAA

[0750] EKTKQGVAEAAGKTKEGVLYVGSKTKEGVVHGVATVAEKTKEQVTNVGGAVVTGVTAVAQKT

[0751] VEGAGSIAAATGFVKKDQLGKNEEGAPQEGILEDMPVDPDNEAYEMPSEEGYQDYEPEA

[0752] SEQ ID NO:46.Asyn-Cry2-mCherry

[0753] MDVFMKGLSKAKEGVVAAAEKTKQGVAEAAGKTKEGVLYVGSKTKEGVVHGVATVAEKTKE

[0754] QVTNVGGAVVTGVTAVAQKTVEGAGSIAAATGFVKKDQLGKNEEGAPQEGILEDMPVDPDNE

[0755] AYEMPSEEGYQDYEPEADPPVATMKMDKKTIVWFRRDLRIEDNPALAAAAHEGSVFPVFIWCP

[0756] EEEGQFYPGRASRWWMKQSLAHLSQSLKALGSDLTLIKTHNTISAILDCIRVTGATKVVFNHLY

[0757] DPVSLVRDHTVKEKLVERGISVQSYNGDLLYEPWEIYCEKGKPFTSFNSYWKKCLDMSIESVML

[0758] PPPWRLMPITAAAEAIWACSIEELGLENEAEKPSNALLTRAWSPGWSNADKLLNEFIEKQLIDYA

[0759] KNSKKVVGNSTSLLSPYLHFGEISVRHVFQCARMKQIIWARDKNSEGEESADLFLRGIGLREYS

[0760] RYICFNFPFTHEQSLLSHLRFFPWDADVDKFKAWRQGRTGYPLVDAGMRELWATGWMHNRIR

[0761] VIVSSFAVKFLLLPWKWGMKYFWDTLLDADLECDILGWQYISGSIPDGHELDRLDNPALQGAK

[0762] YDPEGEYIRQWLPELARLPTEWIHHPWDAPLTVLKASGVELGTNYAKPIVDIDTARELLAKAISR

[0763] TRGAQIMIGAAAMVSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEGRPYEGTQTAKL

[0764] KVTKGGPLPFAWDILSPQFMYGSKAYVKHPADIPDYLKLSFPEGFKWERVMNFEDGGVVTVTQ

[0765] DSSLQDGEFIYKVKLRGTNFPSDGPVMQKKTMGWEASSERMYPEDGALKGEIKQRLKLKDGG

[0766] HYDAEVKTTYKAKKPVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDELYK

[0767] 1. Amino acid sequence of the NcVVD fusion protein:

[0768] A) Full-length α-synuclein (asyn) protein without reporter gene

[0769] SEQ ID NO:47. Asyn-NcVVDY50W

[0770] MDVFMKGLSKAKEGVVAAAEKTKQGVAEAAGKTKEGVLYVGSKTKEGVVHGVATVAEKTKE

[0771] QVTNVGGAVVTGVTAVAQKTVEGAGSIAAATGFVKKDQLGKNEEGAPQEGILEDMPVDPDNE

[0772] AYEMPSEEGYQDYEPEAFHTLYAPGGYDIMGWLIQIMNRPNPQVELGPVDTSCALILCDLKQK

[0773] DTPIVYASEAFLYMTGYSNAEVLGRNCRFLQSPDGMVKPKSTRKYVDSNTINTMRKAIDRNAE

[0774] VQVEVVNFKKNGQRFVNFLTMIPVRDETGEYRYSMGFQCETE

[0775] SEQ ID NO:48.NcVVDY50W-Asyn

[0776] MHTLYAPGGYDIMGWLIQIMNRPNPQVELGPVDTSCALILCDLKQKDTPIVYASEAFLYMTGYS

[0777] NAEVLGRNCRFLQSPDGMVKPKSTRKYVDSNTINTMRKAIDRNAEVQVEVVNFKKNGQRFVN

[0778] FLTMIPVRDETGEYRYSMGFQCETEAMDVFMKGLSKAKEGVVAAAEKTKQGVAEAAGKTKEG

[0779] VLYVGSKTKEGVVHGVATVAEKTKEQVTNVGGAVVTGVTAVAQKTVEGAGSIAAATGFVKKD

[0780] QLGKNEEGAPQEGILEDMPVDPDNEAYEMPSEEGYQDYEPEA

[0781] B) Full-length α-synuclein (asyn) protein + mCherry reporter gene

[0782] SEQ ID NO:49.mCherry-Asyn-NcVVDY50W

[0783] MVSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEGRPYEGTQTAKLKVTKGGPLPFAW

[0784] DILSPQFMYGSKAYVKHPADIPDYLKLSFPEGFKWERVMNFEDGGVVTVTQDSSLQDGEFIYK

[0785] VKLRGTNFPSDGPVMQKKTMGWEASSERMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTYK

[0786] AKKPVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDELYSKMDVFMKGLSKAK

[0787] EGVVAAAEKTKQGVAEAAGKTKEGVLYVGSKTKEGVVHGVATVAEKTKEQVTNVGGAVVTG

[0788] VTAVAQKTVEGAGSIAAATGFVKKDQLGKNEEGAPQEGILEDMPVDPDNEAYEMPSEEGYQDY

[0789] EPEAFHTLYAPGGYDIMGWLIQIMNRPNPQVELGPVDTSCALILCDLKQKDTPIVYASEAFLYMT

[0790] GYSNAEVLGRNCRFLQSPDGMVKPKSTRKYVDSNTINTMRKAIDRNAEVQVEVVNFKKNGQR

[0791] FVNFLTMIPVRDETGEYRYSMGFQCETE

[0792] SEQ ID NO:50.mCherry-NcVVDY50W-Asyn

[0793] MVSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEGRPYEGTQTAKLKVTKGGPLPFAW

[0794] DILSPQFMYGSKAYVKHPADIPDYLKLSFPEGFKWERVMNFEDGGVVTVTQDSSLQDGEFIYK

[0795] VKLRGTNFPSDGPVMQKKTMGWEASSERMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTYK

[0796] AKKPVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDELYKSGLRSRAQRHTLYAP

[0797] GGYDIMGWLIQIMNRPNPQVELGPVDTSCALILCDLKQKDTPIVYASEAFLYMTGYSNAEVLGR

[0798] NCRFLQSPDGMVKPKSTRKYVDSNTINTMRKAIDRNAEVQVEVVNFKKNGQRFVNFLTMIPVR

[0799] DETGEYRYSMGFQCETEALEFCSRRYRGPMDVFMKGLSKAKEGVVAAAEKTKQGVAEAAGK

[0800] TKEGVLYVGSKTKEGVVHGVATVAEKTKEQVTNVGGAVVTGVTAVAQKTVEGAGSIAAATGF

[0801] VKKDQLGKNEEGAPQEGILEDMPVDPDNEAYEMPSEEGYQDYEPEA

[0802] SEQ ID NO:51.NcVVDY50W-Asyn-mCherry

[0803] MHTLYAPGGYDIMGWLIQIMNRPNPQVELGPVDTSCALILCDLKQKDTPIVYASEAFLYMTGYS

[0804] NAEVLGRNCRFLQSPDGMVKPKSTRKYVDSNTINTMRKAIDRNAEVQVEVVNFKKNGQRFVN

[0805] FLTMIPVRDETGEYRYSMGFQCETEAMDVFMKGLSKAKEGVVAAAEKTKQGVAEAAGKTKEG

[0806] VLYVGSKTKEGVVHGVATVAEKTKEQVTNVGGAVVTGVTAVAQKTVEGAGSIAAATGFVKKD

[0807] QLGKNEEGAPQEGILEDMPVDPDNEAYEMPSEEGYQDYEPEAFAPVATMVSKGEEDNMAIIKE

[0808] FMRFKVHMEGSVNGHEFEIEGEGEGRPYEGTQTAKLKVTKGGPLPFAWDILSPQFMYGSKAYV

[0809] KHPADIPDYLKLSFPEGFKWERVMNFEDGGVVTVTQDSSLQDGEFIYKVKLRGTNFPSDGPVM

[0810] QKKTMGWEASSERMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTYKAKKPVQLPGAYNVNI

[0811] KLDITSHNEDYTIVEQYERAEGRHSTGGMDELYK

[0812] SEQ ID NO:52.ɑ-Synuclein-mCherry-NcVVD (Wild type)

[0813] MDVFMKGLSKAKEGVVAAAEKTKQGVAEAAGKTKEGVLYVGSKTKEGVVHGVATVAEKTKE

[0814] QVTNVGGAVVTGVTAVAQKTVEGAGSIAAATGFVKKDQLGKNEEGAPQEGILEDMPVDPDNE

[0815] AYEMPSEEGYQDYEPEALLPVATMVSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEG

[0816] RPYEGTQTAKLKVTKGGPLPFAWDILSPQFMYGSKAYVKHPADIPDYLKLSFPEGFKWERVMN

[0817] FEDGGVVTVTQDSSLQDGEFIYKVKLRGTNFPSDGPVMQKKTMGWEASSERMYPEDGALKGE

[0818] IKQRLKLKDGGHYDAEVKTTYKAKKPVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHST

[0819] GGMDELYKSGLRSRAQASNSAVDGTAGPMHTLYAPGGYDIMGYLIQIMNRPNPQVELGPVDTS

[0820] CALILCDLKQKDTPIVYASEAFLYMTGY2SNAEVLGRNCRFLQSPDGMVKPKSTRKYVDSNTIN

[0821] TMRKAIDRNAEVQVEVVNFKKNGQRFVNFLTMIPVRDETGEYRYSMGFQCETEGIHRI*

[0822] SEQ ID NO:53. mCherry-α-Synuclein-NcVVD (Wild Type)

[0823] MVSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEGRPYEGTQTAKLKVTKGGPLPFAW

[0824] DILSPQFMYGSKAYVKHPADIPDYLKLSFPEGFKWERVMNFEDGGVVTVTQDSSLQDGEFIYK

[0825] VKLRGTNFPSDGPVMQKKTMGWEASSERMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTYK

[0826] AKKPVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDELYKSGLRSRAQMDVFM

[0827] KGLSKAKEGVVAAAEKTKQGVAEAAGKTKEGVLYVGSKTKEGVVHGVATVAEKTKEQVTNV

[0828] GGAVVTGVTAVAQKTVEGAGSIAAATGFVKKDQLGKNEEGAPQEGILEDMPVDPDNEAYEMPS

[0829] EEGYQDYEPEASNSAVDGTAGPMHTLYAPGGYDIMGYLIQIMNRPNPQVELGPVDTSCALILCD

[0830] LKQKDTPIVYASEAFLYMTGYSNAEVLGRNCRFLQSPDGMVKPKSTRKYVDSNTINTMRKAIDRNAEVQVEVVNFKKNGQRFVNFLTMIPVRDETGEYRYSMGFQCETEGIHRI*

[0831] SEQ ID NO:54. mCherry-NcVVD (wild type)-α-synuclein

[0832] MVSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEGRPYEGTQTAKLKVTKGGPLPFAW

[0833] DILSPQFMYGSKAYVKHPADIPDYLKLSFPEGFKWERVMNFEDGGVVTVTQDSSLQDGEFIYK

[0834] VKLRGTNFPSDGPVMQKKTMGWEASSERMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTYK

[0835] AKKPVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDELYKSGLRSRAQASNSAV

[0836] DGTAGPMHTLYAPGGYDIMGYLIQIMNRPNPQVELGPVDTSCALILCDLKQKDTPIVYASEAFL

[0837] YMTGYSNAEVLGRNCRFLQSPDGMVKPKSTRKYVDSNTINTMRKAIDRNAEVQVEVVNFKKN

[0838] GQRFVNFLTMIPVRDETGEYRYSMGFQCETEGMDVFMKGLSKAKEGVVAAAEKTKQGVAEAA

[0839] GKTKEGVLYVGSKTKEGVVHGVATVAEKTKEQVTNVGGAVVTGVTAVAQKTVEGAGSIAAAT

[0840] GFVKKDQLGKNEEGAPQEGILEDMPVDPDNEAYEMPSEEGYQDYEPEAHRI*

[0841] Tau

[0842] SEQ ID NO:55.mCherry-Tau

[0843] MVSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEGRPYEGTQTAKLKVTKGGPLPFAW

[0844] DILSPQFMYGSKAYVKHPADIPDYLKLSFPEGFKWERVMNFEDGGVVTVTQDSSLQDGEFIYK

[0845] VKLRGTNFPSDGPVMQKKTMGWEASSERMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTYK

[0846] AKKPVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDELYKSGLRSRAQASNSAV

[0847] DGTAGPMAEPRQEFEVMEDHAGTYGLGDRKDQGGYTMHQDQEGDTDAGLKESPLQTPTEDG

[0848] SEEPGSETSDAKSTPTAEDVTAPLVDEGAPGKQAAAQPHTEIPEGTTAEEAGIGDTPSLEDEAAG

[0849] HVTQARMVSKSKDGTGSDDKKAKGADGKTKIATPRGAAPPGQKGQANATRIPAKTPPAPKTPP

[0850] SSGEPPKSGDRSGYSSPGSPGTPGSRSRTPSLPTPPTREPKKVAVVRTPPKSPSSAKSRLQTAPVPM

[0851] PDLKNVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKHVPGGGSVQIVYKPV

[0852] DLSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETHKLT

[0853] FRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQLATLADEVSASLAKQGL

[0854] GIHRI*

[0855] SEQ ID NO:56.mCherry-VfAU-Tau

[0856] MVSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEGRPYEGTQTAKLKVTKGGPLPFAW

[0857] DILSPQFMYGSKAYVKHPADIPDYLKLSFPEGFKWERVMNFEDGGVVTVTQDSSLQDGEFIYK

[0858] VKLRGTNFPSDGPVMQKKTMGWEASSERMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTYK

[0859] AKKPVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDELYKSGLRSRAQASNSAV

[0860] DGTAGPMPDYSLVKALQMAQQNFVITDASLPDNPIVYASRGFLTLTGYSLDQILGRNCRFLQGP

[0861] ETDPRAVDKIRNAITKGVDTSVCLLNYRQDGTTFWNLFFVAGLRDSKGNIVNYVGVQSKVSED

[0862] YAKLLVNEQNIEYKGVRTSNMLRRKPGGIHRIMAEPRQEFEVMEDHAGTYGLGDRKDQGGYT

[0863] MHQDQEGDTDAGLKESPLQTPTEDGSEEPGSETSDAKSTPTAEDVTAPLVDEGAPGKQAAAQP

[0864] HTEIPEGTTAEEAGIGDTPSLEDEAAGHVTQARMVSKSKDGTGSDDKKAKGADGKTKIATPRG

[0865] AAPPGQKGQANATRIPAKTPPAPKTPPSSGEPPKSGDRSGYSSPGSPGTPGSRSRTPSLPTPPTREP

[0866] KKVAVVRTPPKSPSSAKSRLQTAPVPMPDLKNVKSKIGSTENLKHQPGGGKVQIINKKLDLSNV

[0867] QSKCGSKDNIKHVPGGGSVQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRV

[0868] QSKIGSLDNITHVPGGGNKKIETHKLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSST

[0869] GSIDMVDSPQLATLADEVSASLAKQGLITDHNQPYHICRGFTCFKKPPTPPPEPET*

[0870] SEQ ID NO:57.mCherry-(y50w)-Tau

[0871] MVSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEGRPYEGTQTAKLKVTKGGPLPFAW

[0872] DILSPQFMYGSKAYVKHPADIPDYLKLSFPEGFKWERVMNFEDGGVVTVTQDSSLQDGEFIYK

[0873] VKLRGTNFPSDGPVMQKKTMGWEASSERMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTYK

[0874] AKKPVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDELYKSGLRSRAQASNSAV

[0875] DGTAGPMHTLYAPGGYDIMGWLIQIMNRPNPQVELGPVDTSCALILCDLKQKDTPIVYASEAFL

[0876] YMTGYSNAEVLGRNCRFLQSPDGMVKPKSTRKYVDSNTINTMRKAIDRNAEVQVEVVNFKKN

[0877] GQRFVNFLTMIPVRDETGEYRYSMGFQCETEGMAEPRQEFEVMEDHAGTYGLGDRKDQGGYT

[0878] MHQDQEGDTDAGLKESPLQTPTEDGSEEPGSETSDAKSTPTAEDVTAPLVDEGAPGKQAAAQP

[0879] HTEIPEGTTAEEAGIGDTPSLEDEAAGHVTQARMVSKSKDGTGSDDKKAKGADGKTKIATPRG

[0880] AAPPGQKGQANATRIPAKTPPAPKTPPSSGEPPKSGDRSGYSSPGSPGTPGSRSRTPSLPTPPTREP

[0881] KKVAVVRTPPKSPSSAKSRLQTAPVPMPDLKNVKSKIGSTENLKHQPGGGKVQIINKKLDLSNV

[0882] QSKCGSKDNIKHVPGGGSVQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRV

[0883] QSKIGSLDNITHVPGGGNKKIETHKLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQLATLADEVSASLAKQGLHRI*

[0884] SEQ ID NO:58.mCherry-Tau-NcVVD(y50w)

[0885] MVSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEGRPYEGTQTAKLKVTKGGPLPFAW

[0886] DILSPQFMYGSKAYVKHPADIPDYLKLSFPEGFKWERVMNFEDGGVVTVTQDSSLQDGEFIYK

[0887] VKLRGTNFPSDGPVMQKKTMGWEASSERMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTYK

[0888] AKKPVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDELYKSGLTMAEPRQEFEV

[0889] MEDHAGTYGLDGDRKDQGGYTMHQDQEGDTDAGLKESPLQTPTEDGSEEPGSETSDAKSTPTA

[0890] EDVTAPLVDEGAPGKQAAAQPHTEIPEGTTAEEAGIGDTPSLEDEAGHVTQARMVSKSKDGT

[0891] GSDDKKAKGADGKTKIATPRGAAPPGQKGQANATRIPAKTPPAKTPPSSGEPPKSGDRSGYSSP

[0892] GSPGTPGSRSRTPSLPTPPTREPKKKVAVVRTPKPSKPSSAKSRLQTAPVPMPDLKNVKSKIGSTENL

[0893] KHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKHVPGGGSVQIVYKPVDLSKVTSKCGSLGNIH

[0894] HKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETHKLTFRENAKAKTDHGAEI

[0895] VYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQLATLADEVSASLAKQGLRRAQRHTLYAPGGY

[0896] DIMGWLIQIMNRPNPQVELGPVDTSCALILCDLKQKDTPIVYASEAFLYMTGYSNAEVLGRNCR

[0897] FLQSPDGMVKPKSTRKYVDSNTINTMRKAIDRNAEVQVEVVNFKKNGQRFVNFLTMIPVRDET

[0898] GEYRYSMGFQCETEALEFCSRRYRGPGIHRI*

[0899] SEQ ID NO:59.mCherry-NcVVD(y50w)-Tau

[0900] MVSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEGRPYEGTQTAKLKVTKGGPLPFAW

[0901] DILSPQFMYGSKAYVKHPADIPDYLKLSFPEGFKWERVMNFEDGGVVTVTQDSSLQDGEFIYK

[0902] VKLRGTNFPSDGPVMQKKTMGWEASSERMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTYK

[0903] AKKPVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDELYKSGLRSRAQRHTLYAP

[0904] GGYDIMGWLIQIMNRPNPQVELGPVDTSCALILCDLKQKDTPIVYASEAFLYMTGYSNAEVLGR

[0905] NCRFLQSPDGMVKPKSTRKYVDSNTINTMRKAIDRNAEVQVEVVNFKKNGQRFVNFLTMIPVR

[0906] DETGEYRYSMGFQCETEALAMAEPRQEFEVMEDHAGTYGLGDRKDQGGYTMHQDQEGDTD

[0907] AGLKESPLQTPTEDGSEEPGSETSDAKSTPTAEDVTAPLVDEGAPGKQAAAQPHTEIPEGTTAEE

[0908] AGIGDTPSLEDEAAGHVTQARMVSKSKDGTGSDDKKAKGADGKTKIATPRGAAPPGQKGQAN

[0909] ATRIPAKTPPAPKTPPSSGEPPKSGDRSGYSSPGSPGTPGSRSRTPSLPTPPTREPKKKVAVVRTPPKS

[0910] PSSAKSRLQTAPVPMPDLKNVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKH

[0911] VPGGGSVQIVYKPVDLSKVTSKCGSLNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHV

[0912] PGGGNKKIETHKLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQLAT

[0913] LADEVSASLAKQGLRCSRRYRGPGIHRI*

[0914] SEQ ID NO:60.Tau-mCherry-NcVVD(y50w)

[0915] MAEPRQEFEVMEDHAGTYGLDGDRKDQGGYTMHQDQEGDTDAGLKESPLQTPTEDGSEEPGSE

[0916] TSDAKSTPTAEDVTAPLVDEGAPGKQAAAQPHTEIPEGTTAEEAGIGDTPSLEDEAAGHVTQAR

[0917] MVSKSKDGTGSDDKKAKGADGKTKIATPRGAAPPGQKGQANATRIPAKTPPAKTPPPSSGEPPK

[0918] SGDRSGYSSPGSPGTPGSRSRTPSLPTPPTREPKKVAVVRTPKSPSSAKSRLQTAPVPMPDLKNV

[0919] KSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKHVPGGGSVQIVYKPVDLSKVTS

[0920] KCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETHKLTFRENAKA

[0921] KTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQLATLADEVSASLAKQGLALPVATM

[0922] VSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEGRPYEGTQTAKLKVTKGGPLPFAWD

[0923] ILSPQFMYGSKAYVKHPADIPDYLKLSFPEGFKWERVMNFEDGGVVTVTQDSSLQDGEFIYKV

[0924] KLRGTNFPSDGPVMQKKTMGWEASSERMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTYKA

[0925] KKPVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDELYKSGLRSRAQRHTLYAPG

[0926] GYDIMGWLIQIMNRPNPQVELGPVDTSCALILCDLKQKDTPIVYASEAFLYMTGYSNAEVLGRN

[0927] CRFLQSPDGMVKPKSTRKYVDSNTINTMRKAIDRNAEVQVEVVNFKKNGQRFVNFLTMIPVRD

[0928] ETGEYRYSMGFQCETEALEFCSRRYRGPGIHRI*

[0929] SEQ ID NO:61.Cry-mCherry-Tau

[0930] MKMDKKTIVWFRRDLRIEDNPALAAAAHEGSVFPVFIWCPEEEGQFYPGRASRWWMKQSLAH

[0931] LSQSLKALGSDLTLIKTHNTISAILDCIRVTGATKVVFNHLYDPVSLVRDHTVKEKLVERGISVQS

[0932] YNGDLLYEPWEIYCEKGKPFTSFNSYWKKCLDMSIESVMLPPPWRLMPITAAAEAIWACSIEEL

[0933] GLENEAEKPSNALLTRAWSPGWSNADKLLNEFIEKQLIDYAKNSKKVVGNSTSLLSPYLHFGEIS

[0934] VRHVFQCARMKQIIWARDKNSEGEESADLFLRGIGLREYSRYICFNFPFTHEQSLLSHLRFFPWD

[0935] ADVDKFKAWRQGRTGYPLVDAGMRELWATGWMHNRIRVIVSSFAVKFLLLPWKWGMKYFWD

[0936] TLLDADLECDILGWQYISGSIPDGHELDRLDNPALQGAKYDPEGEYIRQWLPELARLPTEWIHH

[0937] PWDAPLTVLKASGVELGTNYAKPIVDIDTARELLAKAISRTRGAQIMIGAAARDPPVATMVSKG

[0938] EEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEGRPYEGTQTAKLKVTKGGPLPFAWDILSPQ

[0939] FMYGSKAYVKHPADIPDYLKLSFPEGFKWERVMNFEDGGVVTVTQDSSLQDGEFIYKVKLRGT

[0940] NFPSDGPVMQKKTMGWEASSERMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTYKAKKPVQ

[0941] LPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDELYKSRMAEPRQEFEVMEDHAGTY

[0942] GLGDRKDQGGYTMHQDQEGDTDAGLKESPLQTPTEDGSEEPGSETSDAKSTPTAEDVTAPLVD

[0943] EGAPGKQAAAQPHTEIPEGTTAEEAGIGDTPSLEDEAAGHVTQARMVSKSKDGTGSDDKKAK

[0944] GADGKTKIATPRGAAPPGQKGQANATRIPAKTPPAKTPPPSSGEPPKSGDRSGYSSPGSPGTPGSR

[0945] SRTPSLPTPPTREPKKKVAVVRTPPKSPSSAKSRLQTAPVPMPDLKNVKSKIGSTENLKHQPGGGK

[0946] VQIINKKLDLSNVQSKCGSKDNIKHVPGGGSVQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQVE

[0947] VKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETHKLTFRENAKAKTDHGAEIVYKSPVVSGD

[0948] TSPRHLSNVSSTGSIDMVDSPQLATLADEVSASLAKQGLGDSRS*

[0949] SEQ ID NO:62.Tau-mCherry

[0950] MAEPRQEFEVMEDHAGTYGLDGDRKDQGGYTMHQDQEGDTDAGLKESPLQTPTEDGSEEPGSE

[0951] TSDAKSTPTAEDVTAPLVDEGAPGKQAAAQPHTEIPEGTTAEEAGIGDTPSLEDEAAGHVTQAR

[0952] MVSKSKDGTGSDDKKAKGADGKTKIATPRGAAPPGQKGQANATRIPAKTPPAKTPPPSSGEPPK

[0953] SGDRSGYSSPGSPGTPGSRSRTPSLPTPPTREPKKVAVVRTPKSPSSAKSRLQTAPVPMPDLKNV

[0954] KSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKHVPGGGSVQIVYKPVDLSKVTS

[0955] KCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETHKLTFRENAKA

[0956] KTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQLATLADEVSASLAKQGLFATMVSK

[0957] GEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEGRPYEGTQTAKLKVTKGGPLPFAWDILSP

[0958] QFMYGSKAYVKHPADIPDYLKLSFPEGFKWERVMNFEDGGVVTVTQDSSLQDGEFIYKVKLRG

[0959] TNFPSDGPVMQKKTMGWEASSERMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTYKAKKPV

[0960] QLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDELYKSGLRSRAQASNSAVDGTAGP

[0961] GSTGSR*

[0962] SEQ ID NO:63.Tau-Cry2olig-mCherry

[0963] MAEPRQEFEVMEDHAGTYGLGDRKDQGGYTMHQDQEGDTDAGLKESPLQTPTEDGSEEPGSE

[0964] TSDAKSTPTAEDVTAPLVDEGAPGKQAAAQPHTEIPEGTTAEEAGIGDTPSLEDEAAGHVTQAR

[0965] MVSKSKDGTGSDDKKAKGADGKTKIATPRGAAPPGQKGQANATRIPAKTPPAPKTPPSSGEPPK

[0966] SGDRSGYSSPGSPGTPGSRSRTPSLPTPPTREPKKVAVVRTPPKSPSSAKSRLQTAPVPMPDLKNV

[0967] KSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKHVPGGGSVQIVYKPVDLSKVTS

[0968] KCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETHKLTFRENAKA

[0969] KTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQLATLADEVSASLAKQGLALPDSDL

[0970] EATMKMDKKTIVWFRRDLRIEDNPALAAAAHEGSVFPVFIWCPEEEGQFYPGRASRWWMKQS

[0971] LAHLSQSLKALGSDLTLIKTHNTISAILDCIRVTGATKVVFNHLYDPVSLVRDHTVKEKLVERGIS

[0972] VQSYNGDLLYEPWEIYCEKGKPFTSFNSYWKKCLDMSIESVMLPPPWRLMPITAAAEAIWACSI

[0973] EELGLENEAEKPSNALLTRAWSPGWSNADKLLNEFIEKQLIDYAKNSKKVVGNSTSLLSPYLHF

[0974] GEISVRHVFQCARMKQIIWARDKNSEGEESADLFLRGIGLREYSRYICFNFPFTHEQSLLSHLRFF

[0975] PWDADVDKFKAWRQGRTGYPLVDAGMRELWATGWMHNRIRVIVSSFAVKFLLLPWKWGMKY

[0976] FWDTLLDADLECDILGWQYISGSIPDGHELDRLDNPALQGAKYDPEGEYIRQWLPELARLPTE

[0977] WIHHPWDAPLTVLKASGVELGTNYAKPIVDIDTARELLAKAISRTRGAQIMIGAAARDPPVATM

[0978] VSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEGRPYEGTQTAKLKVTKGGPLPFAWD

[0979] ILSPQFMYGSKAYVKHPADIPDYLKLSFPEGFKWERVMNFEDGGVVTVTQDSSLQDGEFIYKV

[0980] KLRGTNFPSDGPVMQKKTMGWEASSERMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTYKA

[0981] KKPVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDELYK*

[0982] SEQ ID NO:64.Cry2Olig-Tau-mCherry

[0983] MKMDKKTIVWFRRDLRIEDNPALAAAAHEGSVFPVFIWCPEEEGQFYPGRASRWWMKQSLAH

[0984] LSQSLKALGSDLTLIKTHNTISAILDCIRVTGATKVVFNHLYDPVSLVRDHTVKEKLVERGISVQS

[0985] YNGDLLYEPWEIYCEKGKPFTSFNSYWKKCLDMSIESVMLPPPWRLMPITAAAEAIWACSIEEL

[0986] GLENEAEKPSNALLTRAWSPGWSNADKLLNEFIEKQLIDYAKNSKKVVGNSTSLLSPYLHFGEIS

[0987] VRHVFQCARMKQIIWARDKNSEGEESADLFLRGIGLREYSRYICFNFPFTHEQSLLSHLRFFPWD

[0988] ADVDKFKAWRQGRTGYPLVDAGMRELWATGWMHNRIRVIVSSFAVKFLLLPWKWGMKYFWD

[0989] TLLDADLECDILGWQYISGSIPDGHELDRLDNPALQGAKYDPEGEYIRQWLPELARLPTEWIHH

[0990] PWDAPLTVLKASGVELGTNYAKPIVDIDTARELLAKAISRTRGAQIMIGAAAPMAEPRQEFEVM

[0991] EDHAGTYGLDGDRKDQGGYTMHQDQEGDTDAGLKESPQTPTEDGSEEPGSETSDAKSTPTAE

[0992] DVTAPLVDEGAPGKQAAAQPHTEIPEGTTAEEAGIGDTPSLEDEAAGHVTQARMVSKSKDGTG

[0993] SDDKKAKGADGKTKIATPRGAAPPGQKGQANATRIPAKTPPAKTPPSSGEPPKSGDRSGYSSPG

[0994] SPGTPGSRSRTPSLPTPPTREPKKKVAVVRTPKPSKPSSAKSRLQTAPVPMPDLKNVKSKIGSTENLK

[0995] HQPGGGKVQIINKKLDLSNVQSKCGSKDNIKHVPGGGSVQIVYKPVDLSKVTSKCGSLGNIHH

[0996] KPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETHKLTFRENAKAKTDHGAEIV

[0997] YKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQLATLADEVSASLAKQGLGDPPVATMVSKGEEDN

[0998] MAIIKEFMRFKVHMEGSVNGHEFEIEEGEGGRPYEGTQTAKLKVTKGGPLPFAWDILSPQFMYG

[0999] SKAYVKHPADIPDYLKLSFPEGFKWERVMNFEDGGVVTVTQDSSLQDGEFIYKVKLRGTNFPS

[1000] DGPVMQKKTMGWEASSERMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTYKAKKPVQLPG

[1001] AYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDELYK*

[1002] SEQ ID NO:65.Cry-mCherry-Tau

[1003] MKMDKKTIVWFRRDLRIEDNPALAAAAHEGSVFPVFIWCPEEEGQFYPGRASRWWMKQSLAH

[1004] LSQSLKALGSDLTLIKTHNTISAILDCIRVTGATKVVFNHLYDPVSLVRDHTVKEKLVERGISVQS

[1005] YNGDLLYEPWEIYCEKGKPFTSFNSYWKKCLDMSIESVMLPPPWRLMPITAAAEAIWACSIEEL

[1006] GLENEAEKPSNALLTRAWSPGWSNADKLLNEFIEKQLIDYAKNSKKVVGNSTSLLSPYLHFGEIS

[1007] VRHVFQCARMKQIIWARDKNSEGEESADLFLRGIGLREYSRYICFNFPFTHEQSLLSHLRFFPWD

[1008] ADVDKFKAWRQGRTGYPLVDAGMRELWATGWMHNRIRVIVSSFAVKFLLLPWKWGMKYFWD

[1009] TLLDADLECDILGWQYISGSIPDGHELDRLDNPALQGAKYDPEGEYIRQWLPELARLPTEWIHH

[1010] PWDAPLTVLKASGVELGTNYAKPIVDIDTARELLAKAISRTRGAQIMIGAAARDPPVATMVSKG

[1011] EEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEGRPYEGTQTAKLKVTKGGPLPFAWDILSPQ

[1012] FMYGSKAYVKHPADIPDYLKLSFPEGFKWERVMNFEDGGVVTVTQDSSLQDGEFIYKVKLRGT

[1013] NFPSDGPVMQKKTMGWEASSERMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTYKAKKPVQ

[1014] LPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDELYKSRMAEPRQEFEVMEDHAGTY

[1015] GLGDRKDQGGYTMHQDQEGDTDAGLKESPLQTPTEDGSEEPGSETSDAKSTPTAEDVTAPLVD

[1016] EGAPGKQAAAQPHTEIPEGTTAEEAGIGDTPSLEDEAAGHVTQARMVSKSKDGTGSDDKKAK

[1017] GADGKTKIATPRGAAPPGQKGQANATRIPAKTPPAPKTPPSSGEPPKSGDRSGYSSPGSPGTPGSR

[1018] SRTPSLPTPPTREPKKVAVVRTPPKSPSSAKSRLQTAPVPMPDLKNVKSKIGSTENLKHQPGGGK

[1019] VQIINKKLDLSNVQSKCGSKDNIKHVPGGGSVQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQVE

[1020] VKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETHKLTFRENAKAKTDHGAEIVYKSPVVSGD

[1021] TSPRHLSNVSSTGSIDMVDSPQLATLADEVSASLAKQGLGDSRS*

[1022] SEQ ID NO:66.mCherry-Tau-NcVVD(y50w)

[1023] MVSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEEGEGEGRPYEGTQTAKLKVTKGGPLPFAW

[1024] DILSPQFMYGSKAYVKHPADIPDYLKLSFPEGFKWERVMNFEDGGVVTVTQDSSLQDGEFIYK

[1025] VKLRGTNFPSDGPVMQKKTMGWEASSERMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTYK

[1026] AKKPVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDELYKSGLTMAEPRQEFEV

[1027] MEDHAGTYGLDGDRKDQGGYTMHQDQEGDTDAGLKESPLQTPTEDGSEEPGSETSDAKSTPTA

[1028] EDVTAPLVDEGAPGKQAAAQPHTEIPEGTTAEEAGIGDTPSLEDEAGHVTQARMVSKSKDGT

[1029] GSDDKKAKGADGKTKIATPRGAAPPGQKGQANATRIPAKTPPAKTPPSSGEPPKSGDRSGYSSP

[1030] GSPGTPGSRSRTPSLPTPPTREPKKKVAVVRTPKPSKPSSAKSRLQTAPVPMPDLKNVKSKIGSTENL

[1031] KHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKHVPGGGSVQIVYKPVDLSKVTSKCGSLGNIH

[1032] HKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETHKLTFRENAKAKTDHGAEI

[1033] VYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQLATLADEVSASLAKQGLRRAQRHTLYAPGGY

[1034] DIMGWLIQIMNRPNPQVELGPVDTSCALILCDLKQKDTPIVYASEAFLYMTGYSNAEVLGRNCR

[1035] FLQSPDGMVKPKSTRKYVDSNTINTMRKAIDRNAEVQVEVVNFKKNGQRFVNFLTMIPVRDET

[1036] GEYRYSMGFQCETEALEFCSRRYRGPGIHRI*

[1037] SEQ ID NO:67.mCherry-NcVVD(y50w)-Tau

[1038] MVSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEGRPYEGTQTAKLKVTKGGPLPFAW

[1039] DILSPQFMYGSKAYVKHPADIPDYLKLSFPEGFKWERVMNFEDGGVVTVTQDSSLQDGEFIYK

[1040] VKLRGTNFPSDGPVMQKKTMGWEASSERMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTYK

[1041] AKKPVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDELYKSGLRSRAQRHTLYAP

[1042] GGYDIMGWLIQIMNRPNPQVELGPVDTSCALILCDLKQKDTPIVYASEAFLYMTGYSNAEVLGR

[1043] NCRFLQSPDGMVKPKSTRKYVDSNTINTMRKAIDRNAEVQVEVVNFKKNGQRFVNFLTMIPVR

[1044] DETGEYRYSMGFQCETEALAMAEPRQEFEVMEDHAGTYGLGDRKDQGGYTMHQDQEGDTD

[1045] AGLKESPLQTPTEDGSEEPGSETSDAKSTPTAEDVTAPLVDEGAPGKQAAAQPHTEIPEGTTAEE

[1046] AGIGDTPSLEDEAAGHVTQARMVSKSKDGTGSDDKKAKGADGKTKIATPRGAAPPGQKGQAN

[1047] ATRIPAKTPPAPKTPPSSGEPPKSGDRSGYSSPGSPGTPGSRSRTPSLPTPPTREPKKVAVVRTPPKS

[1048] PSSAKSRLQTAPVPMPDLKNVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKH

[1049] VPGGGSVQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHV

[1050] PGGGNKKIETHKLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQLATLADEVSASLAKQGLRCSRRYRGPGIHRI*

[1051] SEQ ID NO:68.Cry-Tau

[1052] MKMDKKTIVWFRRDLRIEDNPALAAAAHEGSVFPVFIWCPEEEGQFYPGRASRWWMKQSLAH

[1053] LSQSLKALGSDLTLIKTHNTISAILDCIRVTGATKVVFNHLYDPVSLVRDHTVKEKLVERGISVQS

[1054] YNGDLLYEPWEIYCEKGKPFTSFNSYWKKCLDMSIESVMLPPPWRLMPITAAAEAIWACSIEEL

[1055] GLENEAEKPSNALLTRAWSPGWSNADKLLNEFIEKQLIDYAKNSKKVVGNSTSLLSPYLHFGEIS

[1056] VRHVFQCARMKQIIWARDKNSEGEESADLFLRGIGLREYSRYICFNFPFTHEQSLLSHLRFFPWD

[1057] ADVDKFKAWRQGRTGYPLVDAGMRELWATGWMHNRIRVIVSSFAVKFLLLPWKWGMKYFWD

[1058] TLLDADLECDILGWQYISGSIPDGHELDRLDNPALQGAKYDPEGEYIRQWLPELARLPTEWIHH

[1059] PWDAPLTVLKASGVELGTNYAKPIVDIDTARELLAKAISRTRGAQIMIGAAAQMAEPRQEFEVM

[1060] EDHAGTYGLGDRKDQGGYTMHQDQEGDTDAGLKESPLQTPTEDGSEEPGSETSDAKSTPTAE

[1061] DVTAPLVDEGAPGKQAAAQPHTEIPEGTTAEEAGIGDTPSLEDEAAGHVTQARMVSKSKDGTG

[1062] SDDKKAKGADGKTKIATPRGAAPPGQKGQANATRIPAKTPPAPKTPPSSGEPPKSGDRSGYSSPG

[1063] SPGTPGSRSRTPSLPTPPTREPKKVAVVRTPPKSPSSAKSRLQTAPVPMPDLKNVKSKIGSTENLK

[1064] HQPGGGKVQIINKKLDLSNVQSKCGSKDNIKHVPGGGSVQIVYKPVDLSKVTSKCGSLGNIHH

[1065] KPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETHKLTFRENAKAKTDHGAEIV

[1066] YKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQLATLADEVSASLAKQGLATLDHNQPYHICRGFT

[1067] CFKKPPTPPPEPET*

[1068] SEQ ID NO:69.NcVVD(y50w)-Tau

[1069] MHTLYAPGGYDIMGWLIQIMNRPNPQVELGPVDTSCALILCDLKQKDTPIVYASEAFLYMTGYS

[1070] NAEVLGRNCRFLQSPDGMVKPKSTRKYVDSNTINTMRKAIDRNAEVQVEVVNFKKNGQRFVN

[1071] FLTMIPVRDETGEMAEPRQEFEVMEDHAGTYGLGDRKDQGGYTMHQDQEGDTDAGLKESPL

[1072] QTPTEDGSEEPGSETSDAKSTPTAEDVTAPLVDEGAPGKQAAAQPHTEIPEGTTAEEAGIGDTPS

[1073] LEDEAAGHVTQARMVSKSKDGTGSDDKKAKGADGKTKIATPRGAAPPGQKGQANATRIPAKT

[1074] PPAPKTPPSSGEPPKSGDRSGYSSPGSPGTPGSRSRTPSLPTPPTREPKKVAVVRTPPKSPSSAKSR

[1075] LQTAPVPMPDLKNVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKHVPGGGS

[1076] VQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGN

[1077] KKIETHKLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQLATLADEV

[1078] SASLAKQGLHRI*

[1079] SEQ ID NO:70.Tau-Cry

[1080] MAEPRQEFEVMEDHAGTYGLGDRKDQGGYTMHQDQEGDTDAGLKESPLQTPTEDGSEEPGSE

[1081] TSDAKSTPTAEDVTAPLVDEGAPGKQAAAQPHTEIPEGTTAEEAGIGDTPSLEDEAAGHVTQAR

[1082] MVSKSKDGTGSDDKKAKGADGKTKIATPRGAAPPGQKGQANATRIPAKTPPAKTPPPSSGEPPK

[1083] SGDRSGYSSPGSPGTPGSRSRTPSLPTPPTREPKKVAVVRTPKSPSSAKSRLQTAPVPMPDLKNV

[1084] KSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKHVPGGGSVQIVYKPVDLSKVTS

[1085] KCGSLGINHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETHKLTFRENAKA

[1086] KTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQLATLADEVSASLAKQGLMKMDKK

[1087] TIVWFRRDLRIEDNPALAAAAHEGSVFPVFIWCPEEEGQFYPGRASRWWMKQSLAHLSQSLKA

[1088] LGSDLTLIKTHNTISAILDCIRVTGATKVVFNHLYDPVSLVRDHTVKEKLVERGISVQSYNGDLLY

[1089] EPWEIYCEKGKPFTSFNSYWKKCLDMSIESVMLPPPWRLMPITAAAAEAIWACSIEELGLENEAE

[1090] KPSNALLTRAWSPGWSNADKLLNEFIEKQLIDYAKNSKKVVGNSTSLSPYLHFGEISVRHVFQ

[1091] CARMKQIIWARDKNSEGEESADLFRGIGLREYSRYICFNFPFTHEQSLLSHLRFFPWDADVDKF

[1092] KAWRQGRTGYPLVDAGMRELWATGWMHNRIRVIVSSFAVKFLLLPWKWGMKYFWDTLLDAD

[1093] LECDILGWQYISGSIPDGHELDRLDNPALQGAKYDPEGEYIRQWLPELARLPTEWIHHPWDAPL

[1094] TVLKASGVELGTNYAKPIVDIDTARELLAKAISRTRGAQIMIGAAATLDHNQPYHICRGFTCFKK

[1095] PPTPPPEPET*

[1096] SEQ ID NO:71.Tau-VfAU

[1097] MAEPRQEFEVMEDHAGTYGLGDRKDQGGYTMHQDQEGDTDAGLKESPLQTPTEDGSEEPGSE

[1098] TSDAKSTPTAEDVTAPLVDEGAPGKQAAAQPHTEIPEGTTAEEAGIGDTPSLEDEAAGHVTQAR

[1099] MVSKSKDGTGSDDKKAKGADGKTKIATPRGAAPPGQKGQANATRIPAKTPPAPKTPPSSGEPPK

[1100] SGDRSGYSSPGSPGTPGSRSRTPSLPTPPTREPKKVAVVRTPPKSPSSAKSRLQTAPVPMPDLKNV

[1101] KSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKHVPGGGSVQIVYKPVDLSKVTS

[1102] KCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETHKLTFRENAKA

[1103] KTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQLATLADEVSASLAKQGLPDYSLVK

[1104] ALQMAQQNFVITDASLPDNPIVYASRGFLTLTGYSLDQILGRNCRFLQGPETDPRAVDKIRNAIT

[1105] KGVDTSVCLLNYRQDGTTFWNLFFVAGLRDSKGNIVNYVGVQSKVSEDYAKLLVNEQNIEYK

[1106] GVRTSNMLRRKPGLQSTVPRARDPPDLDN*

[1107] SEQ ID NO:72.Tau-NcVVD(y50w)

[1108] MAEPRQEFEVMEDHAGTYGLDGDRKDQGGYTMHQDQEGDTDAGLKESPLQTPTEDGSEEPGSE

[1109] TSDAKSTPTAEDVTAPLVDEGAPGKQAAAQPHTEIPEGTTAEEAGIGDTPSLEDEAAGHVTQAR

[1110] MVSKSKDGTGSDDKKAKGADGKTKIATPRGAAPPGQKGQANATRIPAKTPPAKTPPPSSGEPPK

[1111] SGDRSGYSSPGSPGTPGSRSRTPSLPTPPTREPKKVAVVRTPKSPSSAKSRLQTAPVPMPDLKNV

[1112] KSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKHVPGGGSVQIVYKPVDLSKVTS

[1113] KCGSLGINHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETHKLTFRENAKA

[1114] KTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQLATLADEVSASLAKQGLHTLYAPG

[1115] GYDIMGWLIQIMNRPNPQVELGPVDTSCALILCDLKQKDTPIVYASEAFLYMTGYSNAEVLGRN

[1116] CRFLQSPDGMVKPKSTRKYVDSNTINTMRKAIDRNAEVQVEVVNFKKNGQRFVNFLTMIPVRD

[1117] ETGEYRYSMGFQCETELQSTVPRARDPPDLDN*

[1118] SEQ ID NO:73.Tau-NcVVD(wild type)

[1119] MAEPRQEFEVMEDHAGTYGLDGDRKDQGGYTMHQDQEGDTDAGLKESPLQTPTEDGSEEPGSE

[1120] TSDAKSTPTAEDVTAPLVDEGAPGKQAAAQPHTEIPEGTTAEEAGIGDTPSLEDEAAGHVTQAR

[1121] MVSKSKDGTGSDDKKAKGADGKTKIATPRGAAPPGQKGQANATRIPAKTPPAKTPPPSSGEPPK

[1122] SGDRSGYSSPGSPGTPGSRSRTPSLPTPPTREPKKVAVVRTPKSPSSAKSRLQTAPVPMPDLKNV

[1123] KSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKHVPGGGSVQIVYKPVDLSKVTS

[1124] KCGSLGINHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETHKLTFRENAKA

[1125] KTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQLATLADEVSASLAKQGLHTLYAPG

[1126] GYDIMGWLIQIMNRPNPQVELGPVDTSCALILCDLKQKDTPIVYASEAFLYMTGYSNAEVLGRN

[1127] CRFLQSPDGMVKPKSTRKYVDSNTINTMRKAIDRNAEVQVEVVNFKKNGQRFVNFLTMIPVRD

[1128] ETGEYRYSMGFQCETELQSTVPRARDPPDLDN*

[1129] SEQ ID NO:74.VfAU-Tau

[1130] MPDYSLVKALQMAQQNFVITDASLPDNPIVYASRGFLTLTGYSLDQILGRNCRFLQGPETDPRA

[1131] VDKIRNAITKGVDTSVCLLNYRQDGTTFWNLFFVAGLRDSKGNIVNYVGVQSKVSEDYAKLLV

[1132] NEQNIEYKGVRTSNMLRRKPGSLMAEPRQEFEVMEDHAGTYGLDGDRKDQGGYTMHQDQEGD

[1133] TDAGLKESPLQTPTEDGSEEPGSETSDAKSTPTAEDVTAPLVDEGAPGKQAAAQPHTEIPEGTTA

[1134] EEAGIGDTPSLEDEAAGHVTQARMVSKSKDGTGSDDKKAKGADGKTKIATPRGAAPPGQKGQ

[1135] ANATRIPAKTPPAKTPPPSSGEPPKSGDRSGYSPGSPGTPGSRSRTPSLPTPPTREPKKVAVVRTPP

[1136] KSPSSAKSRLQTAPVPMPDLKNVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGSKDNI

[1137] KHVPGGGSVQIVYKPVDLSKVTSKCGSLNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNIT

[1138] HVPGGGNKKIEETHKLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQL

[1139] ATLADEVSASLAKQGLSNAVDGTAGPGSTGSR*

[1140] SEQ ID NO:75.Cry-TDP(F147L)-mCherry

[1141] MKMDKKTIVWFRRDLRIEDNPALAAAAHEGSVFPVFIWCPEEEGQFYPGRASRWWMKQSLAH

[1142] LSQSLKALGSDLTLIKTHNTISAILDCIRVTGATKVVFNHLYDPVSLVRDHTVKEKLVERGISVQS

[1143] YNGDLLYEPWEIYCEKGKPFTSFNSYWKKCLDMSIESVMLPPPWRLMPITAAAEAIWACSIEEL

[1144] GLENEAEKPSNALLTRAWSPGWSNADKLLNEFIEKQLIDYAKNSKKVVGNSTSLLSPYLHFGEIS

[1145] VRHVFQCARMKQIIWARDKNSEGEESADLFLRGIGLREYSRYICFNFPFTHEQSLLSHLRFFPWD

[1146] ADVDKFKAWRQGRTGYPLVDAGMRELWATGWMHNRIRVIVSSFAVKFLLLPWKWGMKYFWD

[1147] TLLDADLECDILGWQYISGSIPDGHELDRLDNPALQGAKYDPEGEYIRQWLPELARLPTEWIHH

[1148] PWDAPLTVLKASGVELGTNYAKPIVDIDTARELLAKAISRTRGAQIMIGAAARGMSEYIRVTEDE

[1149] NDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGILHAPDAGWGNLVYV

[1150] VNYPKDNKRKMDETDASSAVKVKRAVQKTSDLIVLGLPWKTTEQDLKEYFSTFGEVLMVQVK

[1151] KDLKTGHSKGLGFVRFTEYETQVKVMSQRHMIDGRWCDCKLPNSKQSQDEPLRSRKVFVGRC

[1152] TEDMTEDELREFFSQYGDVMDVFIPKPFRAFAFVTFADDQIAQSLCGEDLIIKGISVHISNAEPKH

[1153] NSNRQLERSGRFGGNPGGFGNQGGFGNSRGGGAGLGNNQGSNMGGGMNFGAFSINPAMMAA

[1154] AQAALQSSWGMMGMLASQQNQSGPSGNNQNQGNMQREPNQAFGSGNNSYSGSNSGAAIGW

[1155] GSASNAGSGSGFNGGFGSSMDSKSSGWGMSRDPPVATMVSKGEEDNMAIIKEFMRFKVHMEG

[1156] SVNGHEFEIEGEGEGRPYEGTQTAKLKVTKGGPLPFAWDILSPQFMYGSKAYVKHPADIPDYLK

[1157] LSFPEGFKWERVMNFEDGGVVTVTQDSSLQDGEFIYKVKLRGTNFPSDGPVMQKKTMGWEAS

[1158] SERMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTYKAKKPVQLPGAYNVNIKLDITSHNEDY

[1159] TIVEQYERAEGRHSTGGMDELYK*

[1160] SEQ ID NO:76.Cry-TDP(F229L)-mCherry

[1161] MKMDKKTIVWFRRDLRIEDNPALAAAAHEGSVFPVFIWCPEEEGQFYPGRASRWWMKQSLAH

[1162] LSQSLKALGSDLTLIKTHNTISAILDCIRVTGATKVVFNHLYDPVSLVRDHTVKEKLVERGISVQS

[1163] YNGDLLYEPWEIYCEKGKPFTSFNSYWKKCLDMSIESVMLPPPWRLMPITAAAEAIWACSIEEL

[1164] GLENEAEKPSNALLTRAWSPGWSNADKLLNEFIEKQLIDYAKNSKKVVGNSTSLLSPYLHFGEIS

[1165] VRHVFQCARMKQIIWARDKNSEGEESADLFLRGIGLREYSRYICFNFPFTHEQSLLSHLRFFPWD

[1166] ADVDKFKAWRQGRTGYPLVDAGMRELWATGWMHNRIRVIVSSFAVKFLLLPWKWGMKYFWD

[1167] TLLDADLECDILGWQYISGSIPDGHELDRLDNPALQGAKYDPEGEYIRQWLPELARLPTEWIHH

[1168] PWDAPLTVLKASGVELGTNYAKPIVDIDTARELLAKAISRTRGAQIMIGAAARGMSEYIRVTEDE

[1169] NDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGILHAPDAGWGNLVYV

[1170] VNYPKDNKRKMDETDASSAVKVKRAVQKTSDLIVLGLPWKTTEQDLKEYFSTFGEVLMVQVK

[1171] KDLKTGHSKGFGFVRFTEYETQVKVMSQRHMIDGRWCDCKLPNSKQSQDEPLRSRKVFVGRC

[1172] TEDMTEDELREFFSQYGDVMDVFIPKPFRALAFVTFADDQIAQSLCGEDLIIKGISVHISNAEPKH

[1173] NSNRQLERSGRFGGNPGGFGNQGGFGNSRGGGAGLGNNQGSNMGGGMNFGAFSINPAMMAA

[1174] AQAALQSSWGMMGMLASQQNQSGPSGNNQNQGNMQREPNQAFGSGNNSYSGSNSGAAIGW

[1175] GSASNAGSGSGFNGGFGSSMDSKSSGWGMSRDPPVATMVSKGEEDNMAIIKEFMRFKVHMEG

[1176] SVNGHEFEIEGEGEGRPYEGTQTAKLKVTKGGPLPFAWDILSPQFMYGSKAYVKHPADIPDYLK

[1177] LSFPEGFKWERVMNFEDGGVVTVTQDSSLQDGEFIYKVKLRGTNFPSDGPVMQKKTMGWEAS

[1178] SERMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTYKAKKPVQLPGAYNVNIKLDITSHNEDY

[1179] TIVEQYERAEGRHSTGGMDELYK*

[1180] SEQ ID NO:77.Cry-TDP(S409,410A)-mCherry

[1181] MKMDKKTIVWFRRDLRIEDNPALAAAAHEGSVFPVFIWCPEEEGQFYPGRASRWWMKQSLAH

[1182] LSQSLKALGSDLTLIKTHNTISAILDCIRVTGATKVVFNHLYDPVSLVRDHTVKEKLVERGISVQS

[1183] YNGDLLYEPWEIYCEKGKPFTSFNSYWKKCLDMSIESVMLPPPWRLMPITAAAEAIWACSIEEL

[1184] GLENEAEKPSNALLTRAWSPGWSNADKLLNEFIEKQLIDYAKNSKKVVGNSTSLLSPYLHFGEIS

[1185] VRHVFQCARMKQIIWARDKNSEGEESADLFLRGIGLREYSRYICFNFPFTHEQSLLSHLRFFPWD

[1186] ADVDKFKAWRQGRTGYPLVDAGMRELWATGWMHNRIRVIVSSFAVKFLLLPWKWGMKYFWD

[1187] TLLDADLECDILGWQYISGSIPDGHELDRLDNPALQGAKYDPEGEYIRQWLPELARLPTEWIHH

[1188] PWDAPLTVLKASGVELGTNYAKPIVDIDTARELLAKAISRTRGAQIMIGAAAQMSEYIRVTEDE

[1189] NDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGILHAPDAGWGNLVYV

[1190] VNYPKDNKRKMDETDASSAVKVKRAVQKTSDLIVLGLPWKTTEQDLKEYFSTFGEVLMVQVK

[1191] KDLKTGHSKGFGFVRFTEYETQVKVMSQRHMIDGRWCDCKLPNSKQSQDEPLRSRKVFVGRC

[1192] TEDMTEDELREFFSQYGDVMDVFIPKPFRAFAFVTFADDQIAQSLCGEDLIIKGISVHISNAEPKH

[1193] NSNRQLERSGRFGGNPGGFGNQGGFGNSRGGGAGLGNNQGSNMGGGMNFGAFSINPAMMAA

[1194] AQAALQSSWGMMGMLASQQNQSGPSGNNQNQGNMQREPNQAFGSGNNSYSGSNSGAAIGW

[1195] GSASNAGSGSGFNGGFGSSMDSKAAGWGMWDPPVATMVSKGEEDNMAIIKEFMRFKVHMEG

[1196] SVNGHEFEIEGEGEGRPYEGTQTAKLKVTKGGPLPFAWDILSPQFMYGSKAYVKHPADIPDYLK

[1197] LSFPEGFKWERVMNFEDGGVVTVTQDSSLQDGEFIYKVKLRGTNFPSDGPVMQKKTMGWEAS

[1198] SERMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTYKAKKPVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDELYK*

[1199] SEQ ID NO:78.Cry-TDP(S409,410D)-mCherry

[1200] MKMDKKTIVWFRRDLRIEDNPALAAAAHEGSVFPVFIWCPEEEGQFYPGRASRWWMKQSLAH

[1201] LSQSLKALGSDLTLIKTHNTISAILDCIRVTGATKVVFNHLYDPVSLVRDHTVKEKLVERGISVQS

[1202] YNGDLLYEPWEIYCEKGKPFTSFNSYWKKCLDMSIESVMLPPPWRLMPITAAAEAIWACSIEEL

[1203] GLENEAEKPSNALLTRAWSPGWSNADKLLNEFIEKQLIDYAKNSKKVVGNSTSLLSPYLHFGEIS

[1204] VRHVFQCARMKQIIWARDKNSEGEESADLFLRGIGLREYSRYICFNFPFTHEQSLLSHLRFFPWD

[1205] ADVDKFKAWRQGRTGYPLVDAGMRELWATGWMHNRIRVIVSSFAVKFLLLPWKWGMKYFWD

[1206] TLLDADLECDILGWQYISGSIPDGHELDRLDNPALQGAKYDPEGEYIRQWLPELARLPTEWIHH

[1207] PWDAPLTVLKASGVELGTNYAKPIVDIDTARELLAKAISRTRGAQIMIGAAAQMSEYIRVTEDE

[1208] NDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGILHAPDAGWGNLVYV

[1209] VNYPKDNKRKMDETDASSAVKVKRAVQKTSDLIVLGLPWKTTEQDLKEYFSTFGEVLMVQVK

[1210] KDLKTGHSKGFGFVRFTEYETQVKVMSQRHMIDGRWCDCKLPNSKQSQDEPLRSRKVFVGRC

[1211] TEDMTEDELREFFSQYGDVMDVFIPKPFRAFAFVTFADDQIAQSLCGEDLIIKGISVHISNAEPKH

[1212] NSNRQLERSGRFGGNPGGFGNQGGFGNSRGGGAGLGNNQGSNMGGGMNFGAFSINPAMMAA

[1213] AQAALQSSWGMMGMLASQQNQSGPSGNNQNQGNMQREPNQAFGSGNNSYSGSNSGAAIGW

[1214] GSASNAGSGSGFNGGFGSSMDSKDDGWGMWDPPVATMVSKGEEDNMAIIKEFMRFKVHMEG

[1215] SVNGHEFEIEGEGEGRPYEGTQTAKLKVTKGGPLPFAWDILSPQFMYGSKAYVKHPADIPDYLK

[1216] LSFPEGFKWERVMNFEDGGVVTVTQDSSLQDGEFIYKVKLRGTNFPSDGPVMQKKTMGWEAS

[1217] SERMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTYKAKKPVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDELYK*

[1218] SEQ ID NO:79.Cry-TDP(A321V)-mCherry

[1219] MKMDKKTIVWFRRDLRIEDNPALAAAAHEGSVFPVFIWCPEEEGQFYPGRASRWWMKQSLAH

[1220] LSQSLKALGSDLTLIKTHNTISAILDCIRVTGATKVVFNHLYDPVSLVRDHTVKEKLVERGISVQS

[1221] YNGDLLYEPWEIYCEKGKPFTSFNSYWKKCLDMSIESVMLPPPWRLMPITAAAEAIWACSIEEL

[1222] GLENEAEKPSNALLTRAWSPGWSNADKLLNEFIEKQLIDYAKNSKKVVGNSTSLLSPYLHFGEIS

[1223] VRHVFQCARMKQIIWARDKNSEGEESADLFLRGIGLREYSRYICFNFPFTHEQSLLSHLRFFPWD

[1224] ADVDKFKAWRQGRTGYPLVDAGMRELWATGWMHNRIRVIVSSFAVKFLLLPWKWGMKYFWD

[1225] TLLDADLECDILGWQYISGSIPDGHELDRLDNPALQGAKYDPEGEYIRQWLPELARLPTEWIHH

[1226] PWDAPLTVLKASGVELGTNYAKPIVDIDTARELLAKAISRTRGAQIMIGAAAQMSEYIRVTEDE

[1227] NDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGILHAPDAGWGNLVYV

[1228] VNYPKDNKRKMDETDASSAVKVKRAVQKTSDLIVLGLPWKTTEQDLKEYFSTFGEVLMVQVK

[1229] KDLKTGHSKGFGFVRFTEYETQVKVMSQRHMIDGRWCDCKLPNSKQSQDEPLRSRKVFVGRC

[1230] TEDMTEDELREFFSQYGDVMDVFIPKPFRAFAFVTFADDQIAQSLCGEDLIIKGISVHISNAEPKH

[1231] NSNRQLERSGRFGGNPGGFGNQGGFGNSRGGGAGLGNNQGSNMGGGMNFGAFSINPVMMAA

[1232] AQAALQSSWGMMGMLASQQNQSGPSGNNQNQGNMQREPNQAFGSGNNSYSGSNSGAAIGW

[1233] GSASNAGSGSGFNGGFGSSMDSKSSGWGWDPPVATMVSKGEEDNMAIIKEFMRFKVHMEGSV

[1234] NGHEFEIEGEGEGRPYEGTQTAKLKVTKGGPLPFAWDILSPQFMYGSKAYVKHPADIPDYLKLS

[1235] FPEGFKWERVMNFEDGGVVTVTQDSSLQDGEFIYKVKLRGTNFPSDGPVMQKKTMGWEASSE

[1236] RMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTYKAKKPVQLPGAYNVNIKLDITSHNEDYTIV

[1237] EQYERAEGRHSTGGMDELYK*

[1238] SEQ ID NO:80.Cry-TDP(m337V)-mCherry

[1239] MKMDKKTIVWFRRDLRIEDNPALAAAAHEGSVFPVFIWCPEEEGQFYPGRASRWWMKQSLAH

[1240] LSQSLKALGSDLTLIKTHNTISAILDCIRVTGATKVVFNHLYDPVSLVRDHTVKEKLVERGISVQS

[1241] YNGDLLYEPWEIYCEKGKPFTSFNSYWKKCLDMSIESVMLPPPWRLMPITAAAEAIWACSIEEL

[1242] GLENEAEKPSNALLTRAWSPGWSNADKLLNEFIEKQLIDYAKNSKKVVGNSTSLLSPYLHFGEIS

[1243] VRHVFQCARMKQIIWARDKNSEGEESADLFLRGIGLREYSRYICFNFPFTHEQSLLSHLRFFPWD

[1244] ADVDKFKAWRQGRTGYPLVDAGMRELWATGWMHNRIRVIVSSFAVKFLLLPWKWGMKYFWD

[1245] TLLDADLECDILGWQYISGSIPDGHELDRLDNPALQGAKYDPEGEYIRQWLPELARLPTEWIHH

[1246] PWDAPLTVLKASGVELGTNYAKPIVDIDTARELLAKAISRTRGAQIMIGAAAQMSEYIRVTEDE

[1247] NDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGILHAPDAGWGNLVYV

[1248] VNYPKDNKRKMDETDASSAVKVKRAVQKTSDLIVLGLPWKTTEQDLKEYFSTFGEVLMVQVK

[1249] KDLKTGHSKGFGFVRFTEYETQVKVMSQRHMIDGRWCDCKLPNSKQSQDEPLRSRKVFVGRC

[1250] TEDMTEDELREFFSQYGDVMDVFIPKPFRAFAFVTFADDQIAQSLCGEDLIIKGISVHISNAEPKH

[1251] NSNRQLERSGRFGGNPGGFGNQGGFGNSRGGGAGLGNNQGSNMGGGMNFGAFSINPAMMAA

[1252] AQAALQSSWGMVGMLASQQNQSGPSGNNQNQGNMQREPNQAFGSGNNSYSGSNSGAAIGW

[1253] GSASNAGSGSGFNGGFGSSMDSKSSGWGWDPPVATMVSKGEEDNMAIIKEFMRFKVHMEGSV

[1254] NGHEFEIEGEGEGRPYEGTQTAKLKVTKGGPLPFAWDILSPQFMYGSKAYVKHPADIPDYLKLS

[1255] FPEGFKWERVMNFEDGGVVTVTQDSSLQDGEFIYKVKLRGTNFPSDGPVMQKKTMGWEASSE

[1256] RMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTYKAKKPVQLPGAYNVNIKLDITSHNEDYTIV

[1257] EQYERAEGRHSTGGMDELYK*

[1258] SEQ ID NO:81.Cry-TDP(LCD,A321V)-mCherry

[1259] MKMDKKTIVWFRRDLRIEDNPALAAAAHEGSVFPVFIWCPEEEGQFYPGRASRWWMKQSLAH

[1260] LSQSLKALGSDLTLIKTHNTISAILDCIRVTGATKVVFNHLYDPVSLVRDHTVKEKLVERGISVQS

[1261] YNGDLLYEPWEIYCEKGKPFTSFNSYWKKCLDMSIESVMLPPPWRLMPITAAAEAIWACSIEEL

[1262] GLENEAEKPSNALLTRAWSPGWSNADKLLNEFIEKQLIDYAKNSKKVVGNSTSLLSPYLHFGEIS

[1263] VRHVFQCARMKQIIWARDKNSEGEESADLFLRGIGLREYSRYICFNFPFTHEQSLLSHLRFFPWD

[1264] ADVDKFKAWRQGRTGYPLVDAGMRELWATGWMHNRIRVIVSSFAVKFLLLPWKWGMKYFWD

[1265] TLLDADLECDILGWQYISGSIPDGHELDRLDNPALQGAKYDPEGEYIRQWLPELARLPTEWIHH

[1266] PWDAPLTVLKASGVELGTNYAKPIVDIDTARELLAKAISRTRGAQIMIGAAAQGRFGGNPGGFG

[1267] NQGGFGNSRGGGAGLGNNQGSNMGGGMNFGAFSINPVMMAAAQAALQSSWGMMGMLASQ

[1268] QNQSGPSGNNQNQGNMQREPNQAFGSGNNSYSGSNSGAAIGWGSASNAGSGSGFNGGFGSSM

[1269] DSKSSGWGMRDPPVATMVSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEGRPYEGTQ

[1270] TAKLKVTKGGPLPFAWDILSPQFMYGSKAYVKHPADIPDYLKLSFPEGFKWERVMNFEDGGVV

[1271] TVTQDSSLQDGEFIYKVKLRGTNFPSDGPVMQKKTMGWEASSERMYPEDGALKGEIKQRLKL

[1272] KDGGHYDAEVKTTYKAKKPVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDEL

[1273] YK*

[1274] SEQ ID NO:82.Cry-TDP(LCD,M337V)-mCherry

[1275] MKMDKKTIVWFRRDLRIEDNPALAAAAHEGSVFPVFIWCPEEEGQFYPGRASRWWMKQSLAH

[1276] LSQSLKALGSDLTLIKTHNTISAILDCIRVTGATKVVFNHLYDPVSLVRDHTVKEKLVERGISVQS

[1277] YNGDLLYEPWEIYCEKGKPFTSFNSYWKKCLDMSIESVMLPPPWRLMPITAAAEAIWACSIEEL

[1278] GLENEAEKPSNALLTRAWSPGWSNADKLLNEFIEKQLIDYAKNSKKVVGNSTSLLSPYLHFGEIS

[1279] VRHVFQCARMKQIIWARDKNSEGEESADLFLRGIGLREYSRYICFNFPFTHEQSLLSHLRFFPWD

[1280] ADVDKFKAWRQGRTGYPLVDAGMRELWATGWMHNRIRVIVSSFAVKFLLLPWKWGMKYFWD

[1281] TLLDADLECDILGWQYISGSIPDGHELDRLDNPALQGAKYDPEGEYIRQWLPELARLPTEWIHH

[1282] PWDAPLTVLKASGVELGTNYAKPIVDIDTARELLAKAISRTRGAQIMIGAAAQGRFGGNPGGFG

[1283] NQGGFGNSRGGGAGLGNNQGSNMGGGMNFGAFSINPAMMAAAQAALQSSWGMVGMLASQ

[1284] QNQSGPSGNNQNQGNMQREPNQAFGSGNNSYSGSNSGAAIGWGSASNAGSGSGFNGGFGSSM

[1285] DSKSSGWGMRDPPVATMVSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEGRPYEGTQ

[1286] TAKLKVTKGGPLPFAWDILSPQFMYGSKAYVKHPADIPDYLKLSFPEGFKWERVMNFEDGGVV

[1287] TVTQDSSLQDGEFIYKVKLRGTNFPSDGPVMQKKTMGWEASSERMYPEDGALKGEIKQRLKL

[1288] KDGGHYDAEVKTTYKAKKPVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDEL

[1289] YK*

[1290] SEQ ID NO:83.Cry-TDP(LCD,S409,410A)-mCherry

[1291] MKMDKKTIVWFRRDLRIEDNPALAAAAHEGSVFPVFIWCPEEEGQFYPGRASRWWMKQSLAH

[1292] LSQSLKALGSDLTLIKTHNTISAILDCIRVTGATKVVFNHLYDPVSLVRDHTVKEKLVERGISVQS

[1293] YNGDLLYEPWEIYCEKGKPFTSFNSYWKKCLDMSIESVMLPPPWRLMPITAAAEAIWACSIEEL

[1294] GLENEAEKPSNALLTRAWSPGWSNADKLLNEFIEKQLIDYAKNSKKVVGNSTSLLSPYLHFGEIS

[1295] VRHVFQCARMKQIIWARDKNSEGEESADLFLRGIGLREYSRYICFNFPFTHEQSLLSHLRFFPWD

[1296] ADVDKFKAWRQGRTGYPLVDAGMRELWATGWMHNRIRVIVSSFAVKFLLLPWKWGMKYFWD

[1297] TLLDADLECDILGWQYISGSIPDGHELDRLDNPALQGAKYDPEGEYIRQWLPELARLPTEWIHH

[1298] PWDAPLTVLKASGVELGTNYAKPIVDIDTARELLAKAISRTRGAQIMIGAAAQGRFGGNPGGFG

[1299] NQGGFGNSRGGGAGLGNNQGSNMGGGMNFGAFSINPAMMAAAQAALQSSWGMMGMLASQ

[1300] QNQSGPSGNNQNQGNMQREPNQAFGSGNNSYSGSNSGAAIGWGSASNAGSGSGFNGGFGSSM

[1301] DSKAAGWGMRDPPVATMVSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEGRPYEGT

[1302] QTAKLKVTKGGPLPFAWDILSPQFMYGSKAYVKHPADIPDYLKLSFPEGFKWERVMNFEDGGV

[1303] VTVTQDSSLQDGEFIYKVKLRGTNFPSDGPVMQKKTMGWEASSERMYPEDGALKGEIKQRLK

[1304] LKDGGHYDAEVKTTYKAKKPVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDELYK*

[1305] SEQ ID NO:84.Cry-TDP(LCD,S409,410D)-mCherry

[1306] MKMDKKTIVWFRRDLRIEDNPALAAAAHEGSVFPVFIWCPEEEGQFYPGRASRWWMKQSLAH

[1307] LSQSLKALGSDLTLIKTHNTISAILDCIRVTGATKVVFNHLYDPVSLVRDHTVKEKLVERGISVQS

[1308] YNGDLLYEPWEIYCEKGKPFTSFNSYWKKCLDMSIESVMLPPPWRLMPITAAAEAIWACSIEEL

[1309] GLENEAEKPSNALLTRAWSPGWSNADKLLNEFIEKQLIDYAKNSKKVVGNSTSLLSPYLHFGEIS

[1310] VRHVFQCARMKQIIWARDKNSEGEESADLFLRGIGLREYSRYICFNFPFTHEQSLLSHLRFFPWD

[1311] ADVDKFKAWRQGRTGYPLVDAGMRELWATGWMHNRIRVIVSSFAVKFLLLPWKWGMKYFWD

[1312] TLLDADLECDILGWQYISGSIPDGHELDRLDNPALQGAKYDPEGEYIRQWLPELARLPTEWIHH

[1313] PWDAPLTVLKASGVELGTNYAKPIVDIDTARELLAKAISRTRGAQIMIGAAAPGRFGGNPGGFG

[1314] NQGGFGNSRGGGAGLGNNQGSNMGGGMNFGAFSINPAMMAAAQAALQSSWGMMGMLASQ

[1315] QNQSGPSGNNQNQGNMQREPNQAFGSGNNSYSGSNSGAAIGWGSASNAGSGSGFNGGFGSSM

[1316] DSKDDGWGMTRDPPVATMVSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEGRPYEG

[1317] TQTAKLKVTKGGPLPFAWDILSPQFMYGSKAYVKHPADIPDYLKLSFPEGFKWERVMNFEDGG

[1318] VVTVTQDSSLQDGEFIYKVKLRGTNFPSDGPVMQKKTMGWEASSERMYPEDGALKGEIKQRL

[1319] KLKDGGHYDAEVKTTYKAKKPVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMD

[1320] ELYK*

[1321] SEQ ID NO:85.Cry-TDP(5FL)-mcherry

[1322] MKMDKKTIVWFRRDLRIEDNPALAAAAHEGSVFPVFIWCPEEEGQFYPGRASRWWMKQSLAH

[1323] LSQSLKALGSDLTLIKTHNTISAILDCIRVTGATKVVFNHLYDPVSLVRDHTVKEKLVERGISVQS

[1324] YNGDLLYEPWEIYCEKGKPFTSFNSYWKKCLDMSIESVMLPPPWRLMPITAAAEAIWACSIEEL

[1325] GLENEAEKPSNALLTRAWSPGWSNADKLLNEFIEKQLIDYAKNSKKVVGNSTSLLSPYLHFGEIS

[1326] VRHVFQCARMKQIIWARDKNSEGEESADLFLRGIGLREYSRYICFNFPFTHEQSLLSHLRFFPWD

[1327] ADVDKFKAWRQGRTGYPLVDAGMRELWATGWMHNRIRVIVSSFAVKFLLLPWKWGMKYFWD

[1328] TLLDADLECDILGWQYISGSIPDGHELDRLDNPALQGAKYDPEGEYIRQWLPELARLPTEWIHH

[1329] PWDAPLTVLKASGVELGTNYAKPIVDIDTARELLAKAISRTRGAQIMIGAAAQMSEYIRVTEDE

[1330] NDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGILHAPDAGWGNLVYV

[1331] VNYPKDNKRKMDETDASSAVKVKRAVQKTSDLIVLGLPWKTTEQDLKEYFSTFGEVLMVQVK

[1332] KDLKTGHSKGLGLVRFTEYETQVKVMSQRHMIDGRWCDCKLPNSKQSQDEPLRSRKVLVGRC

[1333] TEDMTEDELREFFSQYGDVMDVFIPKPFRALALVTFADDQIAQSLCGEDLIIKGISVHISNAEPKH

[1334] NSNRQLERSGRFGGNPGGFGNQGGFGNSRGGGAGLGNNQGSNMGGGMNFGAFSINPAMMAA

[1335] AQAALQSSWGMMGMLASQQNQSGPSGNNQNQGNMQREPNQAFGSGNNSYSGSNSGAAIGW

[1336] GSASNAGSGSGFNGGFGSSMDSKSSGWGMWDPPVATMVSKGEEDNMAIIKEFMRFKVHMEGS

[1337] VNGHEFEIEGEGEGRPYEGTQTAKLKVTKGGPLPFAWDILSPQFMYGSKAYVKHPADIPDYLKL

[1338] SFPEGFKWERVMNFEDGGVVTVTQDSSLQDGEFIYKVKLRGTNFPSDGPVMQKKTMGWEASS

[1339] ERMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTYKAKKPVQLPGAYNVNIKLDITSHNEDYTI

[1340] VEQYERAEGRHSTGGMDELYK*

[1341] SEQ ID NO:86.Cry-TDP(RRM1)-mCherry

[1342] MKMDKKTIVWFRRDLRIEDNPALAAAAHEGSVFPVFIWCPEEEGQFYPGRASRWWMKQSLAH

[1343] LSQSLKALGSDLTLIKTHNTISAILDCIRVTGATKVVFNHLYDPVSLVRDHTVKEKLVERGISVQS

[1344] YNGDLLYEPWEIYCEKGKPFTSFNSYWKKCLDMSIESVMLPPPWRLMPITAAAEAIWACSIEEL

[1345] GLENEAEKPSNALLTRAWSPGWSNADKLLNEFIEKQLIDYAKNSKKVVGNSTSLLSPYLHFGEIS

[1346] VRHVFQCARMKQIIWARDKNSEGEESADLFLRGIGLREYSRYICFNFPFTHEQSLLSHLRFFPWD

[1347] ADVDKFKAWRQGRTGYPLVDAGMRELWATGWMHNRIRVIVSSFAVKFLLLPWKWGMKYFWD

[1348] TLLDADLECDILGWQYISGSIPDGHELDRLDNPALQGAKYDPEGEYIRQWLPELARLPTEWIHH

[1349] PWDAPLTVLKASGVELGTNYAKPIVDIDTARELLAKAISRTRGAQIMIGAAAQDLIVLGLPWKT

[1350] TEQDLKEYFSTFGEVLMVQVKKDLKTGHSKGFGFVRFTEYETQVKVMSQRHMIDGRWCDCK

[1351] LPNSKQSQDEPLRSRDPPVATMVSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEGRPY

[1352] EGTQTAKLKVTKGGPLPFAWDILSPQFMYGSKAYVKHPADIPDYLKLSFPEGFKWERVMNFED

[1353] GGVVTVTQDSSLQDGEFIYKVKLRGTNFPSDGPVMQKKTMGWEASSERMYPEDGALKGEIKQ

[1354] RLKLKDGGHYDAEVKTTYKAKKPVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDELYK*

[1355] SEQ ID NO:87.Cry-TDP(RRM2)-mCherry

[1356] MKMDKKTIVWFRRDLRIEDNPALAAAAHEGSVFPVFIWCPEEEGQFYPGRASRWWMKQSLAH

[1357] LSQSLKALGSDLTLIKTHNTISAILDCIRVTGATKVVFNHLYDPVSLVRDHTVKEKLVERGISVQS

[1358] YNGDLLYEPWEIYCEKGKPFTSFNSYWKKCLDMSIESVMLPPPWRLMPITAAAEAIWACSIEEL

[1359] GLENEAEKPSNALLTRAWSPGWSNADKLLNEFIEKQLIDYAKNSKKVVGNSTSLLSPYLHFGEIS

[1360] VRHVFQCARMKQIIWARDKNSEGEESADLFLRGIGLREYSRYICFNFPFTHEQSLLSHLRFFPWD

[1361] ADVDKFKAWRQGRTGYPLVDAGMRELWATGWMHNRIRVIVSSFAVKFLLLPWKWGMKYFWD

[1362] TLLDADLECDILGWQYISGSIPDGHELDRLDNPALQGAKYDPEGEYIRQWLPELARLPTEWIHH

[1363] PWDAPLTVLKASGVELGTNYAKPIVDIDTARELLAKAISRTRGAQIMIGAAAQRKVFVGRCTED

[1364] MTEDELREFFSQYGDVMDVFIPKPFRAFAFVTFADDQIAQSLCGEDLIIKGISVHISNAEPRDPPV

[1365] ATMVSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEGRPYEGTQTAKLKVTKGGPLPF

[1366] AWDILSPQFMYGSKAYVKHPADIPDYLKLSFPEGFKWERVMNFEDGGVVTVTQDSSLQDGEFI

[1367] YKVKLRGTNFPSDGPVMQKKTMGWEASSERMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTYKAKKPVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDELYK*

[1368] SEQ ID NO:88.Cry-TDP(RRM1+2)-mCherry

[1369] MKMDKKTIVWFRRDLRIEDNPALAAAAHEGSVFPVFIWCPEEEGQFYPGRASRWWMKQSLAH

[1370] LSQSLKALGSDLTLIKTHNTISAILDCIRVTGATKVVFNHLYDPVSLVRDHTVKEKLVERGISVQS

[1371] YNGDLLYEPWEIYCEKGKPFTSFNSYWKKCLDMSIESVMLPPPWRLMPITAAAEAIWACSIEEL

[1372] GLENEAEKPSNALLTRAWSPGWSNADKLLNEFIEKQLIDYAKNSKKVVGNSTSLLSPYLHFGEIS

[1373] VRHVFQCARMKQIIWARDKNSEGEESADLFLRGIGLREYSRYICFNFPFTHEQSLLSHLRFFPWD

[1374] ADVDKFKAWRQGRTGYPLVDAGMRELWATGWMHNRIRVIVSSFAVKFLLLPWKWGMKYFWD

[1375] TLLDADLECDILGWQYISGSIPDGHELDRLDNPALQGAKYDPEGEYIRQWLPELARLPTEWIHH

[1376] PWDAPLTVLKASGVELGTNYAKPIVDIDTARELLAKAISRTRGAQIMIGAAAQDLIVLGLPWKT

[1377] TEQDLKEYFSTFGEVLMVQVKKDLKTGHSKGFGFVRFTEYETQVKVMSQRHMIDGRWCDCK

[1378] LPNSKQSQDEPLRSRKVFVGRCTEDMTEDELREFFSQYGDVMDVFIPKPFRAFAFVTFADDQIA

[1379] QSLCGEDLIIKGISVHISNAEPRDPPVATMVSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEG

[1380] EGEGRPYEGTQTAKLKVTKGGPLPFAWDILSPQFMYGSKAYVKHPADIPDYLKLSFPEGFKWER

[1381] VMNFEDGGVVTVTQDSSLQDGEFIYKVKLRGTNFPSDGPVMQKKTMGWEASSERMYPEDGA

[1382] LKGEIKQRLKLKDGGHYDAEVKTTYKAKKPVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEG

[1383] RHSTGGMDELYK*

[1384] SEQ ID NO:89.Cry-TDP(dLCD)-mCherry

[1385] MKMDKKTIVWFRRDLRIEDNPALAAAAHEGSVFPVFIWCPEEEGQFYPGRASRWWMKQSLAH

[1386] LSQSLKALGSDLTLIKTHNTISAILDCIRVTGATKVVFNHLYDPVSLVRDHTVKEKLVERGISVQS

[1387] YNGDLLYEPWEIYCEKGKPFTSFNSYWKKCLDMSIESVMLPPPWRLMPITAAAEAIWACSIEEL

[1388] GLENEAEKPSNALLTRAWSPGWSNADKLLNEFIEKQLIDYAKNSKKVVGNSTSLLSPYLHFGEIS

[1389] VRHVFQCARMKQIIWARDKNSEGEESADLFLRGIGLREYSRYICFNFPFTHEQSLLSHLRFFPWD

[1390] ADVDKFKAWRQGRTGYPLVDAGMRELWATGWMHNRIRVIVSSFAVKFLLLPWKWGMKYFWD

[1391] TLLDADLECDILGWQYISGSIPDGHELDRLDNPALQGAKYDPEGEYIRQWLPELARLPTEWIHH

[1392] PWDAPLTVLKASGVELGTNYAKPIVDIDTARELLAKAISRTRGAQIMIGAAAQMSEYIRVTEDE

[1393] NDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGILHAPDAGWGNLVYV

[1394] VNYPKDNKRKMDETDASSAVKVKRAVQKTSDLIVLGLPWKTTEQDLKEYFSTFGEVLMVQVK

[1395] KDLKTGHSKGFGFVRFTEYETQVKVMSQRHMIDGRWCDCKLPNSKQSQDEPLRSRKVFVGRC

[1396] TEDMTEDELREFFSQYGDVMDVFIPKPFRAFAFVTFADDQIAQSLCGEDLIIKGISVHISNAEPKH

[1397] NSNRQLERSRDPPVATMVSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEGRPYEGTQT

[1398] AKLKVTKGGPLPFAWDILSPQFMYGSKAYVKHPADIPDYLKLSFPEGFKWERVMNFEDGGVVT

[1399] VTQDSSLQDGEFIYKVKLRGTNFPSDGPVMQKKTMGWEASSERMYPEDGALKGEIKQRLKLK

[1400] DGGHYDAEVKTTYKAKKPVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDELY

[1401] K*

[1402] Arrangement of the generated FUS protein:

[1403] 1. Amino acid sequence of the Cry2olig fusion protein:

[1404] A) Full-length FUS protein without a reporter gene

[1405] SEQ ID NO:90. Cry2Olig-FUS

[1406] MKMDKKTIVWFRRDLRIEDNPALAAAAHEGSVFPVFIWCPEEEGQFYPGRASRWWMKQSLAH

[1407] LSQSLKALGSDLTLIKTHNTISAILDCIRVTGATKVVFNHLYDPVSLVRDHTVKEKLVERGISVQS

[1408] YNGDLLYEPWEIYCEKGKPFTSFNSYWKKCLDMSIESVMLPPPWRLMPITAAAEAIWACSIEEL

[1409] GLENEAEKPSNALLTRAWSPGWSNADKLLNEFIEKQLIDYAKNSKKVVGNSTSLLSPYLHFGEIS

[1410] VRHVFQCARMKQIIWARDKNSEGEESADLFLRGIGLREYSRYICFNFPFTHEQSLLSHLRFFPWD

[1411] ADVDKFKAWRQGRTGYPLVDAGMRELWATGWMHNRIRVIVSSFAVKFLLLPWKWGMKYFWD

[1412] TLLDADLECDILGWQYISGSIPDGHELDRLDNPALQGAKYDPEGEYIRQWLPELARLPTEWIHH

[1413] PWDAPLTVLKASGVELGTNYAKPIVDIDTARELLAKAISRTRGAQIMIGAAAQCRATMYPYDVP

[1414] DYAMASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYG

[1415] QSQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSSSYG

[1416] QPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQDQSSM

[1417] SSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYEPRGR

[1418] GGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIESVADYFK

[1419] QIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFSGNPIKVSFATR

[1420] RADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQQRAGDWKCPN

[1421] PTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYDRGGYRGRGGD

[1422] RGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY

[1423] B) Full-length FUS protein + mCherry reporter gene

[1424] SEQ ID NO:91.Cry2Olig-FUS-mCherry

[1425] MKMDKKTIVWFRRDLRIEDNPALAAAAHEGSVFPVFIWCPEEEGQFYPGRASRWWMKQSLAH

[1426] LSQSLKALGSDLTLIKTHNTISAILDCIRVTGATKVVFNHLYDPVSLVRDHTVKEKLVERGISVQS

[1427] YNGDLLYEPWEIYCEKGKPFTSFNSYWKKCLDMSIESVMLPPPWRLMPITAAAEAIWACSIEEL

[1428] GLENEAEKPSNALLTRAWSPGWSNADKLLNEFIEKQLIDYAKNSKKVVGNSTSLLSPYLHFGEIS

[1429] VRHVFQCARMKQIIWARDKNSEGEESADLFLRGIGLREYSRYICFNFPFTHEQSLLSHLRFFPWD

[1430] ADVDKFKAWRQGRTGYPLVDAGMRELWATGWMHNRIRVIVSSFAVKFLLLPWKWGMKYFWD

[1431] TLLDADLECDILGWQYISGSIPDGHELDRLDNPALQGAKYDPEGEYIRQWLPELARLPTEWIHH

[1432] PWDAPLTVLKASGVELGTNYAKPIVDIDTARELLAKAISRTRGAQIMIGAAAQCRATMYPYDVP

[1433] DYAMASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYG

[1434] QSQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSSSYG

[1435] QPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQDQSSM

[1436] SSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYEPRGR

[1437] GGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIESVADYFK

[1438] QIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFSGNPIKVSFATR

[1439] RADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQQRAGDWKCPN

[1440] PTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYDRGGYRGRGGD

[1441] RGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPYWDPPVATMVSKGEEDNMAIIKEFMRF

[1442] KVHMEGSVNGHEFEIEGEGEGRPYEGTQTAKLKVTKGGPLPFAWDILSPQFMYGSKAYVKHPA

[1443] DIPDYLKLSFPEGFKWERVMNFEDGGVVTVTQDSSLQDGEFIYKVKLRGTNFPSDGPVMQKKT

[1444] MGWEASSERMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTYKAKKPVQLPGAYNVNIKLDIT

[1445] SHNEDYTIVEQYERAEGRHSTGGMDELYK

[1446] Amino acid sequence of Aureochrome1 protein (gene is AUREO1) from Vaucheria frigida (yellow-green alga):

[1447] SEQ ID NO:92. VfAU1 (A8QW55):

[1448] MNGLTPPLMFCSRSDDPSSTSNINLDDVFADVFFNSNGELLDIDEIDDFGDNTCPKSSMSVDDDA

[1449] SSQVFQGHLFGNALSSIALSDSGDLSTGIYESQGNASRGKSLRTKSSGSISSELTEAQKVERRERN

[1450] REHAKRSRVRKKFLLESLQQSVNELNHENNCLKESIREHLGPRGDSLIAQCSPEADTLLTDNPSK

[1451] ANRILED PDYSLVKALQMAQQNFVITDASLPDNPIVYASRGFLTLTGYSLDQILGRNCRFLQGPE

[1452] TDPRAVDKIRNAITKGVDTSVCLLNYRQDGTTFWNLFFVAGLRDSKGNIVNYVGVQSKVSEDYAKLLVN EQNIEYKGVRTSNMLRRK

[1453] SEQ ID NO:93. VfAU1-LOV domain:

[1454] PDYSLVKALQMAQQNFVITDASLPDNPIVYASRGFLTLTGYSLDQILGRNCRFLQGPETDPRAVD

[1455] KIRNAITKGVDTSVCLLNYRQDGTTFWNLFFVAGLRDSKGNIVNYVGVQSKVSEDYAKLLVNE

[1456] QNIEYKGVRTS NMLRRK

[1457] SEQ ID NO:94. VfAU1–DNA sequence - VfAU1-LOV domain (without start codon):

[1458] Cctgactacagtctcgtgaaggctctgcaaatggcacaacagaattttgtcattacagacgcctccctcccagacaaccctatcgtctacgccagtaga

[1459] gggtttctgacactgacaggctattctctcgaccagatcctgggcaggaactgcaggtttctgcaagggccagaaacagacccaagagctgtggataa

[1460] gatcaggaatgccatcaccaaaggcgttgataccagtgtctgtctgctgaattatagacaggatggcacaaccttctggaatctcttcttcgtggctggac

[1461] tcagagattctaagggcaatattgtcaactacgtcggagtgcagtcaaaggtgagcgaagattatgccaagctgctggtcaacgagcagaacattgag

[1462] tacaaaggtgtgcgcaccagtaacatgctgcgcagaaag

[1463] SEQ ID NO:95. TDP-43 (TAR DNA-binding protein-43)

[1464] MSEYIRVTEDENDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGILHAPD

[1465] AGWGNLVYVVNYPKDNKRKMDETDASSAVKVKRAVQKTSDLIVLGLPWKTTEQDLKEYFSTF

[1466] GEVLMVQVKKDLKTGHSKGFGFVRFTEYETQVKVMSQRHMIDGRWCDCKLPNSKQSQDEPL

[1467] RSRKVFVGRCTEDMTEDELREFFSQYGDVMDVFIPKPFRAFAFVTFADDQIAQSLCGEDLIIKGI

[1468] SVHISNAEPKHNSNRQLERSGRFGGNPGGFGNQGGFGNSRGGGAGLGNNQGSNMGGGMNFG

[1469] AFSINPAMMAAAQAALQSSWGMMGMLASQQNQSGPSGNNQNQGNMQREPNQAFGSGNNSY

[1470] SGSNSGAAIGWGSASNAGSGSGFNGGFGSSMDSKSSGWGM

[1471] SEQ ID NO:96. TDP-43 (amino acids 105 - 414)

[1472] MDLIVLGLPWKTTEQDLKEYFSTFGEVLMVQVKKDLKTGHSKGFGFVRFTEYETQVKVMSQR

[1473] HMIDGRWCDCKLPNSKQSQDEPLRSRKVFVGRCTEDMTEDELREFFSQYGDVMDVFIPKPFRA

[1474] FAFVTFADDQIAQSLCGEDLIIKGISVHISNAEPKHNSNRQLERSGRFGGNPGGFGNQGGFGNSR

[1475] GGGAGLGNNQGSNMGGGMNFGAFSINPAMMAAAQAALQSSWGMMGMLASQQNQSGPSGN

[1476] NQNQGNMQREPNQAFGSGNNSYSGSNSGAAIGWGSASNAGSGSGFNGGFGSSMDSKSSGWG

[1477] M

[1478] SEQ ID NO:97. TDP-43 (amino acids 191 - 414)

[1479] MRKVFVGRCTEDMTEDELREFFSQYGDVMDVFIPKPFRAFAFVTFADDQIAQSLCGEDLIIKGIS

[1480] VHISNAEPKHNSNRQLERSGRFGGNPGGFGNQGGFGNSRGGGAGLGNNQGSNMGGGMNFGA

[1481] FSINPAMMAAAQAALQSSWGMMGMLASQQNQSGPSGNNQNQGNMQREPNQAFGSGNNSYS​​​​​​​​​​​​​​SGSGFNGGFGSSMDSKSSGWGM

[1487] SEQ ID NO:99.AsLOV2

[1488] GEFLATTLERIEKNFVITDP RLPDNPIIFASDSFLQLTEY SREEILGRNCRFLQGPETDR

[1489] ATVRKIRDAIDNQTEVTVQL INYTKSGKKFWNLFHLQPMR DQKGDVQYFIGVQLDGTEHV

[1490] RDAAEREGVMLIKKTAENID EAAKELPDANLRPEDLWANH G

[1491] SEQ ID NO:100.EL222

[1492] MLDMGQDRPIDGSGAPGADD TRVEVQPPAQ WVLDLIEASPIASVVSDPRL ADNPLIAINQ

[1493] AFTDLTGYSE EECVGRNCRF LAGSGTEPWL TDKIRQGVRE HKPVLVEILN YKKDGTPFRN

[1494] AVLVAPIYDD DDELLYFLGS QVEVDDDQPN MGMARRERAA EMLKTLSPRQ LEVTTLVASG

[1495] LRNKEVAARL GLSEKTVKMH RGLVMEKLNL KTSADLVRIA VEAGI

[1496] SEQ ID NO:101. Ytva

[1497] MASFQSFGIP GQLEVIKKAL DHVRVGVVIT DPALEDNPIV YVNQGFVQMT GYETEEILGK

[1498] NCRFLQGKHT DPAEVDNIRT ALQNKEPVTV QIQNYKKDGT MFWNELNIDP

[1499] MEIEDKTYFV GIQNDITKQK

[1500] EYEKLLEDSL TEITALSTPI VPIRNGISAL PLVGNLTEER FNSIVCTLTN ILSTSKDDYL

[1501] IIDLSGLAQV NEQTADQIFK LSHLLKLTGT ELIITGIKPE LAMKMNKLDA NFSSLKTYSN

[1502] VKDAVKVLPI

[1503] M

[1504] SEQ ID NO:102.RsLOV

[1505] MDQKQFEKIRAVFDRSGVALTLVDMSLPEQPVVLANPPFLRMTGYTEGQILGFNCRFLQRGDEN

[1506] AQARAD

[1507] IRDALKLGRELQVVLRNYRANDEPFDNLLFLHPVGGRPDAPDYFLGSQFELGRSGNSEEAAAA

[1508] GHAGALT

[1509] GELARIGTVAARLEMDSRRHLAQAAAALVRAWERRG

[1510] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the disclosed invention belongs.Publications cited herein and the materials for which they are cited are expressly incorporated herein by reference.

[1511] It will be appreciated by those skilled in the art that many changes and modifications may be made to the preferred embodiments of the present invention, and that these changes and modifications may be made without departing from the spirit of the present invention. Therefore, the appended claims are intended to cover all such equivalent variations that fall within the true spirit and scope of the present invention. Sequence Listing <110> University of Pittsburgh Federal System of Higher Education <120> Optogenetic induction of neurodegenerative disease pathology <130> 10504-011WO1 <160> 102 <170> PatentIn version 3.5 <210> 1 <400> 1 000 <210> 2 <211> 498 <212> PRT <213> Arabidopsis <400> 2 Met Lys Met Asp Lys Lys Thr Ile Val Trp Phe Arg Arg Asp Leu Arg 1 5 10 15 Ile Glu Asp Asn Pro Ala Leu Ala Ala Ala Ala His Glu Gly Ser Val 20 25 30 Phe Pro Val Phe Ile Trp Cys Pro Glu Glu Glu Gly Gln Phe Tyr Pro 35 40 45 Gly Arg Ala Ser Arg Trp Trp Met Lys Gln Ser Leu Ala His Leu Ser 50 55 60 Gln Ser Leu Lys Ala Leu Gly Ser Asp Leu Thr Leu Ile Lys Thr His 65 70 75 80 Asn Thr Ile Ser Ala Ile Leu Asp Cys Ile Arg Val Thr Gly Ala Thr 85 90 95 Lys Val Val Phe Asn His Leu Tyr Asp Pro Val Ser Leu Val Arg Asp 100 105 110 His Thr Val Lys Glu Lys Leu Val Glu Arg Gly Ile Ser Val Gln Ser 115 120 125 Tyr Asn Gly Asp Leu Leu Tyr Glu Pro Trp Glu Ile Tyr Cys Glu Lys 130 135 140 Gly Lys Pro Phe Thr Ser Phe Asn Ser Tyr Trp Lys Lys Cys Leu Asp 145 150 155 160 Met Ser Ile Glu Ser Val Met Leu Pro Pro Pro Trp Arg Leu Met Pro 165 170 175 Ile Thr Ala Ala Ala Glu Ala Ile Trp Ala Cys Ser Ile Glu Glu Leu 180 185 190 Gly Leu Glu Asn Glu Ala Glu Lys Pro Ser Asn Ala Leu Leu Thr Arg 195 200 205 Ala Trp Ser Pro Gly Trp Ser Asn Ala Asp Lys Leu Leu Asn Glu Phe 210 215 220 Ile Glu Lys Gln Leu Ile Asp Tyr Ala Lys Asn Ser Lys Lys Val Val 225 230 235 240 Gly Asn Ser Thr Ser Leu Leu Ser Pro Tyr Leu His Phe Gly Glu Ile 245 250 255 Ser Val Arg His Val Phe Gln Cys Ala Arg Met Lys Gln Ile Ile Trp 260 265 270 Ala Arg Asp Lys Asn Ser Glu Gly Glu Glu Ser Ala Asp Leu Phe Leu 275 280 285 Arg Gly Ile Gly Leu Arg Glu Tyr Ser Arg Tyr Ile Cys Phe Asn Phe 290 295 300 Pro Phe Thr His Glu Gln Ser Leu Leu Ser His Leu Arg Phe Phe Pro 305 310 315 320 Trp Asp Ala Asp Val Asp Lys Phe Lys Ala Trp Arg Gln Gly Arg Thr 325 330 335 Gly Tyr Pro Leu Val Asp Ala Gly Met Arg Glu Leu Trp Ala Thr Gly 340 345 350 Trp Met His Asn Arg Ile Arg Val Ile Val Ser Ser Phe Ala Val Lys 355 360 365 Phe Leu Leu Leu Pro Trp Lys Trp Gly Met Lys Tyr Phe Trp Asp Thr 370 375 380 Leu Leu Asp Ala Asp Leu Glu Cys Asp Ile Leu Gly Trp Gln Tyr Ile 385 390 395 400 Ser Gly Ser Ile Pro Asp Gly His Glu Leu Asp Arg Leu Asp Asn Pro 405 410 415 Ala Leu Gln Gly Ala Lys Tyr Asp Pro Glu Gly Glu Tyr Ile Arg Gln 420 425 430 Trp Leu Pro Glu Leu Ala Arg Leu Pro Thr Glu Trp Ile His His Pro 435 440 445 Trp Asp Ala Pro Leu Thr Val Leu Lys Ala Ser Gly Val Glu Leu Gly 450 455 460 Thr Asn Tyr Ala Lys Pro Ile Val Asp Ile Asp Thr Ala Arg Glu Leu 465 470 475 480 Leu Ala Lys Ala Ile Ser Arg Thr Arg Gly Ala Gln Ile Met Ile Gly 485 490 495 Ala Ala <210> 3 <211> 119 <212> PRT <213> Neurospora <400> 3 Met Thr Ser Cys Ala Leu Ile Leu Cys Asp Leu Lys Gln Lys Asp Thr 1 5 10 15 Pro Ile Val Tyr Ala Ser Glu Ala Phe Leu Tyr Met Thr Gly Tyr Ser 20 25 30 Asn Ala Glu Val Leu Gly Arg Asn Cys Arg Phe Leu Gln Ser Pro Asp 35 40 45 Gly Met Val Lys Pro Lys Ser Thr Arg Lys Tyr Val Asp Ser Asn Thr 50 55 60 Ile Asn Thr Met Arg Lys Ala Ile Asp Arg Asn Ala Glu Val Gln Val 65 70 75 80 Glu Val Val Asn Phe Lys Lys Asn Gly Gln Arg Phe Val Asn Phe Leu 85 90 95 Thr Met Ile Pro Val Arg Asp Glu Thr Gly Glu Tyr Arg Tyr Ser Met 100 105 110 Gly Phe Gln Cys Glu Thr Glu 115 <210> 4 <211> 150 <212> PRT <213> Neurospora <400> 4 His Thr Leu Tyr Ala Pro Gly Gly Tyr Asp Ile Met Gly Tyr Leu Ile 1 5 10 15 Gln Ile Met Asn Arg Pro Asn Pro Gln Val Glu Leu Gly Pro Val Asp 20 25 30 Thr Ser Cys Ala Leu Ile Leu Cys Asp Leu Lys Gln Lys Asp Thr Pro 35 40 45 [[ID=(原内容此处有误,推测应为ID=34]]Ile Val Tyr Ala Ser Glu Ala Phe Leu Tyr Met Thr Gly Tyr Ser Asn 50 55 60 Ala Glu Val Leu Gly Arg Asn Cys Arg Phe Leu Gln Ser Pro Asp Gly 65 70 75 80 Met Val Lys Pro Lys Ser Thr Arg Lys Tyr Val Asp Ser Asn Thr Ile 85 90 95 Asn Thr Met Arg Lys Ala Ile Asp Arg Asn Ala Glu Val Gln Val Glu 100 105 110 Val Val Asn Phe Lys Lys Asn Gly Gln Arg Phe Val Asn Phe Leu Thr 115 120 125 Met Ile Pro Val Arg Asp Glu Thr Gly Glu Tyr Arg Tyr Ser Met Gly 130 135 140 Phe Gln Cys Glu Thr Glu 145 150 <210> 5 <211> 150 <212> PRT <213> Neurospora <400> 5 His Thr Leu Tyr Ala Pro Gly Gly Tyr Asp Ile Met Gly Trp Leu Ile 1 5 10 15 Gln Ile Met Asn Arg Pro Asn Pro Gln Val Glu Leu Gly Pro Val Asp 20 25 30 Thr Ser Cys Ala Leu Ile Leu Cys Asp Leu Lys Gln Lys Asp Thr Pro 35 40 45 Ile Val Tyr Ala Ser Glu Ala Phe Leu Tyr Met Thr Gly Tyr Ser Asn 50 55 60 Ala Glu Val Leu Gly Arg Asn Cys Arg Phe Leu Gln Ser Pro Asp Gly 65 70 75 80 Met Val Lys Pro Lys Ser Thr Arg Lys Tyr Val Asp Ser Asn Thr Ile 85 90 95 Asn Thr Met Arg Lys Ala Ile Asp Arg Asn Ala Glu Val Gln Val Glu 100 105 110 Val Val Asn Phe Lys Lys Asn Gly Gln Arg Phe Val Asn Phe Leu Thr 115 120 125 Met Ile Pro Val Arg Asp Glu Thr Gly Glu Tyr Arg Tyr Ser Met Gly 130 135 140 Phe Gln Cys Glu Thr Glu 145 150 <210> 6 <211> 915 <212> PRT <213> Artificial Sequence <220> <223> Synthetic construct <400> 6 Met Lys Met Asp Lys Lys Thr Ile Val Trp Phe Arg Arg Asp Leu Arg[[ID=3s5]] 1 5 10 15 Ile Glu Asp Asn Pro Ala Leu Ala Ala Ala Ala His Glu Gly Ser Val 20 25 30<s Phe Pro Val Phe Ile Trp Cys Pro Glu Glu Glu Gly Gln Phe Tyr Pro 35 40 45 Gly Arg Ala Ser Arg Trp Trp Met Lys Gln Ser Leu Ala His Leu Ser 50 55 60 Gln Ser Leu Lys Ala Leu Gly Ser Asp Leu Thr Leu Ile Lys Thr His 65 70 75 80 Asn Thr Ile Ser Ala Ile Leu Asp Cys Ile Arg Val Thr Gly Ala Thr 85 90 95 Lys Val Val Phe Asn His Leu Tyr Asp Pro Val Ser Leu Val Arg Asp 100 105 110 His Thr Val Lys Glu Lys Leu Val Glu Arg Gly Ile Ser Val Gln Ser 115 120 125 Tyr Asn Gly Asp Leu Leu Tyr Glu Pro Trp Glu Ile Tyr Cys Glu Lys 130 135 140 Gly Lys Pro Phe Thr Ser Phe Asn Ser Tyr Trp Lys Lys Cys Leu Asp 145 150 155 160 Met Ser Ile Glu Ser Val Met Leu Pro Pro Pro Trp Arg Leu Met Pro 165 170 175 Ile Thr Ala Ala Ala Glu Ala Ile Trp Ala Cys Ser Ile Glu Glu Leu 180 185 190 Gly Leu Glu Asn Glu Ala Glu Lys Pro Ser Asn Ala Leu Leu Thr Arg 195 200 205 Ala Trp Ser Pro Gly Trp Ser Asn Ala Asp Lys Leu Leu Asn Glu Phe 210 215 220 Ile Glu Lys Gln Leu Ile Asp Tyr Ala Lys Asn Ser Lys Lys Val Val 225 230 235 240 Gly Asn Ser Thr Ser Leu Leu Ser Pro Tyr Leu His Phe Gly Glu Ile 245 250 255 Ser Val Arg His Val Phe Gln Cys Ala Arg Met Lys Gln Ile Ile Trp 260 265 270 Ala Arg Asp Lys Asn Ser Glu Gly Glu Glu Ser Ala Asp Leu Phe Leu 275 280 285 Arg Gly Ile Gly Leu Arg Glu Tyr Ser Arg Tyr Ile Cys Phe Asn Phe 290 295 300 Pro Phe Thr His Glu Gln Ser Leu Leu Ser His Leu Arg Phe Phe Pro 305 310 315 320 Trp Asp Ala Asp Val Asp Lys Phe Lys Ala Trp Arg Gln Gly Arg Thr 325 330 335 Gly Tyr Pro Leu Val Asp Ala Gly Met Arg Glu Leu Trp Ala Thr Gly 340 345 350 Trp Met His Asn Arg Ile Arg Val Ile Val Ser Ser Phe Ala Val Lys 355 360 365 Phe Leu Leu Leu Pro Trp Lys Trp Gly Met Lys Tyr Phe Trp Asp Thr 370 375 380 Leu Leu Asp Ala Asp Leu Glu Cys Asp Ile Leu Gly Trp Gln Tyr Ile 385 390 395 400 Ser Gly Ser Ile Pro Asp Gly His Glu Leu Asp Arg Leu Asp Asn Pro 405 410 415 Ala Leu Gln Gly Ala Lys Tyr Asp Pro Glu Gly Glu Tyr Ile Arg Gln 420 425 430 Trp Leu Pro Glu Leu Ala Arg Leu Pro Thr Glu Trp Ile His His Pro 435 440 445 Trp Asp Ala Pro Leu Thr Val Leu Lys Ala Ser Gly Val Glu Leu Gly 450 455 460 Thr Asn Tyr Ala Lys Pro Ile Val Asp Ile Asp Thr Ala Arg Glu Leu 465 470 475 480 Leu Ala Lys Ala Ile Ser Arg Thr Arg Gly Ala Gln Ile Met Ile Gly 485 490 495 Ala Ala Ala Arg Gly Met Ser Glu Tyr Ile Arg Val Thr Glu Asp Glu 500 505 510 Asn Asp Glu Pro Ile Glu Ile Pro Ser Glu Asp Asp Gly Thr Val Leu 515 520 525 Leu Ser Thr Val Thr Ala Gln Phe Pro Gly Ala Cys Gly Leu Arg Tyr 530 535 540 Arg Asn Pro Val Ser Gln Cys Met Arg Gly Val Arg Leu Val Glu Gly 545 550 555 560 Ile Leu His Ala Pro Asp Ala Gly Trp Gly Asn Leu Val Tyr Val Val 565 570 575 Asn Tyr Pro Lys Asp Asn Lys Arg Lys Met Asp Glu Thr Asp Ala Ser 580 585 590 Ser Ala Val Lys Val Lys Arg Ala Val Gln Lys Thr Ser Asp Leu Ile 595 600 605 Val Leu Gly Leu Pro Trp Lys Thr Thr Glu Gln Asp Leu Lys Glu Tyr 610 615 620 Phe Ser Thr Phe Gly Glu Val Leu Met Val Gln Val Lys Lys Asp Leu 625 630 635 640 Lys Thr Gly His Ser Lys Gly Phe Gly Phe Val Arg Phe Thr Glu Tyr 645 650 655 Glu Thr Gln Val Lys Val Met Ser Gln Arg His Met Ile Asp Gly Arg 660 665 670 Trp Cys Asp Cys Lys Leu Pro Asn Ser Lys Gln Ser Gln Asp Glu Pro 675 680 685 Leu Arg Ser Arg Lys Val Phe Val Gly Arg Cys Thr Glu Asp Met Thr 690 695 700 Glu Asp Glu Leu Arg Glu Phe Phe Ser Gln Tyr Gly Asp Val Met Asp 705 710 715 720 Val Phe Ile Pro Lys Pro Phe Arg Ala Phe Ala Phe Val Thr Phe Ala 725 730 735 Asp Asp Gln Ile Ala Gln Ser Leu Cys Gly Glu Asp Leu Ile Ile Lys 740 745 750 Gly Ile Ser Val His Ile Ser Asn Ala Glu Pro Lys His Asn Ser Asn 755 760 765 Arg Gln Leu Glu Arg Ser Gly Arg Phe Gly Gly Asn Pro Gly Gly Phe 770 775 780 Gly Asn Gln Gly Gly Phe Gly Asn Ser Arg Gly Gly Gly Ala Gly Leu 785 790 795 800 Gly Asn Asn Gln Gly Ser Asn Met Gly Gly Gly Met Asn Phe Gly Ala 805 810 815 Phe Ser Ile Asn Pro Ala Met Met Ala Ala Ala Gln Ala Ala Leu Gln 820 825 830 Ser Ser Trp Gly Met Met Gly Met Leu Ala Ser Gln Gln Asn Gln Ser 835 840 845 Gly Pro Ser Gly Asn Asn Gln Asn Gln Gly Asn Met Gln Arg Glu Pro 850 855 860 Asn Gln Ala Phe Gly Ser Gly Asn Asn Ser Tyr Ser Gly Ser Asn Ser 865 870 875 880 Gly Ala Ala Ile Gly Trp Gly Ser Ala Ser Asn Ala Gly Ser Gly Ser 885 890 895 Gly Phe Asn Gly Gly Phe Gly Ser Ser Met Asp Ser Lys Ser Ser Gly 900 905 910 Trp Gly Met 915 <210> 7 <211> �16 <212> PRT<l <213> 人工序列 <220> <223> 合成构建体 <400> 7 Met Ser Glu Tyr Ile Arg Val Thr Glu Asp Glu Asn Asp Glu Pro Ile 1 5 10 15 Glu Ile Pro Ser Glu Asp Asp Gly Thr Val Leu Leu Ser Thr Val Thr 20 25 30 Ala Gln Phe Pro Gly Ala Cys Gly Leu Arg Tyr Arg Asn Pro Val Ser 35 40 45 Gln Cys Met Arg Gly Val Arg Leu Val Glu Gly Ile Leu His Ala Pro 50 55 60 It should be noted that there may be some inaccuracies in the original text, especially the "�" character in line 22 which seems incorrect. This translation is based on the best understanding of the provided text.Asp Ala Gly Trp Gly Asn Leu Val Tyr Val Val Asn Tyr Pro Lys Asp 65 70 75 80 Asn Lys Arg Lys Met Asp Glu Thr Asp Ala Ser Ser Ala Val Lys Val 85 90 95 Lys Arg Ala Val Gln Lys Thr Ser Asp Leu Ile Val Leu Gly Leu Pro 100 105 110 Trp Lys Thr Thr Glu Gln Asp Leu Lys Glu Tyr Phe Ser Thr Phe Gly 115 120 125 Glu Val Leu Met Val Gln Val Lys Lys Asp Leu Lys Thr Gly His Ser 130 135 140 Lys Gly Phe Gly Phe Val Arg Phe Thr Glu Tyr Glu Thr Gln Val Lys 145 150 155 160 Val Met Ser Gln Arg His Met Ile Asp Gly Arg Trp Cys Asp Cys Lys 165 170 175 Leu Pro Asn Ser Lys Gln Ser Gln Asp Glu Pro Leu Arg Ser Arg Lys 180 185 190 Val Phe Val Gly Arg Cys Thr Glu Asp Met Thr Glu Asp Glu Leu Arg 195 200 205 Glu Phe Phe Ser Gln Tyr Gly Asp Val Met Asp Val Phe Ile Pro Lys 210 215 220 Pro Phe Arg Ala Phe Ala Phe Val Thr Phe Ala Asp Asp Gln Ile Ala 225 230 235 240 Gln Ser Leu Cys Gly Glu Asp Leu Ile Ile Lys Gly Ile Ser Val His 245 250 255 Ile Ser Asn Ala Glu Pro Lys His Asn Ser Asn Arg Gln Leu Glu Arg 260 265 270 Ser Gly Arg Phe Gly Gly Asn Pro Gly Gly Phe Gly Asn Gln Gly Gly 275 280 285 Phe Gly Asn Ser Arg Gly Gly Gly Ala Gly Leu Gly Asn Asn Gln Gly 290 295 300 Ser Asn Met Gly Gly Gly Met Asn Phe Gly Ala Phe Ser Ile Asn Pro 305 310 315 320 Ala Met Met Ala Ala Ala Gln Ala Ala Leu Gln Ser Ser Trp Gly Met 325 330 335 Met Gly Met Leu Ala Ser Gln Gln Asn Gln Ser Gly Pro Ser Gly Asn 340 345 350 Asn Gln Asn Gln Gly Asn Met Gln Arg Glu Pro Asn Gln Ala Phe Gly 355 360 365 Ser Gly Asn Asn Ser Tyr Ser Gly Ser Asn Ser Gly Ala Ala Ile Gly 370 375 380 Trp Gly Ser Ala Ser Asn Ala Gly Ser Gly Ser Gly Phe Asn Gly Gly 385 390 395 400 Phe Gly Ser Ser Met Asp Ser Lys Ser Ser Gly Trp Gly Met Leu Glu 405 410 415 Ala Thr Met Lys Met Asp Lys Lys Thr Ile Val Trp Phe Arg Arg Asp 420 425 430 Leu Arg Ile Glu Asp Asn Pro Ala Leu Ala Ala Ala Ala His Glu Gly 435 440 445 Ser Val Phe Pro Val Phe Ile Trp Cys Pro Glu Glu Glu Gly Gln Phe 450 455 460 Tyr Pro Gly Arg Ala Ser Arg Trp Trp Met Lys Gln Ser Leu Ala His 465 470 475 480 Leu Ser Gln Ser Leu Lys Ala Leu Gly Ser Asp Leu Thr Leu Ile Lys 485 490 495 Thr His Asn Thr Ile Ser Ala Ile Leu Asp Cys Ile Arg Val Thr Gly 500 505 510 Ala Thr Lys Val Val Phe Asn His Leu Tyr Asp Pro Val Ser Leu Val 515 520 525 Arg Asp His Thr Val Lys Glu Lys Leu Val Glu Arg Gly Ile Ser Val 530 535 540 Gln Ser Tyr Asn Gly Asp Leu Leu Tyr Glu Pro Trp Glu Ile Tyr Cys 545 550 555 560 Glu Lys Gly Lys Pro Phe Thr Ser Phe Asn Ser Tyr Trp Lys Lys Cys 565 570 575 Leu Asp Met Ser Ile Glu Ser Val Met Leu Pro Pro Pro Trp Arg Leu 580 585 590 Met Pro Ile Thr Ala Ala Ala Glu Ala Ile Trp Ala Cys Ser Ile Glu 595 600 605 Glu Leu Gly Leu Glu Asn Glu Ala Glu Lys Pro Ser Asn Ala Leu Leu 610 615 620 Thr Arg Ala Trp Ser Pro Gly Trp Ser Asn Ala Asp Lys Leu Leu Asn 625 630 635 640 Glu Phe Ile Glu Lys Gln Leu Ile Asp Tyr Ala Lys Asn Ser Lys Lys 645 650 655 Val Val Gly Asn Ser Thr Ser Leu Leu Ser Pro Tyr Leu His Phe Gly 660 665 670 Glu Ile Ser Val Arg His Val Phe Gln Cys Ala Arg Met Lys Gln Ile 675 680 685 Ile Trp Ala Arg Asp Lys Asn Ser Glu Gly Glu Glu Ser Ala Asp Leu 690 695 700 Phe Leu Arg Gly Ile Gly Leu Arg Glu Tyr Ser Arg Tyr Ile Cys Phe 705 710 715 720 Asn Phe Pro Phe Thr His Glu Gln Ser Leu Leu Ser His Leu Arg Phe 725 730 735 Phe Pro Trp Asp Ala Asp Val Asp Lys Phe Lys Ala Trp Arg Gln Gly 740 745 750 Arg Thr Gly Tyr Pro Leu Val Asp Ala Gly Met Arg Glu Leu Trp Ala 755 760 765 Thr Gly Trp Met His Asn Arg Ile Arg Val Ile Val Ser Ser Phe Ala 770 775 780 Val Lys Phe Leu Leu Leu Pro Trp Lys Trp Gly Met Lys Tyr Phe Trp 785 790 795 800 Asp Thr Leu Leu Asp Ala Asp Leu Glu Cys Asp Ile Leu Gly Trp Gln 805 810 815 Tyr Ile Ser Gly Ser Ile Pro Asp Gly His Glu Leu Asp Arg Leu Asp 820 825 830 Asn Pro Ala Leu Gln Gly Ala Lys Tyr Asp Pro Glu Gly Glu Tyr Ile 835 840 845 Arg Gln Trp Leu Pro Glu Leu Ala Arg Leu Pro Thr Glu Trp Ile His 850 855 860 His Pro Trp Asp Ala Pro Leu Thr Val Leu Lys Ala Ser Gly Val Glu 865 870 875 880 Leu Gly Thr Asn Tyr Ala Lys Pro Ile Val Asp Ile Asp Thr Ala Arg 885 890 895 Glu Leu Leu Ala Lys Ala Ile Ser Arg Thr Arg Gly Ala Gln Ile Met 900 905 910 Ile Gly Ala Ala[[ID=1{7]] 915 <210> 8 <211> 644 <212> PRT <213> Synthetic Sequence <220> <223> Synthetic Construct <400> 8 Met Gly Arg Phe Gly Gly Asn Pro Gly Gly Phe Gly Asn Gln Gly Gly 1 5 10 15 Phe Gly Asn Ser Arg Gly Gly Gly Ala Gly Leu Gly Asn Asn Gln Gly 20 25 30 Ser Asn Met Gly Gly Gly Met Asn Phe Gly Ala Phe Ser Ile Asn Pro 35 40 45 Ala Met Met Ala Ala Ala Gln Ala Ala Leu Gln Ser Ser Trp Gly Met 50 55 60 Met Gly Met Leu Ala Ser Gln Gln Asn Gln Ser Gly Pro Ser Gly Asn 65 70 75 80 Asn Gln Asn Gln Gly Asn Met Gln Arg Glu Pro Asn Gln Ala Phe Gly 85 90 95 Ser Gly Asn Asn Ser Tyr Ser Gly Ser Asn Ser Gly Ala Ala Ile Gly 100 105 110 Trp Gly Ser Ala Ser Asn Ala Gly Ser Gly Ser Gly Phe Asn Gly Gly 115 120 125 Phe Gly Ser Ser Met Asp Ser Lys Ser Ser Gly Trp Gly Met Leu Glu 130 135 140 Ala Thr Met Lys Met Asp Lys Lys Thr Ile Val Trp Phe Arg Arg Asp 145 150 155 160 Leu Arg Ile Glu Asp Asn Pro Ala Leu Ala Ala Ala Ala His Glu Gly 165 170 175 Ser Val Phe Pro Val Phe Ile Trp Cys Pro Glu Glu Glu Gly Gln Phe 180 185 190 Tyr Pro Gly Arg Ala Ser Arg Trp Trp Met Lys Gln Ser Leu Ala His 195 200 205 Leu Ser Gln Ser Leu Lys Ala Leu Gly Ser Asp Leu Thr Leu Ile Lys 210 215 220 Thr His Asn Thr Ile Ser Ala Ile Leu Asp Cys Ile Arg Val Thr Gly 225 230 235 240 Ala Thr Lys Val Val Phe Asn His Leu Tyr Asp Pro Val Ser Leu Val 245 250 255 Arg Asp His Thr Val Lys Glu Lys Leu Val Glu Arg Gly Ile Ser Val 260 265 270 Gln Ser Tyr Asn Gly Asp Leu Leu Tyr Glu Pro Trp Glu Ile Tyr Cys 275 280 285 Glu Lys Gly Lys Pro Phe Thr Ser Phe Asn Ser Tyr Trp Lys Lys Cys 290 295 300 Leu Asp Met Ser Ile Glu Ser Val Met Leu Pro Pro Pro Trp Arg Leu 305 310 315 320 Met Pro Ile Thr Ala Ala Ala Glu Ala Ile Trp Ala Cys Ser Ile Glu 325 330 335 Glu Leu Gly Leu Glu Asn Glu Ala Glu Lys Pro Ser Asn Ala Leu Leu 340 345 350 Thr Arg Ala Trp Ser Pro Gly Trp Ser Asn Ala Asp Lys Leu Leu Asn 355 360 365 Glu Phe Ile Glu Lys Gln Leu Ile Asp Tyr Ala Lys Asn Ser Lys Lys 370 375 380 Val Val Gly Asn Ser Thr Ser Leu Leu Ser Pro Tyr Leu His Phe Gly 385 390 395 400 Glu Ile Ser Val Arg His Val Phe Gln Cys Ala Arg Met Lys Gln Ile 405 410 415 Ile Trp Ala Arg Asp Lys Asn Ser Glu Gly Glu Glu Ser Ala Asp Leu 420 425 430 Phe Leu Arg Gly Ile Gly Leu Arg Glu Tyr Ser Arg Tyr Ile Cys Phe 435 440 445 Asn Phe Pro Phe Thr His Glu Gln Ser Leu Leu Ser His Leu Arg Phe 450 455 460 Phe Pro Trp Asp Ala Asp Val Asp Lys Phe Lys Ala Trp Arg Gln Gly 465 470 475 480 Arg Thr Gly Tyr Pro Leu Val Asp Ala Gly Met Arg Glu Leu Trp Ala 485 490 495 Thr Gly Trp Met His Asn Arg Ile Arg Val Ile Val Ser Ser Phe Ala 500 505 510 Val Lys Phe Leu Leu Leu Pro Trp Lys Trp Gly Met Lys Tyr Phe Trp 515 520 525 Asp Thr Leu Leu Asp Ala Asp Leu Glu Cys Asp Ile Leu Gly Trp Gln 530 535 540 Tyr Ile Ser Gly Ser Ile Pro Asp Gly His Glu Leu Asp Arg Leu Asp 545 550 555 560 Asn Pro Ala Leu Gln Gly Ala Lys Tyr Asp Pro Glu Gly Glu Tyr Ile 565 570 575 Arg Gln Trp Leu Pro Glu Leu Ala Arg Leu Pro Thr Glu Trp Ile His 580 585 590 His Pro Trp Asp Ala Pro Leu Thr Val Leu Lys Ala Ser Gly Val Glu 595 600 605 Leu Gly Thr Asn Tyr Ala Lys Pro Ile Val Asp Ile Asp Thr Ala Arg 610 615 620 Glu Leu Leu Ala Lys Ala Ile Ser Arg Thr Arg Gly Ala Gln Ile Met[[ID=Z]] 625 630 635 640 Ile Gly Ala Ala <210> 9 <211> 727 <212> PRT<000361X><213> Artificial Sequence <220> <223> Synthetic Construct <400> 9 Met Arg Lys Val Phe Val Gly Arg Cys Thr Glu Asp Met Thr Glu Asp 1 5 10 15 Glu Leu Arg Glu Phe Phe Ser Gln Tyr Gly Asp Val Met Asp Val Phe 20 25 30 Note: There seems to be a tag error in the original text. I assume you meant instead of <000361X> in the translation for consistency. If this is not correct, please provide the correct information. Ile Pro Lys Pro Phe Arg Ala Phe Ala Phe Val Thr Phe Ala Asp Asp 35 40 45 Gln Ile Ala Gln Ser Leu Cys Gly Glu Asp Leu Ile Ile Lys Gly Ile 50 55 60 Ser Val His Ile Ser Asn Ala Glu Pro Lys His Asn Ser Asn Arg Gln 65 70 75 80 Leu Glu Arg Ser Gly Arg Phe Gly Gly Asn Pro Gly Gly Phe Gly Asn 85 90 95 Gln Gly Gly Phe Gly Asn Ser Arg Gly Gly Gly Ala Gly Leu Gly Asn 100 105 110 Asn Gln Gly Ser Asn Met Gly Gly Gly Met Asn Phe Gly Ala Phe Ser 115 120 125 Ile Asn Pro Ala Met Met Ala Ala Ala Gln Ala Ala Leu Gln Ser Ser 130 135 140 Trp Gly Met Met Gly Met Leu Ala Ser Gln Gln Asn Gln Ser Gly Pro 145 150 155 160 Ser Gly Asn Asn Gln Asn Gln Gly Asn Met Gln Arg Glu Pro Asn Gln 165 170 175 Ala Phe Gly Ser Gly Asn Asn Ser Tyr Ser Gly Ser Asn Ser Gly Ala 180 185 190 Ala Ile Gly Trp Gly Ser Ala Ser Asn Ala Gly Ser Gly Ser Gly Phe 195 200 205 Asn Gly Gly Phe Gly Ser Ser Met Asp Ser Lys Ser Ser Gly Trp Gly 210 215 220 Met Leu Glu Ala Thr Met Lys Met Asp Lys Lys Thr Ile Val Trp Phe 225 230 235 240 Arg Arg Asp Leu Arg Ile Glu Asp Asn Pro Ala Leu Ala Ala Ala Ala 245 250 255 His Glu Gly Ser Val Phe Pro Val Phe Ile Trp Cys Pro Glu Glu Glu 260 265 270 Gly Gln Phe Tyr Pro Gly Arg Ala Ser Arg Trp Trp Met Lys Gln Ser 275 280 285 Leu Ala His Leu Ser Gln Ser Leu Lys Ala Leu Gly Ser Asp Leu Thr 290 295 300 Leu Ile Lys Thr His Asn Thr Ile Ser Ala Ile Leu Asp Cys Ile Arg 305 310 315 320 Val Thr Gly Ala Thr Lys Val Val Phe Asn His Leu Tyr Asp Pro Val 325 330 335 Ser Leu Val Arg Asp His Thr Val Lys Glu Lys Leu Val Glu Arg Gly 340 345 350 Ile Ser Val Gln Ser Tyr Asn Gly Asp Leu Leu Tyr Glu Pro Trp Glu 355 360 365 Ile Tyr Cys Glu Lys Gly Lys Pro Phe Thr Ser Phe Asn Ser Tyr Trp 370 375 380 Lys Lys Cys Leu Asp Met Ser Ile Glu Ser Val Met Leu Pro Pro Pro 385 390 395 400 Trp Arg Leu Met Pro Ile Thr Ala Ala Ala Glu Ala Ile Trp Ala Cys 405 410 415 Ser Ile Glu Glu Leu Gly Leu Glu Asn Glu Ala Glu Lys Pro Ser Asn 420 425 430 Ala Leu Leu Thr Arg Ala Trp Ser Pro Gly Trp Ser Asn Ala Asp Lys 435 440 445 Leu Leu Asn Glu Phe Ile Glu Lys Gln Leu Ile Asp Tyr Ala Lys Asn 450 455 460 Ser Lys Lys Val Val Gly Asn Ser Thr Ser Leu Leu Ser Pro Tyr Leu 465 470 475 480 His Phe Gly Glu Ile Ser Val Arg His Val Phe Gln Cys Ala Arg Met 485 490 495 Lys Gln Ile Ile Trp Ala Arg Asp Lys Asn Ser Glu Gly Glu Glu Ser 500 505 510 Ala Asp Leu Phe Leu Arg Gly Ile Gly Leu Arg Glu Tyr Ser Arg Tyr 515 520 525 Ile Cys Phe Asn Phe Pro Phe Thr His Glu Gln Ser Leu Leu Ser His 530 535 540 Leu Arg Phe Phe Pro Trp Asp Ala Asp Val Asp Lys Phe Lys Ala Trp 545 550 555 560 Arg Gln Gly Arg Thr Gly Tyr Pro Leu Val Asp Ala Gly Met Arg Glu 565 570 575 Leu Trp Ala Thr Gly Trp Met His Asn Arg Ile Arg Val Ile Val Ser 580 585 590 Ser Phe Ala Val Lys Phe Leu Leu Leu Pro Trp Lys Trp Gly Met Lys 595 600 605 Tyr Phe Trp Asp Thr Leu Leu Asp Ala Asp Leu Glu Cys Asp Ile Leu 610 615 620 Gly Trp Gln Tyr Ile Ser Gly Ser Ile Pro Asp Gly His Glu Leu Asp 625 630 635 640 Arg Leu Asp Asn Pro Ala Leu Gln Gly Ala Lys Tyr Asp Pro Glu Gly 645 650 655 Glu Tyr Ile Arg Gln Trp Leu Pro Glu Leu Ala Arg Leu Pro Thr Glu 660 665 670 Trp Ile His His Pro Trp Asp Ala Pro Leu Thr Val Leu Lys Ala Ser 675 680 685 Gly Val Glu Leu Gly Thr Asn Tyr Ala Lys Pro Ile Val Asp Ile Asp 690 695 700 Thr Ala Arg Glu Leu Leu Ala Lys Ala Ile Ser Arg Thr Arg Gly Ala 705 710 715 720 Gln Ile Met Ile Gly Ala Ala 725 <210> 10 <211> 813 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Construct <400> 10 Met Asp Leu Ile Val Leu Gly Leu Pro Trp Lys Thr Thr Glu Gln Asp 1 5 10 15 Leu Lys Glu Tyr Phe Ser Thr Phe Gly Glu Val Leu Met Val Gln Val 20 25 30 Lys Lys Asp Leu Lys Thr Gly His Ser Lys Gly Phe Gly Phe Val Arg 35 40 45 Phe Thr Glu Tyr Glu Thr Gln Val Lys Val Met Ser Gln Arg His Met 50 55 60 Ile Asp Gly Arg Trp Cys Asp Cys Lys Leu Pro Asn Ser Lys Gln Ser 65 70 75 80 Gln Asp Glu Pro Leu Arg Ser Arg Lys Val Phe Val Gly Arg Cys Thr 85 90 95 Glu Asp Met Thr Glu Asp Glu Leu Arg Glu Phe Phe Ser Gln Tyr Gly 100 105 110 Asp Val Met Asp Val Phe Ile Pro Lys Pro Phe Arg Ala Phe Ala Phe 115 120 125 Val Thr Phe Ala Asp Asp Gln Ile Ala Gln Ser Leu Cys Gly Glu Asp 130 135 140 Leu Ile Ile Lys Gly Ile Ser Val His Ile Ser Asn Ala Glu Pro Lys 145 150 155 160 His Asn Ser Asn Arg Gln Leu Glu Arg Ser Gly Arg Phe Gly Gly Asn 165 170 175 Pro Gly Gly Phe Gly Asn Gln Gly Gly Phe Gly Asn Ser Arg Gly Gly 180 185 190 Gly Ala Gly Leu Gly Asn Asn Gln Gly Ser Asn Met Gly Gly Gly Met 195 200 205 Asn Phe Gly Ala Phe Ser Ile Asn Pro Ala Met Met Ala Ala Ala Gln 210 215 220 Ala Ala Leu Gln Ser Ser Trp Gly Met Met Gly Met Leu Ala Ser Gln 225 230 235 240 Gln Asn Gln Ser Gly Pro Ser Gly Asn Asn Gln Asn Gln Gly Asn Met 245 250 255 Gln Arg Glu Pro Asn Gln Ala Phe Gly Ser Gly Asn Asn Ser Tyr Ser 260 265 270 Gly Ser Asn Ser Gly Ala Ala Ile Gly Trp Gly Ser Ala Ser Asn Ala 275 280 285 Gly Ser Gly Ser Gly Phe Asn Gly Gly Phe Gly Ser Ser Met Asp Ser 290 295 300 Lys Ser Ser Gly Trp Gly Met Leu Glu Ala Thr Met Lys Met Asp Lys 305 310 315 320 Lys Thr Ile Val Trp Phe Arg Arg Asp Leu Arg Ile Glu Asp Asn Pro 325 330 335 Ala Leu Ala Ala Ala Ala His Glu Gly Ser Val Phe Pro Val Phe Ile 340 345 350 Trp Cys Pro Glu Glu Glu Gly Gln Phe Tyr Pro Gly Arg Ala Ser Arg 355 360 365 Trp Trp Met Lys Gln Ser Leu Ala His Leu Ser Gln Ser Leu Lys Ala 370 375 380 Leu Gly Ser Asp Leu Thr Leu Ile Lys Thr His Asn Thr Ile Ser Ala 385 390 395 400 Ile Leu Asp Cys Ile Arg Val Thr Gly Ala Thr Lys Val Val Phe Asn 405 410 415 His Leu Tyr Asp Pro Val Ser Leu Val Arg Asp His Thr Val Lys Glu 420 425 430 Lys Leu Val Glu Arg Gly Ile Ser Val Gln Ser Tyr Asn Gly Asp Leu 435 440 445 Leu Tyr Glu Pro Trp Glu Ile Tyr Cys Glu Lys Gly Lys Pro Phe Thr 450 455 460 Ser Phe Asn Ser Tyr Trp Lys Lys Cys Leu Asp Met Ser Ile Glu Ser 465 470 475 480 Val Met Leu Pro Pro Pro Trp Arg Leu Met Pro Ile Thr Ala Ala Ala 485 490 495 Glu Ala Ile Trp Ala Cys Ser Ile Glu Glu Leu Gly Leu Glu Asn Glu 500 505 510 Ala Glu Lys Pro Ser Asn Ala Leu Leu Thr Arg Ala Trp Ser Pro Gly 515 520 525 Trp Ser Asn Ala Asp Lys Leu Leu Asn Glu Phe Ile Glu Lys Gln Leu 530 535 540 Ile Asp Tyr Ala Lys Asn Ser Lys Lys Val Val Gly Asn Ser Thr Ser 545 550 555 560 Leu Leu Ser Pro Tyr Leu His Phe Gly Glu Ile Ser Val Arg His Val 565 570 575 Phe Gln Cys Ala Arg Met Lys Gln Ile Ile Trp Ala Arg Asp Lys Asn 580 585 590 Ser Glu Gly Glu Glu Ser Ala Asp Leu Phe Leu Arg Gly Ile Gly Leu 595 600 605 Arg Glu Tyr Ser Arg Tyr Ile Cys Phe Asn Phe Pro Phe Thr His Glu 610 615 620 Gln Ser Leu Leu Ser His Leu Arg Phe Phe Pro Trp Asp Ala Asp Val 625 630 635 640 Asp Lys Phe Lys Ala Trp Arg Gln Gly Arg Thr Gly Tyr Pro Leu Val 645 650 655 Asp Ala Gly Met Arg Glu Leu Trp Ala Thr Gly Trp Met His Asn Arg 660 665 670 Ile Arg Val Ile Val Ser Ser Phe Ala Val Lys Phe Leu Leu Leu Pro 675 680 685 Trp Lys Trp Gly Met Lys Tyr Phe Trp Asp Thr Leu Leu Asp Ala Asp 690 695 700 Leu Glu Cys Asp Ile Leu Gly Trp Gln Tyr Ile Ser Gly Ser Ile Pro 705 710 715 720 Asp Gly His Glu Leu Asp Arg Leu Asp Asn Pro Ala Leu Gln Gly Ala 725 730 735 Lys Tyr Asp Pro Glu Gly Glu Tyr Ile Arg Gln Trp Leu Pro Glu Leu 740 745 750 Ala Arg Leu Pro Thr Glu Trp Ile His His Pro Trp Asp Ala Pro Leu 755 760 765 Thr Val Leu Lys Ala Ser Gly Val Glu Leu Gly Thr Asn Tyr Ala Lys 770 775 780 Pro Ile Val Asp Ile Asp Thr Ala Arg Glu Leu Leu Ala Lys Ala Ile 785 790 795 800 Ser Arg Thr Arg Gly Ala Gln Ile Met Ile Gly Ala Ala 805 810 <210> 11 <211> 642 <212> PRT <213> artificial sequence <220> <223> composite structure <400> 11 Met Lys Met Asp Lys Lys Thr Ile Val Trp Phe Arg Arg Asp Leu Arg 1 5 10 15 Ile Glu Asp Asn Pro Ala Leu Ala Ala Ala Ala His Glu Gly Ser Val 20 25 30 Phe Pro Val Phe Ile Trp Cys Pro Glu Glu Glu Gly Gln Phe Tyr Pro 35 40 45 Gly Arg Ala Ser Arg Trp Trp Met Lys Gln Ser Leu Ala His Leu Ser 50 55 60 Gln Ser Leu Lys Ala Leu Gly Ser Asp Leu Thr Leu Ile Lys Thr His 65 70 75 80 Asn Thr Ile Ser Ala Ile Leu Asp Cys Ile Arg Val Thr Gly Ala Thr 85 90 95 Lys Val Val Phe Asn His Leu Tyr Asp Pro Val Ser Leu Val Arg Asp 100 105 110 His Thr Val Lys Glu Lys Leu Val Glu Arg Gly Ile Ser Val Gln Ser 115 120 125 Tyr Asn Gly Asp Leu Leu Tyr Glu Pro Trp Glu Ile Tyr Cys Glu Lys 130 135 140 Gly Lys Pro Phe Thr Ser Phe Asn Ser Tyr Trp Lys Lys Cys Leu Asp 145 150 155 160 Met Ser Ile Glu Ser Val Met Leu Pro Pro Pro Trp Arg Leu Met Pro 165 170 175 Ile Thr Ala Ala Ala Glu Ala Ile Trp Ala Cys Ser Ile Glu Glu Leu 180 185 190 Gly Leu Glu Asn Glu Ala Glu Lys Pro Ser Asn Ala Leu Leu Thr Arg 195 200 205 Ala Trp Ser Pro Gly Trp Ser Asn Ala Asp Lys Leu Leu Asn Glu Phe 210 215 220 Ile Glu Lys Gln Leu Ile Asp Tyr Ala Lys Asn Ser Lys Lys Val Val 225 230 235 240 Gly Asn Ser Thr Ser Leu Leu Ser Pro Tyr Leu His Phe Gly Glu Ile 245 250 255 Ser Val Arg His Val Phe Gln Cys Ala Arg Met Lys Gln Ile Ile Trp 260 265 270 Ala Arg Asp Lys Asn Ser Glu Gly Glu Glu Ser Ala Asp Leu Phe Leu 275 280 285 Arg Gly Ile Gly Leu Arg Glu Tyr Ser Arg Tyr Ile Cys Phe Asn Phe 290 295 300 Pro Phe Thr His Glu Gln Ser Leu Leu Ser His Leu Arg Phe Phe Pro 305 310 315 320 Trp Asp Ala Asp Val Asp Lys Phe Lys Ala Trp Arg Gln Gly Arg Thr 325 330 335 Gly Tyr Pro Leu Val Asp Ala Gly Met Arg Glu Leu Trp Ala Thr Gly 340 345 350 Trp Met His Asn Arg Ile Arg Val Ile Val Ser Ser Phe Ala Val Lys 355 360 365 Phe Leu Leu Leu Pro Trp Lys Trp Gly Met Lys Tyr Phe Trp Asp Thr 370 375 380 Leu Leu Asp Ala Asp Leu Glu Cys Asp Ile Leu Gly Trp Gln Tyr Ile 385 390 395 400 Ser Gly Ser Ile Pro Asp Gly His Glu Leu Asp Arg Leu Asp Asn Pro 405 410 415 Ala Leu Gln Gly Ala Lys Tyr Asp Pro Glu Gly Glu Tyr Ile Arg Gln 420 425 430 Trp Leu Pro Glu Leu Ala Arg Leu Pro Thr Glu Trp Ile His His Pro 435 440 445 Trp Asp Ala Pro Leu Thr Val Leu Lys Ala Ser Gly Val Glu Leu Gly 450 455 460 Thr Asn Tyr Ala Lys Pro Ile Val Asp Ile Asp Thr Ala Arg Glu Leu 465 470 475 480 Leu Ala Lys Ala Ile Ser Arg Thr Arg Gly Ala Gln Ile Met Ile Gly 485 490 495 Ala Ala Ala Arg Gly Gly Arg Phe Gly Gly Asn Pro Gly Gly Phe Gly 500 505 510 Asn Gln Gly Gly Phe Gly Asn Ser Arg Gly Gly Gly Ala Gly Leu Gly 515 520 525 Asn Asn Gln Gly Ser Asn Met Gly Gly Gly Met Asn Phe Gly Ala Phe 530 535 540 Ser Ile Asn Pro Ala Met Met Ala Ala Ala Gln Ala Ala Leu Gln Ser 545 550 555 560 Ser Trp Gly Met Met Gly Met Leu Ala Ser Gln Gln Asn Gln Ser Gly 565 570 575 Pro Ser Gly Asn Asn Gln Asn Gln Gly Asn Met Gln Arg Glu Pro Asn 580 585 590 Gln Ala Phe Gly Ser Gly Asn Asn Ser Tyr Ser Gly Ser Asn Ser Gly 595 600 605 Ala Ala Ile Gly Trp Gly Ser Ala Ser Asn Ala Gly Ser Gly Ser Gly 610 615 620 Phe Asn Gly Gly Phe Gly Ser Ser Met Asp Ser Lys Ser Ser Gly Trp 625 630 635 640 Gly Met <210> 12 <211> 725 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Construct <400> 12 Met Lys Met Asp Lys Lys Thr Ile Val Trp Phe Arg Arg Asp Leu Arg 1 5 10 15 Ile Glu Asp Asn Pro Ala Leu Ala Ala Ala Ala His Glu Gly Ser Val 20 25 30 Phe Pro Val Phe Ile Trp Cys Pro Glu Glu Glu Gly Gln Phe Tyr Pro 35 40 45 Gly Arg Ala Ser Arg Trp Trp Met Lys Gln Ser Leu Ala His Leu Ser 50 55 60 Gln Ser Leu Lys Ala Leu Gly Ser Asp Leu Thr Leu Ile Lys Thr His 65 7​​​​​​​​​​​​​​​​Gly Lys Pro Phe Thr Ser Phe Asn Ser Tyr Trp Lys Lys Cys Leu Asp 145 150 155 160 Met Ser Ile Glu Ser Val Met Leu Pro Pro Pro Trp Arg Leu Met Pro 165 170 175 Ile Thr Ala Ala Ala Glu Ala Ile Trp Ala Cys Ser Ile Glu Glu Leu 180 185 190 Gly Leu Glu Asn Glu Ala Glu Lys Pro Ser Asn Ala Leu Leu Thr Arg 195 200 205 Ala Trp Ser Pro Gly Trp Ser Asn Ala Asp Lys Leu Leu Asn Glu Phe 210 215 220 Ile Glu Lys Gln Leu Ile Asp Tyr Ala Lys Asn Ser Lys Lys Val Val 225 230 235 240 Gly Asn Ser Thr Ser Leu Leu Ser Pro Tyr Leu His Phe Gly Glu Ile 245 250 255 Ser Val Arg His Val Phe Gln Cys Ala Arg Met Lys Gln Ile Ile Trp 260 265 270 Ala Arg Asp Lys Asn Ser Glu Gly Glu Glu Ser Ala Asp Leu Phe Leu 275 280 285 Arg Gly Ile Gly Leu Arg Glu Tyr Ser Arg Tyr Ile Cys Phe Asn Phe 290 295 300 Pro Phe Thr His Glu Gln Ser Leu Leu Ser His Leu Arg Phe Phe Pro 305 310 315 320 Trp Asp Ala Asp Val Asp Lys Phe Lys Ala Trp Arg Gln Gly Arg Thr 325 330 335 Gly Tyr Pro Leu Val Asp Ala Gly Met Arg Glu Leu Trp Ala Thr Gly 340 345 350 Trp Met His Asn Arg Ile Arg Val Ile Val Ser Ser Phe Ala Val Lys 355 360 365 Phe Leu Leu Leu Pro Trp Lys Trp Gly Met Lys Tyr Phe Trp Asp Thr 370 375 380 Leu Leu Asp Ala Asp Leu Glu Cys Asp Ile Leu Gly Trp Gln Tyr Ile 385 390 395 400 Ser Gly Ser Ile Pro Asp Gly His Glu Leu Asp Arg Leu Asp Asn Pro 405 410 415 Ala Leu Gln Gly Ala Lys Tyr Asp Pro Glu Gly Glu Tyr Ile Arg Gln 420 425 430 Trp Leu Pro Glu Leu Ala Arg Leu Pro Thr Glu Trp Ile His His Pro 435 440 445 Trp Asp Ala Pro Leu Thr Val Leu Lys Ala Ser Gly Val Glu Leu Gly 450 455 460 Thr Asn Tyr Ala Lys Pro Ile Val Asp Ile Asp Thr Ala Arg Glu Leu 465 470 475 480 Leu Ala Lys Ala Ile Ser Arg Thr Arg Gly Ala Gln Ile Met Ile Gly 485 490 495 Ala Ala Ala Arg Gly Arg Lys Val Phe Val Gly Arg Cys Thr Glu Asp 500 505 510 Met Thr Glu Asp Glu Leu Arg Glu Phe Phe Ser Gln Tyr Gly Asp Val 515 520 525 Met Asp Val Phe Ile Pro Lys Pro Phe Arg Ala Phe Ala Phe Val Thr 530 535 540 Phe Ala Asp Asp Gln Ile Ala Gln Ser Leu Cys Gly Glu Asp Leu Ile 545 550 555 560 Ile Lys Gly Ile Ser Val His Ile Ser Asn Ala Glu Pro Lys His Asn 565 570 575 Ser Asn Arg Gln Leu Glu Arg Ser Gly Arg Phe Gly Gly Asn Pro Gly 580 585 590 Gly Phe Gly Asn Gln Gly Gly Phe Gly Asn Ser Arg Gly Gly Gly Ala 595 600 605 Gly Leu Gly Asn Asn Gln Gly Ser Asn Met Gly Gly Gly Met Asn Phe 610 615 620 Gly Ala Phe Ser Ile Asn Pro Ala Met Met Ala Ala Ala Gln Ala Ala 625 630 635 640 Leu Gln Ser Ser Trp Gly Met Met Gly Met Leu Ala Ser Gln Gln Asn 645 650 655 Gln Ser Gly Pro Ser Gly Asn Asn Gln Asn Gln Gly Asn Met Gln Arg 660 665 670 Glu Pro Asn Gln Ala Phe Gly Ser Gly Asn Asn Ser Tyr Ser Gly Ser 675 680 685 Asn Ser Gly Ala Ala Ile Gly Trp Gly Ser Ala Ser Asn Ala Gly Ser 690 695 700 Gly Ser Gly Phe Asn Gly Gly Phe Gly Ser Ser Met Asp Ser Lys Ser 705 710 715 720 Ser Gly Trp Gly Met 725 <210> 13 <211> 811 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Construct <400> 13 Met Lys Met Asp Lys Lys Thr Ile Val Trp Phe Arg Arg Asp Leu Arg 1 5 10 15 Ile Glu Asp Asn Pro Ala Leu Ala Ala Ala Ala His Glu Gly Ser Val 20 25 30 Phe Pro Val Phe Ile Trp Cys Pro Glu Glu Glu Gly Gln Phe Tyr Pro 35 40 45 Gly Arg Ala Ser Arg Trp Trp Met Lys Gln Ser Leu Ala His Leu Ser 50 55 60 Gln Ser Leu Lys Ala Leu Gly Ser Asp Leu Thr Leu Ile Lys Thr His 65 70 75 80 Asn Thr Ile Ser Ala Ile Leu Asp Cys Ile Arg Val Thr Gly Ala Thr 85 90 95 Lys Val Val Phe Asn His Leu Tyr Asp Pro Val Ser Leu Val Arg Asp 100 105 110 His Thr Val Lys Glu Lys Leu Val Glu Arg Gly Ile Ser Val Gln Ser 115 120 125 Tyr Asn Gly Asp Leu Leu Tyr Glu Pro Trp Glu Ile Tyr Cys Glu Lys 130 135 140 Gly Lys Pro Phe Thr Ser Phe Asn Ser Tyr Trp Lys Lys Cys Leu Asp 145 150 155 160 Met Ser Ile Glu Ser Val Met Leu Pro Pro Pro Trp Arg Leu Met Pro 165 170 175 Ile Thr Ala Ala Ala Glu Ala Ile Trp Ala Cys Ser Ile Glu Glu Leu 180 185 190 Gly Leu Glu Asn Glu Ala Glu Lys Pro Ser Asn Ala Leu Leu Thr Arg 195 200 205 Ala Trp Ser Pro Gly Trp Ser Asn Ala Asp Lys Leu Leu Asn Glu Phe 210 215 220 Ile Glu Lys Gln Leu Ile Asp Tyr Ala Lys Asn Ser Lys Lys Val Val 225 230 235 240 Gly Asn Ser Thr Ser Leu Leu Ser Pro Tyr Leu His Phe Gly Glu Ile 245 250 255 Ser Val Arg His Val Phe Gln Cys Ala Arg Met Lys Gln Ile Ile Trp 260 265 270 Ala Arg Asp Lys Asn Ser Glu Gly Glu Glu Ser Ala Asp Leu Phe Leu 275 280 285 Arg Gly Ile Gly Leu Arg Glu Tyr Ser Arg Tyr Ile Cys Phe Asn Phe 290 295 300 Pro Phe Thr His Glu Gln Ser Leu Leu Ser His Leu Arg Phe Phe Pro 305 310 315 320 Trp Asp Ala Asp Val Asp Lys Phe Lys Ala Trp Arg Gln Gly Arg Thr 325 330 335 Gly Tyr Pro Leu Val Asp Ala Gly Met Arg Glu Leu Trp Ala Thr Gly 340 345 350 Trp Met His Asn Arg Ile Arg Val Ile Val Ser Ser Phe Ala Val Lys 355 360 365 Phe Leu Leu Leu Pro Trp Lys Trp Gly Met Lys Tyr Phe Trp Asp Thr 370 375 380 Leu Leu Asp Ala Asp Leu Glu Cys Asp Ile Leu Gly Trp Gln Tyr Ile 385 390 395 400 Ser Gly Ser Ile Pro Asp Gly His Glu Leu Asp Arg Leu Asp Asn Pro 405 410 415 Ala Leu Gln Gly Ala Lys Tyr Asp Pro Glu Gly Glu Tyr Ile Arg Gln 420 425 430 Trp Leu Pro Glu Leu Ala Arg Leu Pro Thr Glu Trp Ile His His Pro 435 440 445 Trp Asp Ala Pro Leu Thr Val Leu Lys Ala Ser Gly Val Glu Leu Gly 450 455 460 Thr Asn Tyr Ala Lys Pro Ile Val Asp Ile Asp Thr Ala Arg Glu Leu 465 470 475 480 Leu Ala Lys Ala Ile Ser Arg Thr Arg Gly Ala Gln Ile Met Ile Gly 485 490 495 Ala Ala Ala Arg Gly Asp Leu Ile Val Leu Gly Leu Pro Trp Lys Thr 500 505 510 Thr Glu Gln Asp Leu Lys Glu Tyr Phe Ser Thr Phe Gly Glu Val Leu 515 520 525 Met Val Gln Val Lys Lys Asp Leu Lys Thr Gly His Ser Lys Gly Phe 530 535 540 Gly Phe Val Arg Phe Thr Glu Tyr Glu Thr Gln Val Lys Val Met Ser 545 550 555 560 Gln Arg His Met Ile Asp Gly Arg Trp Cys Asp Cys Lys Leu Pro Asn 565 570 575 Ser Lys Gln Ser Gln Asp Glu Pro Leu Arg Ser Arg Lys Val Phe Val 580 585 590 Gly Arg Cys Thr Glu Asp Met Thr Glu Asp Glu Leu Arg Glu Phe Phe 595 600 605 Ser Gln Tyr Gly Asp Val Met Asp Val Phe Ile Pro Lys Pro Phe Arg 610 615 620 Ala Phe Ala Phe Val Thr Phe Ala Asp Asp Gln Ile Ala Gln Ser Leu 625 630 635 640 Cys Gly Glu Asp Leu Ile Ile Lys Gly Ile Ser Val His Ile Ser Asn 645 650 655 Ala Glu Pro Lys His Asn Ser Asn Arg Gln Leu Glu Arg Ser Gly Arg 660 665 670 Phe Gly Gly Asn Pro Gly Gly Phe Gly Asn Gln Gly Gly Phe Gly Asn 675 680 685 Ser Arg Gly Gly Gly Ala Gly Leu Gly Asn Asn Gln Gly Ser Asn Met 690 695 700 Gly Gly Gly Met Asn Phe Gly Ala Phe Ser Ile Asn Pro Ala Met Met 705 710 715 720 Ala Ala Ala Gln Ala Ala Leu Gln Ser Ser Trp Gly Met Met Gly Met 725 730 735 Leu Ala Ser Gln Gln Asn Gln Ser Gly Pro Ser Gly Asn Asn Gln Asn 740 745 750 Gln Gly Asn Met Gln Arg Glu Pro Asn Gln Ala Phe Gly Ser Gly Asn 755 760 765 Asn Ser Tyr Ser Gly Ser Asn Ser Gly Ala Ala Ile Gly Trp Gly Ser 770 775 780 Ala Ser Asn Ala Gly Ser Gly Ser Gly Phe Asn Gly Gly Phe Gly Ser 785 790 795 800 Ser Met Asp Ser Lys Ser Ser Gly Trp Gly Met 805 810 <210> 14 <211> 1159 <212> PRT <213> artificial sequence <220> <223> composite structure <400> 14 Met Lys Met Asp Lys Lys Thr Ile Val Trp Phe Arg Arg Asp Leu Arg 1 5 10 15 Ile Glu Asp Asn Pro Ala Leu Ala Ala Ala Ala His Glu Gly Ser Val 20 25 30 Phe Pro Val Phe Ile Trp Cys Pro Glu Glu Glu Gly Gln Phe Tyr Pro 35 40 45 Gly Arg Ala Ser Arg Trp Trp Met Lys Gln Ser Leu Ala His Leu Ser 50 55 60 Gln Ser Leu Lys Ala Leu Gly Ser Asp Leu Thr Leu Ile Lys Thr His 65 70 75 80 Asn Thr Ile Ser Ala Ile Leu Asp Cys Ile Arg Val Thr Gly Ala Thr 85 90 95 Lys Val Val Phe Asn His Leu Tyr Asp Pro Val Ser Leu Val Arg Asp 100 105 110 His Thr Val Lys Glu Lys Leu Val Glu Arg Gly Ile Ser Val Gln Ser 115 120 125 Tyr Asn Gly Asp Leu Leu Tyr Glu Pro Trp Glu Ile Tyr Cys Glu Lys 130 135 140 Gly Lys Pro Phe Thr Ser Phe Asn Ser Tyr Trp Lys Lys Cys Leu Asp 145 150 155 160 Met Ser Ile Glu Ser Val Met Leu Pro Pro Pro Trp Arg Leu Met Pro 165 170 175 Ile Thr Ala Ala Ala Glu Ala Ile Trp Ala Cys Ser Ile Glu Glu Leu 180 185 190 Gly Leu Glu Asn Glu Ala Glu Lys Pro Ser Asn Ala Leu Leu Thr Arg 195 200 205 Ala Trp Ser Pro Gly Trp Ser Asn Ala Asp Lys Leu Leu Asn Glu Phe 210 215 220 Ile Glu Lys Gln Leu Ile Asp Tyr Ala Lys Asn Ser Lys Lys Val Val 225 230 235 240 Gly Asn Ser Thr Ser Leu Leu Ser Pro Tyr Leu His Phe Gly Glu Ile 245 250 255 Ser Val Arg His Val Phe Gln Cys Ala Arg Met Lys Gln Ile Ile Trp 260 265 270 Ala Arg Asp Lys Asn Ser Glu Gly Glu Glu Ser Ala Asp Leu Phe Leu 275 280 285 Arg Gly Ile Gly Leu Arg Glu Tyr Ser Arg Tyr Ile Cys Phe Asn Phe 290 295 300 Pro Phe Thr His Glu Gln Ser Leu Leu Ser His Leu Arg Phe Phe Pro 305 310 315 320 Trp Asp Ala Asp Val Asp Lys Phe Lys Ala Trp Arg Gln Gly Arg Thr 325 330 335 Gly Tyr Pro Leu Val Asp Ala Gly Met Arg Glu Leu Trp Ala Thr Gly 340 345 350 Trp Met His Asn Arg Ile Arg Val Ile Val Ser Ser Phe Ala Val Lys 355 360 365 Phe Leu Leu Leu Pro Trp Lys Trp Gly Met Lys Tyr Phe Trp Asp Thr 370 375 380 Leu Leu Asp Ala Asp Leu Glu Cys Asp Ile Leu Gly Trp Gln Tyr Ile 385 390 395 400 Ser Gly Ser Ile Pro Asp Gly His Glu Leu Asp Arg Leu Asp Asn Pro 405 410 415 Ala Leu Gln Gly Ala Lys Tyr Asp Pro Glu Gly Glu Tyr Ile Arg Gln 420 425 430 Trp Leu Pro Glu Leu Ala Arg Leu Pro Thr Glu Trp Ile His His Pro 435 440 445 Trp Asp Ala Pro Leu Thr Val Leu Lys Ala Ser Gly Val Glu Leu Gly 450 455 460 Thr Asn Tyr Ala Lys Pro Ile Val Asp Ile Asp Thr Ala Arg Glu Leu 465 470 475 480 Leu Ala Lys Ala Ile Ser Arg Thr Arg Gly Ala Gln Ile Met Ile Gly 485 490 495 Ala Ala Ala Arg Gly Met Ser Glu Tyr Ile Arg Val Thr Glu Asp Glu 500 505 510 Asn Asp Glu Pro Ile Glu Ile Pro Ser Glu Asp Asp Gly Thr Val Leu 515 520 525 Leu Ser Thr Val Thr Ala Gln Phe Pro Gly Ala Cys Gly Leu Arg Tyr 530 535 540 Arg Asn Pro Val Ser Gln Cys Met Arg Gly Val Arg Leu Val Glu Gly 545 550 555 560 Ile Leu His Ala Pro Asp Ala Gly Trp Gly Asn Leu Val Tyr Val Val 565 570 575 Asn Tyr Pro Lys Asp Asn Lys Arg Lys Met Asp Glu Thr Asp Ala Ser 580 585 590 Ser Ala Val Lys Val Lys Arg Ala Val Gln Lys Thr Ser Asp Leu Ile 595 600 605 Val Leu Gly Leu Pro Trp Lys Thr Thr Glu Gln Asp Leu Lys Glu Tyr 610 615 620 Phe Ser Thr Phe Gly Glu Val Leu Met Val Gln Val Lys Lys Asp Leu 625 630 635 640 Lys Thr Gly His Ser Lys Gly Phe Gly Phe Val Arg Phe Thr Glu Tyr 645 650 655 Glu Thr Gln Val Lys Val Met Ser Gln Arg His Met Ile Asp Gly Arg 660 665 670 Trp Cys Asp Cys Lys Leu Pro Asn Ser Lys Gln Ser Gln Asp Glu Pro 675 680 685 Leu Arg Ser Arg Lys Val Phe Val Gly Arg Cys Thr Glu Asp Met Thr 690 695 700 Glu Asp Glu Leu Arg Glu Phe Phe Ser Gln Tyr Gly Asp Val Met Asp 705 710 715 720 Val Phe Ile Pro Lys Pro Phe Arg Ala Phe Ala Phe Val Thr Phe Ala 725 730 735 Asp Asp Gln Ile Ala Gln Ser Leu Cys Gly Glu Asp Leu Ile Ile Lys 740 745 750 Gly Ile Ser Val His Ile Ser Asn Ala Glu Pro Lys His Asn Ser Asn 755 760 765 Arg Gln Leu Glu Arg Ser Gly Arg Phe Gly Gly Asn Pro Gly Gly Phe 770 775 780 Gly Asn Gln Gly Gly Phe Gly Asn Ser Arg Gly Gly Gly Ala Gly Leu 785 790 795 800 Gly Asn Asn Gln Gly Ser Asn Met Gly Gly Gly Met Asn Phe Gly Ala 805 810 815 Phe Ser Ile Asn Pro Ala Met Met Ala Ala Ala Gln Ala Ala Leu Gln 820 825 830 Ser Ser Trp Gly Met Met Gly Met Leu Ala Ser Gln Gln Asn Gln Ser 835 840 845 Gly Pro Ser Gly Asn Asn Gln Asn Gln Gly Asn Met Gln Arg Glu Pro 850 855 860 Asn Gln Ala Phe Gly Ser Gly Asn Asn Ser Tyr Ser Gly Ser Asn Ser 865 870 875 880 Gly Ala Ala Ile Gly Trp Gly Ser Ala Ser Asn Ala Gly Ser Gly Ser 885 890 895 Gly Phe Asn Gly Gly Phe Gly Ser Ser Met Asp Ser Lys Ser Ser Gly 900 905 910 Trp Gly Met Ser Arg Asp Pro Pro Val Ala Thr Met Val Ser Lys Gly 915 920 925 Glu Glu Asp Asn Met Ala Ile Ile Lys Glu Phe Met Arg Phe Lys Val 930 935 940 His Met Glu Gly Ser Val Asn Gly His Glu Phe Glu Ile Glu Gly Glu 945 950 955 960 Gly Glu Gly Arg Pro Tyr Glu Gly Thr Gln Thr Ala Lys Leu Lys Val 965 970 975 Thr Lys Gly Gly Pro Leu Pro Phe Ala Trp Asp Ile Leu Ser Pro Gln 980 985 990 Phe Met Tyr Gly Ser Lys Ala Tyr Val Lys His Pro Ala Asp Ile Pro 995 1000 1005 Asp Tyr Leu Lys Leu Ser Phe Pro Glu Gly Phe Lys Trp Glu Arg 1010 1015 1020 Val Met Asn Phe Glu Asp Gly Gly Val Val Thr Val Thr Gln Asp 1025 1030 1035 Ser Ser Leu Gln Asp Gly Glu Phe Ile Tyr Lys Val Lys Leu Arg 1040 1045 1050 Gly Thr Asn Phe Pro Ser Asp Gly Pro Val Met Gln Lys Lys Thr 1055 1060 1065 Met Gly Trp Glu Ala Ser Ser Glu Arg Met Tyr Pro Glu Asp Gly 1070 1075 1080 Ala Leu Lys Gly Glu Ile Lys Gln Arg Leu Lys Leu Lys Asp Gly 1085 1090 1095 Gly His Tyr Asp Ala Glu Val Lys Thr Thr Tyr Lys Ala Lys Lys 1100 1105 1110 Pro Val Gln Leu Pro Gly Ala Tyr Asn Val Asn Ile Lys Leu Asp 1115 1120 1125 Ile Thr Ser His Asn Glu Asp Tyr Thr Ile Val Glu Gln Tyr Glu 1130 1135 1140​​​​​​​​​​​​​​​​​​​​​​​​​​​​​Ala Gln Phe Pro Gly Ala Cys Gly Leu Arg Tyr Arg Asn Pro Val Ser 35 40 45 Gln Cys Met Arg Gly Val Arg Leu Val Glu Gly Ile Leu His Ala Pro 50 55 60 Asp Ala Gly Trp Gly Asn Leu Val Tyr Val Val Asn Tyr Pro Lys Asp 65 70 75 80 Asn Lys Arg Lys Met Asp Glu Thr Asp Ala Ser Ser Ala Val Lys Val 85 90 95 Lys Arg Ala Val Gln Lys Thr Ser Asp Leu Ile Val Leu Gly Leu Pro 100 105 110 Trp Lys Thr Thr Glu Gln Asp Leu Lys Glu Tyr Phe Ser Thr Phe Gly 115 120 125 Glu Val Leu Met Val Gln Val Lys Lys Asp Leu Lys Thr Gly His Ser 130 135 140 Lys Gly Phe Gly Phe Val Arg Phe Thr Glu Tyr Glu Thr Gln Val Lys 145 150 155 160 Val Met Ser Gln Arg His Met Ile Asp Gly Arg Trp Cys Asp Cys Lys 165 170 175 Leu Pro Asn Ser Lys Gln Ser Gln Asp Glu Pro Leu Arg Ser Arg Lys 180 185 190 Val Phe Val Gly Arg Cys Thr Glu Asp Met Thr Glu Asp Glu Leu Arg 195 200 205 Glu Phe Phe Ser Gln Tyr Gly Asp Val Met Asp Val Phe Ile Pro Lys 210 215 220 Pro Phe Arg Ala Phe Ala Phe Val Thr Phe Ala Asp Asp Gln Ile Ala 225 230 235 240 Gln Ser Leu Cys Gly Glu Asp Leu Ile Ile Lys Gly Ile Ser Val His 245 250 255 Ile Ser Asn Ala Glu Pro Lys His Asn Ser Asn Arg Gln Leu Glu Arg 260 265 270 Ser Gly Arg Phe Gly Gly Asn Pro Gly Gly Phe Gly Asn Gln Gly Gly 275 280 285 Phe Gly Asn Ser Arg Gly Gly Gly Ala Gly Leu Gly Asn Asn Gln Gly 290 295 300 Ser Asn Met Gly Gly Gly Met Asn Phe Gly Ala Phe Ser Ile Asn Pro 305 310 315 320 Ala Met Met Ala Ala Ala Gln Ala Ala Leu Gln Ser Ser Trp Gly Met 325 330 335 Met Gly Met Leu Ala Ser Gln Gln Asn Gln Ser Gly Pro Ser Gly Asn 340 345 350 Asn Gln Asn Gln Gly Asn Met Gln Arg Glu Pro Asn Gln Ala Phe Gly 355 360 365 Ser Gly Asn Asn Ser Tyr Ser Gly Ser Asn Ser Gly Ala Ala Ile Gly 370 375 380 Trp Gly Ser Ala Ser Asn Ala Gly Ser Gly Ser Gly Phe Asn Gly Gly 385 390 395 400 Phe Gly Ser Ser Met Asp Ser Lys Ser Ser Gly Trp Gly Met Leu Glu 405 410 415 Ala Thr Met Lys Met Asp Lys Lys Thr Ile Val Trp Phe Arg Arg Asp 420 425 430 Leu Arg Ile Glu Asp Asn Pro Ala Leu Ala Ala Ala Ala His Glu Gly 435 440 445 Ser Val Phe Pro Val Phe Ile Trp Cys Pro Glu Glu Glu Gly Gln Phe 450 455 460 Tyr Pro Gly Arg Ala Ser Arg Trp Trp Met Lys Gln Ser Leu Ala His 465 470 475 480 Leu Ser Gln Ser Leu Lys Ala Leu Gly Ser Asp Leu Thr Leu Ile Lys 485 490 495 Thr His Asn Thr Ile Ser Ala Ile Leu Asp Cys Ile Arg Val Thr Gly 500 505 510 Ala Thr Lys Val Val Phe Asn His Leu Tyr Asp Pro Val Ser Leu Val 515 520 525 Arg Asp His Thr Val Lys Glu Lys Leu Val Glu Arg Gly Ile Ser Val 530 535 540 Gln Ser Tyr Asn Gly Asp Leu Leu Tyr Glu Pro Trp Glu Ile Tyr Cys 545 550 555 560 Glu Lys Gly Lys Pro Phe Thr Ser Phe Asn Ser Tyr Trp Lys Lys Cys 565 570 575 Leu Asp Met Ser Ile Glu Ser Val Met Leu Pro Pro Pro Trp Arg Leu 580 585 590 Met Pro Ile Thr Ala Ala Ala Glu Ala Ile Trp Ala Cys Ser Ile Glu 595 600 605 Glu Leu Gly Leu Glu Asn Glu Ala Glu Lys Pro Ser Asn Ala Leu Leu 610 615 620 Thr Arg Ala Trp Ser Pro Gly Trp Ser Asn Ala Asp Lys Leu Leu Asn 625 630 635 640 Glu Phe Ile Glu Lys Gln Leu Ile Asp Tyr Ala Lys Asn Ser Lys Lys 645 650 655 Val Val Gly Asn Ser Thr Ser Leu Leu Ser Pro Tyr Leu His Phe Gly 660 665 670 Glu Ile Ser Val Arg His Val Phe Gln Cys Ala Arg Met Lys Gln Ile 675 680 685 Ile Trp Ala Arg Asp Lys Asn Ser Glu Gly Glu Glu Ser Ala Asp Leu 690 695 700 Phe Leu Arg Gly Ile Gly Leu Arg Glu Tyr Ser Arg Tyr Ile Cys Phe 705 710 715 720 Asn Phe Pro Phe Thr His Glu Gln Ser Leu Leu Ser His Leu Arg Phe 725 730 735 Phe Pro Trp Asp Ala Asp Val Asp Lys Phe Lys Ala Trp Arg Gln Gly 740 745 750 Arg Thr Gly Tyr Pro Leu Val Asp Ala Gly Met Arg Glu Leu Trp Ala 755 760 765 Thr Gly Trp Met His Asn Arg Ile Arg Val Ile Val Ser Ser Phe Ala 770 775 780 Val Lys Phe Leu Leu Leu Pro Trp Lys Trp Gly Met Lys Tyr Phe Trp 785 790 795 800 Asp Thr Leu Leu Asp Ala Asp Leu Glu Cys Asp Ile Leu Gly Trp Gln 805 810 815 Tyr Ile Ser Gly Ser Ile Pro Asp Gly His Glu Leu Asp Arg Leu Asp 820 825 830 Asn Pro Ala Leu Gln Gly Ala Lys Tyr Asp Pro Glu Gly Glu Tyr Ile 835 840 845 Arg Gln Trp Leu Pro Glu Leu Ala Arg Leu Pro Thr Glu Trp Ile His 850 855 860 His Pro Trp Asp Ala Pro Leu Thr Val Leu Lys Ala Ser Gly Val Glu 865 870 875 880 Leu Gly Thr Asn Tyr Ala Lys Pro Ile Val Asp Ile Asp Thr Ala Arg 885 890 895 Glu Leu Leu Ala Lys Ala Ile Ser Arg Thr Arg Gly Ala Gln Ile Met 900 905 910 Ile Gly Ala Ala Ala Arg Asp Pro Pro Val Ala Thr Met Val Ser Lys 915 920 925 Gly Glu Glu Asp Asn Met Ala Ile Ile Lys Glu Phe Met Arg Phe Lys 930 935 940 Val His Met Glu Gly Ser Val Asn Gly His Glu Phe Glu Ile Glu Gly 945 950 955 960 Glu Gly Glu Gly Arg Pro Tyr Glu Gly Thr Gln Thr Ala Lys Leu Lys 965 970 975 Val Thr Lys Gly Gly Pro Leu Pro Phe Ala Trp Asp Ile Leu Ser Pro 980 985 990 Gln Phe Met Tyr Gly Ser Lys Ala Tyr Val Lys His Pro Ala Asp Ile 995 1000 1005 Pro Asp Tyr Leu Lys Leu Ser Phe Pro Glu Gly Phe Lys Trp Glu 1010 1015 1020 Arg Val Met Asn Phe Glu Asp Gly Gly Val Val Thr Val Thr Gln 1025 1030 1035 Asp Ser Ser Leu Gln Asp Gly Glu Phe Ile Tyr Lys Val Lys Leu 1040 1045 1050 Arg Gly Thr Asn Phe Pro Ser Asp Gly Pro Val Met Gln Lys Lys 1055 1060 1065 Thr Met Gly Trp Glu Ala Ser Ser Glu Arg Met Tyr Pro Glu Asp 1070 1075 1080 Gly Ala Leu Lys Gly Glu Ile Lys Gln Arg Leu Lys Leu Lys Asp 1085 1090 1095 Gly Gly His Tyr Asp Ala Glu Val Lys Thr Thr Tyr Lys Ala Lys 1100 1105 1110 Lys Pro Val Gln Leu Pro Gly Ala Tyr Asn Val Asn Ile Lys Leu 1115 1120 1125 Asp Ile Thr Ser His Asn Glu Asp Tyr Thr Ile Val Glu Gln Tyr 1130 1135 1140 Glu Arg Ala Glu Gly Arg His Ser Thr Gly Gly Met Asp Glu Leu 1145 1150 1155 Tyr Lys 1160 <210> 16 <211> 1152 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Construct <400> 16 Met Val Ser Lys Gly Glu Glu Asp Asn Met Ala Ile Ile Lys Glu Phe 1 5 10 15 Met Arg Phe Lys Val His Met Glu Gly Ser Val Asn Gly His Glu Phe 20 25 30 Glu Ile Glu Gly Glu Gly Glu Gly Arg Pro Tyr Glu Gly Thr Gln Thr 35 40 45 Ala Lys Leu Lys Val Thr Lys Gly Gly Pro Leu Pro Phe Ala Trp Asp 50 55 60 Ile Leu Ser Pro Gln Phe Met Tyr Gly Ser Lys Ala Tyr Val Lys His 65 70 75 80 Pro Ala Asp Ile Pro Asp Tyr Leu Lys Leu Ser Phe Pro Glu Gly Phe 85 90 95 Lys Trp Glu Arg Val Met Asn Phe Glu Asp Gly Gly Val Val Thr Val 100 105 110 Thr Gln Asp Ser Ser Leu Gln Asp Gly Glu Phe Ile Tyr Lys Val Lys 115 120 125 Leu Arg Gly Thr Asn Phe Pro Ser Asp Gly Pro Val Met Gln Lys Lys 130 135 140 Thr Met Gly Trp Glu Ala Ser Ser Glu Arg Met Tyr Pro Glu Asp Gly 145 150 155 160 Ala Leu Lys Gly Glu Ile Lys Gln Arg Leu Lys Leu Lys Asp Gly Gly 165 170 175 His Tyr Asp Ala Glu Val Lys Thr Thr Tyr Lys Ala Lys Lys Pro Val 180 185 190 Gln Leu Pro Gly Ala Tyr Asn Val Asn Ile Lys Leu Asp Ile Thr Ser 195 200 205 His Asn Glu Asp Tyr Thr Ile Val Glu Gln Tyr Glu Arg Ala Glu Gly 210 215 220 Arg His Ser Thr Gly Gly Met Asp Glu Leu Tyr Lys Met Ser Glu Tyr 225 230 235 240 Ile Arg Val Thr Glu Asp Glu Asn Asp Glu Pro Ile Glu Ile Pro Ser 245 250 255 Glu Asp Asp Gly Thr Val Leu Leu Ser Thr Val Thr Ala Gln Phe Pro 260 265 270 Gly Ala Cys Gly Leu Arg Tyr Arg Asn Pro Val Ser Gln Cys Met Arg 275 280 285 Gly Val Arg Leu Val Glu Gly Ile Leu His Ala Pro Asp Ala Gly Trp 290 295 300 Gly Asn Leu Val Tyr Val Val Asn Tyr Pro Lys Asp Asn Lys Arg Lys 305 310 315 320 Met Asp Glu Thr Asp Ala Ser Ser Ala Val Lys Val Lys Arg Ala Val 325 330 335 Gln Lys Thr Ser Asp Leu Ile Val Leu Gly Leu Pro Trp Lys Thr Thr 340 345 350 Glu Gln Asp Leu Lys Glu Tyr Phe Ser Thr Phe Gly Glu Val Leu Met 355 360 365 Val Gln Val Lys Lys Asp Leu Lys Thr Gly His Ser Lys Gly Phe Gly 370 375 380 Phe Val Arg Phe Thr Glu Tyr Glu Thr Gln Val Lys Val Met Ser Gln 385 390 395 400 Arg His Met Ile Asp Gly Arg Trp Cys Asp Cys Lys Leu Pro Asn Ser 405 410 415 Lys Gln Ser Gln Asp Glu Pro Leu Arg Ser Arg Lys Val Phe Val Gly 420 425 430 Arg Cys Thr Glu Asp Met Thr Glu Asp Glu Leu Arg Glu Phe Phe Ser 435 440 445 Gln Tyr Gly Asp Val Met Asp Val Phe Ile Pro Lys Pro Phe Arg Ala 450 455 460 Phe Ala Phe Val Thr Phe Ala Asp Asp Gln Ile Ala Gln Ser Leu Cys 465 470 475 480 Gly Glu Asp Leu Ile Ile Lys Gly Ile Ser Val His Ile Ser Asn Ala 485 490 495 Glu Pro Lys His Asn Ser Asn Arg Gln Leu Glu Arg Ser Gly Arg Phe 500 505 510 Gly Gly Asn Pro Gly Gly Phe Gly Asn Gln Gly Gly Phe Gly Asn Ser 515 520 525 Arg Gly Gly Gly Ala Gly Leu Gly Asn Asn Gln Gly Ser Asn Met Gly 530 535 540 Gly Gly Met Asn Phe Gly Ala Phe Ser Ile Asn Pro Ala Met Met Ala 545 550 555 560 Ala Ala Gln Ala Ala Leu Gln Ser Ser Trp Gly Met Met Gly Met Leu 565 570 575 Ala Ser Gln Gln Asn Gln Ser Gly Pro Ser Gly Asn Asn Gln Asn Gln 580 585 590 Gly Asn Met Gln Arg Glu Pro Asn Gln Ala Phe Gly Ser Gly Asn Asn 595 600 605 Ser Tyr Ser Gly Ser Asn Ser Gly Ala Ala Ile Gly Trp Gly Ser Ala 610 615 620 Ser Asn Ala Gly Ser Gly Ser Gly Phe Asn Gly Gly Phe Gly Ser Ser 625 630 635 640 Met Asp Ser Lys Ser Ser Gly Trp Gly Met Leu Glu Ala Thr Met Lys 645 650 655 Met Asp Lys Lys Thr Ile Val Trp Phe Arg Arg Asp Leu Arg Ile Glu 660 665 670 Asp Asn Pro Ala Leu Ala Ala Ala Ala His Glu Gly Ser Val Phe Pro 675 680 685 Val Phe Ile Trp Cys Pro Glu Glu Glu Gly Gln Phe Tyr Pro Gly Arg 690 695 700 Ala Ser Arg Trp Trp Met Lys Gln Ser Leu Ala His Leu Ser Gln Ser 705 710 715 720 Leu Lys Ala Leu Gly Ser Asp Leu Thr Leu Ile Lys Thr His Asn Thr 725 730 735 Ile Ser Ala Ile Leu Asp Cys Ile Arg Val Thr Gly Ala Thr Lys Val 740 745 750 Val Phe Asn His Leu Tyr Asp Pro Val Ser Leu Val Arg Asp His Thr 755 760 765 Val Lys Glu Lys Leu Val Glu Arg Gly Ile Ser Val Gln Ser Tyr Asn 770 775 780 Gly Asp Leu Leu Tyr Glu Pro Trp Glu Ile Tyr Cys Glu Lys Gly Lys 785 790 795 800 Pro Phe Thr Ser Phe Asn Ser Tyr Trp Lys Lys Cys Leu Asp Met Ser 805 810 815 Ile Glu Ser Val Met Leu Pro Pro Pro Trp Arg Leu Met Pro Ile Thr 820 825 830 Ala Ala Ala Glu Ala Ile Trp Ala Cys Ser Ile Glu Glu Leu Gly Leu 835 840 845 Glu Asn Glu Ala Glu Lys Pro Ser Asn Ala Leu Leu Thr Arg Ala Trp 850 855 860 Ser Pro Gly Trp Ser Asn Ala Asp Lys Leu Leu Asn Glu Phe Ile Glu 865 870 875 880 Lys Gln Leu Ile Asp Tyr Ala Lys Asn Ser Lys Lys Val Val Gly Asn 885 890 895 Ser Thr Ser Leu Leu Ser Pro Tyr Leu His Phe Gly Glu Ile Ser Val 900 905 910 Arg His Val Phe Gln Cys Ala Arg Met Lys Gln Ile Ile Trp Ala Arg 915 920 925 Asp Lys Asn Ser Glu Gly Glu Glu Ser Ala Asp Leu Phe Leu Arg Gly 930 935 940 Ile Gly Leu Arg Glu Tyr Ser Arg Tyr Ile Cys Phe Asn Phe Pro Phe 945 950 955 960 Thr His Glu Gln Ser Leu Leu Ser His Leu Arg Phe Phe Pro Trp Asp 965 970 975 Ala Asp Val Asp Lys Phe Lys Ala Trp Arg Gln Gly Arg Thr Gly Tyr 980 985 990 Pro Leu Val Asp Ala Gly Met Arg Glu Leu Trp Ala Thr Gly Trp Met 995 1000 1005 His Asn Arg Ile Arg Val Ile Val Ser Ser Phe Ala Val Lys Phe 1010 1015 1020 Leu Leu Leu Pro Trp Lys Trp Gly Met Lys Tyr Phe Trp Asp Thr 1025 1030 1035 Leu Leu Asp Ala Asp Leu Glu Cys Asp Ile Leu Gly Trp Gln Tyr 1040 1045 1050 Ile Ser Gly Ser Ile Pro Asp Gly His Glu Leu Asp Arg Leu Asp 1055 1060 1065 Asn Pro Ala Leu Gln Gly Ala Lys Tyr Asp Pro Glu Gly Glu Tyr 1070 1075 1080 Ile Arg Gln Trp Leu Pro Glu Leu Ala Arg Leu Pro Thr Glu Trp 1085 1090 1095 Ile His His Pro Trp Asp Ala Pro Leu Thr Val Leu Lys Ala Ser 1100 1105 1110 Gly Val Glu Leu Gly Thr Asn Tyr Ala Lys Pro Ile Val Asp Ile 1115 1120 1125 Asp Thr Ala Arg Glu Leu Leu Ala Lys Ala Ile Ser Arg Thr Arg 1130 1135 1140 Gly Ala Gln Ile Met Ile Gly Ala Ala 1145 1150 <210> 17 <211> 888 <212> PRT <213> artificial sequence <220> <223> composite structure <400> 17 Met Gly Arg Phe Gly Gly Asn Pro Gly Gly Phe Gly Asn Gln Gly Gly 1 5 10 15 Phe Gly Asn Ser Arg Gly Gly Gly Ala Gly Leu Gly Asn Asn Gln Gly 20 25 30 Ser Asn Met Gly Gly Gly Met Asn Phe Gly Ala Phe Ser Ile Asn Pro 35 40 45 Ala Met Met Ala Ala Ala Gln Ala Ala Leu Gln Ser Ser Trp Gly Met 50 55 60 Met Gly Met Leu Ala Ser Gln Gln Asn Gln Ser Gly Pro Ser Gly Asn 65 70 75 80 Asn Gln Asn Gln Gly Asn Met Gln Arg Glu Pro Asn Gln Ala Phe Gly 85 90 95 Ser Gly Asn Asn Ser Tyr Ser Gly Ser Asn Ser Gly Ala Ala Ile Gly 100 105 110 Trp Gly Ser Ala Ser Asn Ala Gly Ser Gly Ser Gly Phe Asn Gly Gly 115 120 125 Phe Gly Ser Ser Met Asp Ser Lys Ser Ser Gly Trp Gly Met Leu Glu 130 135 140 Ala Thr Met Lys Met Asp Lys Lys Thr Ile Val Trp Phe Arg Arg Asp 145 150 155 160 Leu Arg Ile Glu Asp Asn Pro Ala Leu Ala Ala Ala Ala His Glu Gly 165 170 175 Ser Val Phe Pro Val Phe Ile Trp Cys Pro Glu Glu Glu Gly Gln Phe 180 185 190 Tyr Pro Gly Arg Ala Ser Arg Trp Trp Met Lys Gln Ser Leu Ala His 195 200 205 Leu Ser Gln Ser Leu Lys Ala Leu Gly Ser Asp Leu Thr Leu Ile Lys 210 215 220 Thr His Asn Thr Ile Ser Ala Ile Leu Asp Cys Ile Arg Val Thr Gly 225 230 235 240 Ala Thr Lys Val Val Phe Asn His Leu Tyr Asp Pro Val Ser Leu Val 245 250 255 Arg Asp His Thr Val Lys Glu Lys Leu Val Glu Arg Gly Ile Ser Val 260 265 270 Gln Ser Tyr Asn Gly Asp Leu Leu Tyr Glu Pro Trp Glu Ile Tyr Cys 275 280 285 Glu Lys Gly Lys Pro Phe Thr Ser Phe Asn Ser Tyr Trp Lys Lys Cys 290 295 300 Leu Asp Met Ser Ile Glu Ser Val Met Leu Pro Pro Pro Trp Arg Leu 305 310 315 320 Met Pro Ile Thr Ala Ala Ala Glu Ala Ile Trp Ala Cys Ser Ile Glu 325 330 335 Glu Leu Gly Leu Glu Asn Glu Ala Glu Lys Pro Ser Asn Ala Leu Leu 340 345 350 Thr Arg Ala Trp Ser Pro Gly Trp Ser Asn Ala Asp Lys Leu Leu Asn 355 360 365 Glu Phe Ile Glu Lys Gln Leu Ile Asp Tyr Ala Lys Asn Ser Lys Lys 370 375 380 Val Val Gly Asn Ser Thr Ser Leu Leu Ser Pro Tyr Leu His Phe Gly 385 390 395 400 Glu Ile Ser Val Arg His Val Phe Gln Cys Ala Arg Met Lys Gln Ile 405 410 415 Ile Trp Ala Arg Asp Lys Asn Ser Glu Gly Glu Glu Ser Ala Asp Leu 420 425 430 Phe Leu Arg Gly Ile Gly Leu Arg Glu Tyr Ser Arg Tyr Ile Cys Phe 435 440 445 Asn Phe Pro Phe Thr His Glu Gln Ser Leu Leu Ser His Leu Arg Phe 450 455 460 Phe Pro Trp Asp Ala Asp Val Asp Lys Phe Lys Ala Trp Arg Gln Gly 465 470 475 480 Arg Thr Gly Tyr Pro Leu Val Asp Ala Gly Met Arg Glu Leu Trp Ala 485 490 495 Thr Gly Trp Met His Asn Arg Ile Arg Val Ile Val Ser Ser Phe Ala 500 505 510 Val Lys Phe Leu Leu Leu Pro Trp Lys Trp Gly Met Lys Tyr Phe Trp 515 520 525 Asp Thr Leu Leu Asp Ala Asp Leu Glu Cys Asp Ile Leu Gly Trp Gln 530 535 540 Tyr Ile Ser Gly Ser Ile Pro Asp Gly His Glu Leu Asp Arg Leu Asp 545 550 555 560 Asn Pro Ala Leu Gln Gly Ala Lys Tyr Asp Pro Glu Gly Glu Tyr Ile 565 570 575 Arg Gln Trp Leu Pro Glu Leu Ala Arg Leu Pro Thr Glu Trp Ile His 580 585 590 His Pro Trp Asp Ala Pro Leu Thr Val Leu Lys Ala Ser Gly Val Glu 595 600 605 Leu Gly Thr Asn Tyr Ala Lys Pro Ile Val Asp Ile Asp Thr Ala Arg 610 615 620 Glu Leu Leu Ala Lys Ala Ile Ser Arg Thr Arg Gly Ala Gln Ile Met 625 630 635 640 Ile Gly Ala Ala Ala Arg Asp Pro Pro Val Ala Thr Met Val Ser Lys 645 650 655 Gly Glu Glu Asp Asn Met Ala Ile Ile Lys Glu Phe Met Arg Phe Lys 660 665 670 Val His Met Glu Gly Ser Val Asn Gly His Glu Phe Glu Ile Glu Gly 675 680 685 Glu Gly Glu Gly Arg Pro Tyr Glu Gly Thr Gln Thr Ala Lys Leu Lys 690 695 700 Val Thr Lys Gly Gly Pro Leu Pro Phe Ala Trp Asp Ile Leu Ser Pro 705 710 715 720 Gln Phe Met Tyr Gly Ser Lys Ala Tyr Val Lys His Pro Ala Asp Ile 725 730 735 Pro Asp Tyr Leu Lys Leu Ser Phe Pro Glu Gly Phe Lys Trp Glu Arg 740 745 750 Val Met Asn Phe Glu Asp Gly Gly Val Val Thr Val Thr Gln Asp Ser 755 760 765 Ser Leu Gln Asp Gly Glu Phe Ile Tyr Lys Val Lys Leu Arg Gly Thr 770 775 780 Asn Phe Pro Ser Asp Gly Pro Val Met Gln Lys Lys Thr Met Gly Trp 785 790 795 800 Glu Ala Ser Ser Glu Arg Met Tyr Pro Glu Asp Gly Ala Leu Lys Gly 805 810 815 Glu Ile Lys Gln Arg Leu Lys Leu Lys Asp Gly Gly His Tyr Asp Ala 820 825 830 Glu Val Lys Thr Thr Tyr Lys Ala Lys Lys Pro Val Gln Leu Pro Gly 835 840 845 Ala Tyr Asn Val Asn Ile Lys Leu Asp Ile Thr Ser His Asn Glu Asp 850 855 860 Tyr Thr Ile Val Glu Gln Tyr Glu Arg Ala Glu Gly Arg His Ser Thr 865 870 875 880 Gly Gly Met Asp Glu Leu Tyr Lys 885 <210> 18 <211> 971 <212> PRT <213> Artificial Sequence <220> <223> Synthetic construct <400> 18 Met Arg Lys Val Phe Val Gly Arg Cys Thr Glu Asp Met Thr Glu Asp 1 5 10 15 Glu Leu Arg Glu Phe Phe Ser Gln Tyr Gly Asp Val Met Asp Val Phe 20 25 30 Ile Pro Lys Pro Phe Arg Ala Phe Ala Phe Val Thr Phe Ala Asp Asp 35 40 45 Gln Ile Ala Gln Ser Leu Cys Gly Glu Asp Leu Ile Ile Lys Gly Ile 50 55 60 Ser Val His Ile Ser Asn Ala Glu Pro Lys His Asn Ser Asn Arg Gln 65 70 75 80 Leu Glu Arg Ser Gly Arg Phe Gly Gly Asn Pro Gly Gly Phe Gly Asn 85 90 95 Gln Gly Gly Phe Gly Asn Ser Arg Gly Gly Gly Ala Gly Leu Gly Asn 100 105 110 Asn Gln Gly Ser Asn Met Gly Gly Gly Met Asn Phe Gly Ala Phe Ser 115 120 125 Ile Asn Pro Ala Met Met Ala Ala Ala Gln Ala Ala Leu Gln Ser Ser 130 135 140 Trp Gly Met Met Gly Met Leu Ala Ser Gln Gln Asn Gln Ser Gly Pro 145 150 155 160 Ser Gly Asn Asn Gln Asn Gln Gly Asn Met Gln Arg Glu Pro Asn Gln 165 170 175 Ala Phe Gly Ser Gly Asn Asn Ser Tyr Ser Gly Ser Asn Ser Gly Ala 180 185 190 Ala Ile Gly Trp Gly Ser Ala Ser Asn Ala Gly Ser Gly Ser Gly Phe 195 200 205 Asn Gly Gly Phe Gly Ser Ser Met Asp Ser Lys Ser Ser Gly Trp Gly 210 215 220 Met Leu Glu Ala Thr Met Lys Met Asp Lys Lys Thr Ile Val Trp Phe 225 230 235 240 Arg Arg Asp Leu Arg Ile Glu Asp Asn Pro Ala Leu Ala Ala Ala Ala 245 250 255 His Glu Gly Ser Val Phe Pro Val Phe Ile Trp Cys Pro Glu Glu Glu 260 265 270 Gly Gln Phe Tyr Pro Gly Arg Ala Ser Arg Trp Trp Met Lys Gln Ser 275 280 285 Leu Ala His Leu Ser Gln Ser Leu Lys Ala Leu Gly Ser Asp Leu Thr 290 295 300 Leu Ile Lys Thr His Asn Thr Ile Ser Ala Ile Leu Asp Cys Ile Arg 305 310 315 320 Val Thr Gly Ala Thr Lys Val Val Phe Asn His Leu Tyr Asp Pro Val 325 330 335 Ser Leu Val Arg Asp His Thr Val Lys Glu Lys Leu Val Glu Arg Gly 340 345 350 Ile Ser Val Gln Ser Tyr Asn Gly Asp Leu Leu Tyr Glu Pro Trp Glu 355 360 365 Ile Tyr Cys Glu Lys Gly Lys Pro Phe Thr Ser Phe Asn Ser Tyr Trp 370 375 380 Lys Lys Cys Leu Asp Met Ser Ile Glu Ser Val Met Leu Pro Pro Pro 385 390 395 400 Trp Arg Leu Met Pro Ile Thr Ala Ala Ala Glu Ala Ile Trp Ala Cys 405 410 415 Ser Ile Glu Glu Leu Gly Leu Glu Asn Glu Ala Glu Lys Pro Ser Asn 420 425 430 Ala Leu Leu Thr Arg Ala Trp Ser Pro Gly Trp Ser Asn Ala Asp Lys 435 440 445 Leu Leu Asn Glu Phe Ile Glu Lys Gln Leu Ile Asp Tyr Ala Lys Asn 450 455 460 Ser Lys Lys Val Val Gly Asn Ser Thr Ser Leu Leu Ser Pro Tyr Leu 465 470 475 480 His Phe Gly Glu Ile Ser Val Arg His Val Phe Gln Cys Ala Arg Met 485 490 495 Lys Gln Ile Ile Trp Ala Arg Asp Lys Asn Ser Glu Gly Glu Glu Ser 500 505 510 Ala Asp Leu Phe Leu Arg Gly Ile Gly Leu Arg Glu Tyr Ser Arg Tyr 515 520 525 Ile Cys Phe Asn Phe Pro Phe Thr His Glu Gln Ser Leu Leu Ser His 530 535 540 Leu Arg Phe Phe Pro Trp Asp Ala Asp Val Asp Lys Phe Lys Ala Trp 545 550 555 560 Arg Gln Gly Arg Thr Gly Tyr Pro Leu Val Asp Ala Gly Met Arg Glu 565 570 575 Leu Trp Ala Thr Gly Trp Met His Asn Arg Ile Arg Val Ile Val Ser 580 585 590 Ser Phe Ala Val Lys Phe Leu Leu Leu Pro Trp Lys Trp Gly Met Lys 595 600 605 Tyr Phe Trp Asp Thr Leu Leu Asp Ala Asp Leu Glu Cys Asp Ile Leu 610 615 620 Gly Trp Gln Tyr Ile Ser Gly Ser Ile Pro Asp Gly His Glu Leu Asp 625 630 635 640 Arg Leu Asp Asn Pro Ala Leu Gln Gly Ala Lys Tyr Asp Pro Glu Gly 645 650 655 Glu Tyr Ile Arg Gln Trp Leu Pro Glu Leu Ala Arg Leu Pro Thr Glu 660 665 670 Trp Ile His His Pro Trp Asp Ala Pro Leu Thr Val Leu Lys Ala Ser 675 680 685 Gly Val Glu Leu Gly Thr Asn Tyr Ala Lys Pro Ile Val Asp Ile Asp 690 695 700 Thr Ala Arg Glu Leu Leu Ala Lys Ala Ile Ser Arg Thr Arg Gly Ala 705 710 715 720 Gln Ile Met Ile Gly Ala Ala Ala Arg Asp Pro Pro Val Ala Thr Met 725 730 735 Val Ser Lys Gly Glu Glu Asp Asn Met Ala Ile Ile Lys Glu Phe Met 740 745 750 Arg Phe Lys Val His Met Glu Gly Ser Val Asn Gly His Glu Phe Glu 755 760 765 Ile Glu Gly Glu Gly Glu Gly Arg Pro Tyr Glu Gly Thr Gln Thr Ala 770 775 780 Lys Leu Lys Val Thr Lys Gly Gly Pro Leu Pro Phe Ala Trp Asp Ile 785 790 795 800 Leu Ser Pro Gln Phe Met Tyr Gly Ser Lys Ala Tyr Val Lys His Pro 805 810 815 Ala Asp Ile Pro Asp Tyr Leu Lys Leu Ser Phe Pro Glu Gly Phe Lys 820 825 830 Trp Glu Arg Val Met Asn Phe Glu Asp Gly Gly Val Val Thr Val Thr 835 840 845 Gln Asp Ser Ser Leu Gln Asp Gly Glu Phe Ile Tyr Lys Val Lys Leu 850 855 860 Arg Gly Thr Asn Phe Pro Ser Asp Gly Pro Val Met Gln Lys Lys Thr 865 870 875 880 Met Gly Trp Glu Ala Ser Ser Glu Arg Met Tyr Pro Glu Asp Gly Ala 885 890 895 Leu Lys Gly Glu Ile Lys Gln Arg Leu Lys Leu Lys Asp Gly Gly His 900 905 910 Tyr Asp Ala Glu Val Lys Thr Thr Tyr Lys Ala Lys Lys Pro Val Gln 915 920 925 Leu Pro Gly Ala Tyr Asn Val Asn Ile Lys Leu Asp Ile Thr Ser His 930 935 940 Asn Glu Asp Tyr Thr Ile Val Glu Gln Tyr Glu Arg Ala Glu Gly Arg 945 950 955 960 His Ser Thr Gly Gly Met Asp Glu Leu Tyr Lys 965 970 <210> 19 <211> 1057 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Construct <400> 19 Met Asp Leu Ile Val Leu Gly Leu Pro Trp Lys Thr Thr Glu Gln Asp 1 5 10 15 Leu Lys Glu Tyr Phe Ser Thr Phe Gly Glu Val Leu Met Val Gln Val 20 25 30 Lys Lys Asp Leu Lys Thr Gly His Ser Lys Gly Phe Gly Phe Val Arg 35 40 45 Phe Thr Glu Tyr Glu Thr Gln Val Lys Val Met Ser Gln Arg His Met 50 55 60 Ile Asp Gly Arg Trp Cys Asp Cys Lys Leu Pro Asn Ser Lys Gln Ser 65 70 75 80 Gln Asp Glu Pro Leu Arg Ser Arg Lys Val Phe Val Gly Arg Cys Thr 85 90 95 Glu Asp Met Thr Glu Asp Glu Leu Arg Glu Phe Phe Ser Gln Tyr Gly 100 105 110 Asp Val Met Asp Val Phe Ile Pro Lys Pro Phe Arg Ala Phe Ala Phe 115 120 125 Val Thr Phe Ala Asp Asp Gln Ile Ala Gln Ser Leu Cys Gly Glu Asp 130 135 140 Leu Ile Ile Lys Gly Ile Ser Val His Ile Ser Asn Ala Glu Pro Lys 145 150 155 160 His Asn Ser Asn Arg Gln Leu Glu Arg Ser Gly Arg Phe Gly Gly Asn 165 170 175 Pro Gly Gly Phe Gly Asn Gln Gly Gly Phe Gly Asn Ser Arg Gly Gly 180 185 190 Gly Ala Gly Leu Gly Asn Asn Gln Gly Ser Asn Met Gly Gly Gly Met 195 200 205 Asn Phe Gly Ala Phe Ser Ile Asn Pro Ala Met Met Ala Ala Ala Gln 210 215 220 Ala Ala Leu Gln Ser Ser Trp Gly Met Met Gly Met Leu Ala Ser Gln 225 230 235 240 Gln Asn Gln Ser Gly Pro Ser Gly Asn Asn Gln Asn Gln Gly Asn Met 245 250 255 Gln Arg Glu Pro Asn Gln Ala Phe Gly Ser Gly Asn Asn Ser Tyr Ser 260 265 270 Gly Ser Asn Ser Gly Ala Ala Ile Gly Trp Gly Ser Ala Ser Asn Ala 275 280 285 Gly Ser Gly Ser Gly Phe Asn Gly Gly Phe Gly Ser Ser Met Asp Ser 290 295 300 Lys Ser Ser Gly Trp Gly Met Leu Glu Ala Thr Met Lys Met Asp Lys 305 310 315 320 Lys Thr Ile Val Trp Phe Arg Arg Asp Leu Arg Ile Glu Asp Asn Pro 325 330 335 Ala Leu Ala Ala Ala Ala His Glu Gly Ser Val Phe Pro Val Phe Ile 340 345 350 Trp Cys Pro Glu Glu Glu Gly Gln Phe Tyr Pro Gly Arg Ala Ser Arg 355 360 365 Trp Trp Met Lys Gln Ser Leu Ala His Leu Ser Gln Ser Leu Lys Ala 370 375 380 Leu Gly Ser Asp Leu Thr Leu Ile Lys Thr His Asn Thr Ile Ser Ala 385 390 395 400 Ile Leu Asp Cys Ile Arg Val Thr Gly Ala Thr Lys Val Val Phe Asn 405 410 415 His Leu Tyr Asp Pro Val Ser Leu Val Arg Asp His Thr Val Lys Glu 420 425 430 Lys Leu Val Glu Arg Gly Ile Ser Val Gln Ser Tyr Asn Gly Asp Leu 435 440 445 Leu Tyr Glu Pro Trp Glu Ile Tyr Cys Glu Lys Gly Lys Pro Phe Thr 450 455 460 Ser Phe Asn Ser Tyr Trp Lys Lys Cys Leu Asp Met Ser Ile Glu Ser 465 470 475 480 Val Met Leu Pro Pro Pro Trp Arg Leu Met Pro Ile Thr Ala Ala Ala 485 490 495 Glu Ala Ile Trp Ala Cys Ser Ile Glu Glu Leu Gly Leu Glu Asn Glu 500 505 510 Ala Glu Lys Pro Ser Asn Ala Leu Leu Thr Arg Ala Trp Ser Pro Gly 515 520 525 Trp Ser Asn Ala Asp Lys Leu Leu Asn Glu Phe Ile Glu Lys Gln Leu 530 535 540 Ile Asp Tyr Ala Lys Asn Ser Lys Lys Val Val Gly Asn Ser Thr Ser 545 550 555 560 Leu Leu Ser Pro Tyr Leu His Phe Gly Glu Ile Ser Val Arg His Val 565 570 575 Phe Gln Cys Ala Arg Met Lys Gln Ile Ile Trp Ala Arg Asp Lys Asn 580 585 590 Ser Glu Gly Glu Glu Ser Ala Asp Leu Phe Leu Arg Gly Ile Gly Leu 595 600 605 Arg Glu Tyr Ser Arg Tyr Ile Cys Phe Asn Phe Pro Phe Thr His Glu 610 615 620 Gln Ser Leu Leu Ser His Leu Arg Phe Phe Pro Trp Asp Ala Asp Val 625 630 635 640 Asp Lys Phe Lys Ala Trp Arg Gln Gly Arg Thr Gly Tyr Pro Leu Val 645 650 655 Asp Ala Gly Met Arg Glu Leu Trp Ala Thr Gly Trp Met His Asn Arg 660 665 670 Ile Arg Val Ile Val Ser Ser Phe Ala Val Lys Phe Leu Leu Leu Pro 675 680 685 Trp Lys Trp Gly Met Lys Tyr Phe Trp Asp Thr Leu Leu Asp Ala Asp 690 695 700 Leu Glu Cys Asp Ile Leu Gly Trp Gln Tyr Ile Ser Gly Ser Ile Pro 705 710 715 720 Asp Gly His Glu Leu Asp Arg Leu Asp Asn Pro Ala Leu Gln Gly Ala 725 730 735 Lys Tyr Asp Pro Glu Gly Glu Tyr Ile Arg Gln Trp Leu Pro Glu Leu 740 745 750 Ala Arg Leu Pro Thr Glu Trp Ile His His Pro Trp Asp Ala Pro Leu 755 760 765 Thr Val Leu Lys Ala Ser Gly Val Glu Leu Gly Thr Asn Tyr Ala Lys 770 775 780 Pro Ile Val Asp Ile Asp Thr Ala Arg Glu Leu Leu Ala Lys Ala Ile 785 790 795 800 Ser Arg Thr Arg Gly Ala Gln Ile Met Ile Gly Ala Ala Ala Arg Asp 805 810 815 Pro Pro Val Ala Thr Met Val Ser Lys Gly Glu Glu Asp Asn Met Ala 820 825 830 Ile Ile Lys Glu Phe Met Arg Phe Lys Val His Met Glu Gly Ser Val 835 840 845 Asn Gly His Glu Phe Glu Ile Glu Gly Glu Gly Glu Gly Arg Pro Tyr 850 855 860 Glu Gly Thr Gln Thr Ala Lys Leu Lys Val Thr Lys Gly Gly Pro Leu 865 870 875 880 Pro Phe Ala Trp Asp Ile Leu Ser Pro Gln Phe Met Tyr Gly Ser Lys 885 890 895 Ala Tyr Val Lys His Pro Ala Asp Ile Pro Asp Tyr Leu Lys Leu Ser 900 905 910 Phe Pro Glu Gly Phe Lys Trp Glu Arg Val Met Asn Phe Glu Asp Gly 915 920 925 Gly Val Val Thr Val Thr Gln Asp Ser Ser Leu Gln Asp Gly Glu Phe 930 935 940 Ile Tyr Lys Val Lys Leu Arg Gly Thr Asn Phe Pro Ser Asp Gly Pro 945 950 955 960 Val Met Gln Lys Lys Thr Met Gly Trp Glu Ala Ser Ser Glu Arg Met 965 970 975 Tyr Pro Glu Asp Gly Ala Leu Lys Gly Glu Ile Lys Gln Arg Leu Lys 980 985 990 Leu Lys Asp Gly Gly His Tyr Asp Ala Glu Val Lys Thr Thr Tyr Lys 995 1000 1005 Ala Lys Lys Pro Val Gln Leu Pro Gly Ala Tyr Asn Val Asn Ile 1010 1015 1020 Lys Leu Asp Ile Thr Ser His Asn Glu Asp Tyr Thr Ile Val Glu 1025 1030 1035 Gln Tyr Glu Arg Ala Glu Gly Arg His Ser Thr Gly Gly Met Asp 1040 1045 1050 Glu Leu Tyr Lys 1055 <210> 20 <211> 878 <212> PRT <213> Artificial sequence <220> <223> Synthetic construct <400> 20 Met Val Ser Lys Gly Glu Glu Asp Asn Met Ala Ile Ile Lys Glu Phe 1 5 10 15 Met Arg Phe Lys Val His Met Glu Gly Ser Val Asn Gly His Glu Phe 20 25 30 Glu Ile Glu Gly Glu Gly Glu Gly Arg Pro Tyr Glu Gly Thr Gln Thr 35 40 45 Ala Lys Leu Lys Val Thr Lys Gly Gly Pro Leu Pro Phe Ala Trp Asp 50 55 60 Ile Leu Ser Pro Gln Phe Met Tyr Gly Ser Lys Ala Tyr Val Lys His 65 70 75 80 Pro Ala Asp Ile Pro Asp Tyr Leu Lys Leu Ser Phe Pro Glu Gly Phe 85 90 95 Lys Trp Glu Arg Val Met Asn Phe Glu Asp Gly Gly Val Val Thr Val 100 105 110 Thr Gln Asp Ser Ser Leu Gln Asp Gly Glu Phe Ile Tyr Lys Val Lys 115 120 125 Leu Arg Gly Thr Asn Phe Pro Ser Asp Gly Pro Val Met Gln Lys Lys 130 135 140 Thr Met Gly Trp Glu Ala Ser Ser Glu Arg Met Tyr Pro Glu Asp Gly 145 150 155 160 Ala Leu Lys Gly Glu Ile Lys Gln Arg Leu Lys Leu Lys Asp Gly Gly 165 170 175 His Tyr Asp Ala Glu Val Lys Thr Thr Tyr Lys Ala Lys Lys Pro Val 180 185 190 Gln Leu Pro Gly Ala Tyr Asn Val Asn Ile Lys Leu Asp Ile Thr Ser 195 200 205 His Asn Glu Asp Tyr Thr Ile Val Glu Gln Tyr Glu Arg Ala Glu Gly 210 215 220 Arg His Ser Thr Gly Gly Met Asp Glu Leu Tyr Lys Met Lys Met Asp 225 230 235 240 Lys Lys Thr Ile Val Trp Phe Arg Arg Asp Leu Arg Ile Glu Asp Asn 245 250 255 Pro Ala Leu Ala Ala Ala Ala His Glu Gly Ser Val Phe Pro Val Phe 260 265 270 Ile Trp Cys Pro Glu Glu Glu Gly Gln Phe Tyr Pro Gly Arg Ala Ser 275 280 285 Arg Trp Trp Met Lys Gln Ser Leu Ala His Leu Ser Gln Ser Leu Lys 290 295 300 Ala Leu Gly Ser Asp Leu Thr Leu Ile Lys Thr His Asn Thr Ile Ser 305 310 315 320 Ala Ile Leu Asp Cys Ile Arg Val Thr Gly Ala Thr Lys Val Val Phe 325 330 335 Asn His Leu Tyr Asp Pro Val Ser Leu Val Arg Asp His Thr Val Lys 340 345 350 Glu Lys Leu Val Glu Arg Gly Ile Ser Val Gln Ser Tyr Asn Gly Asp 355 360 365 Leu Leu Tyr Glu Pro Trp Glu Ile Tyr Cys Glu Lys Gly Lys Pro Phe 370 375 380 Thr Ser Phe Asn Ser Tyr Trp Lys Lys Cys Leu Asp Met Ser Ile Glu 385 390 395 400 Ser Val Met Leu Pro Pro Pro Trp Arg Leu Met Pro Ile Thr Ala Ala 405 410 415 Ala Glu Ala Ile Trp Ala Cys Ser Ile Glu Glu Leu Gly Leu Glu Asn 420 425 430 Glu Ala Glu Lys Pro Ser Asn Ala Leu Leu Thr Arg Ala Trp Ser Pro 435 440 445 Gly Trp Ser Asn Ala Asp Lys Leu Leu Asn Glu Phe Ile Glu Lys Gln 450 455 460 Leu Ile Asp Tyr Ala Lys Asn Ser Lys Lys Val Val Gly Asn Ser Thr 465 470 475 480 Ser Leu Leu Ser Pro Tyr Leu His Phe Gly Glu Ile Ser Val Arg His 485 490 495 Val Phe Gln Cys Ala Arg Met Lys Gln Ile Ile Trp Ala Arg Asp Lys 500 505 510 Asn Ser Glu Gly Glu Glu Ser Ala Asp Leu Phe Leu Arg Gly Ile Gly 515 520 525 Leu Arg Glu Tyr Ser Arg Tyr Ile Cys Phe Asn Phe Pro Phe Thr His 530 535 540 Glu Gln Ser Leu Leu Ser His Leu Arg Phe Phe Pro Trp Asp Ala Asp 545 550 555 560 Val Asp Lys Phe Lys Ala Trp Arg Gln Gly Arg Thr Gly Tyr Pro Leu 565 570 575 Val Asp Ala Gly Met Arg Glu Leu Trp Ala Thr Gly Trp Met His Asn 580 585 590 Arg Ile Arg Val Ile Val Ser Ser Phe Ala Val Lys Phe Leu Leu Leu 595 600 605 Pro Trp Lys Trp Gly Met Lys Tyr Phe Trp Asp Thr Leu Leu Asp Ala 610 615 620 Asp Leu Glu Cys Asp Ile Leu Gly Trp Gln Tyr Ile Ser Gly Ser Ile 625 630 635 640 Pro Asp Gly His Glu Leu Asp Arg Leu Asp Asn Pro Ala Leu Gln Gly 645 650 655 Ala Lys Tyr Asp Pro Glu Gly Glu Tyr Ile Arg Gln Trp Leu Pro Glu 660 665 670 Leu Ala Arg Leu Pro Thr Glu Trp Ile His His Pro Trp Asp Ala Pro 675 680 685 Leu Thr Val Leu Lys Ala Ser Gly Val Glu Leu Gly Thr Asn Tyr Ala 690 695 700 Lys Pro Ile Val Asp Ile Asp Thr Ala Arg Glu Leu Leu Ala Lys Ala 705 710 715 720 Ile Ser Arg Thr Arg Gly Ala Gln Ile Met Ile Gly Ala Ala Ala Arg 725 730 735 Gly Gly Arg Phe Gly Gly Asn Pro Gly Gly Phe Gly Asn Gln Gly Gly 740 745 750 Phe Gly Asn Ser Arg Gly Gly Gly Ala Gly Leu Gly Asn Asn Gln Gly 755 760 765 Ser Asn Met Gly Gly Gly Met Asn Phe Gly Ala Phe Ser Ile Asn Pro 770 775 780 Ala Met Met Ala Ala Ala Gln Ala Ala Leu Gln Ser Ser Trp Gly Met 785 790 795 800 Met Gly Met Leu Ala Ser Gln Gln Asn Gln Ser Gly Pro Ser Gly Asn 805 810 815 Asn Gln Asn Gln Gly Asn Met Gln Arg Glu Pro Asn Gln Ala Phe Gly 820 825 830 Ser Gly Asn Asn Ser Tyr Ser Gly Ser Asn Ser Gly Ala Ala Ile Gly 835 840 845 Trp Gly Ser Ala Ser Asn Ala Gly Ser Gly Ser Gly Phe Asn Gly Gly 850 855 860 Phe Gly Ser Ser Met Asp Ser Lys Ser Ser Gly Trp Gly Met 865 870 875 <210> 21 <211> 961 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Construct <400> 21 Met Val Ser Lys Gly Glu Glu Asp Asn Met Ala Ile Ile Lys Glu Phe 1 5 10 15 Met Arg Phe Lys Val His Met Glu Gly Ser Val Asn Gly His Glu Phe 20 25 30 Glu Ile Glu Gly Glu Gly Glu Gly Arg Pro Tyr Glu Gly Thr Gln Thr 35 40 45 Ala Lys Leu Lys Val Thr Lys Gly Gly Pro Leu Pro Phe Ala Trp Asp 50 55 60 Ile Leu Ser Pro Gln Phe Met Tyr Gly Ser Lys Ala Tyr Val Lys His 65 70 75 80 Pro Ala Asp Ile Pro Asp Tyr Leu Lys Leu Ser Phe Pro Glu Gly Phe 85 90 95 Lys Trp Glu Arg Val Met Asn Phe Glu Asp Gly Gly Val Val Thr Val 100 105 110 Thr Gln Asp Ser Ser Leu Gln Asp Gly Glu Phe Ile Tyr Lys Val Lys 115 120 125 Leu Arg Gly Thr Asn Phe Pro Ser Asp Gly Pro Val Met Gln Lys Lys 130 135 140 Thr Met Gly Trp Glu Ala Ser Ser Glu Arg Met Tyr Pro Glu Asp Gly 145 150 155 160 Ala Leu Lys Gly Glu Ile Lys Gln Arg Leu Lys Leu Lys Asp Gly Gly 165 170 175 His Tyr Asp Ala Glu Val Lys Thr Thr Tyr Lys Ala Lys Lys Pro Val 180 185 190 Gln Leu Pro Gly Ala Tyr Asn Val Asn Ile Lys Leu Asp Ile Thr Ser 195 200 205 His Asn Glu Asp Tyr Thr Ile Val Glu Gln Tyr Glu Arg Ala Glu Gly 210 215 220 Arg His Ser Thr Gly Gly Met Asp Glu Leu Tyr Lys Met Lys Met Asp 225 230 235 240 Lys Lys Thr Ile Val Trp Phe Arg Arg Asp Leu Arg Ile Glu Asp Asn 245 250 255 Pro Ala Leu Ala Ala Ala Ala His Glu Gly Ser Val Phe Pro Val Phe 260 265 270 Ile Trp Cys Pro Glu Glu Glu Gly Gln Phe Tyr Pro Gly Arg Ala Ser 275 280 285 Arg Trp Trp Met Lys Gln Ser Leu Ala His Leu Ser Gln Ser Leu Lys 290 295 300 Ala Leu Gly Ser Asp Leu Thr Leu Ile Lys Thr His Asn Thr Ile Ser 305 310 315 320 Ala Ile Leu Asp Cys Ile Arg Val Thr Gly Ala Thr Lys Val Val Phe 325 330 335 Asn His Leu Tyr Asp Pro Val Ser Leu Val Arg Asp His Thr Val Lys 340 345 350 Glu Lys Leu Val Glu Arg Gly Ile Ser Val Gln Ser Tyr Asn Gly Asp 355 360 365 Leu Leu Tyr Glu Pro Trp Glu Ile Tyr Cys Glu Lys Gly Lys Pro Phe 370 375 380 Thr Ser Phe Asn Ser Tyr Trp Lys Lys Cys Leu Asp Met Ser Ile Glu 385 390 395 400 Ser Val Met Leu Pro Pro Pro Trp Arg Leu Met Pro Ile Thr Ala Ala 405 410 415 Ala Glu Ala Ile Trp Ala Cys Ser Ile Glu Glu Leu Gly Leu Glu Asn 420 425 430 Glu Ala Glu Lys Pro Ser Asn Ala Leu Leu Thr Arg Ala Trp Ser Pro 435 440 445 Gly Trp Ser Asn Ala Asp Lys Leu Leu Asn Glu Phe Ile Glu Lys Gln 450 455 460 Leu Ile Asp Tyr Ala Lys Asn Ser Lys Lys Val Val Gly Asn Ser Thr 465 470 475 480 Ser Leu Leu Ser Pro Tyr Leu His Phe Gly Glu Ile Ser Val Arg His 485 490 495 Val Phe Gln Cys Ala Arg Met Lys Gln Ile Ile Trp Ala Arg Asp Lys 500 505 510 Asn Ser Glu Gly Glu Glu Ser Ala Asp Leu Phe Leu Arg Gly Ile Gly 515 520 525 Leu Arg Glu Tyr Ser Arg Tyr Ile Cys Phe Asn Phe Pro Phe Thr His 530 535 540 Glu Gln Ser Leu Leu Ser His Leu Arg Phe Phe Pro Trp Asp Ala Asp 545 550 555 560 Val Asp Lys Phe Lys Ala Trp Arg Gln Gly Arg Thr Gly Tyr Pro Leu 565 570 575 Val Asp Ala Gly Met Arg Glu Leu Trp Ala Thr Gly Trp Met His Asn 580 585 590 Arg Ile Arg Val Ile Val Ser Ser Phe Ala Val Lys Phe Leu Leu Leu 595 600 605 Pro Trp Lys Trp Gly Met Lys Tyr Phe Trp Asp Thr Leu Leu Asp Ala 610 615 620 Asp Leu Glu Cys Asp Ile Leu Gly Trp Gln Tyr Ile Ser Gly Ser Ile 625 630 635 640 Pro Asp Gly His Glu Leu Asp Arg Leu Asp Asn Pro Ala Leu Gln Gly 645 650 655 Ala Lys Tyr Asp Pro Glu Gly Glu Tyr Ile Arg Gln Trp Leu Pro Glu 660 665 670 Leu Ala Arg Leu Pro Thr Glu Trp Ile His His Pro Trp Asp Ala Pro 675 680 685 Leu Thr Val Leu Lys Ala Ser Gly Val Glu Leu Gly Thr Asn Tyr Ala 690 695 700 Lys Pro Ile Val Asp Ile Asp Thr Ala Arg Glu Leu Leu Ala Lys Ala 705 710 715 720 Ile Ser Arg Thr Arg Gly Ala Gln Ile Met Ile Gly Ala Ala Ala Arg 725 730 735 Gly Arg Lys Val Phe Val Gly Arg Cys Thr Glu Asp Met Thr Glu Asp 740 745 750 Glu Leu Arg Glu Phe Phe Ser Gln Tyr Gly Asp Val Met Asp Val Phe 755 760 765 Ile Pro Lys Pro Phe Arg Ala Phe Ala Phe Val Thr Phe Ala Asp Asp 770 775 780 Gln Ile Ala Gln Ser Leu Cys Gly Glu Asp Leu Ile Ile Lys Gly Ile 785 790 795 800 Ser Val His Ile Ser Asn Ala Glu Pro Lys His Asn Ser Asn Arg Gln 805 810 815 Leu Glu Arg Ser Gly Arg Phe Gly Gly Asn Pro Gly Gly Phe Gly Asn 820 825 830 Gln Gly Gly Phe Gly Asn Ser Arg Gly Gly Gly Ala Gly Leu Gly Asn 835 840 845 Asn Gln Gly Ser Asn Met Gly Gly Gly Met Asn Phe Gly Ala Phe Ser 850 855 860 Ile Asn Pro Ala Met Met Ala Ala Ala Gln Ala Ala Leu Gln Ser Ser 865 870 875 880 Trp Gly Met Met Gly Met Leu Ala Ser Gln Gln Asn Gln Ser Gly Pro 885 890 895 Ser Gly Asn Asn Gln Asn Gln Gly Asn Met Gln Arg Glu Pro Asn Gln 900 905 910 Ala Phe Gly Ser Gly Asn Asn Ser Tyr Ser Gly Ser Asn Ser Gly Ala 915 920 925 Ala Ile Gly Trp Gly Ser Ala Ser Asn Ala Gly Ser Gly Ser Gly Phe 930 935 940 Asn Gly Gly Phe Gly Ser Ser Met Asp Ser Lys Ser Ser Gly Trp Gly 945 950 955 960 Met <210> 22 <211> 1047 <212> PRT <213> Artificial sequence <220> <223> Synthetic construct <400> 22 [[ID=z17]]Met Val Ser Lys Gly Glu Glu Asp Asn Met Ala Ile Ile Lys Glu Phe 1 5 10 15 Met Arg Phe Lys Val His Met Glu Gly Ser Val Asn Gly His Glu Phe 20 25 30 Glu Ile Glu Gly Glu Gly Glu Gly Arg Pro Tyr Glu Gly Thr Gln Thr 35 40 45 Ala Lys Leu Lys Val Thr Lys Gly Gly Pro Leu Pro Phe Ala Trp Asp 50 55 60 Ile Leu Ser Pro Gln Phe Met Tyr Gly Ser Lys Ala Tyr Val Lys His 65 70 75 80 Pro Ala Asp Ile Pro Asp Tyr Leu Lys Leu Ser Phe Pro Glu Gly Phe 85 90 95 Lys Trp Glu Arg Val Met Asn Phe Glu Asp Gly Gly Val Val Thr Val 100 105 110 Thr Gln Asp Ser Ser Leu Gln Asp Gly Glu Phe Ile Tyr Lys Val Lys 115 120 125 Leu Arg Gly Thr Asn Phe Pro Ser Asp Gly Pro Val Met Gln Lys Lys 130 135 140 Thr Met Gly Trp Glu Ala Ser Ser Glu Arg Met Tyr Pro Glu Asp Gly 145 150 155 160 Ala Leu Lys Gly Glu Ile Lys Gln Arg Leu Lys Leu Lys Asp Gly Gly 165 170 175 His Tyr Asp Ala Glu Val Lys Thr Thr Tyr Lys Ala Lys Lys Pro Val 180 185 190 Gln Leu Pro Gly Ala Tyr Asn Val Asn Ile Lys Leu Asp Ile Thr Ser 195 200 205 His Asn Glu Asp Tyr Thr Ile Val Glu Gln Tyr Glu Arg Ala Glu Gly 210 215 220 Arg His Ser Thr Gly Gly Met Asp Glu Leu Tyr Lys Met Lys Met Asp 225 230 235 240 Lys Lys Thr Ile Val Trp Phe Arg Arg Asp Leu Arg Ile Glu Asp Asn 245 250 255 Pro Ala Leu Ala Ala Ala Ala His Glu Gly Ser Val Phe Pro Val Phe 260 265 270 Ile Trp Cys Pro Glu Glu Glu Gly Gln Phe Tyr Pro Gly Arg Ala Ser 275 280 285 Arg Trp Trp Met Lys Gln Ser Leu Ala His Leu Ser Gln Ser Leu Lys 290 295 300 Ala Leu Gly Ser Asp Leu Thr Leu Ile Lys Thr His Asn Thr Ile Ser 305 310 315 320 Ala Ile Leu Asp Cys Ile Arg Val Thr Gly Ala Thr Lys Val Val Phe 325 330 335 Asn His Leu Tyr Asp Pro Val Ser Leu Val Arg Asp His Thr Val Lys 340 345 350 Glu Lys Leu Val Glu Arg Gly Ile Ser Val Gln Ser Tyr Asn Gly Asp 355 360 365 Leu Leu Tyr Glu Pro Trp Glu Ile Tyr Cys Glu Lys Gly Lys Pro Phe 370 375 380 Thr Ser Phe Asn Ser Tyr Trp Lys Lys Cys Leu Asp Met Ser Ile Glu 385 390 395 400 Ser Val Met Leu Pro Pro Pro Trp Arg Leu Met Pro Ile Thr Ala Ala 405 410 415 Ala Glu Ala Ile Trp Ala Cys Ser Ile Glu Glu Leu Gly Leu Glu Asn 420 425 430 Glu Ala Glu Lys Pro Ser Asn Ala Leu Leu Thr Arg Ala Trp Ser Pro 435 440 445 Gly Trp Ser Asn Ala Asp Lys Leu Leu Asn Glu Phe Ile Glu Lys Gln 450 455 460 Leu Ile Asp Tyr Ala Lys Asn Ser Lys Lys Val Val Gly Asn Ser Thr 465 470 475 480 Ser Leu Leu Ser Pro Tyr Leu His Phe Gly Glu Ile Ser Val Arg His 485 490 495 Val Phe Gln Cys Ala Arg Met Lys Gln Ile Ile Trp Ala Arg Asp Lys 500 505 510 Asn Ser Glu Gly Glu Glu Ser Ala Asp Leu Phe Leu Arg Gly Ile Gly 515 520 525 Leu Arg Glu Tyr Ser Arg Tyr Ile Cys Phe Asn Phe Pro Phe Thr His 530 535 540 Glu Gln Ser Leu Leu Ser His Leu Arg Phe Phe Pro Trp Asp Ala Asp 545 550 555 560 Val Asp Lys Phe Lys Ala Trp Arg Gln Gly Arg Thr Gly Tyr Pro Leu 565 570 575 Val Asp Ala Gly Met Arg Glu Leu Trp Ala Thr Gly Trp Met His Asn 580 585 590 Arg Ile Arg Val Ile Val Ser Ser Phe Ala Val Lys Phe Leu Leu Leu 595 600 605 Pro Trp Lys Trp Gly Met Lys Tyr Phe Trp Asp Thr Leu Leu Asp Ala 610 615 620 Asp Leu Glu Cys Asp Ile Leu Gly Trp Gln Tyr Ile Ser Gly Ser Ile 625 630 635 640 Pro Asp Gly His Glu Leu Asp Arg Leu Asp Asn Pro Ala Leu Gln Gly 645 650 655 Ala Lys Tyr Asp Pro Glu Gly Glu Tyr Ile Arg Gln Trp Leu Pro Glu 660 665 670 Leu Ala Arg Leu Pro Thr Glu Trp Ile His His Pro Trp Asp Ala Pro 675 680 685 Leu Thr Val Leu Lys Ala Ser Gly Val Glu Leu Gly Thr Asn Tyr Ala 690 695 700 Lys Pro Ile Val Asp Ile Asp Thr Ala Arg Glu Leu Leu Ala Lys Ala 705 710 715 720 Ile Ser Arg Thr Arg Gly Ala Gln Ile Met Ile Gly Ala Ala Ala Arg 725 730 735 Gly Asp Leu Ile Val Leu Gly Leu Pro Trp Lys Thr Thr Glu Gln Asp 740 745 750 Leu Lys Glu Tyr Phe Ser Thr Phe Gly Glu Val Leu Met Val Gln Val 755 760 765 Lys Lys Asp Leu Lys Thr Gly His Ser Lys Gly Phe Gly Phe Val Arg 770 775 780 Phe Thr Glu Tyr Glu Thr Gln Val Lys Val Met Ser Gln Arg His Met 785 790 795 800 Ile Asp Gly Arg Trp Cys Asp Cys Lys Leu Pro Asn Ser Lys Gln Ser 805 810 815 Gln Asp Glu Pro Leu Arg Ser Arg Lys Val Phe Val Gly Arg Cys Thr 820 825 830 Glu Asp Met Thr Glu Asp Glu Leu Arg Glu Phe Phe Ser Gln Tyr Gly 835 840 845 Asp Val Met Asp Val Phe Ile Pro Lys Pro Phe Arg Ala Phe Ala Phe 850 855 860 Val Thr Phe Ala Asp Asp Gln Ile Ala Gln Ser Leu Cys Gly Glu Asp 865 870 875 880 Leu Ile Ile Lys Gly Ile Ser Val His Ile Ser Asn Ala Glu Pro Lys 885 890 895 His Asn Ser Asn Arg Gln Leu Glu Arg Ser Gly Arg Phe Gly Gly Asn 900 905 910 Pro Gly Gly Phe Gly Asn Gln Gly Gly Phe Gly Asn Ser Arg Gly Gly 915 920 925 Gly Ala Gly Leu Gly Asn Asn Gln Gly Ser Asn Met Gly Gly Gly Met 930 935 940 Asn Phe Gly Ala Phe Ser Ile Asn Pro Ala Met Met Ala Ala Ala Gln 945 950 955 960 Ala Ala Leu Gln Ser Ser Trp Gly Met Met Gly Met Leu Ala Ser Gln 965 970 975 Gln Asn Gln Ser Gly Pro Ser Gly Asn Asn Gln Asn Gln Gly Asn Met 980 985 990 Gln Arg Glu Pro Asn Gln Ala Phe Gly Ser Gly Asn Asn Ser Tyr Ser 995 1000 1005 Gly Ser Asn Ser Gly Ala Ala Ile Gly Trp Gly Ser Ala Ser Asn<00了5344>1010 1015 1020 Ala Gly Ser Gly Ser Gly Phe Asn Gly Gly Phe Gly Ser Ser Met 1025 1030 1035 Asp Ser Lys Ser Ser Gly Trp Gly Met 1040 1045 <210> 23 <211> 886 <212> PRT <213> Artificial Sequence <2~20> It seems there is a small error in the original text where "了" is present in one of the tags in line 26. It should probably be "4" as in the other tags. The above translation is based on the corrected assumption. If this is not the case, please let me know for further adjustments.<223> Synthetic construct <400> 23 Met Lys Met Asp Lys Lys Thr Ile Val Trp Phe Arg Arg Asp Leu Arg 1 5 10 15 Ile Glu Asp Asn Pro Ala Leu Ala Ala Ala Ala His Glu Gly Ser Val 20 25 30 Phe Pro Val Phe Ile Trp Cys Pro Glu Glu Glu Gly Gln Phe Tyr Pro 35 40 45 Gly Arg Ala Ser Arg Trp Trp Met Lys Gln Ser Leu Ala His Leu Ser 50 55 60 Gln Ser Leu Lys Ala Leu Gly Ser Asp Leu Thr Leu Ile Lys Thr His 65 70 75 80 Asn Thr Ile Ser Ala Ile Leu Asp Cys Ile Arg Val Thr Gly Ala Thr 85 90 95 Lys Val Val Phe Asn His Leu Tyr Asp Pro Val Ser Leu Val Arg Asp 100 105 110 His Thr Val Lys Glu Lys Leu Val Glu Arg Gly Ile Ser Val Gln Ser 115 120 125 Tyr Asn Gly Asp Leu Leu Tyr Glu Pro Trp Glu Ile Tyr Cys Glu Lys 130 135 140 Gly Lys Pro Phe Thr Ser Phe Asn Ser Tyr Trp Lys Lys Cys Leu Asp 145 150 155 160 Met Ser Ile Glu Ser Val Met Leu Pro Pro Pro Trp Arg Leu Met Pro 165 170 175 Ile Thr Ala Ala Ala Glu Ala Ile Trp Ala Cys Ser Ile Glu Glu Leu 180 185 190 Gly Leu Glu Asn Glu Ala Glu Lys Pro Ser Asn Ala Leu Leu Thr Arg 195 200 205 Ala Trp Ser Pro Gly Trp Ser Asn Ala Asp Lys Leu Leu Asn Glu Phe 210 215 220 Ile Glu Lys Gln Leu Ile Asp Tyr Ala Lys Asn Ser Lys Lys Val Val 225 230 235 240 Gly Asn Ser Thr Ser Leu Leu Ser Pro Tyr Leu His Phe Gly Glu Ile 245 250 255 Ser Val Arg His Val Phe Gln Cys Ala Arg Met Lys Gln Ile Ile Trp 260 265 270 Ala Arg Asp Lys Asn Ser Glu Gly Glu Glu Ser Ala Asp Leu Phe Leu 275 280 285 Arg Gly Ile Gly Leu Arg Glu Tyr Ser Arg Tyr Ile Cys Phe Asn Phe 290 295 300 Pro Phe Thr His Glu Gln Ser Leu Leu Ser His Leu Arg Phe Phe Pro 305 310 315 320 Trp Asp Ala Asp Val Asp Lys Phe Lys Ala Trp Arg Gln Gly Arg Thr 325 330 335 Gly Tyr Pro Leu Val Asp Ala Gly Met Arg Glu Leu Trp Ala Thr Gly 340 345 350 Trp Met His Asn Arg Ile Arg Val Ile Val Ser Ser Phe Ala Val Lys 355 360 365 Phe Leu Leu Leu Pro Trp Lys Trp Gly Met Lys Tyr Phe Trp Asp Thr 370 375 380 Leu Leu Asp Ala Asp Leu Glu Cys Asp Ile Leu Gly Trp Gln Tyr Ile 385 390 395 400 Ser Gly Ser Ile Pro Asp Gly His Glu Leu Asp Arg Leu Asp Asn Pro 405 410 415 Ala Leu Gln Gly Ala Lys Tyr Asp Pro Glu Gly Glu Tyr Ile Arg Gln 420 425 430 Trp Leu Pro Glu Leu Ala Arg Leu Pro Thr Glu Trp Ile His His Pro 435 440 445 Trp Asp Ala Pro Leu Thr Val Leu Lys Ala Ser Gly Val Glu Leu Gly 450 455 460 Thr Asn Tyr Ala Lys Pro Ile Val Asp Ile Asp Thr Ala Arg Glu Leu 465 470 475 480 Leu Ala Lys Ala Ile Ser Arg Thr Arg Gly Ala Gln Ile Met Ile Gly 485 490 495 Ala Ala Ala Arg Gly Gly Arg Phe Gly Gly Asn Pro Gly Gly Phe Gly 500 505 510 Asn Gln Gly Gly Phe Gly Asn Ser Arg Gly Gly Gly Ala Gly Leu Gly 515 520 525 Asn Asn Gln Gly Ser Asn Met Gly Gly Gly Met Asn Phe Gly Ala Phe 530 535 540 Ser Ile Asn Pro Ala Met Met Ala Ala Ala Gln Ala Ala Leu Gln Ser 545 550 555 560 Ser Trp Gly Met Met Gly Met Leu Ala Ser Gln Gln Asn Gln Ser Gly 565 570 575 Pro Ser Gly Asn Asn Gln Asn Gln Gly Asn Met Gln Arg Glu Pro Asn 580 585 590 Gln Ala Phe Gly Ser Gly Asn Asn Ser Tyr Ser Gly Ser Asn Ser Gly 595 600 605 Ala Ala Ile Gly Trp Gly Ser Ala Ser Asn Ala Gly Ser Gly Ser Gly 610 615 620 Phe Asn Gly Gly Phe Gly Ser Ser Met Asp Ser Lys Ser Ser Gly Trp 625 630 635 640 Gly Met Ser Arg Asp Pro Pro Val Ala Thr Met Val Ser Lys Gly Glu 645 650 655 Glu Asp Asn Met Ala Ile Ile Lys Glu Phe Met Arg Phe Lys Val His 660 665 670 Met Glu Gly Ser Val Asn Gly His Glu Phe Glu Ile Glu Gly Glu Gly 675 680 685 Glu Gly Arg Pro Tyr Glu Gly Thr Gln Thr Ala Lys Leu Lys Val Thr 690 695 700 Lys Gly Gly Pro Leu Pro Phe Ala Trp Asp Ile Leu Ser Pro Gln Phe 705 710 715 720 Met Tyr Gly Ser Lys Ala Tyr Val Lys His Pro Ala Asp Ile Pro Asp 725 730 735 Tyr Leu Lys Leu Ser Phe Pro Glu Gly Phe Lys Trp Glu Arg Val Met 740 745 750 Asn Phe Glu Asp Gly Gly Val Val Thr Val Thr Gln Asp Ser Ser Leu 755 760 765 Gln Asp Gly Glu Phe Ile Tyr Lys Val Lys Leu Arg Gly Thr Asn Phe 770 775 780 Pro Ser Asp Gly Pro Val Met Gln Lys Lys Thr Met Gly Trp Glu Ala 785 790 795 800 Ser Ser Glu Arg Met Tyr Pro Glu Asp Gly Ala Leu Lys Gly Glu Ile 805 810 815 Lys Gln Arg Leu Lys Leu Lys Asp Gly Gly His Tyr Asp Ala Glu Val 820 825 830 Lys Thr Thr Tyr Lys Ala Lys Lys Pro Val Gln Leu Pro Gly Ala Tyr 835 840 845 Asn Val Asn Ile Lys Leu Asp Ile Thr Ser His Asn Glu Asp Tyr Thr 850 855 860 Ile Val Glu Gln Tyr Glu Arg Ala Glu Gly Arg His Ser Thr Gly Gly 865 870 875 880 Met Asp Glu Leu Tyr Lys 885 <210> 24 <211> 969 <212> PRT <213> Artificial Sequence <220> <223> Synthetic construct <400> 24 Met Lys Met Asp Lys Lys Thr Ile Val Trp Phe Arg Arg Asp Leu Arg 1 5 10 15 Ile Glu Asp Asn Pro Ala Leu Ala Ala Ala Ala His Glu Gly Ser Val 20 25 30 Phe Pro Val Phe Ile Trp Cys Pro Glu Glu Glu Gly Gln Phe Tyr Pro 35 40 45 Gly Arg Ala Ser Arg Trp Trp Met Lys Gln Ser Leu Ala His Leu Ser 50 55 60 Gln Ser Leu Lys Ala Leu Gly Ser Asp Leu Thr Leu Ile Lys Thr His 65 70 75 80 Asn Thr Ile Ser Ala Ile Leu Asp Cys Ile Arg Val Thr Gly Ala Thr 85 90 95 Lys Val Val Phe Asn His Leu Tyr Asp Pro Val Ser Leu Val Arg Asp 100 105 110 His Thr Val Lys Glu Lys Leu Val Glu Arg Gly Ile Ser Val Gln Ser 115 120 125 Tyr Asn Gly Asp Leu Leu Tyr Glu Pro Trp Glu Ile Tyr Cys Glu Lys 130 135 140 Gly Lys Pro Phe Thr Ser Phe Asn Ser Tyr Trp Lys Lys Cys Leu Asp 145 150 155 160 Met Ser Ile Glu Ser Val Met Leu Pro Pro Pro Trp Arg Leu Met Pro 165 170 175 Ile Thr Ala Ala Ala Glu Ala Ile Trp Ala Cys Ser Ile Glu Glu Leu 180 185 190 Gly Leu Glu Asn Glu Ala Glu Lys Pro Ser Asn Ala Leu Leu Thr Arg 195 200 205 Ala Trp Ser Pro Gly Trp Ser Asn Ala Asp Lys Leu Leu Asn Glu Phe 210 215 220 Ile Glu Lys Gln Leu Ile Asp Tyr Ala Lys Asn Ser Lys Lys Val Val 225 230 235 240 Gly Asn Ser Thr Ser Leu Leu Ser Pro Tyr Leu His Phe Gly Glu Ile 245 250 255 Ser Val Arg His Val Phe Gln Cys Ala Arg Met Lys Gln Ile Ile Trp 260 265 270 Ala Arg Asp Lys Asn Ser Glu Gly Glu Glu Ser Ala Asp Leu Phe Leu 275 280 285 Arg Gly Ile Gly Leu Arg Glu Tyr Ser Arg Tyr Ile Cys Phe Asn Phe 290 295 300 Pro Phe Thr His Glu Gln Ser Leu Leu Ser His Leu Arg Phe Phe Pro 305 310 315 320 Trp Asp Ala Asp Val Asp Lys Phe Lys Ala Trp Arg Gln Gly Arg Thr 325 330 335 Gly Tyr Pro Leu Val Asp Ala Gly Met Arg Glu Leu Trp Ala Thr Gly 340 345 350 Trp Met His Asn Arg Ile Arg Val Ile Val Ser Ser Phe Ala Val Lys 355 360 365 Phe Leu Leu Leu Pro Trp Lys Trp Gly Met Lys Tyr Phe Trp Asp Thr 370 375 380 Leu Leu Asp Ala Asp Leu Glu Cys Asp Ile Leu Gly Trp Gln Tyr Ile 385 390 395 400 Ser Gly Ser Ile Pro Asp Gly His Glu Leu Asp Arg Leu Asp Asn Pro 405 410 415 Ala Leu Gln Gly Ala Lys Tyr Asp Pro Glu Gly Glu Tyr Ile Arg Gln 420 425 430 Trp Leu Pro Glu Leu Ala Arg Leu Pro Thr Glu Trp Ile His His Pro 435 440 445 Trp Asp Ala Pro Leu Thr Val Leu Lys Ala Ser Gly Val Glu Leu Gly 450 455 460 Thr Asn Tyr Ala Lys Pro Ile Val Asp Ile Asp Thr Ala Arg Glu Leu 465 470 475 480 Leu Ala Lys Ala Ile Ser Arg Thr Arg Gly Ala Gln Ile Met Ile Gly 485 490 495 Ala Ala Ala Arg Gly Arg Lys Val Phe Val Gly Arg Cys Thr Glu Asp 500 505 510 Met Thr Glu Asp Glu Leu Arg Glu Phe Phe Ser Gln Tyr Gly Asp Val 515 520 525 Met Asp Val Phe Ile Pro Lys Pro Phe Arg Ala Phe Ala Phe Val Thr 530 535 540 Phe Ala Asp Asp Gln Ile Ala Gln Ser Leu Cys Gly Glu Asp Leu Ile 545 550 555 560 Ile Lys Gly Ile Ser Val His Ile Ser Asn Ala Glu Pro Lys His Asn 565 570 575 Ser Asn Arg Gln Leu Glu Arg Ser Gly Arg Phe Gly Gly Asn Pro Gly 580 585 590 Gly Phe Gly Asn Gln Gly Gly Phe Gly Asn Ser Arg Gly Gly Gly Ala 595 600 605 Gly Leu Gly Asn Asn Gln Gly Ser Asn Met Gly Gly Gly Met Asn Phe 610 615 620 Gly Ala Phe Ser Ile Asn Pro Ala Met Met Ala Ala Ala Gln Ala Ala 625 630 635 640 Leu Gln Ser Ser Trp Gly Met Met Gly Met Leu Ala Ser Gln Gln Asn 645 650 655 Gln Ser Gly Pro Ser Gly Asn Asn Gln Asn Gln Gly Asn Met Gln Arg 660 665 670 Glu Pro Asn Gln Ala Phe Gly Ser Gly Asn Asn Ser Tyr Ser Gly Ser 675 680 685 Asn Ser Gly Ala Ala Ile Gly Trp Gly Ser Ala Ser Asn Ala Gly Ser 690 695 700 ...

Claims

1. A nucleotide sequence encoding a chimeric polypeptide, the nucleotide sequence comprising: a first nucleotide sequence encoding a light-induced oligomerization domain and a second nucleotide sequence encoding a low complexity domain from a neurodegenerative disease target protein, wherein: The light-induced oligomerization domain is CRY2OLIG, and wherein the low complexity domain from a neurodegenerative disease target protein is TDP-43.

2. An expression vector encoding a chimeric polypeptide, the expression vector comprising: a first nucleotide sequence encoding a light-induced oligomerization domain and a second nucleotide sequence encoding a low complexity domain from a neurodegenerative disease target protein, wherein: The first nucleotide sequence is operably linked to a promoter, wherein the light-induced oligomerization domain is CRY2OLIG, and wherein the low complexity domain from a neurodegenerative disease target protein is TDP-43.

3. A cell comprising a nucleotide sequence encoding a chimeric polypeptide, the cell comprising: a first nucleotide sequence encoding a light-induced oligomerization domain and a second nucleotide sequence encoding a low complexity domain from a neurodegenerative disease target protein, wherein: The light-induced oligomerization domain is CRY2OLIG, and wherein the low complexity domain from a neurodegenerative disease target protein is TDP-43.

4. A chimeric polypeptide comprising: a light-induced oligomerization domain; and Low complexity domains from neurodegenerative disease target proteins, in, The light-induced oligomerization domain is CRY2OLIG, and wherein the low complexity domain from a neurodegenerative disease target protein is TDP-43.

5. A method for inducing neurodegenerative disease pathology in a cell, the method comprising the following steps: An expression vector encoding a chimeric polypeptide is introduced into a cell, wherein the expression vector comprises: a first nucleotide sequence encoding a light-induced oligomerization domain and a second nucleotide sequence encoding a low complexity domain from a neurodegenerative disease target protein, wherein the first nucleotide sequence is operably linked to a promoter, wherein the light-induced oligomerization domain is CRY2OLIG, and wherein the low complexity domain from a neurodegenerative disease target protein is TDP-43; expressing the chimeric polypeptide; and Oligomerization of the chimeric polypeptide is induced by stimulation with blue light.

6. The method of claim 5, wherein: The cells are mammalian cells.

7. The method of claim 6, wherein: The cells are human cells.

8. The method of claim 5, wherein: The wavelength of the blue light is between 405nm and 499nm.

9. A method for screening an agent that modulates protein aggregation, the method comprising the following steps: An expression vector encoding a chimeric polypeptide is introduced into a cell, wherein the expression vector comprises: a first nucleotide sequence encoding a light-induced oligomerization domain and a second nucleotide sequence encoding a low complexity domain from a neurodegenerative disease target protein, wherein the first nucleotide sequence is operably linked to a promoter, wherein the light-induced oligomerization domain is CRY2OLIG, and wherein the low complexity domain from a neurodegenerative disease target protein is TDP-43; expressing the chimeric polypeptide; introducing the agent into a culture medium containing the cells; Inducing oligomerization of the chimeric polypeptide by stimulation with blue light; and Modulation of protein aggregation by the agent is determined.

10. The method of claim 9, wherein: The cells are mammalian cells.

11. The method of claim 10, wherein: The cells are human cells.

12. The method of claim 9, wherein: The wavelength of the blue light is between 405nm and 499nm.

13. The nucleotide sequence of claim 1, wherein the nucleotide sequence encodes a light-induced oligomerization domain, and the light-induced oligomerization domain is SEQ ID NO:

2.

14. The nucleotide sequence of claim 1, wherein the first nucleotide sequence and the second nucleotide sequence encode a chimeric polypeptide, and the chimeric polypeptide is SEQ ID NO:

6.

15. The nucleotide sequence of claim 1, wherein the first nucleotide sequence and the second nucleotide sequence encode a chimeric polypeptide, and the chimeric polypeptide is SEQ ID NO:

13.

16. The nucleotide sequence of claim 1, wherein the nucleotide sequence encodes a low complexity domain, and the low complexity domain is SEQ ID NO:

95.

17. The nucleotide sequence of claim 1, wherein the nucleotide sequence encodes a low complexity domain, and the low complexity domain is SEQ ID NO: 96.